0001125376-19-000102.txt : 20190801 0001125376-19-000102.hdr.sgml : 20190801 20190801160922 ACCESSION NUMBER: 0001125376-19-000102 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 117 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190801 DATE AS OF CHANGE: 20190801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENSIGN GROUP, INC CENTRAL INDEX KEY: 0001125376 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 330861263 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33757 FILM NUMBER: 19992746 BUSINESS ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 BUSINESS PHONE: (949) 487-9500 MAIL ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 FORMER COMPANY: FORMER CONFORMED NAME: ENSIGN GROUP INC DATE OF NAME CHANGE: 20000930 10-Q 1 ensg0630201910q.htm 10-Q Wdesk | Document
false--12-31Q220190001125376P3Y0MP11Y0MP3Y0MP10Y0MP5Y0M0.6800.04500.04750.0010.0017500000010000000055089000558090005258400053272000P12Y0MP30Y0MP3Y11M0000P5Y0MP5Y0MP15Y0MP5Y0MP12Y0M5220000P3Y0M0DP3Y0M9760000019320001941000 0001125376 2019-01-01 2019-06-30 0001125376 2019-07-31 0001125376 2019-06-30 0001125376 2018-12-31 0001125376 2019-04-01 2019-06-30 0001125376 2018-04-01 2018-06-30 0001125376 2018-01-01 2018-06-30 0001125376 2019-03-31 0001125376 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001125376 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0001125376 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001125376 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001125376 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001125376 2019-01-01 2019-03-31 0001125376 us-gaap:CommonStockMember 2019-03-31 0001125376 us-gaap:RetainedEarningsMember 2019-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001125376 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001125376 us-gaap:TreasuryStockMember 2018-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001125376 us-gaap:TreasuryStockMember 2019-06-30 0001125376 us-gaap:CommonStockMember 2019-06-30 0001125376 us-gaap:CommonStockMember 2018-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001125376 us-gaap:TreasuryStockMember 2019-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2019-06-30 0001125376 us-gaap:RetainedEarningsMember 2019-06-30 0001125376 us-gaap:RetainedEarningsMember 2018-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2019-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2017-12-31 0001125376 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001125376 2018-01-01 2018-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0001125376 us-gaap:CommonStockMember 2017-12-31 0001125376 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001125376 us-gaap:RetainedEarningsMember 2018-06-30 0001125376 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001125376 us-gaap:TreasuryStockMember 2018-06-30 0001125376 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001125376 2018-06-30 0001125376 us-gaap:CommonStockMember 2018-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001125376 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001125376 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001125376 us-gaap:TreasuryStockMember 2017-12-31 0001125376 us-gaap:CommonStockMember 2018-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001125376 us-gaap:RetainedEarningsMember 2017-12-31 0001125376 us-gaap:TreasuryStockMember 2018-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001125376 2018-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2018-03-31 0001125376 us-gaap:RetainedEarningsMember 2018-03-31 0001125376 2017-12-31 0001125376 us-gaap:SpinoffMember 2019-05-06 0001125376 ensg:SpinOffTransactionCompanyMember us-gaap:SpinoffMember us-gaap:CommonStockMember 2019-05-06 2019-05-06 0001125376 ensg:RemainingCompanyMember us-gaap:SpinoffMember us-gaap:CommonStockMember 2019-05-06 2019-05-06 0001125376 ensg:RemainingCompanyMember us-gaap:SpinoffMember 2019-05-06 0001125376 ensg:SpinOffTransactionCompanyMember us-gaap:SpinoffMember 2019-05-06 0001125376 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0001125376 srt:MaximumMember 2019-01-01 2019-06-30 0001125376 ensg:PerOccurenceMember stpr:CO naics:ZZ524292 us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 ensg:StopLossInsuranceLimitPerClaimMember ensg:HealthLiabilityInsuranceMember 2019-06-30 0001125376 ensg:StopLossInsuranceLimitPerClaimMember us-gaap:WorkersCompensationInsuranceMember 2019-06-30 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2019-01-01 2019-06-30 0001125376 ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2019-06-30 0001125376 us-gaap:ProfessionalLiabilityInsuranceMember 2019-06-30 0001125376 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001125376 us-gaap:ProfessionalLiabilityInsuranceMember 2018-12-31 0001125376 ensg:StopLossInsuranceLimitPerClaimMember stpr:TX us-gaap:WorkersCompensationInsuranceMember 2019-06-30 0001125376 us-gaap:AccountingStandardsUpdate201602Member us-gaap:OffMarketFavorableLeaseMember 2019-01-01 0001125376 ensg:HealthLiabilityInsuranceMember 2019-06-30 0001125376 ensg:AggregateDeductibleMember stpr:CA srt:ParentCompanyMember us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 ensg:AggregateDeductibleMember ensg:NonCaliforniaDomain srt:ParentCompanyMember us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 ensg:PerOccurenceMember ensg:AllStatesExceptColoradoDomain naics:ZZ524292 us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 ensg:PerFacilityMember stpr:CO naics:ZZ524292 us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 ensg:LossSensitivelimitperclaimMemberMember ensg:OtherstatesexceptCaliforniaTexasandWashingtonDomain us-gaap:WorkersCompensationInsuranceMember 2019-06-30 0001125376 us-gaap:TradeNamesMember 2019-01-01 2019-06-30 0001125376 ensg:BlanketAggregateMember ensg:AllStatesExceptColoradoDomain naics:ZZ524292 us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 ensg:StopLossDeductibleMember ensg:HealthLiabilityInsuranceMember 2019-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2018-12-31 0001125376 ensg:HealthLiabilityInsuranceMember 2018-12-31 0001125376 ensg:PerFacilityMember ensg:AllStatesExceptColoradoDomain naics:ZZ524292 us-gaap:GeneralLiabilityMember 2019-06-30 0001125376 srt:MinimumMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember 2019-06-30 0001125376 ensg:ManagedCareMember 2018-12-31 0001125376 ensg:PrivatePayAndOtherMember 2019-06-30 0001125376 ensg:MedicaidMember 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2018-12-31 0001125376 ensg:MedicaidMember 2018-12-31 0001125376 ensg:MedicareMember 2018-12-31 0001125376 ensg:MedicareMember 2019-06-30 0001125376 us-gaap:CommonClassAMember 2018-04-01 2018-06-30 0001125376 us-gaap:CommonClassAMember 2019-04-01 2019-06-30 0001125376 us-gaap:CommonClassAMember 2019-01-01 2019-06-30 0001125376 us-gaap:CommonClassAMember 2018-01-01 2018-06-30 0001125376 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001125376 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001125376 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001125376 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001125376 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001125376 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2019-06-30 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2018-12-31 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2018-01-01 2018-06-30 0001125376 sic:Z8051 us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SubsequentEventMember 2019-07-01 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingFacilitiesMember 2019-06-30 0001125376 sic:Z8051 2019-06-30 0001125376 ensg:BusinessCombinationMember 2019-01-01 2019-06-30 0001125376 srt:OfficeBuildingMember 2018-01-01 2018-06-30 0001125376 ensg:GoodwillIndefinitelivedIntangibleAssetsMember 2019-01-01 2019-06-30 0001125376 sic:Z8051 us-gaap:SubsequentEventMember 2019-07-01 0001125376 sic:Z8051 2019-01-01 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesandSeniorLivingCampusesMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001125376 ensg:HospiceAgenciesMember 2019-01-01 2019-06-30 0001125376 ensg:AssetAcquisitionMember 2019-01-01 2019-06-30 0001125376 us-gaap:LandMember 2019-01-01 2019-06-30 0001125376 naics:ZZ621610 2019-01-01 2019-06-30 0001125376 ensg:HomeCareAgencyMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingFacilitiesMember 2019-01-01 2019-06-30 0001125376 us-gaap:EquipmentMember 2018-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2019-06-30 0001125376 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001125376 us-gaap:ConstructionInProgressMember 2019-06-30 0001125376 us-gaap:ConstructionInProgressMember 2018-12-31 0001125376 us-gaap:LandMember 2018-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2019-06-30 0001125376 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001125376 us-gaap:LandMember 2019-06-30 0001125376 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001125376 us-gaap:EquipmentMember 2019-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2019-06-30 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2018-12-31 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2019-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2018-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2019-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2019-06-30 0001125376 us-gaap:TradeNamesMember 2019-06-30 0001125376 us-gaap:TradeNamesMember 2018-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2018-12-31 0001125376 us-gaap:OffMarketFavorableLeaseMember 2019-01-01 2019-06-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2019-01-01 2019-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2018-12-31 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2019-01-01 2019-06-30 0001125376 us-gaap:TradeNamesMember 2019-06-30 0001125376 us-gaap:TradeNamesMember 2018-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2018-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2018-12-31 0001125376 ensg:AllOtherMember 2018-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2018-12-31 0001125376 ensg:AllOtherMember 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2018-12-31 0001125376 us-gaap:AccountingStandardsUpdate201602Member ensg:RightofUseAssetMember 2019-01-01 0001125376 us-gaap:AccountingStandardsUpdate201602Member ensg:DepositswithLandlordsMember 2018-12-31 0001125376 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-03-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2018-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2019-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2019-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2018-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2019-06-30 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2018-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2017-12-27 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2016-07-19 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 2016-02-05 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember us-gaap:SubsequentEventMember 2019-07-30 0001125376 srt:MaximumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2017-10-30 2017-12-27 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 2016-02-05 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 0001125376 srt:MinimumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 0001125376 us-gaap:SeniorDebtObligationsMember us-gaap:SecuredDebtMember 2019-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2014-05-30 0001125376 us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2017-12-27 0001125376 srt:MaximumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 2014-12-31 0001125376 srt:MaximumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 0001125376 srt:MinimumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 2014-12-31 0001125376 srt:MinimumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2017-10-30 2017-12-27 0001125376 ensg:ExercisePriceRangeOneMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeSixMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeTenMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeSixMember 2019-06-30 0001125376 ensg:ExercisePriceRangeFourMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeThreeMember 2019-06-30 0001125376 ensg:ExercisePriceRangeMember 2019-06-30 0001125376 ensg:ExercisePriceRangeTwoMember 2019-06-30 0001125376 ensg:ExercisePriceRangeSevenMember 2019-06-30 0001125376 ensg:ExercisePriceRangeTwoMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeTenMember 2019-06-30 0001125376 ensg:ExercisePriceRangeFiveMember 2019-06-30 0001125376 ensg:ExercisePriceRangeFiveMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeSevenMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeNineMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeThreeMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeOneMember 2019-06-30 0001125376 ensg:ExercisePriceRangeEightMember 2019-06-30 0001125376 ensg:ExercisePriceRangeNineMember 2019-06-30 0001125376 ensg:ExercisePriceRangeEightMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeFourMember 2019-06-30 0001125376 ensg:A2017PlanMember 2017-05-25 2017-05-25 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2019-04-01 2019-06-30 0001125376 ensg:A2017PlanMember 2017-05-25 0001125376 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001125376 srt:DirectorMember 2019-04-01 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2019-01-01 2019-06-30 0001125376 srt:DirectorMember ensg:A2017PlanMember 2017-05-25 2017-05-25 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2019-06-30 0001125376 srt:SubsidiariesMember srt:MaximumMember ensg:SubsidiariesStockawardsMember 2019-01-01 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2019-06-30 0001125376 srt:DirectorMember 2019-01-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2018-01-01 2018-06-30 0001125376 ensg:A2017PlanMember 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2018-04-01 2018-06-30 0001125376 ensg:StockAwardsMember 2018-04-01 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001125376 ensg:StockAwardsMember 2019-01-01 2019-06-30 0001125376 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0001125376 ensg:StockAwardsMember 2018-01-01 2018-06-30 0001125376 ensg:StockAwardsMember 2019-04-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2018-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001125376 srt:SubsidiariesMember srt:MinimumMember ensg:SubsidiariesStockawardsMember 2019-01-01 2019-06-30 0001125376 ensg:VariousLandlordsMemberMember srt:MaximumMember 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2019-01-01 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2018-01-01 2018-06-30 0001125376 ensg:CareTrustREITMember 2019-01-01 2019-06-30 0001125376 ensg:CareTrustREITMember 2014-06-01 0001125376 ensg:VariousLandlordsMemberMember srt:MaximumMember 2019-01-01 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2018-04-01 2018-06-30 0001125376 ensg:CareTrustREITMember srt:MaximumMember 2014-06-01 0001125376 ensg:CareTrustREITMember 2019-04-01 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2019-04-01 2019-06-30 0001125376 ensg:CareTrustREITMember 2018-04-01 2018-06-30 0001125376 ensg:CareTrustREITMember srt:MinimumMember 2014-06-01 0001125376 ensg:VariousLandlordsMemberMember 2019-06-30 0001125376 ensg:CareTrustREITMember 2018-01-01 2018-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2018-01-01 2018-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2019-04-01 2019-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2018-04-01 2018-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001125376 ensg:CalculatedunderNewLeaseGuidanceinEffectMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001125376 ensg:AdjustmentsDuetoASC842Member us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001125376 ensg:VariousLandlordsMemberMember srt:MinimumMember 2019-01-01 2019-06-30 0001125376 ensg:VariousLandlordsMemberMember srt:MinimumMember 2019-06-30 0001125376 2017-01-01 2017-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2018-12-31 0001125376 2013-01-01 2013-12-31 0001125376 us-gaap:SubsequentEventMember 2019-07-30 0001125376 us-gaap:CommonStockMember 2018-04-03 0001125376 2018-04-03 2018-04-03 ensg:Segments utreg:Rate xbrli:shares ensg:business iso4217:USD xbrli:shares ensg:Beds ensg:facilities xbrli:pure iso4217:USD ensg:Agreements ensg:Renewals ensg:Operations ensg:installment

 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended June 30, 2019.
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from                      to                     .
Commission file number: 001-33757
__________________________
THE ENSIGN GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)
Delaware
33-0861263
(State or Other Jurisdiction of
(I.R.S. Employer
Incorporation or Organization)
Identification No.)

29222 Rancho Viejo Road, Suite 127
San Juan Capistrano, CA 92675
(Address of Principal Executive Offices and Zip Code)
(949487-9500
(Registrant’s Telephone Number, Including Area Code)
_____________________________

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ENSG
Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
As of July 31, 2019, 53,386,352 shares of the registrant’s common stock were outstanding.



THE ENSIGN GROUP, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019
TABLE OF CONTENTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



PART I.

Item 1.        Financial Statements

THE ENSIGN GROUP, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par values)
(Unaudited)
 
June 30, 2019
 
December 31, 2018
Assets
 

 
Current assets:
 

 
Cash and cash equivalents
$
39,042


$
31,083

Accounts receivable—less allowance for doubtful accounts of $3,726 and $2,886 at June 30, 2019 and December 31, 2018, respectively
296,935


276,099

Investments—current
8,003


8,682

Prepaid income taxes
5,934


6,219

Prepaid expenses and other current assets
25,632


24,130

Assets held for sale - current

 
1,859

Total current assets
375,546


348,072

Property and equipment, net
674,892


618,874

Right-of-use assets (Note 17)
1,074,449

 

Insurance subsidiary deposits and investments
38,929


36,168

Escrow deposits


7,271

Deferred tax assets
8,603


11,650

Restricted and other assets (Note 17)
16,943


20,844

Intangible assets, net (Note 17)
3,829


31,000

Goodwill
97,408


80,477

Other indefinite-lived intangibles
30,922


27,602

Total assets
$
2,321,521


$
1,181,958

Liabilities and equity
 

 
Current liabilities:
 

 
Accounts payable
$
44,694


$
44,236

Accrued wages and related liabilities
116,018


119,656

Lease liabilities—current (Note 17)
59,686

 

Accrued self-insurance liabilities—current
26,981


25,446

Other accrued liabilities
69,816

 
69,784

Current maturities of long-term debt
10,153


10,105

Total current liabilities
327,348


269,227

Long-term debt—less current maturities
268,179


233,135

Long-term lease liabilities—less current portion (Note 17)
988,145

 

Accrued self-insurance liabilities—less current portion
57,565


54,605

Other long-term liabilities
2,977


11,234

Deferred gain related to sale-leaseback (Note 17)


11,417

Total liabilities
1,644,214

 
579,618

 
 
 
 
Commitments and contingencies (Notes 15, 17 and 18)

 

Equity:
 
 
 
Ensign Group, Inc. stockholders' equity:
 
 
 
Common stock; $0.001 par value; 100,000 shares authorized; 55,809 and 53,272 shares issued and outstanding at June 30, 2019, respectively, and 55,089 and 52,584 shares issued and outstanding at December 31, 2018, respectively
55

 
55

Additional paid-in capital
298,891

 
284,384

Retained earnings
401,996

 
344,901

Common stock in treasury, at cost, 1,941 and 1,932 shares at June 30, 2019 and December 31, 2018, respectively
(38,890
)
 
(38,405
)
Total Ensign Group, Inc. stockholders' equity
662,052

 
590,935

Non-controlling interest
15,255

 
11,405

Total equity
677,307


602,340

Total liabilities and equity
$
2,321,521

 
$
1,181,958

See accompanying notes to condensed consolidated financial statements.

1


THE ENSIGN GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
(Unaudited)

 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018

2019

2018
 
 
 
 
 
 
 
 
Revenue
$
575,651

 
$
496,386

 
$
1,124,865

 
$
988,520

Expense







Cost of services
457,000


396,132


887,002


786,375

Return of unclaimed class action settlement (Note 18)






(1,664
)
Rent—cost of services (Note 17)
37,060


34,472


72,846


68,322

General and administrative expense
30,561


22,386


63,585


47,490

Depreciation and amortization
13,184


11,621


25,782


23,243

Total expenses
537,805


464,611


1,049,215


923,766

Income from operations
37,846


31,775


75,650


64,754

Other income (expense):







Interest expense
(3,941
)

(3,869
)

(7,613
)

(7,482
)
Interest income
572


562


1,147


1,010

Other expense, net
(3,369
)

(3,307
)

(6,466
)

(6,472
)
Income before provision for income taxes
34,477


28,468


69,184


58,282

Provision for income taxes
5,552


6,142


12,652


12,663

Net income
28,925


22,326


56,532


45,619

Less: net income attributable to noncontrolling interests
316


315


551


476

Net income attributable to The Ensign Group, Inc.
$
28,609


$
22,011


$
55,981


$
45,143

Net income per share attributable to The Ensign Group, Inc.:
 
 

 
 
 
 
Basic
$
0.54


$
0.42


$
1.05


$
0.87

Diluted
$
0.51


$
0.41


$
1.00


$
0.84

Weighted average common shares outstanding:
 
 
 
 
 
 
 
Basic
53,408


51,880


53,246


51,733

Diluted
56,078


54,251


55,896


53,909

See accompanying notes to condensed consolidated financial statements.

2


THE ENSIGN GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(In thousands)
(Unaudited)
 
Common Stock
 
Additional Paid-In Capital
 
Retained Earnings
 
Treasury Stock
 
Non-Controlling Interest
 
 
 
Shares
 
Amount
 
 
 
Shares
 
Amount
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(In thousands)
Balance - January 1, 2019
52,584

 
$
55

 
$
284,384

 
$
344,901

 
1,932

 
$
(38,405
)
 
$
11,405

 
$
602,340

Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards
371

 

 
5,616

 

 

 

 

 
5,616

Dividends declared ($0.0475 per share)

 

 

 
(2,543
)
 

 

 

 
(2,543
)
Employee stock award compensation

 

 
2,612

 

 

 

 

 
2,612

Noncontrolling interest attributable to subsidiary equity plan (Note 16)

 

 

 
(317
)
 

 

 
658

 
341

Cumulative effect of accounting change, net of tax

 

 

 
9,030

 

 

 

 
9,030

Net income attributable to noncontrolling interest

 

 

 

 

 

 
235

 
235

Net income attributable to the Ensign Group, Inc.

 

 

 
27,372

 

 

 

 
27,372

Balance - March 31, 2019
52,955

 
$
55

 
$
292,612

 
$
378,443

 
1,932

 
$
(38,405
)
 
$
12,298

 
$
645,003

Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards
326

 

 
3,213

 

 

 

 

 
3,213

Shares of common stock used to satisfy tax withholding obligations
(9
)
 

 

 

 
9

 
(485
)
 

 
(485
)
Dividends declared ($0.0475 per share)

 

 

 
(2,559
)
 

 

 

 
(2,559
)
Employee stock award compensation

 

 
3,066

 

 

 

 

 
3,066

Noncontrolling interest attributable to subsidiary equity plan (Note 16)

 

 

 
(2,497
)
 

 

 
2,733

 
236

Distribution to noncontrolling interest holder

 

 

 

 

 

 
(92
)
 
(92
)
Net income attributable to noncontrolling interest

 

 

 

 

 

 
316

 
316

Net income attributable to the Ensign Group, Inc.

 

 

 
28,609

 

 

 

 
28,609

Balance - June 30, 2019
53,272

 
$
55

 
$
298,891

 
$
401,996

 
1,941

 
$
(38,890
)
 
$
15,255

 
$
677,307

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

3


 
Common Stock
 
Additional Paid-In Capital
 
Retained Earnings
 
Treasury Stock
 
Non-Controlling Interest
 
 
 
Shares
 
Amount
 
 
 
Shares
 
Amount
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(In thousands)
Balance - January 1, 2018
51,360

 
$
53

 
$
266,058

 
$
264,691

 
1,932

 
$
(38,405
)
 
$
7,662

 
$
500,059

Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards
404

 
1

 
2,919

 

 

 

 

 
2,920

Dividends declared ($0.0450 per share)

 

 

 
(2,346
)
 

 

 

 
(2,346
)
Employee stock award compensation

 

 
1,971

 

 

 

 

 
1,971

Noncontrolling interest attributable to subsidiary equity plan (Note 16)

 

 

 
(79
)
 

 

 
417

 
338

Distribution to noncontrolling interest holder

 

 

 

 

 

 
(292
)
 
(292
)
Net income attributable to noncontrolling interest

 

 

 

 

 

 
161

 
161

Net income attributable to the Ensign Group, Inc.

 

 

 
23,132

 

 

 

 
23,132

Balance - March 31, 2018
51,764

 
$
54

 
$
270,948

 
$
285,398

 
1,932

 
$
(38,405
)
 
$
7,948

 
$
525,943

Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards
269

 

 
1,857

 

 

 

 

 
1,857

Dividends declared ($0.0450 per share)

 

 

 
(2,367
)
 

 

 

 
(2,367
)
Employee stock award compensation

 

 
2,177

 

 

 

 

 
2,177

Noncontrolling interest attributable to subsidiary equity plan (Note 16)

 

 

 
(1,885
)
 

 

 
2,228

 
343

Net income attributable to noncontrolling interest

 

 

 

 

 

 
315

 
315

Net income attributable to the Ensign Group, Inc.

 

 

 
22,011

 

 

 

 
22,011

Balance - June 30, 2018
52,033

 
$
54

 
$
274,982

 
$
303,157

 
1,932

 
$
(38,405
)
 
$
10,491

 
$
550,279

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See accompanying notes to condensed consolidated financial statements.


4


THE ENSIGN GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
 
Six Months Ended June 30,
 
2019

2018
Cash flows from operating activities:
 
 
 
Net income
$
56,532

 
$
45,619

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
25,782

 
23,243

Impairment of long-lived assets

 
860

Amortization of deferred financing fees
583

 
588

Amortization of deferred gain on sale-leaseback (Note 17)

 
(329
)
Non-cash leasing arrangement (Note 17)
(688
)
 

Provision for doubtful accounts
1,155

 
972

Share-based compensation
6,255

 
4,829

Cash received from insurance proceeds related to replacement properties and business interruptions
638

 

Income tax refund

 
11,000

Change in operating assets and liabilities
 
 
 
Accounts receivable
(22,716
)
 
13,476

Prepaid income taxes
229

 
(129
)
Prepaid expenses and other assets
3,332

 
(3,454
)
Insurance subsidiary deposits

 
(2,571
)
Operating lease obligations
(2,248
)
 

Accounts payable
356

 
(74
)
Accrued wages and related liabilities
(355
)
 
(1,046
)
Other accrued liabilities
(1,566
)
 
2,531

Accrued self-insurance liabilities
3,717

 
5,349

Other long-term liability
1,272

 
376

Net cash provided by operating activities
72,278


101,240

Cash flows from investing activities:
 
 
 
Purchase of property and equipment
(35,762
)
 
(24,295
)
Cash payments for business acquisitions (Note 8)
(21,262
)
 

Cash payments for asset acquisitions (Note 8)
(43,176
)
 
(55,546
)
Escrow deposits

 
(2,652
)
Escrow deposits used to fund acquisitions
7,271

 
228

Cash proceeds from the sale of assets and insurance proceeds
2,575

 
1,610

Investments and change in other assets
(7,902
)
 
(589
)
Net cash used in investing activities
(98,256
)

(81,244
)
Cash flows from financing activities:
 
 
 
Proceeds from revolving credit facility and other debt (Note 15)
535,000

 
405,000

Payments on revolving credit facility and other debt (Note 15)
(500,965
)
 
(439,922
)
Issuance of common stock upon exercise of options
5,547

 
4,778

Repurchase of shares of common stock to satisfy tax withholding obligations
(485
)
 

Proceeds from sale of subsidiary shares (Note 16)
2,293

 

Repurchase of shares of common stock and subsidiary shares (Note 16)
(2,293
)
 

Dividends paid
(5,068
)
 
(4,695
)
Non-controlling interest distribution
(92
)
 
(292
)
Payments of deferred financing costs

 
(18
)
Net cash provided by/(used in) financing activities
33,937


(35,149
)
Net increase/(decrease) in cash and cash equivalents
7,959

 
(15,153
)
Cash and cash equivalents beginning of period
31,083


42,337

Cash and cash equivalents end of period
$
39,042

 
$
27,184

See accompanying notes to condensed consolidated financial statements.

5


THE ENSIGN GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - (Continued)
(In thousands)
(Unaudited)
 
Six Months Ended June 30,
 
2019
 
2018
Supplemental disclosures of cash flow information:
 
 
 
Cash paid during the period for:
 
 
 
Interest
$
7,500

 
$
7,321

Income taxes
$
12,375

 
$
12,925

Lease liabilities
$
73,748

 
$

Non-cash financing and investing activity:
 
 
 

Accrued capital expenditures
$
3,600

 
$
3,600

Accrued dividends declared
$
2,559

 
$
2,367

Note receivable from sale of ancillary business
$

 
$
282

Right-of-use assets obtained in exchange for new operating lease obligation
$
47,748

 
$

See accompanying notes to condensed consolidated financial statements.


6


THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars, shares and options in thousands, except per share data)
(Unaudited)

1. DESCRIPTION OF BUSINESS

The Company - The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum. As of June 30, 2019, the Company operated 254 facilities, 62 home health, hospice and home care agencies and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington, Wisconsin and Wyoming. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living, home health, hospice, home care and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately 20,700 operational skilled nursing beds and 5,900 senior living units. As of June 30, 2019, the Company owned 77 of its 254 affiliated facilities and leased an additional 177 facilities through long-term lease arrangements and had options to purchase 12 of those 177 facilities. As of December 31, 2018, the Company owned 72 of its 244 affiliated facilities and leased an additional 172 facilities through long-term lease arrangements and had options to purchase 12 of those 172 facilities.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide certain accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities.
Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Report is not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.

Proposed Spin-Off Transaction — On May 6, 2019, the Company announced a proposed plan to separate its transitional and skilled nursing services, its home health and hospice operations and substantially all of its senior living operations into two separate, publicly traded companies. See Note 2, Proposed Spin-Off of Subsidiaries.

Other Information — The accompanying condensed consolidated financial statements as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2018 which are included in the Company’s annual report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.

2. PROPOSED SPIN-OFF OF SUBSIDIARIES

On May 6, 2019, the Company announced a proposed plan to separate its transitional and skilled nursing services, its home health and hospice operations and substantially all of its senior living operations into two separate, publicly traded companies:

Ensign, which will include transitional and skilled services, rehabilitative care services, healthcare campuses, post-acute-related new business ventures and real estate investments; and
The Pennant Group, Inc. ("Pennant"), which will be a holding company of operating subsidiaries that provide home health, hospice and senior living.


7

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


The Company intends to accomplish the proposed separation through a spin-off (the Spin-Off), in which it expects to distribute shares of Pennant common stock to the Company’s stockholders, on a pro rata basis. The Company anticipates that at the time of the Spin-Off, Pennant, which is currently a wholly-owned subsidiary of the Company, will consists of 62 home health, hospice and home care agencies and 51 senior living communities as of June 30, 2019. Ensign affiliates will retain ownership of the real estate at 28 of the 51 senior living operations that are being contributed to Pennant. The Company anticipates that after the Spin-Off, all of these properties will be leased to Pennant on a triple-net basis, under which Pennant affiliates will be responsible for all costs at the properties, including property taxes, insurance and maintenance and repair costs.

In accordance with Accounting Standards Codification (ASC) 505-60, Equity-Spinoffs and Reverse Spinoffs, the accounting for the separation of the Company follows its legal form, with Ensign as the legal and accounting spinnor and Pennant as the legal and accounting spinnee, due to the relative significance of Ensign’s healthcare business, the relative fair values of the respective companies, the retention of all senior management, and other relevant indicators.

In connection with the adoption of the stockholder rights plan, the Company anticipates that the board of directors will declare a dividend of one share of Pennant common stock for every two shares of the Company's common stock held by stockholders as of the record date. Pennant is also anticipating that awards of equity of Pennant subsidiaries granted to certain individuals will be exchanged for Pennant common stock immediately prior to the distribution. The number of shares of Ensign common stock each stockholder owns and the related proportionate interest in Ensign will not change as a result of the proposed Spin-Off. Each Ensign stockholder will receive only whole shares of Pennant common stock in the distribution, as well as cash in lieu of any fractional shares. The proposed Spin-Off is subject to customary conditions, including receipt of a tax opinion from counsel, effectiveness of the registration statement filed with the Securities and Exchange Commission, execution of third-party agreements and final approval by Ensign’s board of directors.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and senior living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.
The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three and six months ended June 30, 2019 and 2018.
The Company completed the sale of one of its senior living operations for a sale price of $1,838 during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results. The Company presented property and equipment assets of the senior living operation sold as held for sale in the consolidated balance sheet as of December 31, 2018.
Estimates and Assumptions — The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, intangible assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.

Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.

8

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



Revenue Recognition — On January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) applying the modified retrospective method. The adoption of ASC 606 did not have a material impact on the measurement nor on the recognition of revenue of contracts, for which all revenue had not been recognized, as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of retained earnings at the beginning of 2018. See Note 4, Revenue and Accounts Receivable.
Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence. See Note 4, Revenue and Accounts Receivable.
Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of $705 and $860 during the three and six months ended June 30, 2018. The Company did not record an impairment charge during the three and six months ended June 30, 2019.

Leases and Leasehold Improvements - The Company leases skilled nursing facilities, senior living facilities and commercial office space. On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company estimates this rate based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term excludes lease renewals as the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably assured that the Company will exercise the extension options. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.

The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. See further discussion at Note 17, Leases.
Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.

9

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible assets impairment during the three and six months ended June 30, 2019 and 2018. See further discussion at Note 11, Goodwill and Other Indefinite-Lived Intangible Assets.
Self-Insurance — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas, Washington and Wyoming for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $45,106 and $42,635 as of June 30, 2019 and December 31, 2018, respectively.
 The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington and Wyoming, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington and Wyoming, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas, Washington and Wyoming, the Company has purchased insurance coverage that insures individual claims that exceed $350 per accident. In all states except Washington and Wyoming, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,317 and $24,624 as of June 30, 2019 and December 31, 2018, respectively.
In addition, the Company has recorded an asset and equal liability of $7,747 and $6,969 at June 30, 2019 and December 31, 2018, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $300 for each covered person with an additional one-time aggregate individual stop loss deductible of $75. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of $75. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $6,376 and $5,823 as of June 30, 2019 and December 31, 2018, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific

10

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.

Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Share-Based Compensation — The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

Recent Accounting Pronouncements — Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In February 2016, the FASB established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines.

The Company adopted the standard as of January 1, 2019, electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings, if applicable. The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows the Company to carry forward the historical lease classification. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has made an accounting policy to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. The Company has also elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.

11

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



The adoption of this standard resulted in recognition of right-of-use assets and lease liabilities of $1,051,148 and $1,029,240, respectively, on its condensed consolidated balance sheets as of January 1, 2019. The Company recorded an adjustment, net of tax, of $9,030 to retained earnings, on the adoption date, related to a deferred gain on a previous sale-leaseback transaction, which resulted in an increase in rent expense of $658 annually, as we are no longer able to recognize the gain in our consolidated statement of income as a result of the new lease standard. In addition, initial direct costs associated with its lease agreements and favorable lease assets of $26,939 were classified into right-of-use assets on the adoption date. The standard does not materially affect the Company's consolidated net earnings or have a notable impact on liquidity or debt-covenant compliance under the current agreements. See further discussion at Note 17, Leases.

Prior to the adoption of ASC 842, the Company recognized revenue related to its senior living residency agreements in accordance with the provisions of ASC 840, Leases ("ASC 840").  Subsequent to the adoption of ASU 2016-02, Leases, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of ASC 842 and the non-lease components utilizing the provisions of ASC 606, Revenue from Contracts with Customers. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with ASC 840 prior to the adoption of ASU 2016-02 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of ASC 606 subsequent to the adoption of ASU 2016-02. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of ASU 2016-02 for changes to amounts recognized for these certain components for the transition from ASC 840 to ASC 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, Leases, allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of ASC 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions.

Upon adoption of ASU 2016-02 and ASU 2018-11, the Company elected the lessor practical expedient within ASU 2018-11.  The Company recognizes revenue under these resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under ASC Topic 842 and ASC Topic 606. The Company has concluded that the non-lease components of the agreements with respect to its senior living communities are the predominant component of the contract, therefore, the Company recognizes revenue for these residents agreements under ASC Topic 606. The timing and pattern of revenue recognition is substantially the same as that prior to the adoption of these standards.

In June 2018, the FASB issued ASU 2018-07, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The Company adopted this guidance effective January 1, 2019. The adoption of this guidance did not have a material impact on its consolidated financial statements and related disclosures.

Accounting Standards Recently Issued But Not Yet Adopted by the Company

In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.


12

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of credit Losses on Financial Instruments”, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for fiscal year beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption is permitted. The Company has not yet determined the effect of the ASU on its results of operations, financial condition or cash flows.


4. REVENUE AND ACCOUNTS RECEIVABLE

The Company's revenue is derived primarily from providing healthcare services to its patients. Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in transitional and skilled, home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.
Revenue from the Medicare and Medicaid programs accounted for 68.0% the Company's revenue for both the three and six months ended June 30, 2019, respectively and 68.2% and 68.0% for the three and six months ended June 30, 2018, respectively. Settlement with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue or Interim Financial Statements for the three and six months ended June 30, 2019 and 2018.
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in Note 7, Business Segments.
The Company’s service specific revenue recognition policies are as follows:



13

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


Transitional and Skilled Nursing Revenue
The Company’s revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.
Senior Living Revenue
The Company's senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.

The Company has elected the lessor practical expedient within ASC 842, Leases ("ASC 842") and recognizes, measures, presents, and discloses the revenue for services under the Company's senior living residency agreements based upon the predominant component, either the lease or nonlease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements have the same timing and pattern of transfer. The Company recognizes revenue under ASC 606, Revenue Recognition from Contracts with Customers ("ASC 606") for its senior residency agreements for which it has estimated that the nonlease components of such residency agreements are the predominant component of the contract.
Home Health Revenue
Medicare Revenue
Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.
The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.
In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and the Company’s estimate of the average percentage complete based on visits performed.
Non-Medicare Revenue
Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.
Non-episodic Based Revenue - Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.



14

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


Hospice Revenue
Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care the Company delivers. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and increases to other accrued liabilities.
Revenue for the three and six months ended June 30, 2019 and 2018 is summarized in the following tables:
 
Three Months Ended June 30,
 
2019
 
2018
 
Revenue
 
% of
Revenue
 
Revenue
 
% of
Revenue
Medicaid
$
206,811

 
35.9
%
 
$
173,169

 
34.9
%
Medicare
153,187

 
26.6

 
136,813

 
27.6

Medicaid — skilled
31,792

 
5.5

 
28,298

 
5.7

Total Medicaid and Medicare
391,790

 
68.0

 
338,280

 
68.2

Managed care
93,690

 
16.3

 
80,150

 
16.1

Private and other payors(1)
90,171

 
15.7

 
77,956

 
15.7

Revenue
$
575,651

 
100.0
%
 
$
496,386

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019 and 2018.
 
Six Months Ended June 30,
 
2019
 
2018
 
Revenue
 
% of
Revenue
 
Revenue
 
% of
Revenue
Medicaid
$
401,814

 
35.7
%
 
$
340,794

 
34.5
%
Medicare
300,907

 
26.8

 
276,127

 
27.9

Medicaid — skilled
62,243

 
5.5

 
55,340

 
5.6

Total Medicaid and Medicare
764,964

 
68.0

 
672,261

 
68.0

Managed care
183,538

 
16.3

 
163,866

 
16.6

Private and other payors(1)
176,363

 
15.7

 
152,393

 
15.4

Revenue
$
1,124,865

 
100.0
%
 
$
988,520

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019 and 2018.
Balance Sheet Impact
Included in the Company’s condensed consolidated balance sheet are contract assets, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities as of June 30, 2019 and December 31, 2018, or activity during the three and six months ended June 30, 2019 and 2018.

Accounts receivable as of June 30, 2019 and December 31, 2018 is summarized in the following table:

15

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
June 30, 2019
 
December 31, 2018
Medicaid
$
128,069

 
$
117,984

Managed care
62,605

 
54,682

Medicare
53,232

 
50,994

Private and other payors
56,755

 
55,325

 
300,661

 
278,985

Less: allowance for doubtful accounts
(3,726
)
 
(2,886
)
Accounts receivable, net
$
296,935

 
$
276,099


Practical Expedients and Exemptions
As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.

5. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from continuing operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net income
$
28,925

 
$
22,326

 
$
56,532

 
$
45,619

Less: net income attributable to noncontrolling interests
316

 
315

 
551

 
476

Net income attributable to The Ensign Group, Inc.
$
28,609

 
$
22,011

 
$
55,981

 
$
45,143

 
 
 
 
 
 
 
 
Denominator:

 
 
 
 
 
 
Weighted average shares outstanding for basic net income per share
53,408

 
51,880

 
53,246

 
51,733

Basic net income per common share attributable to The Ensign Group, Inc.
$
0.54

 
$
0.42

 
$
1.05

 
$
0.87



A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

16

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net income
$
28,925

 
$
22,326

 
$
56,532

 
$
45,619

Less: net income attributable to noncontrolling interests
316

 
315

 
551

 
476

Net income attributable to The Ensign Group, Inc.
$
28,609

 
$
22,011

 
$
55,981

 
$
45,143

 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average common shares outstanding
53,408

 
51,880

 
53,246

 
51,733

Plus: incremental shares from assumed conversion (1)
2,670

 
2,371

 
2,650

 
2,176

Adjusted weighted average common shares outstanding
56,078


54,251

 
55,896

 
53,909

Diluted net income per common share attributable to The Ensign Group, Inc.
$
0.51

 
$
0.41

 
$
1.00

 
$
0.84


(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 173 and 322 for the three and six months ended June 30, 2019, respectively, and 196 and 398 for the three and six months ended June 30, 2018, respectively.

6. FAIR VALUE MEASUREMENTS
Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018:
 
 
June 30, 2019
 
December 31, 2018
 
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
Cash and cash equivalents
 
$
39,042

 
$

 
$

 
$
31,083

 
$

 
$



The Company's non-financial assets, which includes goodwill, intangible assets and property and equipment, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. See Note 3, Summary of Significant Accounting Policies for further discussion of the Company's significant accounting policies.

Debt Security Investments - Held to Maturity

At June 30, 2019 and December 31, 2018, the Company had approximately $46,932 and $44,850, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of June 30, 2019, the debt security investments were held in AA, A and BBB rated debt securities.

7. BUSINESS SEGMENTS

The Company has three reportable operating segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities; (2) senior living services, which includes the operation of assisted and independent living facilities; and (3) home health and hospice services, which includes the Company's home health, hospice and home care businesses. The Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, reviews financial information at the operating segment level.


17

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


The Company also reports an “all other” category that includes results from its mobile diagnostics and other ancillary operations. These operations are neither significant individually nor in aggregate, and therefore do not constitute a reportable segment. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations.

As of June 30, 2019, transitional and skilled services included 171 wholly-owned affiliated skilled nursing operations and 27 campuses that provide skilled nursing and rehabilitative care services and senior living services. The Company provided room and board and social services through 56 wholly-owned affiliated senior living operations and 27 campuses as mentioned above. Home health, hospice and home care services were provided to patients through 62 affiliated agencies. As of June 30, 2019, the Company held majority membership interests in other ancillary operations, which operating results are included in the "all other" category.

The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. General and administrative expenses are not allocated to any segment for purposes of determining segment profit or loss, and are included in the "all other" category in the selected segment financial data that follows. The accounting policies of the reporting segments are the same as those described in Note 3, Summary of Significant Accounting Policies. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

Segment revenues by major payor source were as follows:
 
 
Three Months Ended June 30, 2019
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
192,545

 
$
10,333

 
$
3,933

 
$

 
$
206,811

 
35.9
%
Medicare
 
118,807

 

 
34,380

 

 
153,187

 
26.6

Medicaid-skilled
 
31,792

 

 

 

 
31,792

 
5.5

Subtotal
 
343,144

 
10,333

 
38,313

 

 
391,790

 
68.0

Managed care
 
86,491

 

 
7,199

 

 
93,690

 
16.3

Private and other
 
39,603

 
31,713

 
4,696

 
14,159

(1)
90,171

 
15.7

Total revenue
 
$
469,238

 
$
42,046

 
$
50,208

 
$
14,159

 
$
575,651

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019.
 
 
Three Months Ended June 30, 2018
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
161,584

 
$
8,677

 
$
2,908

 
$

 
$
173,169

 
34.9
%
Medicare
 
108,237

 

 
28,576

 

 
136,813

 
27.6

Medicaid-skilled
 
28,298

 

 

 

 
28,298

 
5.7

Subtotal
 
298,119

 
8,677

 
31,484

 

 
338,280

 
68.2

Managed care
 
74,168

 

 
5,982

 

 
80,150

 
16.1

Private and other
 
36,231

 
28,487

 
3,783

 
9,455

(1)
77,956

 
15.7

Total revenue
 
$
408,518

 
$
37,164

 
$
41,249

 
$
9,455

 
$
496,386

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2018.

18

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
 
Six Months Ended June 30, 2019
 
 
Transitional and Skilled Services
 
Assisted and Independent Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
373,839

 
$
20,135

 
$
7,840

 
$

 
$
401,814

 
35.7
%
Medicare
 
235,508

 

 
65,399

 

 
300,907

 
26.8

Medicaid-skilled
 
62,243

 

 

 

 
62,243

 
5.5

Subtotal
 
671,590

 
20,135

 
73,239

 

 
764,964

 
68.0

Managed care
 
169,663

 

 
13,875

 

 
183,538

 
16.3

Private and other
 
77,243

 
62,605

 
9,211

 
27,304

(1)
176,363

 
15.7

Total revenue
 
$
918,496

 
$
82,740

 
$
96,325

 
$
27,304

 
$
1,124,865

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019.

 
 
Six Months Ended June 30, 2018
 
 
Transitional and Skilled Services
 
Assisted and Independent Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
318,095

 
$
16,941

 
$
5,758

 
$

 
$
340,794

 
34.5
%
Medicare
 
220,190

 

 
55,937

 

 
276,127

 
27.9

Medicaid-skilled
 
55,340

 

 

 

 
55,340

 
5.6

Subtotal
 
593,625

 
16,941

 
61,695

 

 
672,261

 
68.0

Managed care
 
151,968

 

 
11,898

 

 
163,866

 
16.6

Private and other
 
69,941

 
56,336

 
7,414

 
18,702

(1)
152,393

 
15.4

Total revenue
 
$
815,534

 
$
73,277

 
$
81,007

 
$
18,702

 
$
988,520

 
100.0
%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2018.

The following table sets forth selected financial data consolidated by business segment:
 
 
Three Months Ended June 30, 2019
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
469,238

 
$
42,046

 
$
50,208

 
$
14,159

 
$

 
$
575,651

Intersegment revenue(1)
 
780

 

 

 
2,149

 
(2,929
)
 

Total revenue
 
$
470,018

 
$
42,046

 
$
50,208

 
$
16,308

 
$
(2,929
)
 
$
575,651

Segment income (loss)(2)
 
$
56,652

 
$
4,821

 
$
7,306

 
$
(30,933
)
 
$

 
$
37,846

Interest expense, net of interest income
 

 

 

 

 
 
 
$
(3,369
)
Income before provision for income taxes
 

 

 

 

 
 
 
$
34,477

Depreciation and amortization
 
$
8,938

 
$
2,019

 
$
320

 
$
1,907

 
$

 
$
13,184

 
 
 
 
 
 
 
 
 
 
 
 
 

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $780. Including these expenses, home health and hospice services segment income would be $6,526. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $2,149.
(3) General and administrative expense are included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.


19

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
 
Three Months Ended June 30, 2018
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
408,518

 
$
37,164

 
$
41,249

 
$
9,455

 
$

 
$
496,386

Intersegment revenue(1)
 
645

 

 

 
1,112

 
(1,757
)
 

Total revenue
 
$
409,163

 
$
37,164

 
$
41,249

 
$
10,567

 
$
(1,757
)
 
$
496,386

Segment income (loss)(2)
 
$
43,210

 
$
4,966

 
$
6,268

 
$
(22,669
)
 
$

 
$
31,775

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(3,307
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
28,468

Depreciation and amortization
 
$
7,708

 
$
1,863

 
$
281

 
$
1,769

 
$

 
$
11,621

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $645.  Including these expenses, home health and hospice services segment income would be $5,623. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $1,112.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
 
 
Six Months Ended June 30, 2019
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
918,496

 
$
82,740

 
$
96,325

 
$
27,304

 
$

 
$
1,124,865

Intersegment revenue(1)
 
1,495

 

 

 
3,861

 
(5,356
)
 

Total revenue
 
$
919,991

 
$
82,740

 
$
96,325

 
$
31,165

 
$
(5,356
)
 
$
1,124,865

Segment income (loss)(2)
 
$
115,416

 
$
9,859

 
$
14,174

 
$
(63,799
)
 
$

 
$
75,650

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(6,466
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
69,184

Depreciation and amortization
 
$
17,552

 
$
3,919

 
$
580

 
$
3,731

 
$

 
$
25,782

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $1,495. Including these expenses, home health and hospice services segment income would be $12,679. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines which are included in the "All Other" category of $3,861.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.



20

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
 
Six Months Ended June 30, 2018
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
815,534

 
$
73,277

 
$
81,007

 
$
18,702

 
$

 
$
988,520

Intersegment revenue(1)
 
1,334

 

 

 
2,194

 
(3,528
)
 

Total revenue
 
$
816,868

 
$
73,277

 
$
81,007

 
$
20,896

 
$
(3,528
)
 
$
988,520

Segment income (loss)(2)
 
$
89,405

 
$
9,629

 
$
12,326

 
$
(46,606
)
 
$

 
$
64,754

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(6,472
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
58,282

Depreciation and amortization
 
$
15,510

 
$
3,460

 
$
526

 
$
3,747

 
$

 
$
23,243

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $1,334.  Including these expenses, home health and hospice services segment income would be $10,992. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $2,194.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
The Company completed the sale of one of its senior living operations for an aggregate sale price of $1,838 during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results.

8. ACQUISITIONS
The acquisition focus of the subsidiaries is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the accompanying Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, the affiliated operations will acquire facilities that have been operating under third-party leases.
During the six months ended June 30, 2019, the Company expanded its operations through a combination of a long-term lease and real estate purchases, with the addition of seven stand-alone skilled nursing operations, one stand-alone senior living operation, three campus operations, two home health agencies, four hospice agencies and two home care agencies. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of 1,088 operational skilled nursing beds and 364 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. The aggregate purchase price for these acquisitions during the six months ended June 30, 2019 was $65,362.
The fair value of assets for eleven of the acquisitions was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions in accordance with Accounting Standards Codification Topic 805, Clarifying the Definition of a Business (ASC 805). The purchase price for the eleven asset acquisitions was $43,176, which mainly consisted of building and improvements of $33,900 and land of $7,660. The fair value of assets for the remaining nine acquisitions was concentrated in goodwill and as such, these transactions were classified as business acquisitions in accordance with ASC 805. The purchase price for the nine business combinations was $22,186, which mainly consisted of goodwill and indefinite-lived intangible assets of $20,251. The Company also entered into a note payable with the seller of $924, which was subsequently paid off in the second quarter of 2019 and included in the payments on revolving credit facility and other debt line item in the consolidated statement of cash flow. As of the date of this filing, the preliminary allocation of the purchase price for the acquisitions in the second quarter was not finalized as necessary valuation information was not yet available.

21

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


During the second quarter of 2018, all of the fair value of the assets acquired were concentrated in property and equipment and as such, the transactions were classified as asset acquisitions in accordance with ASC 805. During the six months ended June 30, 2018, the aggregate purchase price for those acquisitions was $55,546, of which $31,500 was related to an office building acquisition to accommodate its growing Service Center team.

The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The businesses acquired during the six months ended June 30, 2019 were not material acquisitions to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These acquisitions have been included in the June 30, 2019 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the dates the Company gained effective control.

Subsequent to June 30, 2019, the Company expanded its operations through long-term leases, with the addition of one stand-alone skilled nursing operation and one stand-alone senior living operation. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of 27 operational skilled nursing beds and 91 operational senior living units to be operated by the Company's operating subsidiaries. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.

9. PROPERTY AND EQUIPMENT— Net
Property and equipment, net consist of the following:
 
June 30, 2019
 
December 31, 2018
Land
$
68,081

 
$
60,420

Buildings and improvements
449,763

 
411,096

Equipment
220,402

 
202,346

Furniture and fixtures
5,465

 
5,079

Leasehold improvements
127,345

 
112,935

Construction in progress
10,195

 
9,729

 
881,251

 
801,605

Less: accumulated depreciation
(206,359
)
 
(182,731
)
Property and equipment, net
$
674,892

 
$
618,874



See also Note 8, Acquisitions for information on acquisitions during the six months ended June 30, 2019 and 2018.


22

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


10. INTANGIBLE ASSETS — Net
 
 
Weighted Average Life (Years)
 
June 30, 2019
 
December 31, 2018
 
 
 
Gross Carrying Amount
 
Accumulated Amortization
 
 
 
Gross Carrying Amount
 
Accumulated Amortization
 
 
Intangible Assets
 
 
 
 
Net
 
 
 
Net
Lease acquisition costs
 
1.7
 
$
360

 
$
(240
)
 
120

 
$
843

 
$
(251
)
 
$
592

Favorable leases
 
2.1
 
534

 
(316
)
 
218

 
35,650

 
(8,724
)
 
26,926

Assembled occupancy
 
0.4
 
3,180

 
(3,056
)
 
124

 
2,936

 
(2,870
)
 
66

Facility trade name
 
30.0
 
733

 
(330
)
 
403

 
733

 
(317
)
 
416

Customer relationships
 
16.7
 
5,110

 
(2,146
)
 
2,964

 
4,670

 
(1,670
)
 
3,000

Total
 
 
 
$
9,917

 
$
(6,088
)
 
$
3,829

 
$
44,832

 
$
(13,832
)
 
$
31,000



Amortization expense was $1,012 and $1,905 for the three and six months ended June 30, 2019, respectively, and $691 and $1,306 for the three and six months ended June 30, 2018, respectively. Favorable leases and lease acquisition costs of $26,939 were reclassed to right-of-use assets as of January 1, 2019, as a part of the adoption of ASC 842. See Note 17, Leases.
Estimated amortization expense for each of the years ending December 31 is as follows:
Year
Amount
2019 (remainder)
$
567

2020
345

2021
249

2022
249

2023
237

2024
234

Thereafter
1,948

 
$
3,829



11. GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS

The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of Accounting Standards Codification topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a "Step 0" analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs "Step 1" of the traditional two-step goodwill impairment test by comparing the net assets of each reporting unit to their respective fair values. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. In the event a unit's net assets exceed its fair value, an implied fair value of goodwill must be determined by assigning the unit's fair value to each asset and liability of the unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. An impairment loss is measured by the difference between the goodwill carrying value and the implied fair value.

The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of June 30, 2019. See further discussion of goodwill acquired at Note 8, Acquisitions.

The following table represents activity in goodwill by segment as of and for the six months ended June 30, 2019:

23

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
Goodwill
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total
January 1, 2019
$
45,486

 
$
3,958


$
27,250

 
$
3,783

 
$
80,477

Additions

 

 
11,500

 
5,431

 
16,931

June 30, 2019
$
45,486

 
$
3,958

 
$
38,750

 
$
9,214

 
$
97,408



Other indefinite-lived intangible assets consists of the following:
 
June 30, 2019

December 31, 2018
Trade name
$
1,373

 
$
1,217

Medicare and Medicaid licenses
29,549

 
26,385

 
$
30,922

 
$
27,602

As of the date of this filing, the preliminary allocation of the purchase price for the acquisitions in the second quarter, mentioned in Note 8, Acquisitions, was not finalized as necessary valuation information was not yet available. The final allocation could have an impact on the allocation of goodwill and indefinite-lived intangible assets related to these acquisitions.
12. RESTRICTED AND OTHER ASSETS
Restricted and other assets consist of the following:
 
June 30, 2019
 
December 31, 2018
Debt issuance costs, net
$
1,442

 
$
1,892

Long-term insurance losses recoverable asset
7,747

 
6,969

Deposits with landlords
4,148

 
8,694

Capital improvement reserves with landlords and lenders
3,535

 
3,196

Note receivable from sale of ancillary business
71

 
93

Restricted and other assets
$
16,943

 
$
20,844



Included in restricted and other assets as of June 30, 2019 and December 31, 2018 are anticipated insurance recoveries related to the Company's workers' compensation, general and professional liability claims that are recorded on a gross rather than net basis in accordance with an Accounting Standards Update issued by the FASB. Prepaid rent of $5,220, previously included in deposits with landlords above, were reclassed to right-of-use assets as of January 1, 2019, as part of the adoption of ASC 842. See Note 17, Leases.


24

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


13. OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:
 
June 30, 2019
 
December 31, 2018
Quality assurance fee
$
5,639

 
$
5,375

Refunds payable
27,477

 
25,118

Resident advances
4,607

 
8,495

Cash held in trust for patients
2,842

 
2,824

Resident deposits
7,753

 
6,665

Dividends payable
2,559

 
2,525

Property taxes
7,669

 
9,426

Other
11,270

 
9,356

Other accrued liabilities
$
69,816

 
$
69,784



Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying condensed consolidated balance sheets.

14. INCOME TAXES

The Company recorded income tax expense of $12,652 and $12,663 during the six months ended June 30, 2019 and 2018, respectively, or 18.3% of earnings before income taxes for the six months ended June 30, 2019, compared to 21.7% for the six months ended June 30, 2018. The effective tax rate for both six month periods include excess tax benefits from stock-based compensation which were offset by non-deductible expenses including non-deductible compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2019, the statutes of limitations will lapse on the Company's 2015 Federal tax year and certain 2014 and 2015 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the six months ended June 30, 2019 and 2018.

The Company implemented ASC 842 as described in the Summary of Significant Accounting Policies. The new lease standard reduced net deferred assets by $3,044, which is reflected in retained earnings as day one accounting change adjustment.

15. DEBT
Long-term debt consists of the following:
 
June 30, 2019
 
December 31, 2018
Term loan with SunTrust
$
109,375

 
$
113,125

Revolving credit facility with SunTrust
50,000

 
10,000

Mortgage loans and promissory note
121,664

 
122,955

 
281,039

 
246,080

Less: current maturities
(10,153
)
 
(10,105
)
Less: debt issuance costs
(2,707
)
 
(2,840
)
 
$
268,179

 
$
233,135



25

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



Credit Facility with a Lending Consortium Arranged by SunTrust
The Company maintains a credit facility with a lending consortium arranged by SunTrust (as amended to date, the Credit Facility). The Company originally entered into the Credit Facility in an aggregate principal amount of $150,000 in May 2014. Under the Credit Facility, the Company could seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $75,000.

On February 5, 2016, the Company amended its existing revolving credit facility to increase its aggregate principal amount available to $250,000 (the Amended Credit Facility). Under the credit facility, the Company may seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $150,000. The interest rates applicable to loans under the credit facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.75% to 1.75% per annum or LIBOR plus a margin ranging from 1.75% to 2.75% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company pays a commitment fee on the unused portion of the commitments under the credit facility that will range from 0.30% to 0.50% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is permitted to prepay all or any portion of the loans under the credit facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders.

On July 19, 2016, the Company entered into the second amendment to the credit facility (Second Amended Credit Facility), which amended the existing credit agreement to increase the aggregate principal amount up to $450,000. The Second Amended Credit Facility is comprised of a $300,000 revolving credit facility and a $150,000 term loan. Borrowings under the term loan portion of the Second Amended Credit Facility mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to 5.00% per annum of the original principal amount. The interest rates and commitment fee applicable to the Second Amended Credit Facility are similar to the Amended Credit Facility discussed below. Except as set forth in the Second Amended Credit Facility, all other terms and conditions of the Amended Credit Facility remained in full force and effect as described below.

The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The credit facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to consolidated EBITDA ratio (which shall be increased to 3.50:1.00 for the first fiscal quarter and the immediate following three fiscal quarters), and a minimum interest/rent coverage ratio (which cannot be below 1.50:1.00). The majority of lenders can require that the Company and its operating subsidiaries mortgage certain of its real property assets to secure the Amended Credit Facility if an event of default occurs, the Consolidated Total Net Debt to consolidated EBITDA ratio is above 2.75:1.00 for two consecutive fiscal quarters, or its liquidity is equal or less than 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) for ten consecutive business days, provided that such mortgages will no longer be required if the event of default is cured, the Consolidated Total Net Debt to consolidated EBITDA ratio is below 2.75:1.00 for two consecutive fiscal quarters, or its liquidity is above 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) or ninety consecutive days, as applicable. As of June 30, 2019, the Company's operating subsidiaries had $159,375 outstanding under the Credit Facility. The outstanding balance on the term loan was $109,375, of which $7,500 is classified as short-term and the remaining $101,875 is classified as long-term. The outstanding balance on the revolving Credit Facility was $50,000, which is classified as long-term. The Company was in compliance with all loan covenants as of June 30, 2019.

As of July 30, 2019, there was approximately $111,250 outstanding under the Revolving Credit Facility.










26

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)




Mortgage Loans and Promissory Note

In December 2017, 17 of the Company's subsidiaries entered into mortgage loans in the aggregate amount of $112,000. The mortgage loans are insured with Department of Housing and Urban Development (HUD), which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans and note bear fixed interest rates of 3.3% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. During the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms of the mortgage loans are 30 to 35 years. The borrowings were arranged by Lancaster Pollard Mortgage Company, LLC, and insured by HUD. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, to renovate and upgrade existing and future facilities, to cover working capital needs and for other business purposes.

In addition to the HUD mortgage loans above, the Company had outstanding indebtedness under mortgage loans insured with HUD and a promissory note issued in connection with various acquisitions. These mortgage loans and note bear fixed interest rates between 2.6% and 5.3% per annum. Amounts borrowed under the mortgage loans may be prepaid starting after the second anniversary of the notes subject to prepayment fees of the principal balance on the date of prepayment. These prepayment fees are reduced by 1.0% per year for years three through 11 of the loan. There is no prepayment penalty after year 11. The term of the mortgage loans and the note is between 12 and 33 years. The mortgage loans and note are secured by the real property comprising the facilities and the rents, issues and profits thereof, as well as all personal property used in the operation of the facilities.
As of June 30, 2019, the Company's operating subsidiaries had $121,664 outstanding under the mortgage loans and note, of which $2,653 is classified as short-term and the remaining $119,011 is classified as long-term. The Company was in compliance with all loan covenants as of June 30, 2019.
Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.

Off-Balance Sheet Arrangements

During the six months ended June 30, 2019, the Company increased its outstanding letters of credit by $560. As of June 30, 2019, the Company had approximately $5,342 on the credit facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.

16. OPTIONS AND AWARDS
Stock-based compensation expense consists of share-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three and six months ended June 30, 2019 and 2018 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
Stock Options
2017 Omnibus Incentive Plan - The Company has one active stock incentive plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The 2017 Plan provides for the issuance of 6,881 shares of common stock. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over 5 years at 20% per year on the anniversary of the grant date. Options expire 10 years from the date of grant. At June 30, 2019, there were 3,908 unissued shares of common stock available for issuance under this plan.

27

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for all share-based payment awards. Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the grant date requires considerable judgment, including estimating stock price volatility, expected option life and forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Company granted 399 options and 194 restricted stock awards from the 2017 Plan during the six months ended June 30, 2019.
The Company used the following assumptions for stock options granted during the three months ended June 30, 2019 and 2018:
Grant Year
 
Options Granted
 
Weighted Average Risk-Free Rate
 
Expected Life
 
Weighted Average Volatility
 
Weighted Average Dividend Yield
2019
 
258
 
2.1%
 
6.3 years
 
34.0%
 
0.4%
2018
 
227
 
2.7%
 
6.2 years
 
32.0%
 
0.5%


The Company used the following assumptions for stock options granted during the six months ended June 30, 2019 and 2018:
Grant Year
 
Options Granted
 
Weighted Average Risk-Free Rate
 
Expected Life
 
Weighted Average Volatility
 
Weighted Average Dividend Yield
2019
 
399

 
2.2%
 
6.3 years
 
33.9%
 
0.3%
2018
 
395

 
2.7%
 
6.2 years
 
32.0%
 
0.6%

For the six months ended June 30, 2019 and 2018, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant Year
 
Granted
 
Weighted Average Exercise Price
 
Weighted Average Fair Value of Options
2019
 
399

 
$
53.67

 
$
19.35

2018
 
395

 
$
32.33

 
$
11.15



The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended June 30, 2019 and 2018 and therefore, the intrinsic value was $0 at the date of grant.

The following table represents the employee stock option activity during the six months ended June 30, 2019:
 
Number of
Options
Outstanding
 
Weighted
Average
Exercise Price
 
Number of
Options Vested
 
Weighted
Average
Exercise Price
of Options
Vested
January 1, 2019
4,188

 
$
17.35

 
2,431

 
$
12.37

Granted
399

 
53.67

 
 
 
 
Forfeited
(27
)
 
26.16

 
 
 
 
Exercised
(531
)
 
10.45

 
 
 
 
June 30, 2019
4,029

 
$
21.80

 
2,407

 
$
13.88



The following summary information reflects stock options outstanding, vested and related details as of June 30, 2019:

28

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
 
Stock Options Outstanding
 
Stock Options Vested
 
 
 
 
 
 
 
Number Outstanding
 
Black-Scholes Fair Value
 
Remaining Contractual Life (Years)
 
Vested and Exercisable
Year of Grant
 
Exercise Price
 
 
 
 
2009
 
$4.06
-
$4.56
 
40

 
$
83

 
0
 
40

2010
 
4.77
-
4.96
 
50

 
122

 
1
 
50

2011
 
5.90
-
7.99
 
80

 
274

 
2
 
80

2012
 
6.56
-
7.96
 
217

 
797

 
3
 
217

2013
 
7.98
-
11.49
 
355

 
1,712

 
4
 
355

2014
 
10.55
-
18.94
 
1,049

 
5,953

 
5
 
1,025

2015
 
21.47
-
25.24
 
431

 
3,926

 
6
 
272

2016
 
18.79
-
19.89
 
381

 
2,652

 
7
 
180

2017
 
18.64
-
22.90
 
420

 
2,931

 
8
 
118

2018
 
26.53
-
38.59
 
607

 
7,346

 
9
 
70

2019
 
$53.50
-
$53.99
 
399

 
7,724


10


Total
 
 
 
 
 
4,029

 
$
33,520

 
 

2,407


Restricted Stock Awards
The Company granted 89 and 194 restricted stock awards during the three and six months ended June 30, 2019, respectively. The Company granted 217 and 274 restricted stock awards during the three and six months ended June 30, 2018, respectively. All awards were granted at an issued price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the six months ended June 30, 2019 and 2018 ranged from $41.68 to $53.99 and $23.61 to $36.61 respectively. The fair value per share includes quarterly stock awards to non-employee directors.
A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2019 and changes during the six months ended June 30, 2019 is presented below:
 
Non-Vested Restricted Awards
 
Weighted Average Grant Date Fair Value
Nonvested at January 1, 2019
573

 
$
29.31

Granted
194

 
52.16

Vested
(166
)
 
38.79

Forfeited
(5
)
 
28.67

Nonvested at June 30, 2019
596

 
$
34.13



During the three and six months ended June 30, 2019, the Company granted 8 and 14 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards ranged from $41.68 to $51.78 based on the market price on the grant date.

Share-based compensation expense recognized for the Company's equity incentive plans for the three and six months ended June 30, 2019 and 2018 was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Share-based compensation expense related to stock options
$
1,479

 
$
1,292

 
$
2,822

 
$
2,508

Share-based compensation expense related to restricted stock awards
1,199

 
675

 
2,197

 
1,253

Share-based compensation expense related to stock options and restricted stock awards to non-employee directors
388

 
210

 
659

 
387

Total
$
3,066

 
$
2,177

 
$
5,678


$
4,148



29

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



In future periods, the Company expects to recognize approximately $17,760 and $18,860 in share-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of June 30, 2019. Future share-based compensation expense will be recognized over 3.9 weighted average years for both unvested options and restricted stock awards. There were 1,622 unvested and outstanding options at June 30, 2019, of which 1,517 are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest at June 30, 2019 was 6.1 years.

The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of June 30, 2019 and December 31, 2018 is as follows:
Options
 
June 30, 2019
 
December 31, 2018
Outstanding
 
$
141,531

 
$
89,806

Vested
 
103,589

 
64,222

Expected to vest
 
32,597

 
22,963

Exercisable
 
21,118

 
27,646


The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options.
Equity Instrument Denominated in the Shares of a Subsidiary
On May 26, 2016, the Company implemented a management equity plan and granted stock options and restricted stock awards of a subsidiary of the Company to employees and management of that subsidiary (Subsidiary Equity Plan). The Company did not grant any new restricted shares during the six months ended June 30, 2019 and 2018. These awards generally vest over a period of three to five years, or upon the occurrence of certain prescribed events. During both the six months ended June 30, 2019 and 2018, 976 restricted stock awards vested.
The Company granted 221 stock options during the six months ended June 30, 2018. The Company did not grant any new stock options during the six months ended June 30, 2019. The value of the stock options and restricted stock awards is tied to the value of the common stock of the subsidiary. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination.
The grant-date fair value of the awards is recognized as compensation expense over the relevant vesting periods, with a corresponding adjustment to noncontrolling interests. The grant value was determined based on an independent valuation of the subsidiary shares. For the three and six months ended June 30, 2019, the Company expensed $236 and $577, respectively, in share-based compensation related to the Subsidiary Equity Plan. For the three and six months ended June 30, 2018, the Company expensed $343 and $681, respectively, in share-based compensation related to the Subsidiary Equity Plan.
The aggregate number of the Company's common shares that would be required to settle these awards at current estimated fair values, including vested and unvested awards, at June 30, 2019 and 2018 is 328 and 235, respectively.
During the second quarter of 2019, the Company repurchased 469 shares of common stock under the Subsidiary Equity Plan for $2,293. The Company subsequently sold the shares and received net proceeds of $2,293.
17. LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 93 affiliated skilled nursing, senior living facilities used in the Company’s operations under eight “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease.

30

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
Commencing the third year, the rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Total rent expense under the Master Leases was approximately $15,057 and $29,896 for the three and six months ended June 30, 2019, respectively, and $14,538 and $28,956 for the three and six months ended June 30, 2018, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is not aware of any defaults as of June 30, 2019.
The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense, inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37,211 and $73,181 for the three and six months ended June 30, 2019, respectively, and $34,476 and $68,640 for the three and six months ended June 30, 2018, respectively.
Thirty-nine of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
Impact of New Leases Guidance
As described further in Note 3, Summary of Significant Accounting Policies, the Company adopted Topic 842, Leases, as of January 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under Topic 840.
All of the Company's leases are classified as operating leases. The components of lease assets and liabilities are included in the condensed consolidated balance sheets. The following tables summarize the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of June 30, 2019 and the condensed consolidated statement of income for the three and six months ended June 30, 2019, as if the previous accounting guidance was in effect for comparison purposes. There was no impact to the condensed consolidated statement of cash flows for the six months ended June 30, 2019.
The following table summarizes the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of January 1, 2019.


31

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


 
 
Balance at December 31, 2018
 
Adjustments due to new lease guidance
 
January 1, 2019
 
Balance at June 30, 2019
Total assets(1)
 
$
1,181,958

 
$
1,015,937

 
$
2,197,895

 
$
2,321,521

Total liabilities(2)
 
579,618

 
1,006,907

 
1,586,525

 
1,644,214

Total equity
 
602,340

 
9,030

 
611,370

 
677,307

(1) Adjustment in assets includes the reclassification of intangible assets, prepaid rent and deferred rent into right-of-use assets and the decrease in deferred tax assets due to the removal of deferred gain related to sale-leaseback as of January 1, 2019.
(2) Adjustment in liabilities includes the reclassification of other liabilities into lease liabilities and the removal of deferred gain related to sale-lease back as of January 1, 2019.
The components of operating lease expense(1), are as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2019
 
2018
 
2019
 
2018
Rent - cost of services(2)
 
$
37,060

 
$
34,472

 
$
72,846

 
$
68,322

General and administrative expense
 
151

 
168

 
335

 
318

Depreciation and amortization(3)
 
495

 
495

 
990

 
990

 
 
$
37,706

 
$
35,135

 
$
74,171

 
$
69,630

(1) Operating lease expenses include short-term leases and variable lease costs, which are immaterial.
(2) Rent- cost of services includes the amortization of deferred rent of $434 and $688 for the three and six months ended June 30, 2019, respectively.
(3) Depreciation and amortization is related to the amortization of favorable and direct lease costs.

Future minimum lease payments for all leases as of June 30, 2019 are as follows:
Year
 
Amount
2019 (remainder)
 
$
74,865

2020
 
149,083

2021
 
148,086

2022
 
146,540

2023
 
144,852

2024
 
142,880

Thereafter
 
912,928

Total lease payments
 
1,719,234

Less: present value adjustment
 
(646,138
)
Less: variable rent
 
(25,265
)
Present value of total lease liabilities
 
1,047,831

Less: current lease liabilities
 
(59,686
)
Long-term operating lease liabilities
 
$
988,145

Future minimum lease payments for all leases as of December 31, 2018 were as follows:
Year
 
Amount
2019
 
$
142,497

2020
 
141,536

2021
 
140,524

2022
 
139,018

2023
 
137,349

Thereafter
 
967,027

Total lease payments
 
$
1,667,951




32

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2019, the weighted average remaining lease term is 12 years and the weighted average discount rate used to determine the operating lease liability is 8.66%.

18. COMMITMENTS AND CONTINGENCIES
Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information. In late December of 2016, the Company learned of a potential issue at one of its independent operating entities in Arizona which involved the limited and inadvertent disclosure of certain confidential information. The issue has been internally investigated, addressed and disclosed as is required by law. The Company believes that it is presently in compliance in all material respects with applicable HIPAA laws and regulations. As of June 30, 2019, this matter has been resolved.
Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.
Indemnities — From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer by the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.
U.S. Department of Justice Civil Investigative Demand - On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether the Company has violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of the Company’s independently operated skilled nursing facilities and persons who served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 to the present, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 to the present, relating to the same topic. As a general matter, the Company’s independent operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company is fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information. However, the Company cannot predict when the investigation will be resolved, the outcome of the investigation, or its potential impact on the Company.
Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.
In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction

33

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act (FCA) and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of minimum staffing requirements for skilled nursing facilities in those states which have enacted such requirements. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with the requirements of participation under certain state and federal healthcare programs; it may also subject the facility to a deficiency, a citation, a civil money penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.
The Company and its independent operating subsidiaries have in the past been subject to class action litigation involving claims of alleged violations of regulatory requirements related to staffing. While the Company has been able to settle these claims without a material ongoing adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. For example, the Company has been subjected to, and is currently involved in, class action litigation alleging violations of state and federal wage and hour law as related to the alleged failure to pay wages and to timely provide and authorize meal and rest breaks. The Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s business, cash flows, financial condition or results of operations. A significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.
The Company and its independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment, as well as employment related claims. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.
In August of 2011, the Company was named as a Defendant in a class action litigation alleging violations of state and federal wage and hour law. In January of 2017, the Company participated in an initial mediation session with plaintiffs' counsel. As a result of this discussion and due to (i) the fact no class had been certified (ii) the lack of specificity as to legal theories put forth by the plaintiffs (iii) the nature of the remedies sought and (iv) the lack of any basis on which to compute estimated compensatory and/or exemplary damages, the Company could not predict what the outcome of the pending class action lawsuit would be, what the timing of the ultimate resolution of this lawsuit would be, or an estimate and/or range of possible loss related to it.
In March of 2017, the Company was invited to engage in further settlement discussions to determine whether a resolution of the case was possible in advance of a decision on class certification. In April of 2017, the Company reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court.  Based upon the change in case status, the Company recorded an accrual for estimated probable losses of $11,000, exclusive of legal fees, in the first quarter of 2017. The Company funded the settlement amount of $11,000 in December of 2017, and the funds were distributed to the class members in the first quarter of 2018. The Company received back $1,664 related to unclaimed class settlement funds remaining after completion of the settlement process, and the recoveries were recorded in the first quarter of 2018.

Other claims and suits continue to be filed against the Company, its independent operating entities, and other post-acute care providers. In addition, professional negligence claims have been filed and will likely continue to be filed against the Company's independent operating entities by residents or responsible parties.


34

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any litigation were to proceed through trial, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar State and Federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its subsidiaries going forward under a corporate integrity agreement and/or other arrangements.
Medicare Revenue Recoupments — The Company's independent operating entities are subject to regulatory reviews relating to Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC), Unified Program Integrity Contractors (UPIC) and Medicaid Integrity Contributors (MIC) programs collectively referred to as Reviews. As of June 30, 2019, ten of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process, both pre- and post-payment. The Company anticipates that these Reviews will increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. As of June 30, 2019, the Company's independent operating subsidiaries have responded to the requests and the related claims are currently under Review, on appeal or in a dispute resolution process.
U.S. Government Inquiry and Corporate Integrity Agreement — In October 2013, the Company and its independent operating entities completed and executed a settlement agreement (the Settlement Agreement) with the DOJ, which received the final approval of the Office of Inspector General-HHS and the United States District Court for the Central District of California. Pursuant to the Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $48,000 in October 2013. The Company and its independent operating entities have denied engaging in any illegal conduct and agreed to the settlement amount without any admission of wrongdoing in order to resolve the allegations and to avoid the uncertainty and expense of protracted litigation.

In connection with the settlement and effective as of October 1, 2013, the Company and its independent operating entities entered into a five-year corporate integrity agreement (the CIA) with the Office of Inspector General-HHS. CMS acknowledged the existence of the Company’s current compliance program, which is in accord with the Office of the Inspector General (OIG)’s guidance related to an effective compliance program, and required that the Company and its independent operating entities continue during the term of the CIA to maintain a program designed to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs.

In the first quarter of 2019, the Company received notice from the OIG that the Company’s five-year CIA with the OIG has been completed. Upon receipt of the Company’s fifth and final annual report, the OIG confirmed that the term of the CIA is concluded.

Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for approximately 60.3% and 60.6% of its total accounts receivable as of June 30, 2019 and December 31, 2018, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 68.0% of the Company's revenue for both the three and six months ended June 30, 2019, respectively, and 68.2% and 68.0% of the Company's revenue for the three and six months ended June 30, 2018, respectively.

Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of July 30, 2019, the Company had approximately $1,066 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.


35

THE ENSIGN GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


19. COMMON STOCK
As approved by the Board of Directors on April 3, 2018, the Company entered into a stock repurchase program pursuant to which the Company may repurchase up to $30,000 of its common stock under the program for a period of approximately 11 months. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The stock repurchase program expired on February 20, 2019. The Company did not purchase any shares pursuant to this stock repurchase program.

Item 2.        Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto contained in Part I, Item 1 of this Report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Report and in our other reports filed with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K (Annual Report), which discusses our business and related risks in greater detail, as well as subsequent reports we may file from time to time on Forms 10-Q and 8-K, for additional information. The section entitled “Risk Factors” contained in Part II, Item 1A of this Report, and similar discussions in our other SEC filings, also describe some of the important risk factors that may affect our business, financial condition, results of operations and/or liquidity. You should carefully consider those risks, in addition to the other information in this Report and in our other filings with the SEC, before deciding to purchase, hold or sell our common stock.
This Report contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, which include, but are not limited to, the Company’s expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, plans and objectives of management and the proposed Spin-Off. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” contained in Part II, Item 1A of this Report. These forward-looking statements speak only as of the date of this Report, and are based on our current expectations, estimates and projections about our industry and business, management’s beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law. As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, the words, “we,” “our” and “us” refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our affiliated operations, the Service Center and the Captive are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. The use of “we,” “us,” “our” and similar verbiage in this quarterly report is not meant to imply that any of our affiliated operations, the Service Center or the Captive are operated by the same entity. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our consolidated financial statements and related notes included in the Quarterly Report.
Overview
We are a provider of health care services across the post-acute care continuum, as well as other ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington, Wisconsin and Wyoming. Our operating subsidiaries, each of which strives to be the service of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living, home health, hospice, home care and other ancillary services. As of June 30, 2019, we offered skilled nursing, senior living and rehabilitative care services through 254 skilled nursing and senior living facilities. Of the 254 facilities, we owned 77 and operated an additional 177 facilities under long-term lease arrangements, and have options to purchase 12 of those 177 facilities. Our home health and hospice business provides home health, hospice and home care services from 62 agencies across thirteen states.

The following table summarizes our affiliated facilities and operational skilled nursing beds and senior living units by ownership status as of June 30, 2019:

36


 
Owned
 
Leased (with a Purchase Option)
 
Leased (without a Purchase Option)
 
Total
Number of facilities
77

 
12

 
165

 
254

Percentage of total
30.3
%
 
4.7
%
 
65.0
%
 
100.0
%
Operational skilled nursing beds
4,476

 
1,240

 
14,940

 
20,656

Percentage of total
21.7
%
 
6.0
%
 
72.3
%
 
100.0
%
Senior living units
2,642

 
184

 
3,105

 
5,931

Percentage of total
44.5
%
 
3.1
%
 
52.4
%
 
100.0
%
The Ensign Group, Inc. (collectively, Ensign or the Company) is a holding company with no direct operating assets, employees or revenues. Our operating subsidiaries are operated by separate, independent entities, each of which has its own management, employees and assets. In addition, certain of our wholly-owned subsidiaries, referred to collectively as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. We also have a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to our operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities.  References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this quarterly report, are not meant to imply, nor should they be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.
Recent Activities

Proposed Spin-Off of Subsidiaries — On May 6, 2019, we announced a proposed plan to separate our transitional and skilled nursing services, our home health and hospice operations and substantially all of our senior living operations into two separate, publicly traded companies:

Ensign, which will include transitional and skilled services, rehabilitative care services, healthcare campuses, post-acute-related new business ventures and real estate investments; and
The Pennant Group, Inc. (Pennant), which will be a holding company of operating subsidiaries that provide home health, hospice and senior living.

We intend to accomplish the proposed separation through a spin-off (the Spin-Off) in which we expect to distribute shares of Pennant common stock to our stockholders on a pro rata basis. We anticipate that at the time of the Spin-Off, Pennant, which is currently a wholly-owned subsidiary of Ensign, will consist of 62 home health, hospice and home care agencies and 51 senior living communities as of June 30, 2019. Ensign affiliates will retain the ownership of the real estate at 28 of the 51 senior living operations that are being contributed to Pennant. We anticipate that after the Spin-Off, all of these properties will be leased to Pennant on a triple-net basis, under which Pennant affiliates will be responsible for all costs at the properties, including property taxes, insurance and maintenance and repair costs.

In connection with the adoption of the stockholder rights plan, we anticipate that the board of directors will declare a dividend of one share of Pennant common stock for every two shares of Ensign's common stock held by stockholders as of the record date. The number of shares of Ensign common stock each stockholder owns and the related proportionate interest in Ensign will not change as a result of the proposed Spin-Off. Each Ensign stockholder will receive only whole shares of Pennant common stock in the distribution, as well as cash in lieu of any fractional shares. The proposed Spin-Off is subject to customary conditions, including receipt of a tax opinion from counsel, effectiveness of the registration statement filed with the Securities and Exchange Commission, execution of third-party agreements and final approval by Ensign’s board of directors.
Closure of the corporate integrity agreement (the CIA): In the first quarter of 2019, we received notice from the Office of Inspector General (OIG) that our five-year CIA with the OIG has been completed.
Sale of one facility - We completed the sale of one of our senior living operations for a sale price of $1.8 million in the first quarter of 2019.
Adoption of Lease Standard - On January 1, 2019, we adopted Accounting Standards Codification Topic 842, Leases under the transition method that allows us to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The new lease standard requires lessees to recognize leases with terms longer than 12 months, on the balance sheet and

37


disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement.
The new accounting standard had the following effects on our presentation and disclosure:
We made an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the condensed consolidated statement of income on a straight-line basis over the lease term. We also elected the practical expedient to not separate lease and non-lease components for all of our leases as the non-lease components are not significant to the overall lease costs.
Prior period results reflect historical lease classification, under which all of our leases were classified as operating leases.
The adoption of this standard resulted in recognition of net lease assets and lease liabilities of $1.1 billion and $1.0 billion, respectively, on our condensed consolidated balance sheets as of January 1, 2019.
We recorded an adjustment, net of tax, of $9.0 million to retained earnings, on the adoption date, related to a deferred gain on a previous sale-leaseback transaction, which resulted in an increase in rent expense of $0.7 million annually, as we are no longer able to recognize the gain in our consolidated statement of income as a result of the new lease standard. In addition, initial direct costs associated with our lease agreements and favorable lease assets of $26.9 million were classified into right-of-use assets on the adoption date. See further discussion at Note 17, Leases.
Acquisition History

The following table sets forth the location of our facilities and the number of operational beds and units located at our facilities as of June 30, 2019:
 
TX
 
CA
 
AZ
 
WI
 
UT
 
CO
 
WA
 
ID
 
NE
 
KS
 
IA
 
SC
 
NV
 
Total
Number of facilities
Skilled nursing operations
43

 
44

 
26

 
2

 
17

 
9

 
9

 
8

 
4

 

 
4

 
4

 
1

 
171

Senior living communities
11

 
6

 
6

 
19

 
1

 
5

 
1

 
2

 
1

 

 

 

 
4

 
56

Campuses(1)
6

 
3

 
3

 

 
1

 
1

 

 
2

 
2

 
7

 
2

 

 

 
27

Number of operational beds/units
Operational skilled nursing beds
5,867

 
4,747

 
3,790

 
100

 
1,889

 
766

 
814

 
785

 
413

 
601

 
368

 
424

 
92

 
20,656

Senior living units
1,028

 
735

 
1,428

 
758

 
106

 
620

 
98

 
195

 
301

 
246

 
31

 

 
385

 
5,931

(1) Campus represents a facility that offers both skilled nursing and senior living services.
As of June 30, 2019, we provided home health and hospice services through our 62 agencies in Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming.
During the six months ended June 30, 2019, we expanded our operations through a combination of a long-term lease and real estate purchases, with the addition of seven stand-alone skilled nursing operations, one stand-alone senior living operation, three campus operations, two home health agencies, four hospice agencies and two home care agencies. We did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of 1,088 operational skilled nursing beds and 364 operational senior living units to be operated by our affiliated operating subsidiaries. We also invested in new ancillary services that are complementary to our existing businesses. We entered into a separate operations transfer agreement with the prior operator as part of each transaction. The aggregate purchase price for these acquisitions during the six months ended June 30, 2019 was $65.4 million.
Subsequent to June 30, 2019, we expanded our operations through long-term leases, with the addition of one stand-alone skilled nursing operation and one stand-alone senior living operation. We did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of 27 operational skilled nursing beds and 91 operational senior living units to be operated by our operating subsidiaries. We entered into a separate operations transfer agreement with the prior operator as part of each transaction.

38


For further discussion of our acquisitions, see Note 8, Acquisitions in the Notes to Condensed Consolidated Financial Statements.
Key Performance Indicators
We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. Revenue associated with these metrics are generated based on contractually agreed-upon amounts or rate, excluding the estimates of variable consideration under the revenue recognition standard, ASC 606. These indicators and their definitions include the following:
Transitional and Skilled Services
Routine revenue. Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part B therapy services, and are not included in the routine revenue definition.
Skilled revenue. The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients that are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our senior living services.
Skilled mix. The amount of our skilled revenue as a percentage of our total skilled nursing routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving skilled nursing services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.
Quality mix. The amount of skilled nursing routine non-Medicaid revenue as a percentage of our total skilled nursing routine revenue. Quality mix (in days) represents the number of days our non-Medicaid patients are receiving services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.
Average daily rates. The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period.
Occupancy percentage (operational beds). The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.
Number of facilities and operational beds. The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.
Skilled and Quality Mix. Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.

The following table summarizes our overall skilled mix and quality mix from our skilled nursing services for the periods indicated as a percentage of our total skilled nursing routine revenue and as a percentage of total skilled nursing patient days:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Skilled Mix:
 
 
 
 
 
 
 
Days
29.0
%
 
29.7
%
 
29.5
%
 
30.7
%
Revenue
48.7
%
 
50.2
%
 
49.2
%
 
51.2
%
Quality Mix:
 
 
 
 
 
 
 
Days
41.0
%
 
42.1
%
 
41.3
%
 
42.8
%
Revenue
57.2
%
 
58.8
%
 
57.6
%
 
59.7
%

39


Occupancy. We define occupancy derived from our transitional and skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of licensed beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.
The following table summarizes our overall occupancy statistics for skilled nursing operations for the periods indicated:
 
Three Months Ended June 30,
 
Six Months Ended
June 30,
 
2019
 
2018
 
2019
 
2018
Occupancy for transitional and skilled services:
 
 
 
 
 
 
 
Operational beds at end of period
20,656

 
19,267

 
20,656

 
19,267

Available patient days
1,855,909

 
1,735,633

 
3,627,614

 
3,426,846

Actual patient days
1,472,798

 
1,330,057

 
2,879,167

 
2,645,027

Occupancy percentage (based on operational beds)
79.4
%
 
76.6
%
 
79.4
%

77.2
%

Senior Living Services

• Occupancy. We define occupancy derived from our senior living services as the ratio of actual number of days our units are occupied during any measurement period to the number of units in facilities which are available for occupancy during the measurement period.

Average monthly revenue per unit. The revenue for a period at a senior living facility divided by actual occupied units for that revenue source for that given period.

 
Three Months Ended June 30,
 
Six Months Ended
June 30,
 
2019
 
2018
 
2019
 
2018
Occupancy for senior living communities:
 
 
 
 
 
 
 
Occupancy percentage (units)
75.5
%
 
75.2
%
 
75.3
%
 
75.4
%
Average monthly revenue per unit
$
2,900

 
$
2,863

 
$
2,923

 
$
2,860


Home Health and Hospice
Average Medicare revenue per completed episode. The average amount of revenue for each completed 60-day episode generated from patients who are receiving care under Medicare reimbursement programs.
Average daily census. The average number of patients who are receiving hospice care as a percentage of total number of patient days.
The following table summarizes our overall home health and hospice statistics for the periods indicated:
 
Three Months Ended June 30,
 
Six Months Ended
June 30,
 
2019

2018
 
2019
 
2018
Home health services:
 
 
 
 
 
 
 
Average Medicare revenue per completed episode
$
3,077

 
$
3,064

 
$
3,024

 
$
2,951

Hospice services:
 
 

 
 
 

Average daily census
1,673

 
1,290

 
1,544

 
1,275



40


Segments
We have three reportable segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities; (2) senior living services, which includes the operation of assisted and independent facilities; and (3) home health and hospice services, which includes our home health, home care and hospice businesses. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level.

We also report an “all other” category that includes revenue from our mobile diagnostics and other ancillary operations. Our mobile diagnostics and other ancillary operations businesses are neither significant individually nor in aggregate and therefore do not constitute a reportable segment. Our reporting segments are business units that offer different services and that are managed separately to provide greater visibility into those operations.


Revenue Sources
The following table sets forth our total revenue by payor source generated by each of our reportable segments and our "All Other" category and as a percentage of total revenue for the periods indicated (dollars in thousands):
 
 
Three Months Ended June 30, 2019
 
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
 
 
 
 
 
 
 
 
Home Health Services
 
Hospice Services
 
 
Total Revenue
 
Revenue %
 
Medicaid
 
$
192,545

 
$
10,333

 
$
1,515

 
$
2,418

 
$

 
$
206,811

 
35.9
%
 
Medicare
 
118,807

 

 
11,990

 
22,390

 

 
153,187

 
26.6

 
Medicaid-skilled
 
31,792

 

 

 

 

 
31,792

 
5.5

 
Subtotal
 
343,144

 
10,333

 
13,505

 
24,808

 

 
391,790

 
68.0

 
Managed care
 
86,491

 

 
6,829

 
370

 

 
93,690

 
16.3

 
Private and other
 
39,603

 
31,713

 
4,654

 
42

 
14,159

(1)
90,171

 
15.7

 
Total revenue
 
$
469,238

 
$
42,046

 
$
24,988

 
$
25,220

 
$
14,159

 
$
575,651

 
100.0
%
 
(1) Private and other payors in our "All Other" category includes revenue from all payors generated in our other ancillary operations.
 
 
Three Months Ended June 30, 2018
 
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
 
 
 
 
 
 
 
 
Home Health Services
 
Hospice Services
 
 
Total Revenue
 
Revenue %
 
Medicaid
 
$
161,584

 
$
8,677

 
$
1,232

 
$
1,676

 
$

 
$
173,169

 
34.9
%
 
Medicare
 
108,237

 

 
10,486

 
18,090

 

 
136,813

 
27.6

 
Medicaid-skilled
 
28,298

 

 

 

 

 
28,298

 
5.7

 
Subtotal
 
298,119

 
8,677

 
11,718

 
19,766

 

 
338,280

 
68.2

 
Managed care
 
74,168

 

 
5,857

 
125

 

 
80,150

 
16.1

 
Private and other
 
36,231

 
28,487

 
3,746

 
37

 
9,455

(1)
77,956

 
15.7

 
Total revenue
 
$
408,518

 
$
37,164

 
$
21,321

 
$
19,928

 
$
9,455

 
$
496,386

 
100.0
%
 
(1) Private and other payors in our "All Other" category includes revenue from all payors generated in our other ancillary operations.

41


 
 
Six Months Ended June 30, 2019
 
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
 
 
 
 
 
 
 
 
Home Health Services
 
Hospice Services
 
 
Total Revenue
 
Revenue %
 
Medicaid
 
$
373,839

 
$
20,135

 
$
2,953

 
$
4,887

 
$

 
$
401,814

 
35.7
%
 
Medicare
 
235,508

 

 
23,360

 
42,039

 

 
300,907

 
26.8

 
Medicaid-skilled
 
62,243

 

 

 

 

 
62,243

 
5.5

 
Subtotal
 
671,590

 
20,135

 
26,313

 
46,926

 

 
764,964

 
68.0

 
Managed care
 
169,663

 

 
13,185

 
690

 

 
183,538

 
16.3

 
Private and other
 
77,243

 
62,605

 
9,149

 
62

 
27,304

(1)
176,363

 
15.7

 
Total revenue
 
$
918,496

 
$
82,740

 
$
48,647

 
$
47,678

 
$
27,304

 
$
1,124,865

 
100.0
%
 
(1) Private and other payors in our "All Other" category includes revenue from all payors generated in our other ancillary operations.
 
 
Six Months Ended June 30, 2018
 
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
 
 
 
 
 
 
 
 
Home Health Services
 
Hospice Services
 
 
Total Revenue
 
Revenue %
 
Medicaid
 
$
318,095

 
$
16,941

 
$
2,215

 
$
3,543

 
$

 
$
340,794

 
34.5
%
 
Medicare
 
220,190

 

 
20,353

 
35,584

 

 
276,127

 
27.9

 
Medicaid-skilled
 
55,340

 

 

 

 

 
55,340

 
5.6

 
Subtotal
 
593,625

 
16,941

 
22,568

 
39,127

 

 
672,261

 
68.0

 
Managed care
 
151,968

 

 
11,590

 
308

 

 
163,866

 
16.6

 
Private and other
 
69,941

 
56,336

 
7,347

 
67

 
18,702

(1)
152,393

 
15.4

 
Total revenue
 
$
815,534

 
$
73,277

 
$
41,505

 
$
39,502

 
$
18,702

 
$
988,520

 
100.0
%
 
(1) Private and other payors in our "All Other" category includes revenue from all payors generated in our other ancillary operations.

Transitional and Skilled Services

Within our skilled nursing operations, we generate revenue from Medicaid, private pay, managed care and Medicare payors. We believe that our skilled mix, which we define as the number of days Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from senior living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.

We are participating in supplemental payment programs in various states that provide supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as city and county hospital districts. Several of our operating subsidiaries entered into transactions with several such hospital districts providing for the transfer of the licenses for those skilled nursing facilities to the hospital districts. Each affected operating subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status.

Senior Living Services.

Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid or other state-specific programs.





42


Home Health and Hospice Services
Home Health. As of June 30, 2019, we provided home health services in Arizona, California, Colorado, Idaho, Iowa, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. We derive the majority of our revenue from our home health business from Medicare and managed care. The home health prospective payment system provides home health agencies with payments for each 60-day episode of care for each beneficiary. Episodic payments are adjusted for differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. If a beneficiary is still eligible for care after the end of the first episode, a second episode can begin. There are no limits to the number of episodes a beneficiary who remains eligible for the home health benefit can receive. While payment for each episode is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. Episodic payments are also adjusted for certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.
Hospice. As of June 30, 2019, we provided hospice care in Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. We derive the majority of the revenue from our hospice business from Medicare reimbursement. The estimated payment rates are daily rates for each of the levels of care we deliver. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, we monitor our provider numbers and estimate amounts due back to Medicare if we believe a cap has been exceeded.

Beginning January 1, 2016, CMS provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, Medicare is also reimbursing for a Service Intensity Add-on (“SIA”). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.

Other

As of June 30, 2019, we held majority membership interests in our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk.
Critical Accounting Policies

In February 2016, the FASB established Topic 842, Leases (ASC 842), by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines.

We adopted the standard as of January 1, 2019, electing the transition method that allows us to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings, if applicable. We have elected the package of practical expedients permitted under the transition guidance, which among other things, allows us to carryforward the historical lease classification. The new standard also provides practical expedients for an entity’s ongoing accounting. We have elected an accounting policy to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the condensed consolidated statements of income on a straight-line basis over the lease term. We have also elected the practical expedient to not separate lease and non-lease components for all of our leases as the non-lease components are not significant to the overall lease costs.

Other than the adoption of ASC 842, as discussed above, there have been no significant changes during the six months ended June 30, 2019, to the items that we disclosed in our critical accounting policies and estimates in our Annual Report on Form 10-K, during the year ended December 31, 2018, filed with the SEC.


43


Industry Trends
The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting of patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:
Shift of Patient Care to Lower Cost Alternatives. The growth of the senior population in the United States continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals, and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher-acuity patients than in the past.
Significant Acquisition and Consolidation Opportunities. The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides significant acquisition and consolidation opportunities for us.
Improving Supply and Demand Balance. The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.
Increased Demand Driven by Aging Populations. As seniors account for an increasing percentage of the total U.S. population, we believe the demand for home health and hospice and senior living services will continue to increase. According to the census projection released by the U.S. Census Bureau in early 2018, between 2010 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 13% to 21%. The Bureau expects this segment to increase nearly 90% to 73 million, as compared to the total U.S. population which is projected to increase by 17% over that time period. Furthermore, the generation currently retiring has accumulated less savings than in the past, creating demand for more affordable senior housing and in-home care options. As a high quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.
Transition to Value-Based Payment Models. In response to rising healthcare spending in the United States, commercial, government and other payors are generally shifting away from fee-for-service payment models towards value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that patient-centered outcomes driven reimbursement models will continue to grow in prominence. Many of our operations already receive value-based payments, and as valued-based payment systems continue to increase in prominence, it is our view that our strong clinical outcomes will be increasingly rewarded.
Accountable Care Organizations and Reimbursement Reform. A significant goal of federal health care reform is to transform the delivery of health care by changing reimbursement to reflect and support the quality and safety of care that providers deliver, increase efficiency, and reduce growth in spending. Reimbursement models that provide financial incentives to encourage efficiency, affordability, and high-quality care have been developed and implemented by government and commercial third-party payers. The most prolific of these models, the Accountable Care Organization (ACO) model, incentivizes groups of providers to share in savings that are achieved through the coordination of care and chronic disease management of an assigned patient population.  Reimbursement methodology reform includes Value-Based Purchasing (VBP), in which a portion of provider reimbursement is redistributed based on relative performance, or improvement on designated economic, clinical quality, and patient satisfaction metrics.  In addition, CMS is implementing Episode-based demonstration, voluntary and mandatory payment initiatives that bundle acute care and post-acute care reimbursement. These bundled payment models incentivize cross-continuum care coordination and include financial and performance accountability for episodes of care. The first demonstration, Bundled Payments for Care Improvement Initiative (BPCI) Models 1-4, began on April 1, 2013 and concluded September 30, 2018. These reimbursement methodologies and similar programs are likely to continue and expand, both in government and commercial health plans. In January 2015, CMS announced its goal to drive Medicare and the healthcare system toward rewarding for quality of care in lieu of quantity of care. The goals included tying 30% of traditional, or fee-for-service, Medicare payments to quality or value through alternative payment models, such as ACOs or bundled payment arrangements, by the end of 2016 and tying 50% of payments to these models by the end of 2018. In March 2016, the administration announced that it hit its first target 11 months ahead of schedule as of January 2016. On December 1, 2017, CMS issued a final rule that included changes to the Comprehensive Care for Joint Replacement (CJR) Model, in which participation for all rural and low volume providers in CJR became voluntary, as did participation for all providers located in 33 of the 67 Metropolitan Statistical Areas (MSA)s, with an opt-in election period during January 2018.  Additionally,  The Episode

44


Payment Models (EPMs) for AMI and CABG, along with the Cardiac Rehabilitation Incentive Payment Model were cancelled. Changes in the final rule also allowed the agency to engage providers in future voluntary efforts, including additional voluntary episode-based payment models, while easing the burden of mandatory episode payment models. In late January 2018, CMS announced the BPCI-Advanced (BPCI-A) Model, which commenced on October 1, 2018 and runs through December 31, 2023. BPCI-A precludes post-acute providers from participating in a manner similar to the original BPCI Program.
We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size, and the increased number of two-wage earner couples, more residents are looking for alternatives outside the family for their care.
Effects of Changing Prices
Medicare reimbursement rates and procedures are subject to change from time to time, which could materially impact our revenue. Medicare reimburses our skilled nursing operations under a prospective payment system (PPS) for certain inpatient covered services. Under the PPS, facilities are paid a predetermined amount per patient, per day, based on the anticipated costs of treating patients. The amount to be paid is determined by classifying each patient into a resource utilization group (RUG) category that is based upon each patient’s acuity level. As of October 1, 2010, the RUG categories were expanded from 53 to 66 with the introduction of minimum data set (MDS) 3.0. Should future changes in skilled nursing facility payments reduce rates or increase the standards for reaching certain reimbursement levels, our Medicare revenues could be reduced and/or our costs to provide those services could increase, with a corresponding adverse impact on our financial condition or results of operations. On April 25, 2019, CMS announced a proposed rule aimed at updating the payment rates used under PPS. CMS also proposed minor revisions to the regulatory text to reflect the revised assessment schedule under Patient Driven Payment Model (PDPM) and the definition of group therapy under the SNF PPS, and to implement a subregulatory process for updating the code lists (International Classification of Diseases, Tenth Version (ICD-10) codes) used under PDPM. Our business may be impacted depending on the requirements of the final rule because the proposed rule includes policies that would continue a commitment to shift Medicare payments from volume to value.
Our Medicare reimbursement rates and procedures for our home health and hospice operations are based on the severity of the patient’s condition, his or her service needs and other factors relating to the cost of providing services and supplies. Our home health rates and services are bundled into 60-day episodes of care. Payments can be adjusted for: (a) an outlier payment if our patient’s care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (LUPA) if the number of visits during the episode was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services required (with various incremental adjustments made for additional visits, and larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.
Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the ACA). The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. These reforms include modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. The recent congressional elections in the United States and policies implemented by the current administration could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation of Medicare and/or Medicaid, and government policy that could significantly impact our business and the health care industry. We continually monitor these developments in an effort to respond to the changing regulatory environment impacting our business.


45


On April 6, 2018, CMS announced that starting in April 2018, CMS will use Payroll Based Journals (PBJ) data to calculate the staffing ratings used in the Nursing Home Five Star Quality Rating System. Additionally, the staffing information will be calculated using the number of hours facility staff are paid to work each day. Salaried employee information will not reflect actual hours worked, but instead will be limited to eight hours a day. The staffing information is electronically submitted each quarter, and will be adjusted based on the new risk adjusted expected level of staff needed given the number and acuity of the residents in the facility.  In April 2018, new ratings’ thresholds were rolled out resulting in some facilities changing in their rating based on the new system. Additionally, because the PBJ data is used to calculate the staffing Star Rating, some facilities saw an increase or decrease in their overall Star rating depending on whether their PBJ data positively or negatively impacted them.

On April 24, 2019, CMS announced several changes that were made to the Five-Star Quality Rating System. The new changes include separate ratings for short-stay quality of resident care and long-stay quality of resident care in addition to an overall quality of resident care rating. Measures of long-stay hospitalizations and long-stay emergency department (ED) visits were added to the quality measure rating, and the long-stay physical restraints measure was dropped from the quality measure rating. The scoring rules for the quality measures changed to give more weight to measures with greater opportunity for improvement. Further, the staffing rating thresholds were changed, with the staffing level required to receive a 5-star rating determined based on analysis of the relationship between staffing levels and measures of nursing home quality. CMS placed a strong emphasis on registered nurse (RN) staffing; accordingly, the method by which the RN staffing rating and the total nurse staffing rating are combined to generate the overall staffing rating is changing to provide more emphasis on RN staffing. Additionally, the overall and RN staffing ratings are set to one star for nursing homes that report four or more days in the quarter with no RN on-site. Finally, staffing ratings are no longer being suppressed for nursing homes that have five or more days with residents and no nurse staffing hours reported.

Accordingly, the CMS changes include updated thresholds for assigning stars for both the staffing and quality components of the system. CMS estimates the changes will cause 47 percent of all nursing centers to lose stars in their "Quality" ratings. In addition, 33 percent will lose stars in their "Staffing" ratings, and some 36 percent will lose stars in their "Overall" ratings. These changes to update the staffing and quality thresholds could have a negative impact on our star rating in 2019.

On February 12, 2018, the President rolled out a new White House budget for fiscal year 2019, which froze the Medicare market basket rate at 2.4%. As a result, the Congressional Budget Office has estimated a $1.9 billion reduction in Medicare spending over the next decade. The 2019 fiscal year began October 1, 2018.
On October 4, 2016, CMS released a final rule that reforms the requirements for long-term care (LTC) facilities, specifically skilled nursing facilities (SNFs) and nursing facilities (NFs), to participate in the Medicare and Medicaid programs. The regulations have not been updated since 1991 and have been revised to improve quality of life, care and services in LTC facilities, optimize resident safety, reflect current professional standards and improve the logical flow of the regulations. The regulations became effective November 28, 2016 and are being implemented in three phases. The first phase was effective November 28, 2016, the second phase was effective November 28, 2017 and the third phase becomes effective November 28, 2019.
A few highlights from the new regulation include the following:
investigate and report all allegations of abusive conduct, and refrain from employing individuals who have had a disciplinary action taken against their professional license by a state licensure body as a result of a finding of abuse, neglect, mistreatment of residents or misappropriation of their property;
document a transfer or discharge in the medical record and exchange certain information to a receiving provider or facility when a resident is transferred;
develop and implement a baseline care plan for each resident within 48 hours of their admission that includes instructions to provide effective and person-centered care that meets professional standards of quality care;
develop and implement a discharge planning process that prepares residents to be active partners in post-discharge care;
provide the necessary care and services to attain or maintain the highest practicable physical, mental and psychosocial well-being;
add a competency requirement for determining the sufficiency of nursing staff;
require that a pharmacist reviews a resident’s medical chart during each monthly drug regiment review;
refrain from charging a Medicare resident for loss or damage of dentures;

46


provide each resident with a nourishing, palatable and well-balanced diet;
conduct, document and annually review a facility-wide assessment to determine what resources are necessary to care for its residents;
refrain from entering into a binding arbitration agreement until after a dispute arises between the parties;
develop, implement and maintain an effective comprehensive, data-driven quality assurance and performance improvement program;
develop an Infection Prevention and Control Program; and
require their operating organization have in effect a compliance and ethics program.
CMS estimates that the average cost per facility for compliance with the new rule to be approximately $62,900 in the first year and approximately $55,000 in subsequent years. However, these amounts vary per organization. In addition to the monetary costs, these regulations may create compliance issues, as state regulators and surveyors interpret requirements that are less explicit. On June 8, 2017, CMS issued a proposed rule that would remove the provisions prohibiting binding pre-dispute arbitration agreements, but would retain other provisions that protect the interests of LTC residents.
On July 16, 2019, CMS introduced one proposed and one final rule related to the regulatory framework within which long term and post-acute care providers operate. The proposed rule covers changes to the Requirements of Participation (ROP) for the Medicare and Medicaid Programs, and the final rule addresses the use of pre-dispute arbitration agreements with patients/residents. As part of the ROP proposed rule, CMS has proposed a delay in the implementation of both the Quality Assurance and Performance Improvement (QAPI) program and Compliance and Ethics program and training requirements for one year, including the following: (a) QAPI program and documentation; (b) Program Design and Scope; (c) Program Feedback Data Systems, and Monitoring; (d) Program Systematic Analysis and Systematic Action; (e) Program Activities; (f) Governance and Leadership; (g) Compliance and Ethics Program; and (h) QAPI Training and Compliance and Ethics Training. The proposed rule does not delay implementation of the Phase 3 Infection Preventionist requirements of the Compliance and Ethics Program. Likewise, the proposed rule maintains the implementation date of the requirements for culturally competent and trauma-informed care, or the requirements for a call system from the residents' bedsides.
On the issue of pre-dispute binding Arbitration Agreements, the final rule amends the requirements that Long-Term Care (LTC) facilities must meet to participate in the Medicare and Medicaid programs. Specifically, the rule confirms the repeal of the prohibition on the use of pre-dispute, binding arbitration agreements, and strengthens the transparency of arbitration agreements and arbitration in LTC facilities. Included in the final rule is the requirement that facilities ensure the agreement for binding arbitration is in plain language; that facilities post a notice in plain language that describes the policy on the use of agreements for binding arbitration in an area that is visible to residents and visitors; that admission to the facility not be conditioned on the signing of an arbitration agreement; and that the facility explicitly inform the resident or his or her representative of the right not to sign the agreement as a condition of admission. The final rule supports residents' rights to make informed choices about important aspects of their health care.

On September 16, 2016, CMS issued its final rule concerning emergency preparedness requirements for Medicare and Medicaid participating providers, specifically skilled nursing facilities (SNFs), nursing facilities (NFs), and intermediate care facilities for individuals with intellectual disabilities (ICF/IIDs). The rule is designed to ensure providers and suppliers have comprehensive and integrated emergency policies and procedures in place, in particular during natural and man-made disasters. Under the rule, facilities are required to 1) document risk assessment and emergency planning; 2) develop and implement policies and procedures based on that risk assessment; 3) develop and maintain an emergency preparedness communication plan in compliance with both federal and state law; and 4) develop and maintain an emergency preparedness training and testing program.

On June 9, 2017, CMS issued revised requirements for emergency preparedness for Medicare and Medicaid participating providers, including long-term care facilities, hospices, and home health agencies. The revised requirements update the conditions of participation for such providers. Specifically, outpatient facilities, such as home health agencies, are required to ensure that patients with limited mobility are addressed within the emergency plan; home health agencies are also required to develop and implement emergency preparedness policies and procedures that are reviewed and updated at least annually and each patient must have an individual plan; hospice-operated inpatient care facilities are required to provide subsistence needs for hospice employees and patients and a means to shelter in place patients and employees who remain in the hospice; all hospices and home health agencies must implement procedures to follow up with on duty staff and patients to determine services that are needed in the event that there is an interruption in services during or due to an emergency; hospices must train their employees in emergency preparedness

47


policies and long-term care facilities are required to share emergency preparedness plans and policies with family members and resident representatives.
On July 29, 2016, CMS issued its final rule laying out the performance standards relating to preventable hospital readmissions from skilled nursing facilities. The final rule includes the SNF 30-day All Cause Readmission Measure which assesses the risk-standardized rate of all-cause, all condition, unplanned inpatient hospital readmissions for Medicare fee-for-service SNF patients within 30 days of discharge from admission to an inpatient prospective payment system hospital (IPPS), critical access hospital (CAH) or psychiatric hospital. The final rule includes the SNF 30-Day Potentially Preventable Readmission Measure as the SNF all condition risk adjusted potentially preventable hospital readmission measure. This measure assesses the facility-level risk-standardized rate of unplanned, potentially preventable hospital readmissions for SNF patients within 30 days of discharge from a prior admission to an IPPS hospital, CAH, or psychiatric hospital. Hospital readmissions include readmissions to a short-stay acute-care hospital or CAH, with a diagnosis considered to be unplanned and potentially preventable. This measure is claims-based, requiring no additional data collection or submission burden for SNFs.
On August 8, 2018, CMS issued a final rule updating the payment rates used under the prospective payment system for SNFs for fiscal year 2019. This final rule also replaces the existing case-mix classification methodology, the Resource Utilization Groups, Version IV (RUG-IV) model, with a revised case-mix methodology called the Patient-Driven Payment Model (PDPM) beginning on October 1, 2019. The rule finalizes revisions to the regulation text that describes a beneficiary's SNF “resident” status under the consolidated billing provision and the required content of the SNF level of care certification. The rule also finalizes updates to the SNF Quality Reporting Program (QRP) and the Skilled Nursing Facility Value-Based Purchasing (VBP) Program.
On December 20, 2016, the Centers for Medicare & Medicaid Services (CMS) issued the final rule for a new Cardiac Rehabilitation Incentive (CR) model, which includes mandatory bundled payment programs for an acute myocardial infarction (AMI) episode of care or a coronary artery bypass graft (CABG) episode of care, and modifications to the existing Comprehensive Care for Joint Replacement (CJR) model to include surgical hip/femur fracture treatment episodes. The new mandatory cardiac programs mirror the Bundled Payments for Care Improvement (BPCI) and Comprehensive Care for Joint Replacement (CJR) models in that actual episode payments will be retrospectively compared against a target price. Similar to CJR, participating hospitals will be at risk for Medicare Part A and B payments in the inpatient admission and 90 days post-discharge. BPCI episodes would continue to take precedence over episodes in the CJR program and in the new cardiac bundled payment program. The cardiac model will be mandatory in 98 randomly selected geographic areas and the hip/femur procedure model will be mandatory in the same 67 geographic areas that were selected for CJR. CMS is also providing “Cardiac Rehabilitation Incentive Payments”, which can be used by hospitals to facilitate cardiac rehabilitation plans and adherence. The incentive will be provided to hospitals in 45 of the 98 geographic areas included in the mandatory bundled payment program and 45 geographic areas outside of the program. On December 1, 2017, CMS issued a final rule which officially canceled the Episode Payment Models and Cardiac Rehabilitation Incentive Payment Model, rescinding the regulations governing these models. Additionally, the final rule implemented certain revisions to the CJR program, including making participation voluntary for approximately half of the geographic areas, along with other technical refinements. These regulation changes became effective January 1, 2018 and are effective for five performance years.
On January 9, 2018, CMS launched a new voluntary bundled payment called Bundled Payments for Care Improvement Advanced (BPCI Advanced), which replaced the BPCI initiative that terminates on September 30, 2018. The Model Performance Period for BPCI Advanced commenced on October 1, 2018 and runs through December 31, 2023. Under the advanced bundled payment model, participants can earn additional payment if all expenditures for a beneficiary’s episode of care are under a spending target that factors in quality. The BPCI Advanced model changes the BPCI initiative in a number of ways. Most importantly, it eliminates the BPCI Model 3 which allows post-acute care providers to participate as episode initiators. Episode initiators under the new BPCI Advanced initiative are called Non-Convener Participants and only include Acute Care Hospitals and Physician Group Practices.  As a result, once BCPI Advanced is implemented, post-acute care providers will only be able to participate as “Convener Participants.”  A Convener Participant is a participant that brings together the episode initiators, which are the Acute Care Hospital or the Physician Group Practice. The Convener Participant facilitates coordination among the episode initiators and bears and apportions financial risk under BCPI Advanced. Thus post-acute care providers may only participate in BPCI Advanced as Convener Participants.
BPCI Advanced will qualify as the first Advanced Alternative Payment Model (Advanced APM) under the Quality Payment Program (QPP). In 2015, Congress passed the Medicare Access and Chip Reauthorization Act (MACRA). MACRA requires CMS to implement a program called the Quality Payment Program or QPP, which changes the way physicians are paid who participate in Medicare. QPP creates two tracks for physician payment - the Merit-Based Incentive Payment System (MIPS) track and the Advanced APM track. Under MIPS, providers have to report a range of performance metrics and their payment amount is adjusted based on their performance. Under Advanced APMs, providers take on financial risk to earn the Advanced APM incentive payment that they are participating in.

48


On April 16, 2019 CMS issued a final rule revising Medicare Advantage Program (Part C) regulations and Prescription Drug Benefit Program (Part D) regulations to implement certain provisions of the Bipartisan Budget Act of 2018 effective as of January 1, 2020. This final rule makes several revisions and additions to the preclusion list provisions finalized in the April 2018 final rule. Further, this final rule will also revise the appeals and grievances requirements for certain Medicaid managed care and Medicare Advantage special needs plans for dual eligible individuals to implement certain provisions of the Bipartisan Budget Act of 2018.

Skilled Nursing

CMS Payment Rules. On August 8, 2018, CMS issued a final rule outlining Fiscal Year 2019 Medicare payments and quality changes for skilled nursing facilities. The final rule revises the case-mix classification system used under the SNF Prospective Payment System (the SNF PPS Rule). The SNF PPS Rule reduces documentation requirements, updates the data used to evaluate reimbursement amounts, and ties reimbursement to patients’ conditions and care needs, (clinically relevant factors) rather than the volume of services provided.
The SNF PPS Rule will be effective October 1, 2019. The SNF PPS Rule includes a new case-mix model that focuses on the patient’s condition and resulting care needs (clinically relevant factors), rather than on the volume of care provided, to determine reimbursement from Medicare. The case mix-model is called the Patient-Driven Payment Model (PDPM), which utilizes clinically relevant factors for determining Medicare payment by using ICD-10 diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy (PT), occupational therapy (OT), speech language pathology (SLP), nursing and social services (nursing) and non-therapy ancillary services (NTA). It also uses a sixth non-case mix component to cover utilization of SNF resources that do not vary depending on resident characteristics.
PDPM will replace the existing case-mix classification methodology, Resource Utilization Groups, Version IV (RUG-IV). The structure of PDPM moves Medicare towards a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident’s care, thereby more accurately addressing costs associated with medically complex patients. PDPM also removes therapy minutes as the basis for therapy payment. Finally, PDPM adjusts the SNF per diem payments to reflect varying costs throughout the stay, through the PT, OT and NTA components.
In addition, PDPM is intended to reduce paperwork requirements for performing patient assessments. Under the new SNF PPS PDPM system, the payment to skilled nursing facilities and nursing homes will be based heavily on the patient’s condition rather than the specific services provided by each skilled nursing facility.

Subsequently, on July 30, 2019, CMS issued a final rule for fiscal year 2020 that updates the Medicare payment rates and the quality programs for skilled nursing facilities. Under the final rule, effective October 1, 2019, the aggregate payments to skilled nursing facilities will increase by 2.4% for fiscal year 2020, compared to fiscal year 2019. This estimated increase is attributable to a 2.8% market basket increase factor, with a 0.4% point reduction for multifactor productivity adjustment. The final rule also updated the Skilled Nursing Facility Value-Based Purchasing Program (VBP), which took effect on October 1, 2018, to ensure that CMS publishes accurate performance information for low-volume SNFs and a new 30-day deadline for Phase One Review and Corrections requests. In addition, CMS is adopting two new quality measures in fiscal year 2020 under the SNF Quality Reporting Program (QRP) to assess whether certain health information is provided by the SNF at the time of transfer or discharge. The two measures are: 1) Transfer of Health Information to the Provider-Post-Acute Care and 2) Transfer of Health Information to the Patient-Post-Acute Care. Further, the final rule includes the change of the group therapy definition, which consists of treating two to six patients doing the same or similar activities.

On July 31, 2017, CMS issued its final rule outlining fiscal year 2018 Medicare payment rates for skilled nursing facilities. Under the final rule, the market basket index is revised and rebased by updating the base year from 2010 to 2014 and adding a new cost category for Installation, Maintenance, and Repair Services. The rule also includes revisions to the SNF Quality Reporting Program, including measure and standardized patient assessment data policies, as well as policies related to public display. In addition, it finalized policies for the Skilled Nursing Facility VBP that will affect Medicare payment to SNFs beginning in fiscal year 2019 and clarification of the requirements regarding the composition of professionals for the survey team. The final rule uses a market basket percentage of 1% to update the federal rates, but if a SNF fails to submit quality reporting program requirements there will be a 2% reduction to the market basket update for the fiscal year involved. Thus, the increase in the proposed federal rates may increase the amount of our reimbursements for SNF services so long as we meet the reporting requirements.    
Further, effective October 1, 2018, the SNF Value Based Purchasing Program applies either positive or negative incentive payments to skilled nursing facilities based on their performance on the program’s readmissions measures. The single claims-based, all cause thirty-day hospital readmissions, measure aims to improve individual outcomes through rewarding providers that take steps to limit the readmission of their patients to a hospital and penalize providers that do not take such steps to limit readmission of their patients.

49



On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates and quality programs for skilled nursing facilities. The policies in the finalized rule continue to shift Medicare payments from volume to value. The aggregate payments to skilled nursing facilities increased by a net 2.4% for fiscal year 2017. This estimate increase reflected a 2.7% market basket increase, reduced by a 0.3% multi-factor productivity (MFP) adjustment required by the Patient Protection and ACA. This final rule also further defines the skilled nursing facilities Quality Reporting Program and clarifies the Value-Based Purchasing Program to establish performance standards, baseline and performance periods, performance scoring methodology and feedback reports.

The Value-Based Purchasing Program rewards skilled nursing facilities with incentive payments for the quality of care they give to people with Medicare. The final rule specifies the skilled nursing facility 30-day potentially preventable readmission measure, which assesses the facility-level risk standardized rate of unplanned, potentially preventable hospital readmissions for skilled nursing facility patients within 30 days of discharge from a prior admission to a hospital paid under the Inpatient Prospective Payment System, a critical access hospital, or a psychiatric hospital. There is also finalized additional policies related to the Value-Based Purchasing Program including: establishing performance standards; establishing baseline and performance periods; adopting a performance scoring methodology; and providing confidential feedback reports to the skilled nursing facilities. This SNF Value-Based Purchasing Program became effective on October 1, 2018.

On July 30, 2015, CMS issued its final rule outlining fiscal year 2016 Medicare payment rates for skilled nursing facilities. The aggregate payments to skilled nursing facilities increased by 1.2% for fiscal year 2016. This increase reflected a 2.3% market basket increase, reduced by a 0.6% point forecast error adjustment and further reduced by 0.5% MFP adjustment required by the Patient Protection and Affordable Care Act (ACA). This final rule also identified a new skilled nursing facility value-based purchasing program and all-cause all-condition hospital readmission measure.

Should future changes in reimbursement systems include further reduced rates or increased standards for reaching certain reimbursement levels, our Medicare revenues derived from our affiliated skilled nursing facilities (including rehabilitation therapy services provided at our affiliated skilled nursing facilities) could be reduced, with a corresponding adverse impact on our financial condition or results of operations.

CMS issued a final rule on June 3, 2019 which updates the requirements for the Programs of All-Inclusive Care for the Elderly (PACE) under the Medicare and Medicaid programs. The regulation is intended to provide greater operational flexibility, remove redundancies and outdated information and codify existing programs. Such flexibility includes, (i) more lenient standards applicable to the current requirement that the PACE organization be monitored for compliance with the PACE program requirements during and after a 3-year trial period and (ii) relieving certain restrictions placed upon the interdisciplinary team that comprehensively assesses and provides for the individual needs of each PACE participant by allowing one person to fill two roles and permitting secondary participation in the PACE program. Further, non-physician primary care providers are able to provide certain services in place of primary care physicians.

Home Health

On July 11, 2019, CMS issued a proposed rule updating the Medicare Home Health Prospective Payment System (HH PPS) rates and wage index for calendar year 2020.  The rule proposes a 1.3% increase in home health payments, resulting from a 1.5% payment percentage update and a 0.2% decrease in aggregate payments because of changes to the rural add-on policy. The proposed rule implements the Patient‑Driven Groupings Model (PDGM), a revised case‑mix adjustment methodology, for home health services beginning on or after January 1, 2020, and proposes to adjust reimbursement under PDGM for assumed provider behavioral changes.  The proposed rule also changes the unit of payment from 60‑day episodes of care to 30-day periods of care, modifies payment regulations related to the content of the home health plan of care; allows therapist assistants to furnish maintenance therapy under the supervision of a licensed therapist; and proposes to change and eventually eliminate the split percentage payment approach under the HH PPS.  Finally, this rule will include proposals related to the implementation of the permanent home infusion therapy benefit in 2021. These include proposed payment categories, amounts, and required and optional adjustments.  


50


On November 13, 2018, CMS published a final rule which updates Medicare Home Health Prospective Payment System (HH PPS) rates, including the conversion factor and case-mix weights for calendar years 2019 and 2020. This rule finalizes the definition of remote patient monitoring which will be allowed as an administrative expense on the home health agency’s cost report. Further, effective January 1, 2020, CMS will implement PDGM as mandated by the Bipartisan Budget Act of 2018. Under PDGM, the initial certification of patient eligibility, plan of care, and comprehensive assessment will remain valid for 60-day episodes of care, but payments for home health services will be made based upon 30-day payment periods. PDGM refines case mix calculation methodology by removing therapy thresholds and calculating reimbursement based on clinical characteristics including clinical group coding, comorbidity coding, and achievement of LUPA thresholds. While the proposed changes are to be implemented in a budget neutral manner to the industry, CMS’s current proposal includes a negative 6.42% adjustment to account for assumed provider behavioral changes. The ultimate impact of these changes will vary by provider based on factors including patient mix and admission source. The finalization of these assumptions could negatively impact our future rate of reimbursement and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. This rule also finalizes changes to the Home Health Value-Based Purchasing (HHVBP) model and Home Health Quality Reporting Program (HHQRP). These changes focus on providing value over volume of services to patients. Once the changes are implemented, health payments will no longer be based on the number of visits provided, but rather the patient’s medical condition and care needs. In calendar year 2019, there was an increase of 2.2% in reimbursement to home health agencies based on the agency’s finalized policies.
On November 1, 2017, CMS issued a final rule that became effective on January 1, 2018 and updated the calendar year 2018 Medicare payment rates and the wage index for home health agencies serving Medicare beneficiaries. The rule also finalized proposals for the HHVBP model and the HHQRP. Under the final rule, Medicare payments will be reduced by 0.4%. This decrease reflects the effects of a 1.0% home health payment update, an adjustment to the national, standardized 60-day episode payment rate to account for nominal case-mix growth for an impact of negative 0.9%, and the distributional effects of a 0.5% reduction in payments due to the sunset of the rural add-on provision.
On January 13, 2017, CMS issued a final rule that modernized the Home Health Conditions of Participation (“CoPs”). This rule is a continuation of CMS’s effort to improve quality of care while streamlining provider requirements to reduce unnecessary procedural requirements. The rule makes significant revisions to the conditions currently in place, including (1) adding new conditions of participation related to quality assurance and performance improvement programs and infection control; and (2) expanding or revising requirements related to patient rights, comprehensive evaluations, coordination and care planning, home health aide training and supervision, and discharge and transfer summary and time frames. The new CoPs became effective on January 13, 2018.
On October 31, 2016, CMS issued final payment changes to HH PPS for calendar year 2017. Under this rule, Medicare payments were reduced by 0.7%. This decrease reflects a negative 0.97% adjustment to the national, standardized 60-day episode payment rate to account for nominal case-mix growth from 2012 through 2014; a 2.3% reduction in payments due to the final year of the four-year phase-in of the rebasing adjustments to the national, standardized 60-day episode payment rate, the national per-visit payment rates and the non-routine medical supplies conversion factor; and the effects of the revised fixed-dollar loss ratio used in determining outlier payments; partially offset by the home health payment update of 2.5%.

Hospice
On July 31, 2019, CMS issued a final rule that updated the fiscal year 2020 hospice payment rates, wage index and cap amount.  The final rule calls for a 2.6% increase in hospice payment rates for fiscal year 2020. This increase is based on the fiscal year 2020 hospital market basket increase of 3.0%, reduced by the multifactor productivity adjustment of 0.4%. The rule establishes a rebasing of the continuous home care, general inpatient care, and the inpatient respite care per diem payment rates in a budget-neutral manner to more accurately align Medicare payments with the costs of providing care. Specifically, the rule increases these rates by 36.6%, 161.2%, and 31.0% respectively to account for the disparity between reimbursement and cost.  In order to maintain budget neutrality, the rule reduces the Routine Home Care rate by 2.7%. Hospices that fail to meet quality reporting requirements continue to receive a 2.0% reduction to the annual market basket update for the year. Further, the rule establishes the hospice cap amount for the fiscal year 2020 at $29,964.78, which is equal to the fiscal year 2019 cap amount of $29,205.44, updated by the final rule for fiscal year 2020 hospice payment update percentage of 2.6%. In addition to the payment updates, the final rule contains new regulations that modify election statement requirements and require hospices to prepare an addendum to the election entitled “Patient Notification of Hospice Non-Covered Items, Services, and Drugs," which will provide the patient with information related to any diagnoses, treatment, or medications that are considered by the hospice to be unrelated to the terminal diagnoses. In addition to its preparation, the hospice is required to provide the addendum upon request by the patient or the patients representative within five days, if requested at the time of election, or within 72 hours if requested thereafter.

51


On August 1, 2018, CMS issued its final rule outlining the fiscal year 2019 Medicare payment rates, wage index, and cap amount for hospices serving Medicare beneficiaries. Under the final rule, the hospice payment update is 1.8%, which reflects a market basket update of 2.9%, reduced 0.8% by a MFP adjustment, as well as another 0.3% reduction, which decreases are mandated by the ACA. Hospice payments will be reduced by an additional 2.0%, for a net negative 0.2%, for hospices that do not submit the required quality data. The final rule also specifies that the hospice cap will be updated using the hospice payment update percentage rather than the consumer price index, thus it is anticipated there will be a 1.8% increase in aggregate cap payments made to hospices annually. The final rule also includes language that reflects the change in the Bipartisan Budget Act of 2018 which recognizes physician assistants as attending physicians for Medicare hospice beneficiaries, effective January 1, 2019. Physician assistants will be reimbursed at 85% of the fee schedule amount for their services as designated attending physicians. This change may positively impact reimbursement from Medicare as this may increase the number of episodes that can be reimbursed by Medicare in the aggregate by physicians, nurse practitioners and physician assistants. Additionally, the rule finalizes changes to the Hospice Quality Reporting Program (HQRP), also effective January 1, 2019, including changes to the data review and correction timeline for data submitted using the Hospice Item Set.

On August 1, 2017, CMS issued its final rule outlining the fiscal year 2018 Medicare payment rates, wage index and cap amount for hospices serving Medicare beneficiaries. The final rule uses a net market basket percentage increase of 1.0% to update the federal rates, as mandated by section 411(d) of the MACRA. Although, if a hospice fails to comply with quality reporting program requirements, there will be a net 2.0% reduction to the market basket update for the fiscal year involved. The hospice cap amount for fiscal year 2018 was increased by 1.0%, which is equal to the 2017 cap amount updated by the fiscal year 2018 hospice payment update percentage of 1.0%. In addition, this rule discusses changes to the HQRP, including changes to the Consumer Assessment of Healthcare Providers & Systems (CAHPS) hospice survey measures and plans for sharing HQRP data in fiscal year 2017.
On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates, wage index and cap amount for hospices serving Medicare beneficiaries. Under the final rule, there was a net 2.1% increase in hospices’ payments effective October 1, 2016. The hospice payment increase was the net result of a 2.7% inpatient hospital market basket update, reduced by a 0.3% productivity adjustment and by a 0.3% adjustment set by the ACA. The hospice cap amount for fiscal year 2017 increased by 2.1%, which is equal to the 2016 cap amount updated by the fiscal year 2017 hospice payment update percentage of 2.1%. In addition, this rule changes the hospice quality reporting program requirements, including care surveys and two new quality measures that will assess hospice staff visits to patients and caregivers in the last three and seven days of life and the percentage of hospice patients who received care processes consistent with guidelines.

Medicare Part B Therapy Cap. Some of our rehabilitation therapy revenue is paid by the Medicare Part B program under a fee schedule. Congress has established annual caps that limit the amounts that can be paid (including deductible and coinsurance amounts) for rehabilitation therapy services rendered to any Medicare beneficiary under Medicare Part B. The Deficit Reduction Act of 2005 (DRA) added Sec. 1833(g)(5) of the Social Security Act and directed CMS to develop a process that allows exceptions for Medicare beneficiaries to therapy caps when continued therapy is deemed medically necessary.

Annual limitations on beneficiary incurred expenses for outpatient therapy services under Medicare Part B are commonly referred to as “therapy caps.” All beneficiaries began a new cap year on January 1, 2019 since the therapy caps are determined on a calendar year (CY) basis. For physical therapy (PT) and speech-language pathology services (SLP) combined, the limit on incurred expenses is $2,040 in 2019 compared to $2,010 in 2018. The cap limit is the same for occupational therapy (OT) services. Deductible and coinsurance amounts paid by the beneficiary for therapy services are applied towards the cap limit. A KX Modifier Applied to the claim for beneficiaries exceeding the $2,040 Cap communicates ongoing Medical Necessity for services delivered.

On February 9, 2018, President Trump signed into law the Bipartisan Budget Act of 2018. This new law includes several provisions related to Medicare payments for services beginning on January 1, 2018. With regard to payment for outpatient therapy services, the law repeals application of the Medicare outpatient therapy caps but retains the former cap amounts as a threshold above for services that are medically necessary. The new law retains the targeted medical review process, but at a lower threshold amount. It also extends several recently expired Medicare legislative provisions affecting health care providers and beneficiaries, including the Medicare physician fee schedule work geographic adjustment floor.


52


On November 1, 2018, CMS issued a final rule that revises the payment policies under the Medicare Physician Fee Schedule which includes other revisions to Medicare Part B and the Quality Payment Program for current year 2019. One of the proposed revisions relates to functional reporting by therapists who provide outpatient services (including services to long term care (LTC) Residents of the SNF under the Medicare Part B program). To date therapists that provide outpatient services are required to include functional status information and at certain intervals the patient’s severity on claims for such therapy services. Consistent with CMS’ “Patients over Paperwork” initiative the agency eliminated the burdensome claims-based functional reporting requirements for Part B therapy services. In January 2019, SNFs are no longer required to append selected G-codes or the severity modifiers on outpatient therapy claims. This reduces the reporting burden on therapists providing outpatient services and increase the amount of time that therapists can spend with their patients. This may result in greater reimbursement for outpatient therapy services as therapists who provide outpatient services may spend more time with patients.

A second part to the Physician Fee Schedule Final Rule is that CMS established new therapy assistant claim modifiers that will be required starting in CY 2020. When a physical therapist assistant (PTA) or occupational therapy assistant (OTA) provides all or part of treatment on a given day, the Balance Budget Act requires a 15 percent therapist assistant payment reduction be applied to the claim for that day starting in 2022.

The Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes 1) facilities that provide Medicare Part B speech-language pathology, occupational therapy, and physical therapy services and bill under the same provider number; and 2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.
Medicare Coverage Settlement Agreement. A proposed federal class action settlement was filed in federal district court on October 16, 2012 that would end the Medicare coverage standard for skilled nursing, home health and outpatient therapy services that a beneficiary's condition must be expected to improve. The settlement was approved on January 24, 2013, which tasked CMS with revising its Medicare Benefit Manual and numerous other policies, guidelines and instructions to ensure that Medicare coverage is available for skilled maintenance services in the home health, skilled nursing and outpatient settings. CMS was also required to develop and implement a nationwide education campaign for all who make Medicare determinations to ensure that beneficiaries with chronic conditions are not denied coverage for critical services because their underlying conditions will not improve, after which the members of the class were given the opportunity for re-review of their claims. The major provisions of this settlement agreement have been implemented by CMS, which could favorably impact Medicare coverage reimbursement for our services. However, health care providers may be subject to liability in the event they fail to appropriately adapt to the newly clarified reimbursement rules and consequently overbill state Medicaid programs in connection with services rendered to dual-eligible Medicare patients (i.e., by not maximizing Medicare coverage before billing Medicaid).

Historically, adjustments to reimbursement under Medicare have had a significant effect on our revenue. For a discussion of historic adjustments and recent changes to the Medicare program and related reimbursement rates, see Part II, Item 1A Risk Factors under the headings Risks Related to Our Business and Industry - “Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicaid and Medicare,” “Our future revenue, financial condition and results of operations could be impacted by continued cost containment pressures on Medicaid spending,” “We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations” and “Reforms to the U.S. healthcare system will impose new requirements upon us and may lower our reimbursements.” The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.

Results of Operations

The following table sets forth details of our revenue, expenses and earnings as a percentage of total revenue for the periods indicated:

53


 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018
 
2019
 
2018
 
 
 
 
 
 
 
 
Revenue
100.0
 %
 
100.0
 %
 
100.0
 %
 
100.0
 %
Expense
 
 
 
 
 
 
 
Cost of services
79.4

 
79.8

 
78.9

 
79.5

Return of unclaimed class action settlement

 

 

 
(0.2
)
Rent—cost of services
6.3

 
7.0

 
6.5

 
6.9

General and administrative expense
5.3

 
4.5

 
5.6

 
4.8

Depreciation and amortization
2.3

 
2.3

 
2.3

 
2.4

Total expenses
93.3

 
93.6

 
93.3

 
93.4

Income from operations
6.7

 
6.4

 
6.7

 
6.6

Other income (expense):
 
 
 
 
 
 
 
Interest expense
(0.7
)
 
(0.8
)
 
(0.7
)
 
(0.8
)
Interest income
0.1

 
0.1

 
0.1

 
0.1

Other expense, net
(0.6
)
 
(0.7
)
 
(0.6
)
 
(0.7
)
Income before provision for income taxes
6.1

 
5.7

 
6.1

 
5.9

Provision for income taxes
1.0

 
1.2

 
1.1

 
1.3

Net income
5.1

 
4.5

 
5.0

 
4.6

Less: net income attributable to noncontrolling interests
0.1

 
0.1

 

 

Net income attributable to The Ensign Group, Inc.
5.0
 %
 
4.4
 %
 
5.0
 %
 
4.6
 %
 
 
 
 
 
 
 
 

 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
(In thousands)
Non-GAAP Financial Measures:
 

 
 
 
 
 
 
Performance Metrics
 
 
 
 
 
 
 
EBITDA
$
50,714

 
$
43,081

 
$
100,881

 
$
87,521

Adjusted EBITDA
56,776

 
46,321

 
113,530

 
92,956

Valuation Metric
Adjusted EBITDAR
$
93,727

 
$
77,147

 
$
186,184

 
$
153,975


The following discussion includes references to EBITDA, Adjusted EBITDA and Adjusted EBITDAR which are non-GAAP financial measures (collectively, Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Exchange Act define and prescribe the conditions for use of certain non-GAAP financial information. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP. These non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. These non-GAAP financial measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.
We believe the presentation of Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as interest expense, net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and


54


they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.

We use Non-GAAP Financial Measures:

as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;

to allocate resources to enhance the financial performance of our business;

to assess the value of a potential acquisition;

to assess the value of a transformed operation's performance;

to evaluate the effectiveness of our operational strategies; and

to compare our operating performance to that of our competitors.

We typically use Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as net interest expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets.

Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:

they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;

they do not reflect changes in, or cash requirements for, our working capital needs;

they do not reflect the net interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;

they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;

they do not reflect any income tax payments we may be required to make;

although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and

other companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.

We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

Management strongly encourages investors to review our consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP Financial Measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our consolidated financial statements and related notes included elsewhere in this document.

55



We use the following Non-GAAP Financial Measures that we believe are useful to investors as key valuation and operating performance measures:
EBITDA

We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate EBITDA as net income from continuing operations, adjusted for net losses attributable to noncontrolling interest, before (a) interest expense, net, (b) provision for income taxes, and (c) depreciation and amortization.

Adjusted EBITDA

We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income (loss) attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance. 

Adjusted EBITDA is EBITDA adjusted for non-core business items, which for the reported periods includes, to the extent applicable:

results related to closed operations and operations not at full capacity;
results at facilities currently being constructed and other start-up operations;
return of unclaimed class action settlement funds;
share-based compensation expense;
expenses incurred in connection with the proposed spin-off;
acquisition related costs; and
business interruption recoveries.

Adjusted EBITDAR

 We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements.  Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense.

The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.
We believe the use of Adjusted EBITDAR allows the investor to compare operational results of companies who have operating and capital leases. A significant portion of capital lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:


56


 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
(In thousands)
Consolidated statements of income data:
 
 
 
 
 
 
 
Net income
$
28,925

 
$
22,326

 
$
56,532

 
$
45,619

Less: net income attributable to noncontrolling interests
316

 
315

 
551

 
476

Add: Interest expense, net
3,369

 
3,307

 
6,466

 
6,472

Provision for income taxes
5,552

 
6,142

 
12,652

 
12,663

Depreciation and amortization
13,184

 
11,621

 
25,782

 
23,243

EBITDA
$
50,714

 
$
43,081

 
$
100,881

 
$
87,521

 
 
 
 
 
 
 
 
Results related to closed operations and operations not at full capacity(a)
365

 
209

 
629

 
325

Losses/(earnings) related to operations in the start-up phase(b)
82

 
(2,543
)
 
317

 
(4,794
)
Return of unclaimed class action settlement

 

 

 
(1,664
)
Share-based compensation expense
3,302

 
2,520

 
6,255

 
4,829

Proposed spin-off transaction costs(c)
1,658

 

 
4,648

 

Acquisition related costs(d)
546

 
83

 
608

 
111

Business interruption recoveries(e)

 
(675
)
 

 
(675
)
Rent related to items above
109

 
3,646

 
192

 
7,303

Adjusted EBITDA
$
56,776

 
$
46,321

 
$
113,530

 
$
92,956

Rent—cost of services
37,060

 
34,472

 
72,846

 
68,322

Less: rent related to items above
(109
)
 
(3,646
)
 
(192
)
 
(7,303
)
Adjusted EBITDAR
$
93,727

 
$
77,147

 
$
186,184

 
$
153,975

 
 
 
 
 
 
 
 
(a)
Results at closed operations and operations not at full capacity during the three and six months ended June 30, 2019 and 2018.
(b)
Represents results related to facilities currently in the start up phase after construction was completed. This amount excludes rent, depreciation and interest expense.
(c)
Costs incurred in connection with our proposed spin-off of our home health and hospice operations and substantially all of our senior living operations to a newly formed publicly traded company.
(d)
Costs incurred to acquire operations which are not capitalizable.
(e)
Business interruption recoveries related to insurance claims with respect to the California fires that occurred in the fourth quarter of 2017.


Three Months Ended June 30, 2019 Compared to the Three Months Ended June 30, 2018

Revenue
 
 
Three Months Ended June 30,
 
 
2019

2018
 
 
$
 
%
 
$
 
%
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
Transitional and skilled services
 
$
469,238


81.5
%

$
408,518


82.3
%
Senior living services
 
42,046


7.3


37,164


7.5

Home health and hospice services:
 







Home health
 
24,988


4.3


21,321


4.3

Hospice
 
25,220


4.4


19,928


4.0

Total home health and hospice services
 
50,208


8.7


41,249


8.3

All other (1)
 
14,159


2.5


9,455


1.9

Total revenue
 
$
575,651


100.0
%

$
496,386


100.0
%
(1) Includes revenue from services generated in our ancillary services.


57


Our consolidated revenue increased $79.3 million, or 16.0%. Our transitional and skilled services revenue increased by $60.7 million, or 14.9%, mainly attributable to the increase in patient days, revenue per patient day and the impact of acquisitions. Our senior living services revenue increased by $4.9 million, or 13.1%, mainly due to the impact of acquisitions, coupled with an increase in average monthly revenue per unit. Our home health and hospice services revenue increased by $9.0 million, or 21.7%, mainly due to increases in census in existing agencies and rate per episode combined with new acquisitions. Revenue from operations acquired on or subsequent to January 1, 2018 for all segments increased our consolidated revenue by $36.2 million during the three months ended June 30, 2019, when compared to the same period in 2018.

Transitional and Skilled Services

The following table presents the transitional and skilled services revenue and key performance metrics by category during the three months ended June 30, 2019 and 2018:
 
Three Months Ended June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Total Facility Results:
 
 
 
 
 
 
 
Transitional and skilled revenue
$
469,238


$
408,518


$
60,720


14.9
 %
Number of facilities at period end
171


162


9


5.6
 %
Number of campuses at period end*
27


22


5


22.7
 %
Actual patient days
1,472,798


1,330,057


142,741


10.7
 %
Occupancy percentage — Operational beds
79.4
%

76.6
%

 

2.8
 %
Skilled mix by nursing days
29.0
%

29.7
%

 

(0.7
)%
Skilled mix by nursing revenue
48.7
%

50.2
%

 

(1.5
)%
 
Three Months Ended June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Same Facility Results(1):
 
 
 
 
 
 
 
Transitional and skilled revenue
$
348,623


$
322,922


$
25,701


8.0
 %
Number of facilities at period end
127


127




 %
Number of campuses at period end*
14


14




 %
Actual patient days
1,054,389


1,015,579


38,810


3.8
 %
Occupancy percentage — Operational beds
80.1
%

77.4
%

 

2.7
 %
Skilled mix by nursing days
31.0
%

31.4
%

 

(0.4
)%
Skilled mix by nursing revenue
50.9
%

51.7
%

 

(0.8
)%
 
Three Months Ended June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Transitioning Facility Results(2):
 
 
 
 
 
 
 
Transitional and skilled revenue
$
89,359


$
79,801

 
$
9,558

 
12.0
%
Number of facilities at period end
33


33

 

 
%
Number of campuses at period end*
7


7

 

 
%
Actual patient days
310,474


295,103

 
15,371

 
5.2
%
Occupancy percentage — Operational beds
78.0
%

74.3
%
 
 
 
3.7
%
Skilled mix by nursing days
25.4
%

24.6
%
 
 
 
0.8
%
Skilled mix by nursing revenue
44.6
%

44.6
%
 
 
 
%

58


 
Three Months Ended June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Recently Acquired Facility Results(3):
 
 
 
 
 
 
 
Transitional and skilled revenue
$
31,256


$
5,795


$
25,461

 
NM
Number of facilities at period end
11


2


9

 
NM
Number of campuses at period end*
6


1


5

 
NM
Actual patient days
107,935


19,375


88,560

 
NM
Occupancy percentage — Operational beds
76.3
%

75.7
%



 
NM
Skilled mix by nursing days
20.8
%

23.4
%

 

 
NM
Skilled mix by nursing revenue
35.2
%

38.8
%

 

 
NM
* Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
(1)
Same Facility results represent all facilities purchased prior to January 1, 2016.
(2)
Transitioning Facility results represent all facilities purchased from January 1, 2016 to December 31, 2017.
(3)
Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2018.

Transitional and skilled services revenue increased $60.7 million, or 14.9% as compared to the second quarter of 2018. Of the $60.7 million increase, Medicaid custodial revenue increased $31.0 million, or 19.2%, Medicare and managed care revenue increased $22.9 million, or 12.6%, Medicaid skilled revenue increased $3.5 million, or 12.3%, and private and other revenue increased $3.4 million, or 9.3%.

Transitional and skilled services revenue generated by Same Facilities increased $25.7 million, or 8.0%. Same store revenue was driven by the following factors:
Skilled mix revenue increased by $8.4 million, or 5.1%. The change is driven by the increase in our managed care revenue of $4.9 million due to the growth in patient days of 5.4% and an increase in managed care revenue per patient day of 2.7%. Our other skilled revenue increased by $2.4 million primarily attributable to growth in patient days of 2.5% and revenue per day of 5.4%.
Our Medicare revenue increased by $3.5 million. The change is driven by the increase in our Medicare revenue per patient day of 2.1%.
We continue to experience growth in revenue with our Medicaid plans. Our Medicaid revenue, excluding Medicaid-skilled revenue, increased by $13.1 million, mainly driven by an increase in Medicaid days. We also experienced an increase in Medicaid revenue per patient day of 4.0% as a result of our participation in the quality improvement programs and the supplemental programs in various states.

Transitional and skilled services revenue generated by Transitioning Facilities increased $9.6 million, or 12.0%. This is due to increases in total patient days and revenue per patient day of 5.2% and 4.8%, respectively. Our overall managed care revenue increased by $3.1 million, mainly due to an increase in managed care days of 21.6%. Our Medicaid revenue, excluding Medicaid-skilled revenue, increased by $4.3 million, mainly driven by a 5.8% increase in Medicaid days and an increase in Medicaid revenue per patient day of 6.6%, as a result of our participation in the quality improvement programs and supplemental programs in various states. Our Medicare revenue, increased by $1.9 million, mainly due to an increase in Medicare revenue per patient day of 2.8%.

Transitional and skilled services revenue generated by Recently Acquired Facilities increased by approximately $25.5 million, mainly due to 14 operations acquired between July 1, 2018 and June 30, 2019 in six states.
In the future, if we acquire additional turnaround or start up operations, we expect to see lower occupancy and skilled mix, and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates, lower skilled mix and quality mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth.
The following table reflects the change in the skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate:

59


 
Three Months Ended June 30,
 
Same Facility
 
Transitioning
 
Acquisitions
 
Total
 
2019

2018

2019

2018

2019

2018

2019

2018
Skilled Nursing Average Daily Revenue Rates:
Medicare
$
614.76


$
602.08


$
534.84


$
520.22


$
572.34


$
526.05


$
594.59


$
582.05

Managed care
466.48


454.13


419.73


410.79


421.67


427.64


454.37


445.48

Other skilled
493.47


468.18


462.28


467.78


330.42


250.64


488.04


467.19

Total skilled revenue
529.62


516.38


478.10


472.27


483.79


462.85


517.71


507.68

Medicaid
229.48


220.74


202.91


190.39


234.49


219.92


224.27


213.86

Private and other payors
236.16


226.10


204.60


196.25


233.55


236.72


227.22


217.35

Total skilled nursing revenue
$
323.49


$
314.46


$
273.32


$
260.74


$
286.20


$
279.56


$
310.16


$
302.01


Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 2.1% and 2.8%, respectively. The increase is attributable to the 2.4% net market basket increase that became effective in October 2018 compared to 1.0% that became effective we in October 2017, coupled with the continuous shift towards higher acuity patients.

Our average Medicaid rates increased 4.9%, primarily due to our participation in supplemental Medicaid payment programs and quality improvement programs in various states.

Payor Sources as a Percentage of Skilled Nursing Services. We use both our skilled mix and quality mix as measures of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods. The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:
 
Three Months Ended June 30,
 
Same Facility
 
Transitioning
 
Acquisitions
 
Total
 
2019

2018

2019

2018

2019

2018

2019

2018
Percentage of Skilled Nursing Revenue:
Medicare
23.0
%

24.2
%

24.7
%

26.8
%

19.2
%

20.9
%

23.1
%

24.7
%
Managed care
18.5


18.2


18.5


16.4


14.0


16.5


18.2


17.8

Other skilled
9.4


9.3


1.4


1.4


2.0


1.4


7.4


7.7

Skilled mix
50.9


51.7


44.6


44.6


35.2


38.8


48.7


50.2

Private and other payors
7.6


7.7


11.4


12.2


11.5


13.6


8.5


8.6

Quality mix
58.5


59.4


56.0


56.8


46.7


52.4


57.2


58.8

Medicaid
41.5


40.6


44.0


43.2


53.3


47.6


42.8


41.2

Total skilled nursing
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
Three Months Ended June 30,
 
Same Facility
 
Transitioning
 
Acquisitions
 
Total
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
Percentage of Skilled Nursing Days:
Medicare
12.1
%

12.6
%

12.6
%

13.4
%

9.6
%

11.1
%

12.0
%

12.8
%
Managed care
12.8


12.5


12.0


10.4


9.5


10.8


12.4


12.0

Other skilled
6.1


6.3


0.8


0.8


1.7


1.5


4.6


4.9

Skilled mix
31.0


31.4


25.4


24.6


20.8


23.4


29.0


29.7

Private and other payors
10.7


11.1


15.5


16.4


14.3


16.1


12.0


12.4

Quality mix
41.7


42.5


40.9


41.0


35.1


39.5


41.0


42.1

Medicaid
58.3


57.5


59.1


59.0


64.9


60.5


59.0


57.9

Total skilled nursing
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%


60


Senior Living Services
 
Three Months Ended June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Resident fee revenue
$
42,046


$
37,164


$
4,882


13.1
%
Number of facilities at period end
56


51


5


9.8
%
Number of campuses at period end
27


22


5


22.7
%
Occupancy percentage (units)
75.5
%

75.2
%

 

0.3
%
Average monthly revenue per unit
$
2,900


$
2,863


$
37


1.3
%
Senior living revenue increased 13.1%, to $42.0 million, primarily due to an increase in average monthly revenue per unit of 1.3%, an increase in occupancy of 0.3%, and revenue generated from the addition of ten facilities in five states between July 1, 2018 and June 30, 2019.
Home Health and Hospice Services
 
Three Months Ended June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Home health and hospice revenue
 
 
 
 
 
 
 
Home health services
$
24,988

 
$
21,321


$
3,667


17.2
%
Hospice services
25,220

 
19,928


5,292


26.6

Total home health and hospice revenue
$
50,208

 
$
41,249


$
8,959


21.7
%
 
 
 
 
 
 
 
 
Home health, hospice and home care agencies
62

 
46

 
16

 
34.8
%
Home health services:

 
 




Average Medicare revenue per completed episode
$
3,077

 
$
3,064


$
13


0.4
%
Hospice services:

 





Average daily census
1,673

 
1,290


383


29.7
%
Home health and hospice revenue increased $9.0 million, or 21.7%. Of the $9.0 million increase, Medicare and managed care revenue increased $7.0 million, or 20.3%. The increase in revenue is primarily due to the increase in census in existing agencies and rate per episode, coupled with the addition of 16 home health and hospice operations in seven states between July 1, 2018 and June 30, 2019.
Cost of Services

The following table sets forth total cost of services by each of our reportable segments and our "All Other" category for the periods indicated (dollars in thousands):
 
Three Months Ended June 30,
 
2019
 
2018
 
 
 
 
 
(In thousands)
Transitional and skilled services
$
373,992

 
$
329,768

Senior living services
28,784

 
24,407

Home health and hospice services
41,806

 
34,148

All other
12,418

 
7,809

Total cost of services
$
457,000

 
$
396,132


Consolidated cost of services increased $60.9 million, or 15.4% compared to the three months ended June 30, 2018. Consolidated cost of services as a percentage of revenue decreased by 0.4% to 79.4%.



61


Transitional and Skilled Services
 
 
Three Months Ended June 30,
 
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Cost of service
 
$
373,992

 
$
329,768

 
$
44,224

 
13.4
 %
Revenue percentage
 
79.7
%
 
80.7
%
 
 
 
(1.0
)%

Cost of services related to our transitional and skilled services segment increased $44.2 million, or 13.4%, due primarily to additional costs at Recently Acquired Facilities of $21.0 million. Cost of services as a percentage of revenue decreased to 79.7%, mainly due to improvements in collections efforts, operational improvements and a decrease in healthcare expenses.

Senior Living Services
 
 
Three Months Ended June 30,
 
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Cost of service
 
$
28,784

 
$
24,407

 
$
4,377

 
17.9
%
Revenue percentage
 
68.5
%
 
65.7
%
 
 
 
2.8
%

Cost of services related to our senior living services segment increased $4.4 million, or 17.9%, primarily due to recently acquired operations and organic operational growth. Cost of services as a percentage of total revenue increased to 68.5% primarily due to the increase in certain costs associated with newly acquired facilities and additional field-based resources to support our growing infrastructure. Our acquisition focus is to strategically acquire underperforming operations with strong opportunities for return. Historically, we generally experienced higher cost of services at newly acquired operations; and therefore, we anticipate lower margins at these operations during years of growth.

Home Health and Hospice Services
 
 
Three Months Ended June 30,
 
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Cost of service
 
$
41,806

 
34,148

 
$
7,658

 
22.4
%
Revenue percentage
 
83.3
%
 
82.8
%
 
 
 
0.5
%

Cost of services related to our home health and hospice services segment increased $7.7 million, or 22.4%, due to newly acquired operations and organic operational growth. Cost of services as a percentage of total revenue increased by 0.5% primarily due to the increase in certain costs associated with newly acquired operations. Included in cost of services is one-time broker fee of $0.4 million related to new agencies acquired in the current period. Without this fee, cost of services would have been 82.4%, which is 0.4% lower than prior year.

Rent — cost of services. Our rent — cost of services as a percentage of total revenue decreased by 0.7% to 6.3%, primarily due to our recent acquisitions including real estate assets, coupled with the growth in revenue outpacing the increase in rent expense.
General and administrative expense. Our general and administrative expense as percentage of revenue increased by 0.8% to 5.3%, mainly related to transaction costs related to our proposed Spin-Off and an increase in incentives due to operational improvements.
Depreciation and amortization. Depreciation and amortization expense increased $1.6 million, or 13.4%, to $13.2 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations. Depreciation and amortization remained consistent at 2.3%, as a percentage of revenue.
Other expense, net. Other expense, net as a percentage of revenue remained relatively consistent at 0.6%. Other expense mainly includes interest expense related to borrowings under our credit facility and HUD mortgages.

62


Provision for income taxes.  Our effective tax rate was 16.1% for the three months ended June 30, 2019, compared to 21.6% for the same period in 2018. The lower effective tax rate reflects an increase in an additional tax benefit from share-based payment awards. The lower effective tax rate was partially offset by increases in certain non-deductible items. See Note 14, Income Taxes, in the Notes to Condensed Consolidated Financial Statements for further discussion.
Six Months Ended June 30, 2019 Compared to the Six Months Ended June 30, 2018

Revenue
 
 
Six Months Ended June 30,
 
 
2019
 
2018
 
 
$
 
%
 
$
 
%
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
Transitional and skilled services
 
$
918,496

 
81.7
%
 
$
815,534

 
82.5
%
Senior living services
 
82,740

 
7.4

 
73,277

 
7.4

Home health and hospice services:
 
 
 
 
 
 
 
 
Home health
 
48,647

 
4.3

 
41,505

 
4.2

Hospice
 
47,678

 
4.2

 
39,502

 
4.0

Total home health and hospice services
 
96,325

 
8.5

 
81,007

 
8.2

All other (1)
 
27,304

 
2.4

 
18,702

 
1.9

Total revenue
 
$
1,124,865

 
100.0
%
 
$
988,520

 
100.0
%
(1) Includes revenue from services generated in our ancillary services.

Our consolidated revenue increased $136.3 million, or 13.8% as compared to the first half of 2018. Our transitional and skilled services revenue increased by $103.0 million, or 12.6%, mainly attributable to the increase in patient days, revenue per patient day and the impact of acquisitions. Our senior living services revenue increased by $9.5 million, or 12.9%, mainly due to the increase in average monthly revenue per unit, coupled with the impact of acquisitions. Our home health and hospice services revenue increased by $15.3 million, or 18.9%, mainly due to an increases in census in existing agencies and rate per episode combined with new acquisitions. Revenue from operations acquired on or subsequent to January 1, 2018 for all segments increased our consolidated revenue by $59.6 million during the six months ended June 30, 2019 when compared to the same period in 2018.
Transitional and Skilled Services

The following table presents the transitional and skilled services revenue and key performance metrics by category during the six months ended June 30, 2019 and 2018:
 
Six Months Ended
June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Total Facility Results:
 
 
 
 
 
 
 
Transitional and skilled revenue
$
918,496

 
$
815,534

 
$
102,962

 
12.6
 %
Number of facilities at period end
171

 
162

 
9

 
5.6
 %
Number of campuses at period end*
27

 
22

 
5

 
22.7
 %
Actual patient days
2,879,167

 
2,645,027

 
234,140

 
8.9
 %
Occupancy percentage — Operational beds
79.4
%
 
77.2
%
 
 
 
2.2
 %
Skilled mix by nursing days
29.5
%
 
30.7
%
 
 
 
(1.2
)%
Skilled mix by nursing revenue
49.2
%
 
51.2
%
 
 
 
(2.0
)%

63


 
Six Months Ended
June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Same Facility Results(1):
 
 
 
 
 
 
 
Transitional and skilled revenue
$
693,180

 
$
647,995

 
$
45,185

 
7.0
 %
Number of facilities at period end
127

 
127

 

 
 %
Number of campuses at period end*
14

 
14

 

 
 %
Actual patient days
2,093,819

 
2,034,749

 
59,070

 
2.9
 %
Occupancy percentage — Operational beds
80.1
%
 
77.9
%
 
 
 
2.2
 %
Skilled mix by nursing days
31.3
%
 
32.0
%
 
 
 
(0.7
)%
Skilled mix by nursing revenue
51.3
%
 
52.4
%
 
 
 
(1.1
)%
 
Six Months Ended
June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Transitioning Facility Results(2):
 
 
 
 
 
 
 
Transitional and skilled revenue
$
177,783

 
$
161,744

 
$
16,039

 
9.9
 %
Number of facilities at period end
33

 
33

 

 
 %
Number of campuses at period end*
7

 
7

 

 
 %
Actual patient days
620,434

 
590,903

 
29,531

 
5.0
 %
Occupancy percentage — Operational beds
78.4
%
 
74.8
%
 
 
 
3.6
 %
Skilled mix by nursing days
25.7
%
 
26.2
%
 
 
 
(0.5
)%
Skilled mix by nursing revenue
45.0
%
 
46.7
%
 
 
 
(1.7
)%
 
Six Months Ended
June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Recently Acquired Facility Results(3):
 
 
 
 
 
 
 
Transitional and skilled revenue
$
47,533

 
$
5,795

 
$
41,738

 
NM
Number of facilities at period end
11

 
2

 
9

 
NM
Number of campuses at period end*
6

 
1

 
5

 
NM
Actual patient days
164,914

 
19,375

 
145,539

 
NM
Occupancy percentage — Operational beds
74.2
%
 
75.7
%
 
 
 
NM
Skilled mix by nursing days
20.3
%
 
23.4
%
 
 

 
NM
Skilled mix by nursing revenue
33.9
%
 
38.8
%
 
 

 
NM
* Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
(1)
Same Facility results represent all facilities purchased prior to January 1, 2016.
(2)
Transitioning Facility results represent all facilities purchased from January 1, 2016 to December 31, 2017.
(3)
Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2018.
Transitional and skilled services revenue increased $103.0 million, or 12.6% as compared to the first half of 2018. Of the $103.0 million increase, Medicare and managed care revenue increased $33.0 million, or 8.9%, Medicaid custodial revenue increased $55.7 million, or 17.5%, private and other revenue increased $7.3 million, or 10.4%, and Medicaid skilled revenue increased $6.9 million, or 12.5%.

Transitional and skilled services revenue generated by Same Facilities increased $45.2 million, or 7.0%. The same store revenue was driven by the following factors:
Skilled mix revenue increased by $11.4 million, or 3.4%. The majority of the increase related to other skilled and managed care revenue. Our other skilled revenue increased by $4.9 million, mainly driven by growth in patient days of 3.0% and other skilled revenue per patient day of 5.4%. Our skilled managed care revenue increased by $4.8 million, due to an increase in managed care revenue per patient day and growth in patient days.

64


Our Medicare revenue increased by $6.5 million, or 3.8%, driven by the increase in Medicare revenue per patient day.
We continue to experience growth in revenue with our Medicaid plans. Our Medicaid revenue, excluding Medicaid-skilled revenue, increased by 9.6%, mainly driven by an increase in Medicaid days. We also experienced an increase in Medicaid revenue per patient day of 4.0% as a result of our participation in the quality improvement programs and the supplemental programs in various states.

Transitional and skilled services revenue generated by Transitioning Facilities increased $16.0 million, or 9.9%. This is due to increases in total patient days and revenue per patient day of 5.0% and 2.8%, respectively. We continued to experience growth in revenue with our Medicaid and managed care plans. Our Medicaid revenue, excluding Medicaid-skilled revenue, increased by $9.5 million, mainly driven by an 8.5% increase in Medicaid days and Medicaid revenue per patient day. Our overall managed care revenue increased by $5.1 million, mainly driven by an increase in managed care days of 14.7%.
Transitional and skilled services revenue generated by Recently Acquired Facilities increased by approximately $41.7 million, mainly due to 14 operations we acquired between July 1, 2018 and June 30, 2019 in six states.
In the future, if we acquire additional turnaround or start up operations, we expect to see lower occupancy and skilled mix, and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates, lower skilled mix and quality mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth.
The following table reflects the change in the skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate:
 
Six Months Ended June 30,
 
Same Facility
 
Transitioning
 
Acquisitions
 
Total
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
Skilled Nursing Average Daily Revenue Rates:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medicare
$
613.55

 
$
598.45

 
$
533.06

 
$
517.82

 
$
553.27

 
$
526.05

 
$
592.89

 
$
578.24

Managed care
464.81

 
452.75

 
417.42

 
410.42

 
424.10

 
427.64

 
453.16

 
444.31

Other skilled
492.54

 
467.50

 
489.70

 
472.81

 
322.78

 
250.64

 
489.47

 
467.16

Total skilled revenue
529.09

 
514.35

 
477.56

 
471.69

 
475.36

 
462.85

 
517.29

 
505.91

Medicaid
229.65

 
220.76

 
200.49

 
189.13

 
238.30

 
219.92

 
223.83

 
213.61

Private and other payors
235.03

 
225.95

 
207.84

 
201.42

 
234.47

 
236.72

 
227.54

 
218.67

Total skilled nursing revenue
$
324.28

 
$
315.80

 
$
272.86

 
$
265.35

 
$
286.07

 
$
279.56

 
$
311.00

 
$
304.24

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 2.5% and 2.9%, respectively. The increase is attributable to the 2.4% net market basket increase that became effective in October 2018 compared to 1.0% that became effective in October 2017, coupled with the continuous shift towards higher acuity patients.

Our average Medicaid rates increased 4.8% primarily due to our participation in supplemental Medicaid payment programs and quality improvement programs in various states.

Payor Sources as a Percentage of Skilled Nursing Services. We use both our skilled mix and quality mix as measures of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods. The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:


65


 
Six Months Ended June 30,
 
Same Facility
 
Transitioning
 
Acquisitions
 
Total
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
Percentage of Skilled Nursing Revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medicare
23.5
%
 
24.6
%
 
25.1
%
 
28.5
%
 
17.8
%
 
20.9
%
 
23.5
%
 
25.3
%
Managed care
18.4

 
18.8

 
18.4

 
17.0

 
14.5

 
16.5

 
18.2

 
18.4

Other skilled
9.4

 
9.0

 
1.5

 
1.2

 
1.6

 
1.4

 
7.5

 
7.5

Skilled mix
51.3

 
52.4

 
45.0

 
46.7

 
33.9

 
38.8

 
49.2

 
51.2

Private and other payors
7.5

 
7.5

 
11.2

 
12.0

 
12.6

 
13.6

 
8.4

 
8.5

Quality mix
58.8

 
59.9

 
56.2

 
58.7

 
46.5

 
52.4

 
57.6

 
59.7

Medicaid
41.2

 
40.1

 
43.8

 
41.3

 
53.5

 
47.6

 
42.4

 
40.3

Total skilled nursing
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%

 
Six Months Ended June 30,
 
Same Facility
 
Transitioning
 
Acquisitions
 
Total
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
Percentage of Skilled Nursing Days:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medicare
12.4
%
 
12.9
%
 
12.8
%
 
14.6
%
 
9.2
%
 
11.1
%
 
12.3
%
 
13.3
%
Managed care
12.8

 
13.0

 
12.0

 
11.0

 
9.7

 
10.8

 
12.5

 
12.6

Other skilled
6.1

 
6.1

 
0.9

 
0.6

 
1.4

 
1.5

 
4.7

 
4.8

Skilled mix
31.3

 
32.0

 
25.7

 
26.2

 
20.3

 
23.4

 
29.5

 
30.7

Private and other payors
10.7

 
10.9

 
14.9

 
16.0

 
15.7

 
16.1

 
11.8

 
12.1

Quality mix
42.0

 
42.9

 
40.6

 
42.2

 
36.0

 
39.5

 
41.3

 
42.8

Medicaid
58.0

 
57.1

 
59.4

 
57.8

 
64.0

 
60.5

 
58.7

 
57.2

Total skilled nursing
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
Senior Living Services
 
Six Months Ended
June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Resident fee revenue
$
82,740

 
$
73,277

 
$
9,463

 
12.9
 %
Number of facilities at period end
56

 
51

 
5

 
9.8
 %
Number of campuses at period end
27

 
22

 
5

 
22.7
 %
Occupancy percentage (units)
75.3
%
 
75.4
%
 
 
 
(0.1
)%
Average monthly revenue per unit
$
2,923

 
$
2,860

 
$
63

 
2.2
 %
Senior living revenue increased $9.5 million or 12.9%, primarily due to an increase in average monthly revenue per unit of 2.2% and revenue generated from the addition of ten assisted and independent living operations in five state between July 1, 2018 and June 30, 2019. These increases were partially offset by a decrease in occupancy of 0.1%, mainly in our recently acquired operations as these acquisitions have lower occupancy rates.





66


Home Health and Hospice Services
 
Six Months Ended
June 30,
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Home health and hospice revenue
 
 
 
 
 
 
 
Home health services
$
48,647

 
$
41,505

 
$
7,142

 
17.2
%
Hospice services
47,678

 
39,502

 
8,176

 
20.7

Total home health and hospice revenue
$
96,325

 
$
81,007

 
$
15,318

 
18.9
%
 
 
 
 
 
 
 
 
Home health, hospice and home care agencies
62

 
46

 
16

 
34.8
%
Home health services:
 
 
 
 
 
 
 
Average Medicare revenue per completed episode
$
3,024

 
$
2,951

 
$
73

 
2.5
%
Hospice services:
 
 
 
 
 
 
 
Average daily census
1,544

 
1,275

 
269

 
21.1
%
Home health and hospice revenue increased $15.3 million, or 18.9% as compared to the first half of 2018. Of the $15.3 million increase, Medicare and managed care revenue increased $11.4 million, or 16.9%. The increase in revenue is primarily due to the increase in volume and average daily census in existing agencies and rate per episode, coupled with the addition of 16 home health and hospice operations in seven states between July 1, 2018 and June 30, 2019.
Cost of Services

The following table sets forth total cost of services by each of our reportable segments and our "All Other" category for the periods indicated (dollars in thousands):

 
 
Six Months Ended June 30,
 
 
2019
 
2018
 
 
 
 
 
 
 
(Dollars in thousands)
Transitional and skilled services
 
$
727,309

 
$
656,009

Senior living services
 
56,153

 
47,881

Home health and hospice services
 
80,159

 
67,066

All other
 
23,381

 
15,419

Total cost of services
 
$
887,002

 
$
786,375


Consolidated cost of services increased $100.6 million, or 12.8% as compared to the first half of 2018. Consolidated cost of services as a percentage of revenue decreased by 0.6% to 78.9%.
Transitional and Skilled Services

 
 
Six Months Ended
June 30,
 
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Cost of service
 
$
727,309

 
$
656,009

 
$
71,300

 
10.9
 %
Revenue percentage
 
79.2
%
 
80.4
%
 
 
 
(1.2
)%

Cost of services related to our transitional and skilled services segment increased $71.3 million, or 10.9%, due primarily to additional costs at Recently Acquired Facilities of $34.6 million and organic operational growth. Cost of services as a percentage of revenue decreased to 79.2%, mainly due to operational improvements, cash collection improvements and a decrease in health insurance.

67


Senior Living Services
 
 
Six Months Ended
June 30,
 
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Cost of service
 
$
56,153

 
$
47,881

 
$
8,272

 
17.3
%
Revenue percentage
 
67.9
%
 
65.3
%
 
 
 
2.6
%

Cost of services related to our senior living services segment increased $8.3 million, or 17.3%, primarily due to recently acquired operations and organic operational growth. Cost of services as a percentage of total revenue increased by 2.6% primarily due to higher costs of services associated with newly acquired operations and additional field-based resources to support our growing infrastructure. Our acquisition focus is to strategically acquire underperforming operations with strong opportunities for return. Historically, we generally experienced higher cost of services at newly acquired operations; and therefore, we anticipate lower margins at these operations during years of growth.
Home Health and Hospice Services
 
 
Six Months Ended
June 30,
 
 
 
 
 
 
2019
 
2018
 
Change
 
% Change
 
 
 
 
 
 
 
 
 
 
 
(Dollars in thousands)
 
 
 
 
Cost of service
 
$
80,159

 
$
67,066

 
$
13,093

 
19.5
%
Revenue percentage
 
83.2
%
 
82.8
%
 
 
 
0.4
%

Cost of services related to our home health and hospice services segment increased $13.1 million, or 19.5%, due to newly acquired operations and organic operational growth. Cost of services as a percentage of total revenue increased by 0.4% primarily due to the increase in certain costs associated with newly acquired operations. Included in cost of services is one-time broker fee of $0.4 million related to new agencies acquired in the current year. Without this fee, cost of services would have been 82.8%, which is consistent with prior year.

Rent — cost of services. Our rent — cost of services as a percentage of total revenue decreased by 0.4% to 6.5% primarily due to more of our acquisitions including real estate assets coupled with the growth in revenue outpacing the increase in rent expense.
General and administrative expense. Our general and administrative expense increased as a percentage of revenue by 0.8% to 5.6%, mainly due to transaction costs related to our proposed Spin-Off and an increase in incentives due to operational improvements.
Depreciation and amortization. Depreciation and amortization expense increased $2.5 million, or 10.9%, to $25.8 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations. Depreciation and amortization expense as a percentage of revenue decreased slightly to 2.3%.
Other expense, net. Other expense, net as a percentage of revenue remained relatively consistent at 0.6%, or $6.5 million. Other expense mainly includes interest expense related to borrowings under our credit facility and HUD mortgages.
Provision for income taxes.  Our effective tax rate was 18.3% for the six months ended June 30, 2019 compared to 21.7% for the same period in 2018. The lower effective tax rate reflects an increase in an additional tax benefit from share-based payment awards. The lower effective tax rate was partially offset by increases in certain non-deductible items. See Note 14, Income Taxes, in the Notes to Condensed Consolidated Financial Statements for further discussion.



68


Liquidity and Capital Resources
Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our revolving credit facilities.
Historically, we have financed the majority of our acquisitions primarily by financing our operating subsidiaries through mortgages, our revolving credit facility, and cash generated from operations. Cash paid to fund acquisitions was $57.2 million and $58.0 million for the six months ended June 30, 2019 and 2018, respectively. Total capital expenditures for property and equipment were $35.8 million and $24.3 million for the six months ended June 30, 2019 and 2018, respectively. We currently have approximately $60.0 million budgeted for renovation projects for 2019. We believe our current cash balances, our cash flow from operations and the amounts available under our credit facility will be sufficient to cover our operating needs for at least the next 12 months.

We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.

Our cash and cash equivalents as of June 30, 2019 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of June 30, 2019, we held debt security investments of approximately $46.9 million, which were split between AA, A and BBB rated securities.

The following table presents selected data from our condensed consolidated statement of cash flows for the periods presented:
 
Six Months Ended June 30,
 
2019
 
2018
 
 
 
 
 
(In thousands)
Net cash provided by operating activities
$
72,278

 
$
101,240

Net cash used in investing activities
(98,256
)
 
(81,244
)
Net cash provided by/(used in) financing activities
33,937

 
(35,149
)
Net increase/(decrease) in cash and cash equivalents
7,959

 
(15,153
)
Cash and cash equivalents at beginning of period
31,083

 
42,337

Cash and cash equivalents at end of period
$
39,042

 
$
27,184

Six Months Ended June 30, 2019 Compared to Six Months Ended June 30, 2018
Our net cash provided by operating activities for the six months ended June 30, 2019 decreased by $28.9 million. The decrease was primarily due to the timing of collections of accounts receivable partially offset by the timing of payments of prepaid expenses and other assets. In addition, we received $11.0 million in income tax refund in 2018 that did not recur in 2019.
Our net cash used in investing activities for the six months ended June 30, 2019 increased by $17.0 million. The change was primarily due to an increase in capital expenditure spending by $11.5 million.
Our net cash provided by/(used in) financing activities increased by $69.0 million. In 2019, we had net borrowing of $34.0 million compared to net re-payments of $34.9 million in the comparable period in 2018.
Principal Debt Obligations and Capital Expenditures

Credit Facility with a Lending Consortium Arranged by SunTrust
We maintain a credit facility with a lending consortium arranged by SunTrust (as amended to date, the Credit Facility). We originally entered into the Credit Facility in an aggregate principal amount of $150.0 million in May 2014. Under the Credit Facility, we could seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $75.0 million.


69


On February 5, 2016, we amended our existing revolving credit facility to increase our aggregate principal amount available to $250.0 million (the Amended Credit Facility). Under the Amended Credit Facility, we may seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $150.0 million. The interest rates applicable to loans under the Amended Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.75% to 1.75% per annum or LIBOR plus a margin ranging from 1.75% to 2.75% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, we pay a commitment fee on the unused portion of the commitments under the Amended Credit Facility that will range from 0.3% to 0.5% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and our subsidiaries. We are permitted to prepay all or any portion of the loans under the Amended Credit Facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders.

On July 19, 2016, we entered into the second amendment to the credit facility (Second Amended Credit Facility), which amended the existing credit agreement to increase the aggregate principal amount up to $450.0 million. The Second Amended Credit Facility comprised of a $300.0 million revolving credit facility and a $150.0 million term loan. Borrowings under the term loan portion of the Second Amended Credit Facility will mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to 5.0% per annum of the original principal amount. The interest rates and commitment fee applicable to the Second Amended Credit Facility are similar to the Amended Credit Facility discussed below. Except as set forth in the Second Amended Credit Facility, all other terms and conditions of the Amended Credit Facility remained in full force and effect as described below.

The Credit Facility is guaranteed, jointly and severally, by certain of our wholly owned subsidiaries, and is secured by a pledge of stock of our material operating subsidiaries as well as a first lien on substantially all of our personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and our operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, we must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to Consolidated EBITDA ratio (which shall be increased to 3.50:1.00 for the first fiscal quarter and the immediate following three fiscal quarters), and a minimum interest/rent coverage ratio (which cannot be below 1.50:1.00). The majority of lenders can require that we and our operating subsidiaries mortgage certain of our real property assets to secure the credit facility if an event of default occurs, the Consolidated Total Net Debt to Consolidated EBITDA ratio is above 2.75:1.00 for two consecutive fiscal quarters, or our liquidity is equal or less than 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) for ten consecutive business days, provided that such mortgages will no longer be required if the event of default is cured, the Consolidated Total Net Debt to Consolidated EBITDA ratio is below 2.75:1.00 for two consecutive fiscal quarters, or our liquidity is above 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) or ninety consecutive days, as applicable. As of June 30, 2019, our operating subsidiaries had $159.4 million outstanding under the Credit Facility. The outstanding balance on the term loan was $109.4 million, of which $7.5 million is classified as short-term and the remaining $101.9 million is classified as long-term. The outstanding balance on the revolving Credit Facility was $50.0 million, which is classified as long-term. We were in compliance with all loan covenants as of June 30, 2019.

As of July 30, 2019, there was approximately $111.3 million outstanding under the Revolving Credit Facility.

Mortgage Loans and Promissory Note

During the fourth quarter of 2017, 17 of our subsidiaries entered into mortgage loans in the aggregate amount of $112.0 million. The mortgage loans are insured with Department of Housing and Urban Development (HUD), which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans and note bear fixed interest rates of 3.3% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. During the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The term of the mortgage loans are 30 to 35-years. The borrowings were arranged by Lancaster Pollard Mortgage Company, LLC, and insured by HUD. Loan proceeds were used to pay down previously drawn amounts on our revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped used to fund acquisitions, to renovate and upgrade existing and future facilities, to cover working capital needs and for other business purposes.


70


In addition to the HUD mortgage loans above, we have outstanding indebtedness under mortgage loans insured with HUD and promissory note issued in connection with various acquisitions. These mortgage loans and note bear fixed interest rates between 2.6% and 5.3% per annum. Amounts borrowed under the mortgage loans may be prepaid starting after the second anniversary of the notes subject to prepayment fees of the principal balance on the date of prepayment. These prepayment fees are reduced by 1.0% per year for years three through eleven of the loan. There is no prepayment penalty after year eleven. The terms of the mortgage loans and note are between 12 and 33 years. The mortgage loans and note are secured by the real property comprising the facilities and the rents, issues and profits thereof, as well as all personal property used in the operation of the facilities.

As of June 30, 2019, our operating subsidiaries had $121.7 million outstanding under the mortgage loans and note, of which $2.7 million is classified as short-term and the remaining $119.0 million is classified as long-term.
Contractual Obligations, Commitments and Contingencies
We lease from CareTrust REIT, Inc. (CareTrust) real property associated with 93 affiliated skilled nursing, senior living facilities used in our operations under the Master Leases as a result of the tax free spin-off (the CareTrust Spin-Off). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%.
We do not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, we may be liable for damages and incur charges such as continued payment of rent through the end of the lease term and as well as maintenance and repair costs for the leased property.
The Master Leases arrangement is commonly known as a triple-net lease. Accordingly, in addition to rent, we are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor), (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties, (3) all insurance required in connection with the leased properties and the business conducted on the leased properties, (4) all facility maintenance and repair costs and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Total rent expense under the Master Leases was approximately $15.1 million and $29.9 million, for the three and six months ended June 30, 2019, respectively, and approximately $14.5 million and $29.0 million, for the three and six months ended June 30, 2018, respectively.
At our option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease.
Among other things, under the Master Leases, we must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. As of June 30, 2019, we were in compliance with the Master Leases' covenants.
We also lease certain affiliated facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. We have entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense, inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37.2 million and $73.2 million for the three and six months ended June 30, 2019, respectively, and $34.5 million and $68.6 million for the three and six months ended June 30, 2018, respectively.
Thirty-nine of our affiliated facilities, excluding the facilities that are operated under the Master Leases from CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other affiliated facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease

71


portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
We implemented the new lease accounting standard as described in Note 3, Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements.
Class Action Lawsuit
Since 2011, we have been involved in a class action litigation claim alleging violations of state and federal wage and hour laws. In January 2017, we participated in an initial mediation session with plaintiffs' counsel. 
In March 2017, we were invited to engage in further mediation discussions to determine whether settlement in advance of a determination on class certification was possible. In April 2017, we reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court.  Based upon the recent change in case status, we recorded an accrual for estimated probable losses of $11.0 million in the first quarter of 2017. In June 2017, the settlement of the class action lawsuit and the settlement was approved by the Court. We made a lump-sum payment in the amount of $11.0 million in December 2017 and the funds were distributed to the class members in the first quarter of 2018. We received $1.7 million related to unclaimed class settlement funds remaining after completion of the settlement process, and the recoveries were recorded in the first quarter of 2018.
U.S. Government Inquiry and Corporate Integrity Agreement

In late 2006, we learned that we might be the subject of an on-going criminal and civil investigation by the DOJ. This was confirmed in March 2007. The investigation was prompted by a whistleblower complaint and related primarily to claims submitted to the Medicare program for rehabilitation services provided at certain of our independently operating skilled nursing facilities in Southern California. We resolved and settled the matter for $48.0 million in 2013. In October 2013, we and the government executed a final settlement agreement in accordance with the April 2013 agreement and we remitted full payment of $48.0 million. In addition, we executed a five-year corporate integrity agreement with the Office of Inspector General HHS as part of the resolution. In the first quarter of 2019, we received notice from the Office of Inspector General (OIG) that our five-year corporate integrity agreement with the OIG has been completed. Upon receipt of our fifth and final annual report, the OIG confirmed that the term of the CIA is concluded.
See additional description of our contingencies in Note 15, Debt, Note 17, Leases and Note 18, Commitments and Contingencies in Notes to Condensed Consolidated Financial Statements.
U.S. Department of Justice Civil Investigative Demand
On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether we have violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our skilled nursing facilities and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 to the present, and was limited in scope to ten of our Southern California skilled nursing facilities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 to the present, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements.
Inflation

We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state’s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.

Labor and supply expenses make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. We may not be successful in offsetting future cost increases.



72


Recent Accounting Pronouncements

Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to us. We have reviewed the FASB issued Accounting Standards Update (ASU) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. For any new pronouncements announced, we consider whether the new pronouncements could alter previous generally accepted accounting principles and determine whether any new or modified principles will have a material impact on our reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In February 2016, the FASB established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines.

We adopted the standard as of January 1, 2019, electing the transition method that allows us to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings, if applicable. We have elected the package of practical expedients permitted under the transition guidance, which among other things, allows us to carry forward the historical lease classification. The new standard also provides practical expedients for an entity’s ongoing accounting. We have elected an accounting policy to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. We have also elected the practical expedient to not separate lease and non-lease components for all of our leases as the non-lease components are not significant to the overall lease costs.

The adoption of this standard resulted in recognition of net lease assets and lease liabilities of $1.1 billion and $1.0 billion, respectively, on our condensed consolidated balance sheets as of January 1, 2019. We recorded an adjustment, net of tax, of $9.0 million to retained earnings, on the adoption date, related to a deferred gain on a previous sale-leaseback transaction, which resulted in an increase in rent expense of $0.7 million annually, as we are no longer able to recognize the gain in our consolidated statement of income as a result of the new lease standard. In addition, initial direct costs associated with our lease agreements and favorable lease assets of $26.9 million were classified into right-of-use assets on the adoption date. The standard does not materially affect our consolidated net earnings or have a notable impact on liquidity or debt-covenant compliance under the current agreements.

Prior to the adoption of ASC 842, we recognized revenue related to its senior living residency agreements in accordance with the provisions of ASC 840, Leases ("ASC 840").  Subsequent to the adoption of ASU 2016-02, Leases, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of ASC 842 and the non-lease components utilizing the provisions of ASC 606, Revenue from Contracts with Customers. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with ASC 840 prior to the adoption of ASU 2016-02 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of ASC 606 subsequent to the adoption of ASU 2016-02. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of ASU 2016-02 for changes to amounts recognized for these certain components for the transition from ASC 840 to ASC 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, Leases, allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of ASC 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions.

Upon adoption of ASU 2016-02 and ASU 2018-11, we elected the lessor practical expedient within ASU 2018-11. We recognize revenue under these resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under ASC Topic 842 and ASC Topic 606. We have concluded that the non-lease components of the agreements with respect to our senior living communities

73


are the predominant component of the contract, therefore, we recognize revenue for these residents agreements under ASC Topic 606. The timing and pattern of revenue recognition is substantially the same as that prior to the adoption of these standards.

In June 2018, the FASB issued ASU 2018-07, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. We adopted this guidance effective January 1, 2019. The adoption of this guidance did not have a material impact on our consolidated financial statements and related disclosures.

Accounting Standards Recently Issued But Not Yet Adopted by the Company

In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be our fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be our fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of credit Losses on Financial Instruments”, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for fiscal year beginning after December 15, 2019, which will be our fiscal year 2020, with early adoption is permitted. We have not yet determined the effect of the ASU on our results of operations, financial condition or cash flows.

Off-Balance Sheet Arrangements

During the six months ended June 30, 2019, we increased our outstanding letters of credit by $0.6 million. As of June 30, 2019, we had approximately $5.3 million on our credit facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.

Item 3.        Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk. We are exposed to risks associated with market changes in interest rates. Our credit facility exposes us to variability in interest payments due to changes in LIBOR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory notes require principal and interest payments through maturity pursuant to amortization schedules.

Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.

74


On July 19, 2016, we entered into the Second Amended Credit Facility with a lending consortium arranged by SunTrust to make available a credit facility consisting of a $300.0 million revolving line of credit and a $150.0 million term loan component. Borrowings under the term loan portion of the credit facility mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to 5.0% per annum of the original principal amount. The interest rates, at our option, are equal to either a base rate plus a premium or LIBOR plus a premium. In addition, we are subject to pay a commitment fee on the unused portion of the commitments under the credit facility discussed in Item 2 of this Report under the heading “Liquidity and Capital Resources.” Our exposure to fluctuations in interest rates may increase or decrease in the future with increases or decreases in the outstanding amount under the credit facility. As of June 30, 2019, our operating subsidiaries had $159.4 million outstanding under the Credit Facility. The outstanding balance on the term loan was $109.4 million, of which $7.5 million is classified as short-term and the remaining $101.9 million is classified as long-term. The outstanding balance on the revolving Credit Facility was $50.0 million, which is classified as long-term.

We have outstanding indebtedness under mortgage loans insured with Department of Housing and Urban Development (HUD) and promissory note. The mortgage loans and note bear fixed interest rates and amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. The outstanding balance under the mortgage loans and note was $121.7 million, of which $2.7 million is classified as short-term and the remaining $119.0 million is classified as long-term.

Our cash and cash equivalents as of June 30, 2019 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of June 30, 2019, we held debt security investments of approximately $46.9 million, which were split between AA, A, and BBB rated securities. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

The above only incorporates those exposures that exist as of June 30, 2019 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.

Item 4. Controls and Procedures
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective.
We implemented certain internal controls in connection with our adoption of Topic 842, Leases, in the first quarter of 2019. There were no other changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.

Item 1.        Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3. Legal Proceedings, of our Annual Report on Form 10-K for the year ended December 31, 2018. In addition, for more information regarding our legal proceedings, please see Note 18, Commitments and Contingencies included in Part 1, Item 1 of this Form 10-Q.

Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to
interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation and failure to comply can result in significant regulatory action, including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information. In

75


late December of 2016, we learned of a potential issue at one of our independent operating entities in Arizona which involved the limited and inadvertent disclosure of certain confidential information. The issue has been fully investigated, addressed and disclosed as required by law. We believe that we are presently in compliance in all material respects with applicable HIPAA laws and regulations. As of June 30, 2019, this matter has been resolved.

Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.

Indemnities — From time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer by the Company's independent operating subsidiary, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and employees, under which we may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.
U.S. Department of Justice Civil Investigative Demand - On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether we have violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our independently operated skilled nursing facilities and persons who served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 to the present, and was limited in scope to ten of our Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 to the present, relating to the same topic. As a general matter, our independent operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. We are fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information. However, we cannot predict when the investigation will be resolved, the outcome of the investigation, or its potential impact on the Company.

Litigation — We are party to various legal actions and administrative proceedings, and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients have resulted in injury or death and claims related to employment and commercial matters. Although we intend to vigorously defend ourselves in response to these claims, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. In certain states in which we have or have had independent operating entities, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law public policy prohibitions. There can be no assurance that our independent operating entities will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.

The skilled nursing and post-acute care industry is extremely regulated. As such, in the ordinary course of business, we are continuously subject to state and federal regulatory scrutiny, supervision and control. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight of state and federal regulatory agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements, which could subject us to civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their program. We believe that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations, and cash flows.

In addition to the potential lawsuits and claims described above, we are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally-funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created

76


incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, we could face increased scrutiny, potential liability, and legal expenses and costs based on claims under state false claims acts in markets in which our independent operating subsidiaries do business.

In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act (FCA) and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and our independent operating entities are routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of minimum staffing requirements for skilled nursing facilities in those states which have enacted such requirements. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with requirements of participation under certain state and federal healthcare programs; it may also subject the facility to a notice of deficiency, a citation, a civil money penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.
We and our independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment as well as employment related claims. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.
In August 2011, we were named as a Defendant in a class action litigation alleging violations of state and federal wage and hour law. In January 2017, we participated in an initial mediation session with plaintiffs' counsel. 
In March 2017, we were invited to engage in further settlement discussions to determine whether a resolution of the case was possible in advance of a decision on class certification. In April 2017, we reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court.  Based upon the change in case status, we recorded an accrual for estimated probable losses of $11.0 million, exclusive of legal fees, in the first quarter of 2017. In June 2017, the settlement of the class action lawsuit was approved by the Court. We funded the settlement amount of $11.0 million in December 2017, and the funds were distributed to the class members in the first quarter of 2018. We received back $1.7 million related to unclaimed class settlement funds remaining after completion of the settlement process, and the recoveries were recorded in the first quarter of 2018.
A class action staffing suit was previously filed against us and certain of our California independent operating entities, alleging, among other things, violations of certain Health and Safety Code provisions and a violation of the Consumer Legal Remedies Act. In 2007, we settled this class action suit, and the settlement was approved by the affected class and the Court. A second such class action staffing suit was filed in Los Angeles in 2010 and was resolved in a settlement and Court approval in 2012. Neither of the referenced lawsuits or settlements had a material ongoing adverse effect on our business, financial condition or results of operations.

Other claims and suits, including class actions, continue to be filed against us and other companies in the post-acute care industry. For example, we and our independent operating entities have been subjected to, and are currently involved in, class action litigation alleging violations of state and federal wage and hour law as related to the alleged failure to pay wages and to timely provide and authorize meal and rest breaks. We do not believe that the ultimate resolution of these actions will have a material adverse effect on our business, cash flows, financial condition or results of operations. A significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect our business, financial condition, results of operations and cash flows.

We and our independent operating entities have in the past been subject to class action litigation involving claims of violations of various regulatory requirements. While we have been able to settle these claims without a material ongoing adverse effect on our business, future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits continue to be filed against us and other companies in the industry. In addition, professional negligence

77


claims have been filed and will likely continue to be filed against our independent operating entities by residents or resident responsible parties.
Medicare Revenue Recoupments — We and our independent operating subsidiaries are subject to regulatory reviews relating to Medicare services, billings and potential overpayments resulting from RAC, ZPIC, PSC, UPIC and MIC (collectively referred to as Reviews). As of June 30, 2019, ten of our independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process, both pre- and post-payment. The Company anticipates that these Reviews will increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to all billing in the same time period. As of June 30, 2019, the affiliated independent operating subsidiaries have responded to the requests and the related claims are currently under Review, on appeal or in a dispute resolution process.

U.S. Government Inquiry and Corporate Integrity Agreement — In late 2006, we learned that we might be the subject of an on-going criminal and civil investigation by the DOJ. This was confirmed in March 2007. The investigation was prompted by a whistleblower complaint and related primarily to claims submitted to the Medicare program for rehabilitation services provided at certain of our independently operating skilled nursing facilities in Southern California. We resolved and settled the matter for $48.0 million in 2013. In October 2013, we executed a final settlement agreement with the Government and remitted full payment of $48.0 million. In addition, we executed a corporate integrity agreement with the Office of Inspector General HHS as part of the resolution. In the first quarter of 2019, we received notice from the OIG that our five-year CIA with the OIG has been completed.  Upon receipt of our fifth and final annual report, the OIG confirmed that the term of the CIA is concluded.

See additional description of our contingencies in Notes 15, Debt, 17, Leases and 18, Commitments and Contingencies in
Notes to Condensed Consolidated Financial Statements.

Item 1A.    Risk Factors
Risks Related to Our Business and Industry
Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicaid and Medicare.

We derived 41.4% and 41.2% of our revenue from the Medicaid programs for the three and six months ended June 30, 2019, respectively, and 40.6% and 40.1% of our revenue from the Medicaid programs for the three and six months ended June 30, 2018, respectively. We derived 26.6% and 26.8% of our revenue from the Medicare programs for the three and six months ended June 30, 2019, respectively, and 27.6% and 27.9% of our revenue from the Medicare programs for the three and six months ended June 30, 2018, respectively. If reimbursement rates under these programs are reduced or fail to increase as quickly as our costs, or if there are changes in the way these programs pay for services, our business and results of operations would be adversely affected. The services for which we are currently reimbursed by Medicaid and Medicare may not continue to be reimbursed at adequate levels or at all. Further limits on the scope of services being reimbursed, delays or reductions in reimbursement or changes in other aspects of reimbursement could impact our revenue. For example, in the past, the enactment of the Deficit Reduction Act of 2005 (DRA), the Medicaid Voluntary Contribution and Provider-Specific Tax Amendments of 1991 and the Balanced Budget Act of 1997 (BBA) caused changes in government reimbursement systems, which, in some cases, made obtaining reimbursements more difficult and costly and lowered or restricted reimbursement rates for some of our patients.

The Medicaid and Medicare programs are subject to statutory and regulatory changes affecting base rates or basis of payment, retroactive rate adjustments, annual caps that limit the amount that can be paid (including deductible and coinsurance amounts) for rehabilitation therapy services rendered to Medicare beneficiaries, administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates and frequency at which these programs reimburse us for our services. For example, the Medicaid Integrity Contractor (MIC) program is increasing the scrutiny placed on Medicaid payments, and could result in recoupments of alleged overpayments in an effort to rein in Medicaid spending.  Recent budget proposals and legislation at both the federal and state levels have called for cuts in reimbursement for healthcare providers participating in the Medicare and Medicaid programs.  Measures to reduce or delay reimbursement could result in substantial reductions in our revenue and profitability. Payors may disallow our requests for reimbursement based on determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered medically necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.


78


On February 12, 2018, the President rolled out a new White House budget for fiscal year 2019, which began October 1, 2018, freezing the Medicare market basket rate at 2.4%. As a result, the Congressional Budget Office has estimated a $1.9 billion reduction in Medicare spending over the next decade.
On December 20, 2016, the Centers for Medicare & Medicaid Services (CMS) issued the final rule for a new Cardiac Rehabilitation Incentive (CR) model, which includes mandatory bundled payment programs for an acute myocardial infarction (AMI) episode of care or a coronary artery bypass graft (CABG) episode of care, and modifications to the existing Comprehensive Care for Joint Replacement (CJR) model to include surgical hip/femur fracture treatment episodes. On December 1, 2017, CMS issued a final rule which officially canceled the Episode Payment Models and Cardiac Rehabilitation Incentive Payment Model, rescinding the regulations governing these models. Additionally, the final rule implemented certain revisions to the CJR program, including making participation voluntary for approximately half of the geographic areas, along with other technical refinements. In releasing the final rule, CMS stressed that “value-based payment methodologies will continue to play an essential role in lowering costs and improving quality of care, which will be necessary in order to maintain Medicare's fiscal solvency” and reiterated its commitment to developing value-based models that would allow for Advanced APM participation in 2018 and beyond. These regulation changes became effective January 1, 2018 and are effective for five performance years.
On January 9, 2018, CMS launched a new voluntary bundled payment called Bundled Payments for Care Improvement Advanced (BPCI Advanced), which replaced the BPCI initiative that terminated on September 30, 2018. The Model Performance Period for BPCI Advanced commences on October 1, 2018 and runs through December 31, 2023. Under the advanced bundled payment model, participants can earn additional payment if all expenditures for a beneficiary’s episode of care are under a spending target that factors in quality. The BPCI Advanced model changes the BPCI initiative in a number of ways. Most importantly, it eliminates the BPCI Model 3 which allows post-acute care providers to participate as episode initiators. Episode initiators under the new BPCI Advanced initiative are called Non-Convener Participants and only include Acute Care Hospitals and Physician Group Practices.  As a result, once BCPI Advanced is implemented, post-acute care providers will only be able to participate as “Convener Participants.”  A Convener Participant is a participant that brings together the episode initiators, which are the Acute Care Hospital or the Physician Group Practice. The Convener Participant facilitates coordination among the episode initiators and bears and apportions financial risk under BCPI Advanced. Thus post-acute care providers may only participate in BPCI Advanced as Convener Participants.
Of note, BPCI Advanced will qualify as the first Advanced Alternative Payment Model (Advanced APM) under the Quality Payment Program. In 2015, Congress passed the Medicare Access and Chip Reauthorization Act or MACRA. MACRA requires CMS to implement a program called the Quality Payment Program or QPP, which changes the way physicians are paid who participate in Medicare. QPP creates two tracks for physician payment - the Merit-Based Incentive Payment System or MIPS track and the Advanced APM track. Under MIPS, providers have to report a range of performance metrics and their payment amount is adjusted based on their performance. Under Advanced APMs, providers take on financial risk to earn the Advanced APM incentive payment that they are participating in.
On October 1, 2015, International Classification of Diseases (ICD) 10 was implemented as the new medical coding system. Some of the main points include: Claims with antibiotic removal devices (ARDs) on or after October 1, 2015 must contain a valid ICD-10 code.  CMS will reject MDS assessments if a Section I diagnosis code version does not apply for the ARD entered. Flexibility is being provided to physician providers with coding, but this flexibility will not be passed on to facility-based providers, including skilled nursing facilities that are providing Part B services.
Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the ACA). The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. These reforms include the possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. As discussed below under the heading “Our business may be materially impacted if certain aspects of the ACA are amended, repealed, or successfully challenged," any further amendments or revisions to the ACA or its implementing regulations could materially impact our business.
Skilled Nursing

On August 8, 2018, CMS issued a final rule outlining Fiscal Year 2019 Medicare payments and quality changes for skilled nursing facilities. The final rule revises the case-mix classification system used under the SNF Prospective Payment System (the SNF PPS Rule). The SNF PPS Rule reduces documentation requirements, updates the data used to evaluate reimbursement amounts, and ties reimbursement to patients’ conditions and care needs, (clinically relevant factors) rather than the volume of services provided.

79


The SNF PPS Rule will be effective October 1, 2019. The SNF PPS Rule includes a new case-mix model that focuses on the patient’s condition and resulting care needs, (clinically relevant factors) rather than on the volume of care provided, to determine reimbursement from Medicare. The case mix-model is called the Patient-Driven Payment Model (PDPM), which utilizes clinically relevant factors for determining Medicare payment by using ICD-10 diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy (PT), occupational therapy (OT), speech language pathology (SLP), nursing and social services (nursing) and non-therapy ancillary services (NTA). It also uses a sixth non-case mix component to cover utilization of SNF resources that do not vary depending on resident characteristics.
PDPM will replace the existing case-mix classification methodology, Resource Utilization Groups, Version IV (RUG-IV). The structure of the PDPM moves Medicare towards a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident’s care, thereby more accurately addressing costs associated with medically complex patients. PDPM also removes therapy minutes as the basis for therapy payment. Finally, PDPM adjusts the SNF per diem payments to reflect varying costs throughout the stay, through the PT, OT and NTA components.
In addition, PDPM is intended to reduce paperwork requirements for performing patient assessments. Under the new SNF PPS PDPM system, the payment to skilled nursing facilities and nursing homes will be based heavily on the patient’s condition rather than the specific services provided by each skilled nursing facility.
Subsequently, on July 30, 2019, CMS issued a final rule for fiscal year 2020 that updates the Medicare payment rates and the quality programs for skilled nursing facilities. Under the final rule, effective October 1, 2019, the aggregate payments to skilled nursing facilities will increase by 2.4% for fiscal year 2020, compared to fiscal year 2019. This estimated increase is attributable to a 2.8% market basket increase factor with a 0.4% point reduction for multifactor productivity adjustment. The final rule also updated the Skilled Nursing Facility Value-Based Purchasing Program (VBP), which took effect on October 1, 2018, to ensure that CMS publishes accurate performance information for low-volume SNFs and a new 30-day deadline for Phase One Review and Corrections requests. In addition, CMS is adopting two new quality measures in fiscal year 2020 under the SNF Quality Reporting Program (QRP) to assess whether certain health information is provided by the SNF at the time of transfer or discharge. The two measures are: 1) Transfer of Health Information to the Provider-Post-Acute Care and 2) Transfer of Health Information to the Patient-Post-Acute Care. Further, the final rule includes the change of the group therapy definition, which consists of treating two to six patients doing the same or similar activities.

On July 31, 2017, CMS issued its final rule outlining fiscal year 2018 Medicare payment rates for skilled nursing facilities. Under the final rule, the market basket index is revised and rebased by updating the base year from 2010 to 2014 and adding a new cost category for Installation, Maintenance, and Repair Services. The rule also includes revisions to the SNF Quality Reporting Program, including measure and standardized patient assessment data policies, as well as policies related to public display. In addition, it finalized policies for the SNF Value-Based Purchasing Program (VBP) that will affect Medicare payment to SNFs beginning in fiscal year 2019 and clarification of the requirements regarding the composition of professionals for the survey team.  The final rule uses a market basket percentage of 1% to update the federal rates, but if a SNF fails to submit quality reporting program requirements there will be a 2% reduction to the market basket update for the fiscal year involved.  Thus, the increase in the proposed federal rates may increase the amount of our reimbursements for SNF services so long as we meet the reporting requirements.    
Further, effective October 1, 2018, the SNF Value Based Purchasing Program will apply either positive or negative incentive payments to skilled nursing facilities based on their performance on the program’s readmissions measures. The single claims-based, all cause thirty-day hospital readmissions measure aims to improve individual outcomes through rewarding providers that take steps to limit the readmission of their patients to a hospital and penalize providers that do not take such steps to limit readmission of their patients.
On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates and quality programs for skilled nursing facilities. The policies in the finalized rule continue to shift Medicare payments from volume to value. The aggregate payments to skilled nursing facilities increased by a net 2.4% for fiscal year 2017. This increase reflected a 2.7% market basket increase, reduced by a 0.3% multi-factor productivity (MFP) adjustment required by ACA. This final rule also further defines the skilled nursing facilities Quality Reporting Program and clarifies the VBP to establish performance standards, baseline and performance periods, performance scoring methodology and feedback reports.
The VBP final rule specifies the skilled nursing facility 30-day potentially preventable readmission measure, which assesses the facility-level risk standardized rate of unplanned, potentially preventable hospital readmissions for skilled nursing facility patients within 30 days of discharge from a prior admission to a hospital paid under the Inpatient Prospective Payment System, a critical access hospital, or a psychiatric hospital. There is also finalized additional policies related to the VBP including: establishing performance standards; establishing baseline and performance periods; adopting a performance scoring methodology; and providing confidential feedback reports to the skilled nursing facilities. This VBP became effective on October 1, 2018.

80



CMS issued a final rule on June 3, 2019 which updates the requirements for the Programs of All-Inclusive Care for the Elderly (PACE) under the Medicare and Medicaid programs. The regulation is intended to provide greater operational flexibility, remove redundancies and outdated information and codify existing programs. Such flexibility includes, (i) more lenient standards applicable to the current requirement that the PACE organization be monitored for compliance with the PACE program requirements during and after a 3-year trial period and (ii) relieving certain restrictions placed upon the interdisciplinary team that comprehensively assesses and provides for the individual needs of each PACE participant by allowing one person to fill two roles and permitting secondary participation in the PACE program. Further, non-physician primary care providers are able to provide certain services in place of primary care physicians.

Home Health

On July 11, 2019, CMS issued a proposed rule updating the Medicare Home Health Prospective Payment System (HH PPS) rates and wage index for calendar year 2020.  The rule proposes a 1.3% increase in home health payments, resulting from a 1.5% payment percentage update and a 0.2% decrease in aggregate payments because of changes to the rural add-on policy. The proposed rule implements the Patient‑Driven Groupings Model (PDGM), a revised case‑mix adjustment methodology, for home health services beginning on or after January 1, 2020, and proposes to adjust reimbursement under PDGM for assumed provider behavioral changes.  The proposed rule also changes the unit of payment from 60‑day episodes of care to 30-day periods of care, modifies payment regulations related to the content of the home health plan of care; allows therapist assistants to furnish maintenance therapy under the supervision of a licensed therapist; and proposes to change and eventually eliminate the split percentage payment approach under the HH PPS.  Finally, this rule will include proposals related to the implementation of the permanent home infusion therapy benefit in 2021. These include proposed payment categories, amounts, and required and optional adjustments.  
On November 13, 2018, CMS published a final rule which updates Medicare Home Health Prospective Payment System (HH PPS) rates, including the conversion factor and case-mix weights for calendar years 2019 and 2020. This rule finalizes the definition of remote patient monitoring which will be allowed as an administrative expense on the home health agency’s cost report. Further, effective January 1, 2020, CMS will implement PDGM as mandated by the Bipartisan Budget Act of 2018. Under PDGM, the initial certification of patient eligibility, plan of care, and comprehensive assessment will remain valid for 60-day episodes of care, but payments for home health services will be made based upon 30-day payment periods. PDGM refines case mix calculation methodology by removing therapy thresholds and calculating reimbursement based on clinical characteristics including clinical group coding, comorbidity coding, and achievement of LUPA thresholds. While the proposed changes are to be implemented in a budget neutral manner to the industry, CMS’s current proposal includes a negative 6.42% adjustment to account for assumed provider behavioral changes. The ultimate impact of these changes will vary by provider based on factors including patient mix and admission source. The finalization of these assumptions could negatively impact our future rate of reimbursement and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. This rule also finalizes changes to the Home Health Value-Based Purchasing (HHVBP) model and Home Health Quality Reporting Program (HHQRP). These changes focus on providing value over volume of services to patients. Once the changes are implemented, health payments will no longer be based on the number of visits provided, but rather the patient’s medical condition and care needs. In calendar year 2019, there was an increase of 2.2% in reimbursement to home health agencies based on the agency’s finalized policies.
On November 1, 2017, CMS issued a final rule that became effective on January 1, 2018 and updated the calendar year 2018 Medicare payment rates and the wage index for home health agencies serving Medicare beneficiaries. The rule also finalized proposals for the HHVBP model and the HHQRP. Under the final rule, Medicare payments will be reduced by 0.4%. This decrease reflects the effects of a 1.0% home health payment update, an adjustment to the national, standardized 60-day episode payment rate to account for nominal case-mix growth for an impact of negative 0.9%, and the distributional effects of a 0.5% reduction in payments due to the sunset of the rural add-on provision.
On January 13, 2017, CMS issued a final rule that modernized the Home Health Conditions of Participation (“CoPs”). This rule is a continuation of CMS’s effort to improve quality of care while streamlining provider requirements to reduce unnecessary procedural requirements. The rule makes significant revisions to the conditions currently in place, including (1) adding new conditions of participation related to quality assurance and performance improvement programs and infection control; and (2) expanding or revising requirements related to patient rights, comprehensive evaluations, coordination and care planning, home health aide training and supervision, and discharge and transfer summary and time frames. The new CoPs became effective on January 13, 2018.
On October 31, 2016, CMS issued final payment changes to HH PPS for calendar year 2017. Under this rule, Medicare payments were reduced by 0.7%. This decrease reflects a negative 0.97% adjustment to the national, standardized 60-day episode payment rate to account for nominal case-mix growth from 2012 through 2014; a 2.3% reduction in payments due to the final

81


year of the four-year phase-in of the rebasing adjustments to the national, standardized 60-day episode payment rate, the national per-visit payment rates and the non-routine medical supplies conversion factor; and the effects of the revised fixed-dollar loss ratio used in determining outlier payments; partially offset by the home health payment update of 2.5%.

Hospice

On July 31, 2019, CMS issued a final rule that updated the fiscal year 2020 hospice payment rates, wage index and cap amount.  The final rule calls for a 2.6% increase in hospice payment rates for fiscal year 2020. This increase is based on the fiscal year 2020 hospital market basket increase of 3.0%, reduced by the multifactor productivity adjustment of 0.4%. The rule establishes a rebasing of the continuous home care, general inpatient care, and the inpatient respite care per diem payment rates in a budget-neutral manner to more accurately align Medicare payments with the costs of providing care. Specifically, the rule increases these rates by 36.6%, 161.2%, and 31.0% respectively to account for the disparity between reimbursement and cost.  In order to maintain budget neutrality, the rule reduces the Routine Home Care rate by 2.7%. Hospices that fail to meet quality reporting requirements continue to receive a 2.0% reduction to the annual market basket update for the year. Further, the rule establishes the hospice cap amount for the fiscal year 2020 at $29,964.78, which is equal to the fiscal year 2019 cap amount of $29,205.44, updated by the final rule for fiscal year 2020 hospice payment update percentage of 2.6%. In addition to the payment updates, the final rule contains new regulations that modify election statement requirements and require hospices to prepare an addendum to the election entitled “Patient Notification of Hospice Non-Covered Items, Services, and Drugs," which will provide the patient with information related to any diagnoses, treatment, or medications that are considered by the hospice to be unrelated to the terminal diagnoses. In addition to its preparation, the hospice is required to provide the addendum upon request by the patient or the patients representative within five days, if requested at the time of election, or within 72 hours if requested thereafter.
On August 1, 2018, CMS issued its final rule outlining the fiscal year 2019 Medicare payment rates, wage index, and cap amount for hospices serving Medicare beneficiaries. Under the final rule, the hospice payment update is 1.8%, which reflects a market basket update of 2.9%, reduced 0.8% by a MFP adjustment, as well as another 0.3% reduction, which decreases are mandated by the ACA. Hospice payments will be reduced by an additional 2.0%, for a net negative 0.2%, for hospices that do not submit the required quality data. The final rule also specifies that the hospice cap will be updated using the hospice payment update percentage rather than the consumer price index, thus it is anticipated there will be a 1.8% increase in aggregate cap payments made to hospices annually. The final rule also includes language that reflects the change in the Bipartisan Budget Act of 2018 which recognizes physician assistants as attending physicians for Medicare hospice beneficiaries, effective January 1, 2019. Physician assistants will be reimbursed at 85% of the fee schedule amount for their services as designated attending physicians. This change may positively impact reimbursement from Medicare as this may increase the number of episodes that can be reimbursed by Medicare in the aggregate by physicians, nurse practitioners and physician assistants. Additionally, the rule finalizes changes to the Hospice Quality Reporting Program (HQRP), also effective January 1, 2019, including changes to the data review and correction timeline for data submitted using the Hospice Item Set.

On August 1, 2017, CMS issued its final rule outlining the fiscal year 2018 Medicare payment rates, wage index and cap amount for hospices serving Medicare beneficiaries. The final rule uses a net market basket percentage increase of 1.0% to update the federal rates, as mandated by section 411(d) of the MACRA. Although, if a hospice fails to comply with quality reporting program requirements, there will be a net 2.0% reduction to the market basket update for the fiscal year involved. The hospice cap amount for fiscal year 2018 was increased by 1.0%, which is equal to the 2017 cap amount updated by the fiscal year 2018 hospice payment update percentage of 1.0%. In addition, this rule discusses changes to the HQRP, including changes to the Consumer Assessment of Healthcare Providers & Systems (CAHPS) hospice survey measures and plans for sharing HQRP data in fiscal year 2017.
On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates, wage index and cap amount for hospices serving Medicare beneficiaries. Under the final rule, there was a net 2.1% increase in hospices’ payments effective October 1, 2016. The hospice payment increase was the net result of a 2.7% inpatient hospital market basket update, reduced by a 0.3% productivity adjustment and by a 0.3% adjustment set by the ACA. The hospice cap amount for fiscal year 2017 increased by 2.1%, which is equal to the 2016 cap amount updated by the fiscal year 2017 hospice payment update percentage of 2.1%. In addition, this rule changes the hospice quality reporting program requirements, including care surveys and two new quality measures that will assess hospice staff visits to patients and caregivers in the last three and seven days of life and the percentage of hospice patients who received care processes consistent with guidelines.

Senior Living Communities

82


Senior living services revenue is primarily derived from private pay residents at rates we establish based upon the needs of the resident, the amount of services we provide the resident, and market conditions in the area of operation. In addition, Medicaid or other state-specific programs may supplement payments for board and care services provided in senior living communities. A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities under waivers granted by or under Medicaid state plans approved by CMS. State Medicaid programs control costs for assisted living and other home and community based services by various means such as restrictive financial and functional eligibility standards, enrollment limits and waiting lists. Because rates paid to senior living community operators are generally lower than rates paid to SNF operators, some states use Medicaid funding of senior living services as a means of lowering the cost of services for residents who may not need the higher level of health services provided in SNFs. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the services at, and physical conditions of, the participating communities. As a result of the growth of assisted living in recent years, states have adopted licensing standards applicable to assisted living communities. Most state licensing standards apply to assisted living communities regardless of whether they accept Medicaid funding.
Since 2003, CMS has commenced a series of actions to increase its oversight of state quality assurance programs for senior living communities and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid for through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home and community based services as alternatives to institutional services, pursuant to provisions of the ACA, and other authorities, through the use of several programs.
Regulations
On April 1, 2014, President Obama signed into law the Protecting Access to Medicare Act of 2014, which averted a 24% cut in Medicare payments to physicians and other Part B providers until March 31, 2015. In addition, this law maintained the 0.5% update for such services through December 31, 2014 and provides a 0.0% update to the 2015 Medicare Physician Fee Schedule (MPFS) through March 31, 2015. Among other things, this law provides the framework for implementation of a value-based purchasing program for skilled nursing facilities. Under this legislation HHS is required to develop by October 1, 2016 measures and performance standards regarding preventable hospital readmissions from skilled nursing facilities. Beginning October 1, 2018, HHS will withhold 2% of Medicare payments to all skilled nursing facilities and distribute this pool of payment to skilled nursing facilities as incentive payments for preventing readmissions to hospitals.
On April 16, 2015, President Obama signed MACRA into law. This bill includes a number of provisions, including replacement of the Sustainable Growth Rate (SGR) formula used by Medicare to pay physicians with new systems for establishing annual payment rate updates for physicians' services. In addition, it increases premiums for Part B and Part D of Medicare for beneficiaries with income above certain levels and makes numerous other changes to Medicare and Medicaid. On April 1, 2019, CMS announced that it has finalized Medicare Advantage and Part D payment and policy updates to maximize competition and coverage. As of 2019, Medicare Advantage plans can offer supplemental benefits that are not covered under Medicare Parts A or B, if they diagnose, compensate for physical impairments, diminish the impact of injuries or health conditions, and/or reduce avoidable emergency room utilization. On April 16, 2019, CMS issued a final rule revising Medicare Advantage Program (Part C) regulations and Prescription Drug Benefit Program (Part D) regulations to implement certain provisions of the Bipartisan Budget Act of 2018 effective as of January 1, 2020. This final rule makes several revisions and additions to the preclusion list provisions finalized in the April 2018 final rule. Further, this final rule will also revise the appeals and grievances requirements for certain Medicaid managed care and Medicare Advantage special needs plans for dual eligible individuals to implement certain provisions of the Bipartisan Budget Act of 2018.
Effective January 1, 2018, CMS published a final rule with comment period on November 16, 2017, that reduces certain burdens on physicians for participation in Merit-Based Incentive Payment Systems (MIPs) and Alternative Payment Models (APMs), for 2018, another transition year. MACRA in general affects reimbursement for services of certain physicians who receive reimbursement under Medicare Part B through different payment models. The rule changes some of the qualifications for APMs and MIPs, such as quality and cost measures. The rule creates various new APMs for physicians to participate in lieu of MIPs. This rule may impact reimbursement to physicians who provide services at SNFs, HHAs and hospices, but the application of the rule to reimbursement for the Company’s facilities is uncertain at this time.
The Improving Medicare Post-Acute Care Transformation Act of 2014 (the “IMPACT Act”), which was signed into law on October 6, 2014, requires the submission of standardized assessment data for quality improvement, payment and discharge planning purposes across the spectrum of post-acute care providers (“PACs”), including home health agencies. The IMPACT Act will require PACs to begin reporting: (1) standardized patient assessment data at admission and discharge by January 1, 2019 for home health agencies; (2) new quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls, and patient preference regarding treatment and discharge at various intervals between October 1, 2016 and January 1, 2019; and

83


(3) resource use measures, including Medicare spending per beneficiary, discharge to community, and hospitalization rates of potentially preventable readmissions by January 1, 2017 for home health agencies. Failure to report such data when required would subject a PAC to a two percent reduction in market basket prices then in effect.
The IMPACT Act also included provisions impacting Medicare-certified hospices, including: (1) increasing survey frequency for Medicare-certified hospices to once every 36 months; (2) imposing a medical review process for operations with a high percentage of stays in excess of 180 days; and (3) updating the annual aggregate Medicare payment cap. On March 15, 2019, the Medicare Payment Advisory Commission submitted its Medicare payment policy report to Congress, again recommending a 5% home health payment rate reduction for the coming year.
On January 2, 2013 President Obama signed the American Taxpayer Relief Act of 2012 into law. This statute delayed significant cuts in Medicare rates for physician services until December 31, 2013. The statute also created a Commission on Long-Term Care, the goal of which was to develop a plan for the establishment, implementation, and financing of a comprehensive, coordinated, and high-quality system that ensures the availability of long-term care services and supports for individuals in need of such services and supports.
On February 22, 2012, President Obama signed into law H.R. 3630, which among other things, delayed a cut in physician and Part B services.  In establishing the funding for the law, payments to nursing facilities for patients' unpaid Medicare A co-insurance was reduced. The Deficit Reduction Act of 2005 had previously limited reimbursement of bad debt to 70% on privately responsibility co-insurance. However, under H.R. 3630, this reimbursement will be reduced to 65%.
Further, prior to the introduction of H.R. 3630, we were reimbursed for 100% of bad debt related to dual-eligible Medicare patients' co-insurance.  H.R. 3630 will phase down the dual-eligible reimbursement over three years.  Effective October 1, 2012, Medicare dual-eligible co-insurance reimbursement decreased from 100% to 88%, with further reductions to 77% and 65% as of October 1, 2013 and 2014, respectively.  Any reductions in Medicare or Medicaid reimbursement could materially adversely affect our profitability.
On October 17, 2018, CMS announced its Medicare Part B monthly actuarial rates, premium rates and annual deductible beginning on January 1, 2019. The monthly actuarial rates for 2019 are $264.90 for aged enrollees and $315.40 for disabled. Further, on November 23, 2018 CMS issued a final rule addressing the changes to the Medicare physician fee schedule (PFS) and other Medicare Part B policies. The statute requires CMS to establish payments under the PFS based on national uniform relative value units (RVUs) that account for the relative resources used in furnishing a service. The statute requires that RVUs be established for three categories of resources: Work; practice expense (PE); and malpractice (MP) expense. In addition, the statute requires that CMS establish by regulation each year's payment amounts for all physicians' services paid under the PFS, incorporating geographic adjustments to reflect the variations in the costs of furnishing services in different geographic areas. In this final rule, CMS establishes RVUs for CY 2019 for the PFS, and other Medicare Part B payment policies, to ensure that its payment systems are updated to reflect changes in medical practice and the relative value of services, as well as changes in the statute.
On April 25, 2019, CMS issued a final rule effective as of June 24, 2019. This final rule sets forth payment parameters and provisions related to the risk adjustment and risk adjustment data validation programs; cost-sharing parameters; and user fees for Federally-facilitated Exchanges (FFEs) and State-based Exchanges on the Federal Platform (SBE-FPs). It finalizes changes that will allow greater flexibility related to the duties and training requirements for the Navigator program and changes that will provide greater flexibility for direct enrollment entities, while strengthening program integrity oversight over those entities. It finalizes a change intended to reduce the costs of prescription drugs. This final rule also includes changes to Exchange standards related to eligibility and enrollment; exemptions; and other related topics.
Additionally, there has been a trend of the Trump administration implementing work requirements for potential Medicaid beneficiaries. A federal court recently struck down these work requirements for Medicaid beneficiaries in Arkansas and Kentucky. However, on March 29, 2019, after the aforementioned decision, the Trump administration imposed work requirements for Medicaid beneficiaries in Utah. This may have an impact on the amount of patients who qualify for Medicaid and may, as a result, have an adverse impact our operations.

Our business could be adversely affected by various proposals, such as the Expanded and Improved Medicare for All Act, currently being contemplated and which would change Medicare coverage pursuant to a single-payer, national health insurance systems. If enacted, such proposals could have a significant impact on our industry depending on numerous factors. At this stage, we cannot predict how such legislation will affect our business.

Our future revenue, financial condition and results of operations could be impacted by continued cost containment pressures on Medicaid spending.


84


Medicaid, which is largely administered by the states, is a significant payor for our skilled nursing services. Rapidly increasing Medicaid spending, combined with slow state revenue growth, has led many states to institute measures aimed at controlling spending growth. For example, in February 2009, the California legislature approved a new budget to help relieve a $42 billion budget deficit. The budget package was signed after months of negotiation, during which time California's governor declared a fiscal state of emergency in California. The new budget implemented spending cuts in several areas, including Medi-Cal spending. Further, California initially had extended its cost-based Medi-Cal long-term care reimbursement system enacted through Assembly Bill 1629 (A.B.1629) through the 2009-2010 and 2010-2011 rate years with a growth rate of up to five percent for both years. However, due to California's severe budget crisis, in July 2009, the State passed a budget-balancing proposal that eliminated this five percent growth cap by amending the current statute to provide that, for the 2009-2010 and 2010-2011 rate years, the weighted average Medi-Cal reimbursement rate paid to long-term care facilities shall not exceed the weighted average Medi-Cal reimbursement rate for the 2008-2009 rate year. In addition, the budget proposal increased the amounts that California nursing facilities will pay to Medi-Cal in quality assurance fees for the 2009-2010 and 2010-2011 rate years by including Medicare revenue in the calculation of the quality assurance fee that nursing facilities pay under A.B. 1629. Although overall reimbursement from Medi-Cal remained stable, individual facility rates varied.

California's Governor signed the budget trailer into law in October 2010. Despite its enactment, these changes in reimbursement to long-term care facilities were to be implemented retroactively to the beginning of the calendar quarter in which California submitted its request for federal approval of CMS. California’s Governor released a 2014-2015 budget that includes $1.2 billion in additional Medi-Cal funding.  This proposal, however, would not eliminate retroactive rate cuts for hospital-based skilled nursing facilities.

Because state legislatures control the amount of state funding for Medicaid programs, cuts or delays in approval of such funding by legislatures could reduce the amount of, or cause a delay in, payment from Medicaid to skilled nursing facilities. Since a significant portion of our revenue is generated from our skilled nursing operating subsidiaries in California, these budget reductions, if approved, could adversely affect our net patient service revenue and profitability. We can expect continuing cost containment pressures on Medicaid outlays for skilled nursing facilities, and any such decline could adversely affect our financial condition and results of operations.

To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements such as provider taxes. Under provider tax arrangements, states collect taxes or fees from healthcare providers and then return the revenue to these providers as Medicaid expenditures. Congress, however, has placed restrictions on states' use of provider tax and donation programs as a source of state matching funds. Under the Medicaid Voluntary Contribution and Provider-Specific Tax Amendments of 1991, the federal medical assistance percentage available to a state was reduced by the total amount of healthcare related taxes that the state imposed, unless certain requirements are met. The federal medical assistance percentage is not reduced if the state taxes are broad-based and not applied specifically to Medicaid reimbursed services. In addition, the healthcare providers receiving Medicaid reimbursement must be at risk for the amount of tax assessed and must not be guaranteed to receive reimbursement through the applicable state Medicaid program for the tax assessed. Lower Medicaid reimbursement rates would adversely affect our revenue, financial condition and results of operations.

Future cost containment initiatives undertaken by private third party payors may limit our future revenue and profitability.

Our non-Medicare and non-Medicaid revenue and profitability are affected by continuing efforts of third party payors to maintain or reduce costs of healthcare by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates. There can be no assurance that third party payors will make timely payments for our services, or that we will continue to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare and non-Medicaid sources of revenue and any changes in payment levels from current or future third party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.


85


Skilled nursing facilities are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement essentially confers on the skilled nursing facility itself the Medicare billing responsibility for the entire package of care that its patients receive in these situations. The BBA also affected skilled nursing facility payments by requiring that post-hospitalization skilled nursing services be “bundled” into the hospital's Diagnostic Related Group (DRG) payment in certain circumstances. Where this rule applies, the hospital and the skilled nursing facility must, in effect, divide the payment which otherwise would have been paid to the hospital alone for the patient's treatment, and no additional funds are paid by Medicare for skilled nursing care of the patient. At present, this provision applies to a limited number of DRGs, but already is apparently having a negative effect on skilled nursing facility utilization and payments, either because hospitals are finding it difficult to place patients in skilled nursing facilities which will not be paid as before or because hospitals are reluctant to discharge the patients to skilled nursing facilities and lose part of their payment. This bundling requirement could be extended to more DRGs in the future, which would accentuate the negative impact on skilled nursing facility utilization and payments. We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

Reforms to the U.S. healthcare system could impose new requirements upon us and may lower our reimbursements.

The ACA and the Health Care and Education Reconciliation Act of 2010 (the Reconciliation Act) include sweeping changes to how healthcare is paid for and furnished in the United States. As discussed below under the heading “-Our business may be materially impacted if certain aspects of the ACA are amended, repealed, or successfully challenged,” any further amendments or revisions to the ACA or its implementing regulations could materially impact our business. The recent presidential and congressional elections in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation of Medicare and/or Medicaid, and government policy that could significantly impact our business and the healthcare industry. We continually monitor these developments in an effort to respond to the changing regulatory environment impacting our business.

The ACA, as modified by the Reconciliation Act, is projected to expand access to Medicaid for approximately 11 million to 13 million additional people each year between 2015 and 2024. It also reduces the projected growth of Medicare by $106 billion by 2020 by tying payments to providers more closely to quality outcomes. It also imposes new obligations on skilled nursing facilities, requiring them to disclose information regarding ownership, expenditures and certain other information. This information is disclosed on a website for comparison by members of the public.

To address potential fraud and abuse in federal healthcare programs, including Medicare and Medicaid, ACA includes provider screening and enhanced oversight periods for new providers and suppliers, as well as enhanced penalties for submitting false claims. It also provides funding for enhanced anti-fraud activities. The new law imposes enrollment moratoria in elevated risk areas by requiring providers and suppliers to establish compliance programs. The ACA also provides the federal government with expanded authority to suspend payment if a provider is investigated for allegations or issues of fraud. Section 6402 of the ACA provides that Medicare and Medicaid payments may be suspended pending a “credible investigation of fraud,” unless the Secretary of the United States Department of Health and Human Services (HHS) determines that good cause exists not to suspend payments. To the extent the Secretary applies this suspension of payments provision to one of our affiliated facilities for allegations of fraud, such a suspension could adversely affect our results of operations.

Under the ACA, HHS will establish, test and evaluate alternative payment methodologies for Medicare services through a five-year, national, voluntary pilot program, which started in 2013. This program provides incentives for providers to coordinate patient care across the continuum and to be jointly accountable for an entire episode of care centered around a hospitalization. HHS develops qualifying provider payment methods that may include bundled payments and bids from entities for episodes of care. The bundled payment will cover the costs of acute care inpatient services; physicians’ services delivered in and outside of an acute care hospital; outpatient hospital services including emergency department services; post-acute care services, including home health services, skilled nursing services; inpatient rehabilitation services; and inpatient hospital services. The payment methodology includes payment for services, such as care coordination, medication reconciliation, discharge planning and transitional care services, and other patient-centered activities. Payments for items and services cannot result in spending more than would otherwise be expended for such entities if the pilot program was not implemented. As with Medicare’s shared savings program discussed above, payment arrangements among providers on the backside of the bundled payment must take into account significant hurdles under the Anti-Kickback Statue, the Stark Law and the Civil Monetary Penalties Law.


86


The ACA attempts to improve the healthcare delivery system through incentives to enhance quality, improve beneficiary outcomes and increase value of care. One of these key delivery system reforms is the encouragement of Accountable Care Organizations (ACOs). ACOs will facilitate coordination and cooperation among providers to improve the quality of care for Medicare beneficiaries and reduce unnecessary costs. Participating ACOs that meet specified quality performance standards will be eligible to receive a share of any savings if the actual per capita expenditures of their assigned Medicare beneficiaries are a sufficient percentage below their specified benchmark amount. Quality performance standards will include measures in such categories as clinical processes and outcomes of care, patient experience and utilization of services.

We routinely receive Requests for Information (RFIs) from active referral and managed care networks asking for quality, rating, performance and other information about our SNFs operating in the geographic areas that they are being serviced.  The RFIs are used to evaluate which SNFs should be included in each network of preferred providers.  For those SNFs included in the network, the ACO and its associated providers may then recommend the SNF as a “preferred provider” to patients in need of skilled care.  In the past, after responding to such RFIs, our SNFs have in some instances been rewarded with inclusion in a network of preferred providers, and in other instances have not been included.  While referrals to a SNF in a preferred provider network will always be subject to a patient’s freedom of choice, as well as the patient’s physician’s medical judgment as to which facility will best serve the patient’s needs, the inclusion as a preferred provider in a network will likely result in an increase in overall admissions to that SNF.  On the other hand, the failure to be included could result in some volume of patient admissions being shifted to other facilities that have been designated instead as preferred providers. As a result, to the extent that one of our SNF is not included in a preferred provider network, our revenues and results of operations could be adversely affected.

In addition, ACA required HHS to develop a plan to implement a value-based purchasing program for Medicare payments to skilled nursing facilities. HHS delivered a report to Congress outlining its plans for implementing this value-based purchasing program. The value-based purchasing program would provide payment incentives for Medicare-participating skilled nursing facilities to improve the quality of care provided to Medicare beneficiaries. Among the most relevant factors in HHS' plans to implement value-based purchasing for skilled nursing facilities is the current Nursing Home Value-Based Purchasing Demonstration Project, which concluded in 2012. HHS provided Congress with an outline of plans to implement a value-based purchasing program, and any permanent value-based purchasing program for skilled nursing facilities will be implemented after that evaluation.
On October 4, 2016, CMS released a final rule that reforms the requirements for long-term care (LTC) facilities, specifically skilled nursing facilities (SNFs) and nursing facilities (NFs), to participate in the Medicare and Medicaid programs. The regulations have not been updated since 1991 and have been revised to improve quality of life, care and services in LTC facilities, optimize resident safety, reflect current professional standards and improve the logical flow of the regulations. The regulations are effective November 28, 2016 and will be implemented in three phases. The first phase was effective November 28, 2016, the second phase was effective November 28, 2017 and the third phase becomes effective November 28, 2019.
A few highlights from the new regulation include the following:
investigate and report all allegations of abusive conduct, and refrain from employing individuals who have had a disciplinary action taken against their professional license by a state licensure body as a result of a finding of abuse, neglect, mistreatment of residents or misappropriation of their property;
document a transfer or discharge in the medical record and exchange certain information to a receiving provider or facility when a resident is transferred;
develop and implement a baseline care plan for each resident within 48 hours of their admission that includes instructions to provide effective and person-centered care that meets professional standards of quality care;
develop and implement a discharge planning process that prepares residents to be active partners in post-discharge care;
provide the necessary care and services to attain or maintain the highest practicable physical, mental and psychosocial well-being;
add a competency requirement for determining the sufficiency of nursing staff;
require that a pharmacist reviews a resident’s medical chart during each monthly drug regiment review;
refrain from charging a Medicare resident for loss or damage of dentures;

87


provide each resident with a nourishing, palatable and well-balanced diet;
conduct, document and annually review a facility-wide assessment to determine what resources are necessary to care for its residents;
refrain from entering into a binding arbitration agreement until after a dispute arises between the parties;
develop, implement and maintain an effective comprehensive, data-driven quality assurance and performance improvement program;
develop an Infection Prevention and Control Program; and
require their operating organization have in effect a compliance and ethics program.
CMS estimates that the average cost per facility for compliance with the new rule to be approximately $62,900 in the first year and approximately $55,000 in subsequent years. However, these amounts vary per organization. In addition to the monetary costs, these regulations may create compliance issues, as state regulators and surveyors interpret requirements that are less explicit. On June 8, 2017, CMS issued a proposed rule that would remove the provisions prohibiting binding pre-dispute arbitration agreements, but would retain other provisions that protect the interests of LTC residents.
On July 16, 2019, CMS introduced one proposed and one final rule related to the regulatory framework within which long term and post-acute care providers operate. The proposed rule covers changes to the Requirements of Participation (ROP) for the Medicare and Medicaid Programs, and the final rule addresses the use of pre-dispute arbitration agreements with patients/residents. As part of the ROP proposed rule, CMS has proposed a delay in the implementation of both the Quality Assurance and Performance Improvement (QAPI) program and Compliance and Ethics program and training requirements for one year, including the following: (a) QAPI program and documentation; (b) Program Design and Scope; (c) Program Feedback Data Systems, and Monitoring; (d) Program Systematic Analysis and Systematic Action; (e) Program Activities; (f) Governance and Leadership; (g) Compliance and Ethics Program; and (h) QAPI Training and Compliance and Ethics Training. The proposed rule does not delay implementation of the Phase 3 Infection Preventionist requirements of the Compliance and Ethics Program. Likewise, the proposed rule maintains the implementation date of the requirements for culturally competent and trauma-informed care, or the requirements for a call system from the residents' bedsides.
On the issue of pre-dispute binding Arbitration Agreements, the final rule amends the requirements that Long-Term Care (LTC) facilities must meet to participate in the Medicare and Medicaid programs. Specifically, the rule confirms the repeal of the prohibition on the use of pre-dispute, binding arbitration agreements, and strengthens the transparency of arbitration agreements and arbitration in LTC facilities. Included in the final rule is the requirement that facilities ensure the agreement for binding arbitration is in plain language; that facilities post a notice in plain language that describes the policy on the use of agreements for binding arbitration in an area that is visible to residents and visitors; that admission to the facility not be conditioned on the signing of an arbitration agreement; and that the facility explicitly inform the resident or his or her representative of the right not to sign the agreement as a condition of admission. The final rule supports residents' rights to make informed choices about important aspects of their health care.

On June 9, 2017, CMS issued revised requirements for emergency preparedness for Medicare and Medicaid participating providers, including long-term care facilities, hospices, and home health agencies. The revised requirements update the conditions of participation for such providers. Specifically, outpatient facilities, such as home health agencies, are required to ensure that patients with limited mobility are addressed within the emergency plan; home health agencies are also required to develop and implement emergency preparedness policies and procedures that are reviewed and updated at least annually and each patient must have an individual plan; hospice-operated inpatient care facilities are required to provide subsistence needs for hospice employees and patients and a means to shelter in place patients and employees who remain in the hospice; all hospices and home health agencies must implement procedures to follow up with on duty staff and patients to determine services that are needed in the event that there is an interruption in services during or due to an emergency; and hospices must train their employees in emergency preparedness policies and long-term care facilities are required to share emergency preparedness plans and policies with family members and resident representatives.


88


On September 16, 2016, CMS issued its final rule concerning emergency preparedness requirements for Medicare and Medicaid participating providers, specifically SNFs, NFs, and intermediate care facilities for individuals with intellectual disabilities (ICF/IIDs). The rule is designed to ensure providers and suppliers have comprehensive and integrated emergency policies and procedures in place, in particular during natural and man-made disasters. Under the rule, facilities are required to 1) document risk assessment and emergency planning; 2) develop and implement policies and procedures based on that risk assessment; 3) develop and maintain an emergency preparedness communication plan in compliance with both federal and state law; and 4) develop and maintain an emergency preparedness training and testing program.
On July 29, 2016, CMS issued its final rule laying out the performance standards relating to preventable hospital readmissions from skilled nursing facilities. The final rule includes the SNF 30-day All Cause Readmission Measure which assesses the risk-standardized rate of all-cause, all condition, unplanned inpatient hospital readmissions for Medicare fee-for-service SNF patients within 30 days of discharge from admission to an inpatient prospective payment system hospital (IPPS), critical access hospital (CAH) or psychiatric hospital. The final rule includes the SNF 30-Day Potentially Preventable Readmission Measure as the SNF all condition risk adjusted potentially preventable hospital readmission measure. This measure assesses the facility-level risk-standardized rate of unplanned, potentially preventable hospital readmissions for SNF patients within 30 days of discharge from a prior admission to an IPPS hospital, CAH, or psychiatric hospital. Hospital readmissions include readmissions to a short-stay acute-care hospital or CAH, with a diagnosis considered to be unplanned and potentially preventable. This measure is claims-based, requiring no additional data collection or submission burden for SNFs.
On August 8, 2018, CMS issued a final rule updating the payment rates used under the prospective payment system for SNFs for fiscal year 2019. This final rule also replaces the existing case-mix classification methodology, the Resource Utilization Groups, Version IV (RUG-IV) model, with a revised case-mix methodology called the PDPM beginning on October 1, 2019. The rule finalizes revisions to the regulation text that describes a beneficiary's SNF “resident” status under the consolidated billing provision and the required content of the SNF level of care certification. The rule also finalizes updates to the SNF Quality Reporting Program (QRP) and the VBP Program.
On February 2, 2016, CMS issued its final rule concerning face-to-face requirements for Medicaid home health services. Under the rule, the Medicaid home health service definition was revised consistent with applicable sections of the ACA and H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The rule also requires that for the initial ordering of home health services, the physician must document that a face-to-face encounter that is related to the primary reason the beneficiary requires home health services occurred no more than 90 days before or 30 days after the start of services. The final rule also requires that for the initial ordering of certain medical equipment, the physician or authorized non-physician provider (NPP) must document that a face-to-face encounter that is related to the primary reason the beneficiary requires medical equipment occurred no more than 6 months prior to the start of services.

On April 27, 2016, CMS added six new quality measures to its consumer-based Nursing Home Compare website. These quality measures include the rate of rehospitalization, emergency room use, community discharge, improvements in function, independently worsened and antianxiety or hypnotic medication among nursing home residents. Beginning in July 2016, CMS incorporates all of these measures, except for the antianxiety/hypnotic medication measure, into the calculation of the Nursing Home Five-Star Quality Ratings. As of July 2018, CMS provides rates of hospitalizations for long-stay residents in each facility’s confidential “Nursing Home Compare Five-Star Ratings of Nursing Homes Provider Rating Report.” As of October 2018, the long-stay hospitalization measure is posted on the Nursing Home Compare website as a long-stay quality measure. On March 5, 2019, CMS announced additional updates to Nursing Home Compare, including revisions to the inspection process, enhancement of new staffing information, and implementation of new quality measures, adding measures of long-stay hospitalizations and emergency room transfers and removing duplicative and less meaningful measures.

On July 6, 2015, CMS launched a Home Health Value-Based Purchasing model to test whether incentives for better care can improve outcomes in the delivery of home health services. The model applies a payment reduction or increase to current Medicare-certified home health agency payments, depending on quality performance, for all agencies delivering services within nine randomly-selected states. Payment adjustments are applied on an annual basis, beginning at 5.0% in each of the first two payment adjustment years, 6.0% in the third payment adjustment year and 8.0% in the final two payment adjustment years.

On April 1, 2014, the President signed into law the Protecting Access to Medicare Act of 2014 which, among other things, provides the framework for implementation of a value-based purchasing program for skilled nursing facilities. Under this legislation HHS is required to develop by October 1, 2016 measures and performance standards regarding preventable hospital readmissions from skilled nursing facilities. Beginning October 1, 2018, HHS withholds 2% of Medicare payments to all skilled nursing facilities and distribute this pool of payment to skilled nursing facilities as incentive payments for preventing readmissions to hospitals.


89


CMS has issued and will continue to issue rules to implement the ACA. Courts will continue to interpret and apply the ACA’s provisions. We cannot predict what effect these changes will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement and adversely affect our business.

The Affordable Care Act and its implementation could impact our business.

In addition, the Affordable Care Act could result in sweeping changes to the existing U.S. system for the delivery and financing of healthcare. The details for implementation of many of the requirements under the Affordable Care Act will depend on the promulgation of regulations by a number of federal government agencies, including the HHS. It is impossible to predict the outcome of these changes, what many of the final requirements of the Health Reform Law will be, and the net effect of those requirements on us. As such, we cannot predict the impact of the Affordable Care Act on our business, operations or financial performance.

A significant goal of federal healthcare reform is to transform the delivery of healthcare by changing reimbursement for healthcare services to hold providers accountable for the cost and quality of care provided.  Medicare and many commercial third party payors are implementing Accountable Care Organization models in which groups of providers share in the benefit and risk of providing care to an assigned group of individuals at lower cost. Other reimbursement methodology reforms include value-based purchasing, in which a portion of provider reimbursement is redistributed based on relative performance on designated economic, clinical quality, and patient satisfaction metrics. In addition, CMS is implementing programs to bundle acute care and post-acute care reimbursement to hold providers accountable for costs across a broader continuum of care.  These reimbursement methodologies and similar programs are likely to continue and expand, both in public and commercial health plans. Providers who respond successfully to these trends and are able to deliver quality care at lower cost are likely to benefit financially.

The Affordable Care Act and the programs implemented by the law may reduce reimbursements for our services and may impact the demand for the Company’s products. In addition, various healthcare programs and regulations may be ultimately implemented at the federal or state level. Failure to respond successfully to these trends could negatively impact our business, results of operations and/or financial condition. As discussed below under the heading “Our business may be materially impacted if certain aspects of the Affordable Care Act are amended, repealed, or successfully challenged,” any further amendments or revisions to ACA or its implementing regulations could materially impact our business.

Our business may be materially impacted if certain aspects of the Affordable Care Act are amended, repealed, or successfully challenged.
A number of lawsuits have been filed challenging various aspects of the ACA and related regulations. In addition, the efficacy of the ACA is the subject of much debate among members of Congress and the public. On December 14, 2018, the U.S. District Judge Reed O'Connor of the Northern District of Texas held the individual mandate provisions, and therefore the entirety of ACA, unconstitutional. The impact of the ruling is stayed as it is appealed to the Fifth Circuit Court of Appeals. The U.S. House has voted to condemn the Trump administration for backing the lawsuit. The Fifth Circuit Court of Appeals is expected to hear the case in 2019. The Trump administration has stated that it supports the Texas District Court’s ruling and will back efforts to eliminate the ACA.
In an unrelated case, on March 26, 2019, a federal judge struck down the Trump administration’s rule which allows small businesses to band together and set up health insurance plans and overlook the requirements of the ACA. This case may be a trend of decisions supporting the ACA and undermining the hurdles implemented by the Trump administration. There is a lot of uncertainty around the status of the ACA and how it will be changed (or unchanged) in the near future. Our business may be materially impacted if the ACA in part, or in its entirety, is ruled unconstitutional. Furthermore, the uncertainty regarding the constitutionality of the ACA, or specific provisions therein, may negatively affect our business. In addition, on July 19, 2019, a federal judge ruled that the Trump administration can expand the sale of short-term health insurance policies that do not meet the standards of the ACA, which limits the ACA. As some decisions expand the ACA, while others limit the ACA, the impact of the ACA on our business is difficult to predict.

90


Presidential and Congressional elections in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation of Medicare and/or Medicaid, and government policy that could significantly impact our business and the healthcare industry. In the event that legal challenges are successful or the ACA is repealed or materially amended, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of the ACA, and the new administration could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.

Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.

Our success depends upon our ability to retain and attract nurses, Certified Nurse Assistants, social workers and speech, physical and occupational therapists. Our success also depends upon our ability to retain and attract skilled management personnel who are responsible for the day-to-day operations of each of our affiliated facilities. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff that is directly responsible for day-to-day care of the patients and marketing and community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.

We operate one or more affiliated skilled nursing facilities in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. With the exception of Utah, which follows federal regulations, each of these states has established minimum staffing requirements for facilities operating in that state. Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. In addition, if a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk. Deficiencies (depending on the level) may also result in the suspension of patient admissions and/or the termination of Medicaid participation, or the suspension, revocation or nonrenewal of the skilled nursing facility's license. If the federal or state governments were to issue regulations which materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly.

Increased competition for, or a shortage of, nurses or other trained personnel, or general inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. We may not be able to offset such added costs by increasing the rates we charge to the patients of our operating subsidiaries. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility. An increase in costs associated with, or a shortage of, skilled nurses, could negatively impact our business. In addition, if we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations effectively could be harmed.

We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.

As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with these programs and applicable laws and regulations. We are subject to regulatory reviews relating to Medicare services, billings and potential overpayments resulting from Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors and Medicaid Integrity Contributors programs, (collectively referred to as Reviews), in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare programs. Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry. We are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:


91


an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;

state or federal agencies imposing fines, penalties and other sanctions on us;

loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;

an increase in private litigation against us; and

damage to our reputation in various markets.

In 2004, our Medicare fiscal intermediaries began to conduct selected reviews of claims previously submitted by and paid to some of our affiliated facilities. While we have always been subject to post-payment audits and reviews, more intensive “probe reviews” appear to be a permanent procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal through the CMS defined continuum. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, we utilize all defenses reasonably available to us to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.

If the government or court were to conclude that such errors and deficiencies constituted criminal violations, or were to conclude that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or if it were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and/or civil claims, administrative sanctions and penalties for amounts that could be material to our business, results of operations and financial condition. In addition, we and/or some of the key personnel of our operating subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare. In any event, it is likely that a governmental investigation alone, regardless of its outcome, would divert material time, resources and attention from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings.

In cases where claim and documentation review by any CMS contractor results in repeated poor performance, an operation can be subjected to protracted oversight. This oversight may include repeat education and re-probe, extended pre-payment review, referral to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement outside of specifically reviewed claims. Sustained failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of June 30, 2019, we had ten operating subsidiaries that had Reviews scheduled, on appeal, or in a dispute resolution process, both pre- and post-payment.

Public and government calls for increased survey and enforcement efforts toward long-term care facilities could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.

CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state actions. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards, and to identify multi-facility providers with patterns of noncompliance. In addition, HHS has adopted a rule that requires CMS to charge user fees to healthcare facilities cited during regular certification, recertification or substantiated complaint surveys for deficiencies, which require a revisit to assure that corrections have been made. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently.


92


The intensified and evolving enforcement environment impacts providers like us because of the increase in the scope or number of inspections or surveys by governmental authorities and the severity of consequent citations for alleged failure to comply with regulatory requirements. We also divert personnel resources to respond to federal and state investigations, audits and other enforcement actions. The diversion of these resources, including our management team, clinical and compliance staff, and others take away from the time and energy that these individuals could otherwise spend on routine operations. As noted, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. The focus of these deficiency reports tends to vary from year to year and state to state. Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility, which could result in the imposition of fines, imposition of a license to a conditional or provisional status, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future. We currently have no affiliated facilities operating under provisional licenses which were the result of inspection deficiencies.

Furthermore, in some states, citations in one facility impact other facilities in the state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. If state or federal regulators were to determine, formally or otherwise, that one facility's regulatory history ought to impact another of our existing or prospective facilities, this could also increase costs, result in increased scrutiny by state and federal survey agencies, and even impact our expansion plans. Therefore, our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and results of operations as a whole.

Depending on the type of operation and state regulation, unannounced surveys or inspections may occur annually, every other year, or every third year and following a regulator's receipt of a complaint from a patient, resident or employee of an affiliated operation. During such surveys or inspections, operations may be found to be deficient under Medicare, Medicaid or state licensing standards. Most deficiencies can be resolved through a written plan of corrective action, but the reviewing agency may also have authority to impose additional sanctions on a provider, including civil monetary penalties or other fines, a provisional or conditional license, the suspension or revocation of a license, or a suspension of new admissions or denial of payment for new Medicaid and Medicare admissions, civil monetary penalties, focused state and federal oversight and even loss of eligibility for Medicaid and Medicare participation or state licensure. Sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice. This possibility sometimes leaves affected operators, including us, with the difficult task of deciding whether to continue accepting patients after the potential denial of payment date, thus risking the retroactive denial of revenue associated with those patients' care if the operators are later found to be out of compliance, or simply refusing admissions from the potential denial of payment date until the facility is actually found to be in compliance. In the past, some of our affiliated facilities have been in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of the revenue associated with the Medicare and Medicaid patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, these sanctions, entailing various remedies up to and including decertification, would further negatively affect our financial condition and results of operations. In 2016, we elected to voluntarily close one operating subsidiary as a result of multiple regulatory deficiencies in order to avoid continued strain on our staff and other resources and to avoid restrictions on our ability to acquire new facilities or expand or operate existing facilities. In addition, from time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.
 
Facilities with otherwise acceptable regulatory histories generally are given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within nine months, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, are not generally given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners (including us, historically) nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously-certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before we acquire

93


them and that develop new deficiencies after we acquire them are more likely to have sanctions imposed upon them by CMS or state regulators. In addition, CMS has increased its focus on facilities with a history of serious quality of care problems through the special focus facility initiative. A facility's administrators and owners are notified when it is identified as a special focus facility. This information is also provided to the general public. The special focus facility designation is based in part on the facility's compliance history typically dating before our acquisition of the facility. Local state survey agencies recommend to CMS that facilities be placed on special focus status. A special focus facility receives heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility “graduates” from the program once it demonstrates significant improvements in quality of care that are continued over time.

We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our affiliated facilities. We have had several affiliated facilities placed on special focus facility status, due largely or entirely to their respective regulatory histories prior to our acquisition of the operating subsidiaries, and have successfully graduated five operating subsidiaries from the program to date. We currently have one facility placed on special focus facility status. Other operating subsidiaries may be identified for such status in the future.

Annual caps that limit the amounts that can be paid for outpatient therapy services rendered to any Medicare beneficiary may reduce our future revenue and profitability or cause us to incur losses.

Some of our rehabilitation therapy revenue is paid by the Medicare Part B program under a fee schedule. Congress has established annual caps that limit the amounts that can be paid (including deductible and coinsurance amounts) for rehabilitation therapy services rendered to any Medicare beneficiary under Medicare Part B. The Deficit Reduction Act of 2005 (DRA) added Section 1833(g)(5) of the Social Security Act and directed CMS to develop a process that allows exceptions for Medicare beneficiaries to therapy caps when continued therapy is deemed medically necessary.

Annual limitations on beneficiary incurred expenses for outpatient therapy services under Medicare Part B are commonly referred to as “therapy caps.” All beneficiaries began a new cap year on January 1, 2019 since the therapy caps are determined on a calendar year basis. For physical therapy (PT) and speech-language pathology services (SLP) combined, the limit on incurred expenses is $2,040 for 2019 compared to $2,010 in 2018. The cap limit is the same for occupational therapy (OT) services. Deductible and coinsurance amounts paid by the for therapy services are applied towards the cap limit. A KX Modifier Applied to the claim for beneficiaries exceeding the $2,040 Cap communicates ongoing Medical Necessity for services delivered.

On February 9, 2018, President Trump signed into law the Bipartisan Budget Act of 2018 (BBA of 2018). This new law includes several provisions related to Medicare payments for services beginning on January 1, 2018. With regard to payment for outpatient therapy services, the law repeals application of the Medicare outpatient therapy caps but retains the former cap amounts as a threshold above for services that are medically necessary. The new law retains the targeted medical review process, but at a lower threshold amount. It also extends several recently expired Medicare legislative provisions affecting health care providers and beneficiaries, including the Medicare physician fee schedule work geographic adjustment floor.

On November 1, 2018, CMS issued a final rule that revises the payment policies under the Medicare Physician Fee Schedule which includes other revisions to Medicare Part B and the Quality Payment Program for CY 2019. One of the proposed revisions relates to functional reporting by therapists who provide outpatient services (including services to LTC Residents of the SNF under the Medicare Part B program). To date, therapists that provide outpatient services are required to include functional status information and at certain intervals the patient’s severity on claims for such therapy services. Consistent with CMS’ “Patients over Paperwork” initiative the agency eliminated the burdensome claims-based functional reporting requirements for Part B therapy services. Starting January 2019, SNFs are no longer required to append the following non-payable functional limitation G-codes-G8978 through G8999 and G9158 through G9186 or the following severity modifiers-CH through CN-to any outpatient therapy claim. This would reduce the reporting burden on therapists providing outpatient services and increase the amount of time that therapists can spend with their patients. This may result in greater reimbursement for outpatient therapy services as therapists who provide outpatient services may spend more time with patients.

A second part to the Physician Fee Schedule Final Rule is that CMS established new therapy assistant claim modifiers that will be required starting in CY 2020. When a physical therapist assistant (PTA) or occupational therapy assistant (OTA) provides all or part of treatment on a given day, the Balance Budget Act requires a 15 percent therapist assistant payment reduction be applied to the claim for that day starting in 2022.

The Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes (1) facilities that provide Medicare Part B

94


speech-language pathology, occupational therapy, and physical therapy services and bill under the same provider number; and (2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.

The BBA of 2018 implemented a targeted medical review program for some PT/SLP and OT services over $3,000 per year. Some of our rehabilitation therapy revenue is paid by the Medicare Part B program under a fee schedule. The calendar year 2019 conversion factor is $36.0391 which reflects the update adjustment factor of 0.25 percent and the budget neutrality adjustment of -0.14%. Further, the BBA of 2018, Section 50201 - Extension of Work Geographic Practice Cost Index (GPCI) Floor, extended a provision raising the Work GPCI to 1.000 for all localities that currently have a Work GPCI of less than 1.000 through December 31, 2019. Additionally, as required by the ACA, the 1.5 work GPCI floor for Alaska and the 1.0 practice expense GPCI floor for frontier states are permanent, and therefore, applicable in calendar year 2019.

After all required adjustments, the conversion factor has increased from $35.9996 for calendar year 2018 to $36.0391 for calendar year 2019. However, Table 94 in the Final Rule titled calendar year 2019 PFS Estimated Impact on Total Allowed Charges by Specialty indicates that, due to relative changes in the weights of various PFS procedure codes, the value of Part B physical and occupational therapy code payments in aggregate will decrease approximately 1.0% in 2019. We have experienced a decrease with the new physician fee schedule.

The application of annual caps, or the discontinuation of exceptions to the annual caps, could have an adverse effect on our revenue.

Our hospice operating subsidiaries are subject to annual Medicare caps calculated by Medicare. If such caps were to be exceeded by any of our hospice providers, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.

With respect to our hospice operating subsidiaries, overall payments made by Medicare to each provider number are subject to an inpatient cap amount and an overall payment cap, which are calculated and published by the Medicare fiscal intermediary on an annual basis covering the period from October 1 through September 30. The caps are detailed below.

The inpatient cap limits hospice care provided on an inpatient basis. This cap limits the number of days that are paid at the higher inpatient care rate to 20% of the total number of days of hospice care that are provided to all Medicare beneficiaries served by a provider. The daily rate for all days exceeding the cap is the standard Medicare hospice daily rate, and the provider must reimburse Medicare for any payments in excess of that amount.

The overall payment cap is calculated by the Medicare fiscal intermediary at the end of each hospice cap period to determine the maximum allowable payments to a hospice provider during the period. We estimate our potential cap exposure by using available information to compare our actual reimbursement for all hospice services provided during the period to the number of beneficiaries we served multiplied by the statutory per beneficiary cap amount.

If payments received by any one of our hospice provider numbers exceeds either of these caps, we are required to reimburse Medicare for payments received in excess of the caps, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. During the six months ended June 30, 2019, we recorded $0.2 million of hospice cap expense.

Failure to comply with quality reporting requirements may negatively impact reimbursement to our home health and hospice operating subsidiaries.
The ACA mandated the establishment of quality reporting requirements for home health and hospice providers. Beginning in fiscal year 2014, CMS mandated that failure to submit required quality data would result in a 2.0% reduction to the hospice provider’s market basket percentage increase for that fiscal year. For 2019, hospices are required to submit 12 months of data to the Consumer Assessment of Healthcare Providers & Systems (“CAHPS”) Hospice Survey Data Warehouse. The participation requirements for calendar year 2019 will affect the fiscal year 2021 annual payment update. Participation requirements for subsequent years will impact subsequent annual payment updates. The HQRP is currently “pay-for-reporting,” meaning it is the act of submitting timely and complete data that determines compliance with the requirements.

In the calendar year 2015 Home Health Final Rule, CMS proposed to establish a new “Pay-for-Reporting Performance Requirement” with which provider compliance with quality reporting program requirements can be measured. Home health providers that do not submit quality reporting data to CMS are subject to a 2.0% reduction in their annual home health payment update percentage. Home health providers are required to report prescribed quality assessment data for a minimum of 90.0% of all patients with episodes of care that occur on or after July 1, 2017.

95


Should our operating subsidiaries fail to meet quality reporting requirements in the future, it may result in one or more of our operations seeing a reduction in its Medicare reimbursements. We have incurred and are likely to continue to incur additional expenses in attempting to comply with these quality reporting requirements.

We are subject to extensive and complex federal and state government laws and regulations which could change at any time and increase our cost of doing business and subject us to enforcement actions.

We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:

facility and professional licensure, certificates of need, permits and other government approvals;
adequacy and quality of healthcare services;
qualifications of healthcare and support personnel;
quality of medical equipment;
confidentiality, maintenance and security issues associated with medical records and claims processing;
relationships with physicians and other referral sources and recipients;
constraints on protective contractual provisions with patients and third-party payors;
operating policies and procedures;
certification of additional facilities by the Medicare program; and
payment for services.

The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we do business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. We believe that such regulations may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. Changes in existing laws or regulations, or the enactment of new laws or regulations, could negatively impact our business. If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs.

We are subject to federal and state laws, such as the federal False Claims Act (FCA), state false claims acts, the illegal remuneration provisions of the Social Security Act, the federal anti-kickback laws, state anti-kickback laws, and the federal “Stark” laws, which govern financial and other arrangements among healthcare providers, their owners, vendors and referral sources, and that are intended to prevent healthcare fraud and abuse. Among other things, these laws prohibit kickbacks, bribes and rebates, as well as other direct and indirect payments or fee-splitting arrangements that are designed to induce the referral of patients to a particular provider for medical products or services payable by any federal healthcare program, and prohibit presenting a false or misleading claim for payment under a federal or state program. They also prohibit some physician self-referrals. Possible sanctions for violation of any of these restrictions or prohibitions include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. Changes in these laws could increase our cost of doing business. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties. For example, in April 2013, we announced that we reached a tentative settlement with the Department of Justice (DOJ) regarding their investigation related to claims submitted to the Medicare program for rehabilitation services provided at skilled nursing facilities in Southern California. As part of the settlement, we entered into a Corporate Integrity Agreement with the Office of Inspector General-HHS. Failure to comply with the terms of a Corporate Integrity Agreement could result in substantial civil or criminal penalties and being excluded from government health care programs, which could adversely affect our financial condition and results of operations. In March 2019, we were notified by the OIG that the five year term of the CIA has been concluded and effectively released from the CIA.


96


In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) of 2009 which made significant changes to the FCA, expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, healthcare providers face significant penalties for known retention of government overpayments, even if no false claim was involved. Healthcare providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. The ACA supplements FERA by imposing an affirmative obligation on healthcare providers to return an overpayment to CMS within 60 days of “identification” or the date any corresponding cost report is due, whichever is later. On August 3, 2015, the U.S. District Court for the Southern District of New York held that the 60 day clock following “identification” of an overpayment begins to run when a provider is put on notice of a potential overpayment, rather than the moment when an overpayment is conclusively ascertained. On February 12, 2016, CMS published a final rule with respect to Medicare Parts A and B clarifying that providers have an obligation to proactively exercise “reasonable diligence,” and that the 60 day clock begins to run after the reasonable diligence period has concluded, which may take at most 6 months from the from receipt of credible information, absent extraordinary circumstances. Retention of any overpayment beyond this period may result in FCA liability. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.

We are also required to comply with state and federal laws governing the transmission, privacy and security of health information. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires us to comply with certain standards for the use of individually identifiable health information within our company, and the disclosure and electronic transmission of such information to third parties, such as payors, business associates and patients. These include standards for common electronic healthcare transactions and information, such as claim submission, plan eligibility determination, payment information submission and the use of electronic signatures; unique identifiers for providers, employers and health plans; and the security and privacy of individually identifiable health information. In addition, some states have enacted comparable or, in some cases, more stringent privacy and security laws. If we fail to comply with these state and federal laws, we could be subject to criminal penalties and civil sanctions and be forced to modify our policies and procedures.

On January 25, 2013, HHS promulgated new HIPAA privacy, security, and enforcement regulations, which increase significantly the penalties and enforcement practices of the Department regarding HIPAA violations. In addition, any breach of individually identifiable health information can result in obligations under HIPAA and state laws to notify patients, federal and state agencies, and in some cases media outlets, regarding the breach incident. Breach incidents and violations of HIPAA or state privacy and security laws could subject us to significant penalties, and could have a significant impact on our business. The new HIPAA regulations are effective as of March 26, 2013, and compliance was required by September 23, 2013.

Our failure to obtain or renew required regulatory approvals or licenses or to comply with applicable regulatory requirements, the suspension or revocation of our licenses or our disqualification from participation in federal and state reimbursement programs, or the imposition of other harsh enforcement sanctions could increase our cost of doing business and expose us to potential sanctions. Furthermore, if we were to lose licenses or certifications for any of our affiliated facilities as a result of regulatory action or otherwise, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness and lease obligations.

Increased civil and criminal enforcement efforts of government agencies against skilled nursing facilities could harm our business, and could preclude us from participating in federal healthcare programs.

Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, skilled nursing facilities. The focus of these investigations includes, among other things:

cost reporting and billing practices;

quality of care;

financial relationships with referral sources; and

medical necessity of services provided.

If any of our affiliated facilities is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our affiliated facilities could harm our reputation for quality care and lead to a reduction in the patient referrals of our operating subsidiaries and ultimately a reduction in occupancy

97


at these facilities. Also, responding to enforcement efforts would divert material time, resources and attention from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.

Federal law provides that practitioners, providers and related persons may not participate in most federal healthcare programs, including the Medicaid and Medicare programs, if the individual or entity has been convicted of a criminal offense related to the delivery of a product or service under these programs or if the individual or entity has been convicted under state or federal law of a criminal offense relating to neglect or abuse of patients in connection with the delivery of a healthcare product or service. Other individuals or entities may be, but are not required to be, excluded from such programs under certain circumstances, including, but not limited to, the following:

medical necessity of services provided;

conviction related to fraud;

conviction relating to obstruction of an investigation;

conviction relating to a controlled substance;

licensure revocation or suspension;

exclusion or suspension from state or other federal healthcare programs;

filing claims for excessive charges or unnecessary services or failure to furnish medically necessary services;

ownership or control of an entity by an individual who has been excluded from the Medicaid or Medicare programs, against whom a civil monetary penalty related to the Medicaid or Medicare programs has been assessed or who has been convicted of a criminal offense under federal healthcare programs; and

the transfer of ownership or control interest in an entity to an immediate family or household member in anticipation of, or following, a conviction, assessment or exclusion from the Medicare or Medicaid programs.

The OIG, among other priorities, is responsible for identifying and eliminating fraud, abuse and waste in certain federal healthcare programs. The OIG has implemented a nationwide program of audits, inspections and investigations and from time to time issues “fraud alerts” to segments of the healthcare industry on particular practices that are vulnerable to abuse. The fraud alerts inform healthcare providers of potentially abusive practices or transactions that are subject to criminal activity and reportable to the OIG. An increasing level of resources has been devoted to the investigation of allegations of fraud and abuse in the Medicaid and Medicare programs, and federal and state regulatory authorities are taking an increasingly strict view of the requirements imposed on healthcare providers by the Social Security Act and Medicaid and Medicare programs. Although we have created a corporate compliance program that we believe is consistent with the OIG guidelines, the OIG may modify its guidelines or interpret its guidelines in a manner inconsistent with our interpretation or the OIG may ultimately determine that our corporate compliance program is insufficient.

In some circumstances, if one facility is convicted of abusive or fraudulent behavior, then other facilities under common control or ownership may be decertified from participating in Medicaid or Medicare programs. Federal regulations prohibit any corporation or facility from participating in federal contracts if it or its principals have been barred, suspended or declared ineligible from participating in federal contracts. In addition, some state regulations provide that all facilities under common control or ownership licensed within a state may be de-licensed if one or more of the facilities are de-licensed. If any of our operating subsidiaries were decertified or excluded from participating in Medicaid or Medicare programs, our revenue would be adversely affected.

The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

In March 2019, the OIG announced that it will be conducting an investigation relating to the “Post- hospital skilled nursing facility care provided to dually eligible beneficiaries.” The OIG indicated that during previous reviews some nursing facility residents who were receiving Medicaid-covered nursing home care were admitted to a hospital and returned to the same facility to receive Medicare-covered post-hospital SNF care. In some cases, hospital physicians discharged beneficiaries to “home” rather

98


than “SNF,” yet nursing facility physicians certified that skilled care was needed. Because Medicare pays substantially more for SNF care than Medicaid for nursing home care, nursing facilities have financial incentives to increase the level of care to “skilled.” The OIG will determine whether the post-hospital SNF care provided to dually eligible beneficiaries met the level of care requirements. The findings of this report which is expected to be issued in 2020 may have an impact on our industry (i.e. may encourage additional oversight or stricter compliance standards).

In July 2018, the OIG released a report entitled “Vulnerabilities in the Medicare Hospice Program Affect Quality Care and Program Integrity: an OIG Portfolio” (the “OIG Portfolio”).  The OIG Portfolio’s methodology included a review of hospice services provided and claims billed since 2005, including looking at eligibility determinations and billing practices. The OIG found that improper billing by hospices costs Medicare hundreds of millions of dollars each year, including billing for ineligible patients, improper levels of care, duplicative services, and other forms of fraud. Among a total of 15 recommendations, the OIG recommended that CMS (1) strengthen the hospice survey process, including analyzing claims to identify hospices that engage in concerning practices, (2) create additional remedies for poor regulatory performance, and (3) improve billing oversight, including taking steps to tie payment to patient acuity and needs.  Of these recommendations, CMS concurred with six recommendations and did not concur with nine recommendations.  The OIG remains committed to enhanced oversight of the hospice benefit.   

In March 2016, the OIG released a report entitled “Hospices Inappropriately Billed Medicare Over $250 Million for General Inpatient Care.” The report analyzed the results of a medical record review of 2012 hospice general inpatient care stays to estimate the percentage of such stays that were billed inappropriately, and found that hospices billed one-third of general inpatient stays inappropriately, costing Medicare $268 million in 2012. Consequently, the OIG recommended, and CMS concurred with such recommendations, that CMS (1) increase its oversight of hospice general inpatient stay claims and review Part D payments for drugs for hospice beneficiaries; (2) ensure that a physician is involved in the decision to use general inpatient care; (3) conduct prepayment reviews for lengthy general inpatient care stays; (4) increase surveyor efforts to ensure that hospices meet care planning requirements; (5) establish additional enforcement remedies for poor hospice performance; and (6) follow up on inappropriate general inpatient care stays.

In January 2015, the OIG released a report entitled “Medicare Hospices Have Financial Incentives to Provide Care in Assisted Living Facilities.” The report analyzed all Medicare hospices claims from 2007 through 2012, and raised concerns about the financial incentives created by the current payment system and the potential for hospices-especially for-profit hospices-to target beneficiaries in assisted living facilities because they may offer the hospices the greatest financial gain. Accordingly, the report recommended that CMS reform payments to reduce the incentive for hospices to target beneficiaries with certain diagnoses and those likely to have long stays, target certain hospices for review, develop and adopt claims-based measures of quality, make hospice data publicly available for the beneficiaries, and provide additional information to hospices to educate them about how they compare to their peers. CMS concurred with all five recommendations.
Additionally, following recommendations made by the OIG in an April 2014 report entitled “Limited Compliance with Medicare’s Home Health Face-to-Face Documentation Requirements,” CMS committed to implement a plan for oversight of home health agencies through Supplemental Medical Review Contractor audits of every home health agency in the country. In addition, in many of its recent OIG Work Plans, it indicated that it will review compliance with various aspects which impact reimbursement to home health or hospice providers, including the documentation in support of the claims paid by Medicare. Recent OIG Work Plans provides that the OIG will review documentation to determine if it meets the requirements for certain billing documentation related to Medicare payments for hospice and home health services to ensure they were made in accordance with Medicare requirements.
In August 2012, the OIG released a report entitled “Inappropriate and Questionable Billing for Medicare Home Health Agencies.” The report analyzed data from home health, inpatient hospital, and skilled nursing facilities claims from 2010 to identify inappropriate home health payments. The report found that in 2010, Medicare made overpayments largely in connection with three specific errors: overlapping with claims for inpatient hospital stays, overlapping with claims for skilled nursing facility stays, or billing for services on dates after beneficiaries’ deaths. The report also concluded that home health agencies with questionable billing were located mostly in Texas, Florida, California, and Michigan. The report recommended that CMS implement claims processing edits or improve existing edits to prevent inappropriate payments for the three specific errors referenced above, increase monitoring of billing for home health services, enforce and consider lowering the ten percent cap on the total outlier payments a home health agency may receive annually, consider imposing a temporary moratorium on new home health agency enrollments in Florida and Texas, and take appropriate action regarding the inappropriate payments identified and home health agencies with questionable billing. CMS concurred with all five recommendations.
Moratoria on enrollment of new home health agencies were subsequently put in place effective July 31, 2013, and were extended multiple times through January 31, 2019. These moratoria were enforced in states or various counties in Florida, Michigan, Texas, Illinois, Pennsylvania and New Jersey. Effective February 1, 2019, all moratoria have been lifted, and there are no active Medicare provider enrollment moratoria in the United States.

99



In December 2010, the OIG released a report entitled “Questionable Billing by Skilled Nursing Facilities.” The report examined the billing practices of skilled nursing facilities based on Medicare Part A claims from 2006 to 2008 and found, among other things, that for-profit skilled nursing facilities were more likely to bill for higher paying therapy resource utilization groups (RUGs), particularly in the ultra high therapy categories, than government and not-for-profit operators. It also found that for-profit skilled nursing facilities showed a higher incidence of patients using RUGs with higher activities of daily living (ADL) scores, and had a “long” average length of stay among Part A beneficiaries, compared to their government and not-for-profit counterparts. The OIG recommended that CMS vigilantly monitor overall payments to skilled nursing facilities, adjust RUG rates annually, change the method for determining how much therapy is needed to ensure appropriate payments and conduct additional reviews for skilled nursing operators that exceed certain thresholds for higher paying therapy RUGs. CMS concurred with and agreed to take action on three of the four recommendations, declining only to change the methodology for assessing a patient's therapy needs. The OIG issued a separate memorandum to CMS listing 384 specific facilities that the OIG had identified as being in the top one percent for use of ultra high therapy, RUGs with high ADL scores, or “long” average lengths of stay, and CMS agreed to forward the list to the appropriate fiscal intermediaries or other contractors for follow up. Although we believe our therapy assessment and billing practices are consistent with applicable law and CMS requirements, we cannot predict the extent to which the OIG's recommendations to CMS will be implemented and, what effect, if any, such proposals would have on us. Two of our affiliated facilities have been listed on the report. Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity and higher-RUGs patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording ADL services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others, as well as other government agencies, unions, advocacy groups and others who seek to pursue their own mandates and agendas. In its fiscal year 2014 work plan, OIG specifically stated that it will continue to study and report on questionable Part A and Part B billing practices amongst skilled nursing facilities.
In addition, in its 2017 Work Plan, the OIG indicated that it will review compliance with various aspects which impact reimbursement to SNF, home health, or hospice providers, including the documentation in support of the claims paid by Medicare. According to the 2017 Work Plan, prior OIG reviews found that SNFs are billing for higher levels of therapy than were provided or were reasonable or necessary and also that Medicare payments were not compliant with the requirement of a 3-day inpatient hospital stay within 30 days of a SNF admission. The OIG’s 2017 Work Plan provides that the OIG will review documentation at selected SNFs to determine if it meets the requirements for each particular RUG, compliance with SNF prospective payment system requirements related to a 3-day qualifying inpatient hospital stay, and other billing documentation related to Medicare payments for hospice and home health services to ensure they were made in accordance with Medicare requirements.

Efforts by officials and others to make or advocate for any increase in regulatory monitoring and oversight, adversely change RUG rates, reduce payment rates, revise methodologies for assessing and treating patients, conduct more frequent or intense reviews of our treatment and billing practices, or implement moratoria in areas where we operate or propose to expand, could reduce our reimbursement, increase our costs of doing business and otherwise adversely affect our business, financial condition and results of operations.

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers, including skilled nursing facilities, to obtain prior approval, known as a certificate of need, for:

the purchase, construction or expansion of healthcare facilities;

capital expenditures exceeding a prescribed amount; or

changes in services or bed capacity.

In addition, other states that do not require certificates of need have effectively barred the expansion of existing facilities and the establishment of new ones by placing partial or complete moratoria on the number of new Medicaid beds they will certify in certain areas or in the entire state. Other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states the acquisition of a facility being operated by a non-profit organization requires the approval of the state Attorney General.

100



Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, certificate of need approval, Medicaid certification, Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

Changes in federal and state employment-related laws and regulations could increase our cost of doing business.

Our operating subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act which governs such matters as minimum wages, overtime and other working conditions, the Americans with Disabilities Act (ADA) and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the Equal Employment Opportunity Commission (EEOC), regulations of the Office of Civil Rights, regulations of state Attorneys General, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters. Because labor represents such a large portion of our operating costs, changes in federal and state employment-related laws and regulations could increase our cost of doing business.

The compliance costs associated with these laws and evolving regulations could be substantial. For example, all of our affiliated facilities are required to comply with the ADA. The ADA has separate compliance requirements for “public accommodations” and “commercial properties,” but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could experience damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.
The operations of our operating subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, including in connection with the spin-off, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid as well as third party payors. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals, which could negatively impact our cash position.

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.

We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our affiliated facilities. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.

In addition, we are required to operate our affiliated facilities in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our affiliated skilled nursing facilities are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements.


101


We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.

Our revenue is affected by the percentage of the patients of our operating subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability because we generally receive higher reimbursement rates for high acuity patients and because the payors reimburse us at different rates. For both the three and six months ended June 30, 2019, 68.0% of our revenue was provided by government payors that reimburse us at predetermined rates, respectively. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. Among other initiatives, these payors attempt to control healthcare costs by contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

Compliance with state and federal employment, immigration, licensing and other laws could increase our cost of doing business.

We have hired personnel, including skilled nurses and therapists, from outside the United States. If immigration laws are changed, or if new and more restrictive government regulations proposed by the Department of Homeland Security are enacted, our access to qualified and skilled personnel may be limited.

We operate in at least one state that requires us to verify employment eligibility using procedures and standards that exceed those required under federal Form I-9 and the statutes and regulations related thereto. Proposed federal regulations would extend similar requirements to all of the states in which our affiliated facilities operate. To the extent that such proposed regulations or similar measures become effective, and we are required by state or federal authorities to verify work authorization or legal residence for current and prospective employees beyond existing Form I-9 requirements and other statutes and regulations currently in effect, it may make it more difficult for us to recruit, hire and/or retain qualified employees, may increase our risk of non-compliance with state and federal employment, immigration, licensing and other laws and regulations and could increase our cost of doing business.

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.

The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our operating subsidiaries and the services we provide. We and others in our industry are subject to a large and increasing number of claims and lawsuits, including professional liability claims, alleging that our services have resulted in personal injury, elder abuse, wrongful death or other related claims. The defense of these lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. Plaintiffs tend to sue every healthcare provider who may have been involved in the patient's care and, accordingly, we respond to multiple lawsuits and claims every year.

In addition, plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers and other long-term care companies, and have employed a wide variety of advertising and publicity strategies. Among other things, these strategies include establishing their own Internet websites, paying for premium advertising space on other websites, paying Internet search engines to optimize their plaintiff solicitation advertising so that it appears in advantageous positions on Internet search results, including results from searches for our company and affiliated facilities, using newspaper, magazine and television ads targeted at customers of the healthcare industry generally, as well as at customers of specific providers, including us. From time to time, law firms claiming to specialize in long-term care litigation have named us, our affiliated facilities and other specific healthcare providers and facilities in their advertising and solicitation materials. These advertising and solicitation activities could result in more claims and litigation, which could increase our liability exposure and legal expenses, divert the time and attention of the personnel of our operating subsidiaries from day-to-day business operations, and materially and adversely affect our financial condition and results of operations. Furthermore, to the extent the frequency and/or severity of losses from such claims and suits increases, our liability insurance premiums could increase and/or available insurance coverage levels could decline, which could materially and adversely affect our financial condition and results of operations.

102


Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and we are routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of state-established minimum staffing requirements for skilled nursing facilities. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with conditions of participation under certain state and federal healthcare programs; it may also subject the facility to a notice of deficiency, a citation, civil monetary penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and have become more prevalent in the wake of a previous substantial jury award against one of our competitors. We expect the plaintiff's bar to continue to be aggressive in their pursuit of these staffing and similar claims.
We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements. While we have been able to settle these claims without a material ongoing adverse effect on our business, future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against us and other companies in our industry. For example, there has been an increase in the number of wage and hour class action claims filed in several of the jurisdictions where we are present. Allegations typically include claimed failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows. In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.

Were litigation to be instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.

On February 26, 2009, Congress reintroduced the Fairness in Nursing Home Arbitration Act of 2009. After failing to be enacted into law in the 110th Congress in 2008, the Fairness in Nursing Home Arbitration Act of 2009 was introduced in the 111th Congress and referred to the House and Senate judiciary committees in March 2009. The 111th Congress did not pass the bill and therefore has been cleared from the present agenda. This bill was reintroduced in the 112th Congress as the Fairness in Nursing Home Arbitration Act of 2012, and was referred to the House Judiciary committee. There has not been significant movement on this bill in some time. However if this bill is ever enacted, this bill would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. We use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.

The U.S. Department of Justice has conducted investigations into the billing and reimbursement processes of some of our operating subsidiaries, which could adversely affect our operations and financial condition.

In October 2013, we entered into the Settlement Agreement with the DOJ pertaining to an investigation of certain of our operating subsidiaries. Pursuant to the Settlement Agreement, we made a single lump-sum remittance to the government in the amount of $48.0 million in October 2013. We have denied engaging in any illegal conduct, and have agreed to the settlement amount without any admission of wrongdoing in order to resolve the allegations and to avoid the uncertainty and expense of protracted litigation.

In connection with the settlement and effective as of October 1, 2013, we entered into a five-year corporate integrity agreement (the CIA) with the Office of Inspector General-HHS. CMS acknowledged the existence of our current compliance program, which is in accord with the Office of the Inspector General (OIG)’s guidance related to an effective compliance program, and required that we continue during the term of the CIA to maintain said compliance program designed to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs. In March 2019, we were notified by the OIG that the five year term of the CIA has been concluded and effectively released from the CIA.


103


On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating the Company to determine whether we have violated the FCA and/or the Anti-Kickback Statute with respect to the relationships between certain of our skilled nursing facilities and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 to the present, and was limited in scope to ten of our Southern California skilled nursing facilities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 to the present, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the FCA, the Anti-Kickback Statute, and other applicable regulatory requirements. We are fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information. However, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on the Company.

If any additional litigation or government enforcement actions were to proceed in the future, and we are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the federal FCA, or similar state and federal statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement and/or other arrangement with the government.

We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.

As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs.  Our compliance program includes, among other things, (1) policies and procedures modeled after applicable laws, regulations, government manuals and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries, (2) training about our compliance process for all of the employees of our operating subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees, and (3) internal controls that monitor, for example, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).

From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and would continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our affiliated skilled nursing facilities, which were detected by our internal compliance team in the course of its ongoing reviews.

Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have also identified and, at the conclusion of such investigations, assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our affiliated skilled nursing facilities in these areas. We continue to monitor the measures implemented for effectiveness, and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.

If additional reviews result in identification and quantification of additional amounts to be refunded, we would accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course. Furthermore, failure to refund overpayments within required time frames (as described in greater detail above) could result in FCA liability. If future investigations ultimately result in findings of significant billing and reimbursement noncompliance which could require us to record significant additional provisions or remit payments, our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.

We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic operating subsidiaries, which would also decrease our revenue.


104


To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.

We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, the purchase price of the facilities, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.

We have also historically acquired a few facilities, either because they were included in larger, indivisible groups of facilities or under other circumstances, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities which are more desirable. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenues might decrease.

We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions.

We may not be able to successfully or efficiently integrate new acquisitions with our existing operating subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources, and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly operating subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.

During the six months ended June 30, 2019, we expanded our operations through a combination of a long-term lease and real estate purchases, with the addition of seven stand-alone skilled nursing operations, one stand-alone senior living operation, three campus operations, two home health agencies, four hospice agencies and two home care agencies with a total of 1,088 operational skilled nursing beds and 364 operational senior living units. We also invested in new ancillary services that are complementary to its existing businesses. During the year ended December 31, 2018, we added to our operations four stand-alone skilled nursing operations, seven stand-alone senior living operations, three campus operations, four home health agencies, three hospice agencies and two home care agencies with a total of 744 operational skilled nursing beds and 650 senior living units. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our facility acquisitions, and our business may suffer.

In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.

In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved operating subsidiaries and patient care at affiliated facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further,

105


we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable. For example, in July of 2006 we acquired a facility that had a history of intermittent noncompliance. Although the affiliated facility had already been surveyed once by the local state survey agency after being acquired by us, and that survey would have met the heightened requirements of the special focus facility program, based upon the facility's compliance history prior to our acquisition, in January 2008, state officials nevertheless recommended to CMS that the facility be placed on special focus facility status. In addition, in October of 2006, we acquired a facility which had a history of intermittent non-compliance. This affiliated facility was surveyed by the local state survey agency during the third quarter of 2008 and passed the heightened survey requirements of the special focus facility program. Both affiliated facilities have successfully graduated from the Centers for Medicare and Medicaid Services' Special Focus program. We've had other affiliated facilities that have successfully graduated from the program. Other affiliated facilities may be identified for special focus status in the future.

In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determines that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. For example, one of our operating subsidiaries acquired a home health agency that had a history of intermittent noncompliance. In October 2012, a ZPIC reopened claims at the agency for home health services provided prior to our period of ownership. In March 2014, the ZPIC completed its review and notified the agency of its findings, including a finding that the agency would be required to repay a significant amount of its Medicare reimbursement. While in this instance our operating subsidiary was indemnified for its losses by the prior operator, in future situations where the prior operator is defunct or otherwise unable to reimburse us, we may be unable to recover these funds. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities, negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.

We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.

Termination of our patient admission agreements and the resulting vacancies in our affiliated facilities could cause revenue at our affiliated facilities to decline.

Most state regulations governing skilled nursing and senior living facilities require written patient admission agreements with each patient. Several of these regulations also require that each patient have the right to terminate the patient agreement for any reason and without prior notice. Consistent with these regulations, all of our skilled nursing patient agreements allow patients to terminate their agreements without notice, and all of our senior living resident agreements allow patients to terminate their agreements upon thirty days' notice. Patients and residents terminate their agreements from time to time for a variety of reasons, causing some fluctuations in our overall occupancy as patients and residents are admitted and discharged in normal course. If an unusual number of patients or residents elected to terminate their agreements within a short time, occupancy levels at our affiliated facilities could decline. As a result, beds may be unoccupied for a period of time, which would have a negative impact on our revenue, financial condition and results of operations.

We face significant competition from other healthcare providers and may not be successful in attracting patients and residents to our affiliated facilities.


106


The post-acute care industry is highly competitive, and we expect that our industry may become increasingly competitive in the future. Our affiliated skilled nursing facilities compete primarily on a local and regional basis with many long-term care providers, from national and regional multi-facility providers that have substantially greater financial resources to small providers who operate a single nursing facility. We also compete with other skilled nursing and senior living facilities, and with inpatient rehabilitation facilities, long-term acute care hospitals, home healthcare and other similar services and care alternatives. Increased competition could limit our ability to attract and retain patients, attract and retain skilled personnel, maintain or increase private pay and managed care rates or expand our business.

We may not be successful in attracting patients to our operating subsidiaries, particularly Medicare, managed care, and private pay patients who generally come to us at higher reimbursement rates. Some of our competitors have greater financial and other resources than us, may have greater brand recognition and may be more established in their respective communities than we are. Competing companies may also offer newer facilities or different programs or services than we do and may thereby attract current or potential patients. Other competitors may have lower expenses or other competitive advantages, and, therefore, present significant price competition for managed care and private pay patients. In addition, some of our competitors operate on a not-for-profit basis or as charitable organizations and have the ability to finance capital expenditures on a tax-exempt basis or through the receipt of charitable contributions, neither of which are available to us.

If we do not achieve and maintain competitive quality of care ratings from CMS and private organizations engaged in similar monitoring activities, or if the frequency of CMS surveys and enforcement sanctions increases, our business may be negatively affected.

CMS, as well as certain private organizations engaged in similar monitoring activities, provides comparative data available to the public on its web site, rating every skilled nursing facility operating in each state based upon quality-of-care indicators. These quality-of-care indicators include such measures as percentages of patients with infections, bedsores and unplanned weight loss. Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. Clinical quality is becoming increasingly important within our industry. Effective October 2012, Medicare began to impose a financial penalty upon hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge. We believe this regulation provides a competitive advantage to home health providers who can differentiate themselves based upon quality, particularly by achieving low patient acute care hospitalization readmission rates and by implementing disease management programs designed to be responsive to the needs of patients served by referring hospitals. We are focused intently upon improving our patient outcomes, particularly our patient acute care hospitalization readmission rates. If we should fail to attain our goals regarding acute care hospitalization readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.
Medicare has established consumer-facing websites, Home Health Compare and Hospice Compare that present data regarding our performance on certain quality measures compared to state and national averages. If we should fail to achieve or exceed these averages, it may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.

CMS has undertaken an initiative to increase Medicaid and Medicare survey and enforcement activities, to focus more survey and enforcement efforts on facilities with findings of condition level deficiencies or repeat violations of Medicaid and Medicare standards, and to require state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified. We have found a correlation between negative Medicaid and Medicare surveys and the incidence of professional liability litigation. From time to time, we experience a higher than normal number of negative survey findings in some of our affiliated facilities.

In December 2008, CMS introduced the Five-Star Quality Rating System to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each nursing home a rating of between one and five stars in various categories. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating.


107


On February 20, 2015, CMS modified the Five Star Quality Rating System for nursing homes to include the use of antipsychotics in calculating the star ratings, modified calculations for staffing levels and reflect higher standards for nursing homes to achieve a high rating on the quality measure dimension. On July 1, 2016, CMS implemented its first mandatory reporting period that required Skilled Nursing Facilities to submit information annually on staffing and census data on the Payroll-Based Journal (PBJ) system. CMS has long identified staffing as one of the vital components of a skilled nursing facility’s ability to provide quality care. The PBJ system allows staffing and census information to be easily collected by CMS. The staffing information gathered is not consistent with the actual hours worked, but instead based upon an established set of regulations.

On August 10, 2016, CMS modified the Five Star Quality Rating System for nursing homes to include five of the six new quality measures added April 27, 2016 to its consumer-based Nursing Home Compare website as part of an initiative to broaden the quality of information available on that site. They include the rate of rehospitalization, emergency room use, community discharge, improvements in function, and independently worsened ability to move. In 2017, CMS issued a temporary freeze of the Health Inspection Five Star Ratings beginning in 2018 that is scheduled to end in the spring of 2019. The health inspection star rating for recertification surveys and complaints conducted on or after November 28, 2017 will be frozen. The freeze of the Health Inspection Five Star Ratings and the increase in the standards for performance on quality measures could reduce the number of our 4 and 5 star facilities. If we are unable to achieve quality of care ratings that are comparable or superior to those of our competitors, our ability to attract and retain patients could be adversely affected.

On April 6, 2018, CMS announced that starting in April 2018, CMS will use PBJ data to calculate the staffing ratings used in the Nursing Home Five Star Quality Rating System. CMS will be using a new risk adjustment methodology to calculate the nursing staff component of the Star Rating. Additionally, the staffing information will be calculated using the number of hours facility staff are paid to work each day. Salaried employee information will not reflect actual hours worked, but instead will be limited to eight hours a day. The staffing information is electronically submitted each quarter, and will be adjusted based on the expected level of staff needed given the number and acuity of the residents in the facility.  In April 2018, new ratings’ thresholds were rolled out resulting in some facilities changing in their rating based on the new system. Additionally, because the PBJ data is used to calculate the staffing Star Rating, some facilities saw an increase or decrease in their overall Star rating depending on whether their PBJ data positively or negatively impacted them.

On April 24, 2019, CMS announced several changes that were made to the Five-Star Quality Rating System. The new changes include separate ratings for short-stay quality of resident care and long-stay quality of resident care in addition to an overall quality of resident care rating. Measures of long-stay hospitalizations and long-stay emergency department (ED) visits were added to the quality measure rating, and the long-stay physical restraints measure was dropped from the quality measure rating. The scoring rules for the quality measures changed to give more weight to measures with greater opportunity for improvement. Further, the staffing rating thresholds were changed, with the staffing level required to receive a 5-star rating determined based on analyses of the relationship between staffing levels and measures of nursing home quality. CMS placed a strong emphasis on registered nurse (RN) staffing, accordingly the method by which the RN staffing rating and the total nurse staffing rating are combined to generate the overall staffing rating is changing to provide more emphasis on RN staffing. Additionally, the overall and RN staffing ratings are set to one star for nursing homes that report four or more days in the quarter with no RN onsite. Finally, staffing ratings are no longer being suppressed for nursing homes that have five or more days with residents and no nurse staffing hours reported.

Accordingly, the CMS changes include updated thresholds for assigning stars for both the staffing and quality components of the system. CMS estimates the changes will cause 47 percent of all nursing centers to lose stars in their "Quality" ratings. In addition, 33 percent will lose stars in their "Staffing" ratings, and some 36 percent will lose stars in their "Overall" ratings. These changes to update the staffing and quality thresholds could have a negative impact on our star rating in 2019.

On July 17, 2015, CMS announced Home Health Star Ratings for home health agencies. All Medicare-certified home health agencies are potentially eligible to receive a Quality of Patient Care Star Rating. The Star rating includes assessments of quality of patient care based on Medicare claims data and patient experience of care. The Star rating may impact patient choice of home health agencies and reimbursement from home health agencies, as a higher Star rating indicates better patient care than a lower Star rating. A low Star rating may decrease the number of patients for Medicare reimbursement. On December 14, 2017, CMS announced that the influenza vaccination measure would be removed from consideration in the Quality of Patient Care Star Rating beginning with the April 2018 Home Health Compare refresh, reducing the number of quality measures used from nine to eight.

If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.


108


It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates:

we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;

we receive survey deficiencies or citations of higher-than-normal scope or severity;

we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;

insurers tighten underwriting standards applicable to us or our industry; or

insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.

If any of these potential circumstances were to occur, our insurance carriers may require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.
 
In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, also could inhibit our ability to attract patients or expand our business, and could require our management to devote time to matters unrelated to the day-to-day operation of our business.

With few exceptions, workers' compensation and employee health insurance costs have also increased markedly in recent years. To partially offset these increases, we have increased the amounts of our self-insured retention (SIR) and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, except Washington, Wyoming and Texas, and elected non-subscriber status for workers' compensation in Texas. In Washington and Wyoming, the insurance coverage is financed through premiums paid by the employers and employees. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.

Our self-insurance programs may expose us to significant and unexpected costs and losses.

We have maintained general and professional liability insurance since 2002 and workers' compensation insurance since 2005 through a wholly-owned subsidiary insurance company, Standardbearer Insurance Company, Ltd. (Standardbearer), to insure our self-insurance reimbursements (SIR) and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.

Further, because our SIR under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.


109


In May 2006, we began self-insuring our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.

The geographic concentration of our affiliated facilities could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our affiliated facilities located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies, changes in governmental rules, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since over 21% of our affiliated facilities are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as fires, earthquakes or mudslides.

In addition, our affiliated facilities in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our operating subsidiaries and our affiliated facilities, which could have an adverse impact on the patients of our operating subsidiaries and our business. In order to provide care for the patients of our operating subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our affiliated facilities, and the availability of employees to provide services at our affiliated facilities. If the delivery of goods or the ability of employees to reach our affiliated facilities were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our affiliated facilities and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events could harm the patients and employees of our operating subsidiaries, severely damage or destroy one or more of our affiliated facilities, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.

The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

We continue to maintain our right to inform the employees of our operating subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. With one exception, to our knowledge the staffs at our affiliated facilities that have been approached to unionize have uniformly rejected union organizing efforts. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.

The unwillingness on the part of both our management and staff to accede to union demands for “neutrality” and other concessions has resulted in a negative labor campaign by at least one labor union, the Service Employees International Union. From 2002 to 2007, this union, and individuals and organizations allied with or sympathetic to this union actively prosecuted a negative retaliatory publicity action, also known as a “corporate campaign,” against us and filed, promoted or participated in multiple legal actions against us. The union's campaign asserted, among other allegations, poor treatment of patients, inferior clinical services provided by the employees of our operating subsidiaries, poor treatment of the employees of our operating subsidiaries, and health code violations by our operating subsidiaries. In addition, the union has publicly mischaracterized actions taken by the DHS against us and our affiliated facilities. In numerous cases, the union's allegations created the false impression that violations and other events that occurred at facilities prior to our acquisition of those facilities were caused by us. Since a large component of our business involves acquiring underperforming and distressed facilities, and improving the quality of operations at these facilities, we may have been associated with the past poor performance of these facilities. To the extent this union or another elects to directly or indirectly prosecute a corporate campaign against us or any of our affiliated facilities, our business could be negatively affected.

The Service Employees International Union has issued in the past, and may again issue in the future, public statements alleging that we or other for-profit skilled nursing operators have engaged in unfair, questionable or illegal practices in various areas, including staffing, patient care, patient evaluation and treatment, billing and other areas and activities related to the industry and our operating subsidiaries. We continue to anticipate similar criticisms, charges and other negative publicity from such sources on a regular basis, particularly in the current political environment and following the December 2010 OIG report entitled

110


“Questionable Billing by Skilled Nursing Facilities," described above in "The Office of the Inspector General or other organizations may choose to more closely scrutinize the billing practices of for-profit skilled nursing facilities, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations." Two of our affiliated facilities have been listed on the report. Such reports provide unions and their allies with additional opportunities to make negative statements about, and to encourage regulators to seek investigatory and enforcement actions against, the industry in general and non-union operators like us specifically. Although we believe that our operations and business practices substantially conform to applicable laws and regulations, we cannot predict the extent to which we might be subject to adverse publicity or calls for increased regulatory scrutiny from union and union ally sources, or what effect, if any, such negative publicity would have on us, but to the extent they are successful, our revenue may be reduced, our costs may be increased and our profitability and business could be adversely affected.

This union has also in the past attempted to pressure hospitals, doctors, insurers and other healthcare providers and professionals to cease doing business with or referring patients to us. If this union or another union is successful in convincing the patients of our operating subsidiaries, their families or our referral sources to reduce or cease doing business with us, our revenue may be reduced and our profitability could be adversely affected. Additionally, if we are unable to attract and retain qualified staff due to negative public relations efforts by this or other union organizations, our quality of service and our revenue and profits could decline. Our strategy for responding to union allegations involves clear public disclosure of the union's identity, activities and agenda, and rebuttals to its negative campaign.

Our ability to respond to unions, however, may be limited by some state laws, which purport to make it illegal for any recipient of state funds to promote or deter union organizing. For example, such a state law passed by the California Legislature was successfully challenged on the grounds that it was preempted by the National Labor Relations Act, only to have the challenge overturned by the Ninth Circuit in 2006 before being ultimately upheld by the United States Supreme Court in 2008. In addition, proposed legislation making it more difficult for employees and their supervisors to educate co-workers and oppose unionization, such as the proposed Employee Free Choice Act which would allow organizing on a single “card check” and without a secret ballot and similar changes to federal law, regulation and labor practice being advocated by unions and considered by Congress and the National Labor Relations Board, could make it more difficult to maintain union-free workplaces in our affiliated facilities. Further, the expedited election rules adopted by the National Labor Relations Board took effect on April 14, 2015 and make it far easier for unions to organize employees.  These and similar laws have the potential to facilitate unionization procedures or hinder employer responses thereto, which may hinder our ability to oppose unionization efforts and negatively affect our business.

Because we lease substantially all of our affiliated facilities, we could experience risks associated with leased property, including risks relating to lease termination, lease extensions and special charges, which could adversely affect our business, financial position or results of operations.
As of June 30, 2019, we leased 177 of our 254 affiliated facilities. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.
Each lease provides that the landlord may terminate the lease for a number of reasons, including, subject to applicable cure periods, the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.
In 2017, we voluntarily discontinued operations at one of our skilled nursing facilities after determining that the facility could not competitively operate in the marketplace without substantial investment renovating the building. After careful consideration, we determined that the costs to renovate the facility would outweigh the future returns from the operation. As part of the arrangement, we remain obligated for lease payments and other obligations under the lease agreement. We have in the past, and may in the future, continued to be obligated for lease payments and other obligations under the leases even if we decided to no longer operate those locations. We could incur special charges relating to the closing of such facilities including lease termination costs, impairment charges and other special charges that would reduce our net income and could adversely affect our business, financial condition and results of operations.

Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.

111



We maintain a revolving credit facility with a lending consortium. As of June 30, 2019, our operating subsidiaries had $159.4 million outstanding under our credit facility. On February 5, 2016, we amended our existing revolving credit facility to increase our aggregate principal amount available to $250.0 million. On July 19, 2016, we entered into the Second Amended Credit Facility to increase the aggregate principal amount up to $450.0 million comprised of a $300.0 million revolving credit facility and a $150.0 million term loan. In December 2017, 17 of our subsidiaries entered into mortgage loans in the aggregate amount of $112.0 million under Department of Housing and Urban Development (HUD) insured loans. The terms of the mortgage loans range from 30- or 35-years. We also had other outstanding indebtedness of approximately $12.4 million as of June 30, 2019 under other HUD-insured loans and promissory note issued in connection with various acquisitions with maturity dates ranging from 2027 through 2052. Because these mortgage loans are insured with HUD, our borrower subsidiaries under these loans are subject to HUD oversight and periodic inspections.

In addition, we had $1.7 billion of future operating lease obligations as of June 30, 2019. We intend to continue financing our operating subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain.

We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding credit facilities and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under existing credit facilities or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.

From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.

Because our term loans, promissory notes, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our operating subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all.

Further, a substantial portion of our long-term indebtedness bears interest at fluctuating interest rates, primarily based on the London interbank offered rate for deposits of U.S. dollars (LIBOR). LIBOR tends to fluctuate based on general interest rates, rates set by the Federal Reserve and other central banks, the supply of and demand for credit in the London interbank market and general economic conditions. On July 27, 2017, the Financial Conduct Authority (the authority that regulates LIBOR) announced that it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. It is unclear whether new methods

112


of calculating LIBOR will be established such that it continues to exist after 2021. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, is considering replacing U.S. dollar LIBOR with a newly created index, calculated with a broad set of short-term repurchase agreements backed by treasury securities. It is not possible to predict the effect of these changes, other reforms or the establishment of alternative reference rates in the United States or elsewhere. To the extent these interest rates increase, our interest expense will increase, in which event we may have difficulties making interest payments and funding our other fixed costs, and our available cash flow for general corporate requirements may be adversely affected.

As we expand our presence in the senior living, home health or hospice industries, we would become subject to risks in a market in which we have limited experience.

The majority of our affiliated facilities have historically been skilled nursing facilities. As we expand our presence in the senior living, home health and hospice services or other relevant healthcare service, our existing overall business model will continue to change and expose our company to risks in a market in which we have limited experience. Although senior living operating subsidiaries generally have lower costs and higher margins than skilled nursing, they typically generate lower overall revenue than skilled nursing operating subsidiaries. In addition, senior living revenue is derived primarily from private payors as opposed to government reimbursement. In most states, skilled nursing, senior living, home health and hospice care are regulated by different agencies, and we have less experience with the agencies that regulate senior living, home health and hospice care. In general, we believe that senior living is a more competitive industry than skilled nursing. As we expand our presence in the senior living, home health and hospice services, and other ancillary services we expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.

A housing downturn could decrease demand for senior living services.
Seniors often use the proceeds of home sales to fund their admission to senior living facilities. A downturn in the housing markets could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.

If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.

We rely significantly on appropriate referrals from physicians, hospitals and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our affiliated facilities. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.

Our systems are subject to security breaches and other cyber-security incidents.

Our business is dependent on the proper functioning and availability of our computer systems and networks. While we have taken steps to protect the safety and security of our information systems and the patient health information and other data maintained within those systems, we cannot assure you that our safety and security measures and disaster recovery plan will prevent damage, interruption or breach of our information systems and operations. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, we may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our information systems. Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deceiving our employees or contractors.

On occasion, we have acquired additional information systems through our business acquisitions. We have upgraded and expanded our information system capabilities and have committed significant resources to maintain, protect, enhance existing systems and develop new systems to keep pace with continuing changes in technology, evolving industry and regulatory standards, and changing customer preferences.


113


We license certain third party software to support our operations and information systems. Our inability, or the inability of third party software providers, to continue to maintain and upgrade our information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.

A cyber security attack or other incident that bypasses our information systems security could cause a security breach which may lead to a material disruption to our information systems infrastructure or business and may involve a significant loss of business or patient health information. If a cyber security attack or other unauthorized attempt to access our systems or facilities were to be successful, it could result in the theft, destructions, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber security attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to substantial penalties under HIPAA and other federal and state privacy laws, in addition to private litigation with those affected.

Failure to maintain the security and functionality of our information systems and related software, or a failure to defend a cyber security attack or other attempt to gain unauthorized access to our systems, facilities or patient health information could expose us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, the OIG or state attorneys general), fines, private litigation with those affected by the data breach, loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations and liquidity.

We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.

Our ability to maintain and enhance our operating subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our affiliated facilities and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.

The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.

Financial markets experienced significant disruptions from 2008 through 2010. These disruptions impacted liquidity in the debt markets, making financing terms for borrowers less attractive and, in certain cases, significantly reducing the availability of certain types of debt financing. As a result of these market conditions, the cost and availability of credit has been and may continue to be adversely affected by illiquid credit markets and wider credit spreads. Concern about the stability of the markets has led many lenders and institutional investors to reduce, and in some cases, cease to provide credit to borrowers.

Further, our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, credit and financial market conditions, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which

114


were invested in U.S. treasury securities. Further, unless and until the current U.S. and global political, credit and financial market crisis has been sufficiently resolved, it may be difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Though we anticipate that the cash amounts generated internally, together with amounts available under the revolving credit facility portion of the Credit Facility, will be sufficient to implement our business plan for the foreseeable future, we may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. We cannot assure you that additional capital will be available or available on terms favorable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.

Delays in reimbursement may cause liquidity problems.

If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews.

Many of the states in which we operate are operating with budget deficits for their current fiscal year. These and other states may in the future delay reimbursement, which would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital.

In August 2016, CMS initiated its implementation of a three-year Medicare pre-claim review demonstration for home health services provided to beneficiaries in the state of Illinois. As of December 10, 2018 this demonstration was set to expand to other states including Ohio, North Carolina, Florida and Texas; however, CMS suspended the program indefinitely, but can restart the demonstration in the announced states after providing 30 days' notice. If the program were to restart, this process could result in increased administrative costs or delays in reimbursement for home health services in states subject to the demonstration. We currently operate in the state of Texas and would be impacted by the expansion of the demonstration in that state.

Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.

Nineteen of our affiliated facilities are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. In 2006, one of our HUD-insured mortgaged facilities did not pass its HUD inspection. Following an unsuccessful appeal of the decision, we requested a re-inspection. The re-inspection occurred in the fourth quarter of 2009 and the facility passed its HUD re-inspection. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities.

Failure to comply with existing environmental laws could result in increased expenditures, litigation and potential loss to our business and in our asset value.

Our operating subsidiaries are subject to regulations under various federal, state and local environmental laws, primarily those relating to the handling, storage, transportation, treatment and disposal of medical waste; the identification and warning of the presence of asbestos-containing materials in buildings, as well as the encapsulation or removal of such materials; and the presence of other substances in the indoor environment.

Our affiliated facilities generate infectious or other hazardous medical waste due to the illness or physical condition of the patients. Each of our affiliated facilities has an agreement with a waste management company for the proper disposal of all infectious medical waste, but the use of a waste management company does not immunize us from alleged violations of such laws for operating subsidiaries for which we are responsible even if carried out by a third party, nor does it immunize us from third-party claims for the cost to cleanup disposal sites at which such wastes have been disposed.


115


Some of the affiliated facilities we lease, own or may acquire may have asbestos-containing materials. Federal regulations require building owners and those exercising control over a building's management to identify and warn their employees and other employers operating in the building of potential hazards posed by workplace exposure to installed asbestos-containing materials and potential asbestos-containing materials in their buildings. Significant fines can be assessed for violation of these regulations. Building owners and those exercising control over a building's management may be subject to an increased risk of personal injury lawsuits. Federal, state and local laws and regulations also govern the removal, encapsulation, disturbance, handling and disposal of asbestos-containing materials and potential asbestos-containing materials when such materials are in poor condition or in the event of construction, remodeling, renovation or demolition of a building. Such laws may impose liability for improper handling or a release into the environment of asbestos containing materials and potential asbestos-containing materials and may provide for fines to, and for third parties to seek recovery from, owners or operators of real properties for personal injury or improper work exposure associated with asbestos-containing materials and potential asbestos-containing materials. The presence of asbestos-containing materials, or the failure to properly dispose of or remediate such materials, also may adversely affect our ability to attract and retain patients and staff, to borrow when using such property as collateral or to make improvements to such property.

The presence of mold, lead-based paint, underground storage tanks, contaminants in drinking water, radon and/or other substances at any of the affiliated facilities we lease, own or may acquire may lead to the incurrence of costs for remediation, mitigation or the implementation of an operations and maintenance plan and may result in third party litigation for personal injury or property damage. Furthermore, in some circumstances, areas affected by mold may be unusable for periods of time for repairs, and even after successful remediation, the known prior presence of extensive mold could adversely affect the ability of a facility to retain or attract patients and staff and could adversely affect a facility's market value and ultimately could lead to the temporary or permanent closure of the facility.

If we fail to comply with applicable environmental laws, we would face increased expenditures in terms of fines and remediation of the underlying problems, potential litigation relating to exposure to such materials, and a potential decrease in value to our business and in the value of our underlying assets.

In addition, because environmental laws vary from state to state, expansion of our operating subsidiaries to states where we do not currently operate may subject us to additional restrictions in the manner in which we operate our affiliated facilities.

If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties.

Each of our affiliated facilities is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.

We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

We are a holding company with no direct operating assets, employees or revenues. Each of our affiliated facilities is operated through a separate, wholly-owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.

Changes in federal and state income tax laws and regulations could adversely affect our provision for income taxes and estimated income tax liabilities.

We are subject to both state and federal income taxes. Our effective tax rate could be adversely affected by changes in the mix of earnings in states with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws and regulations, changes in our interpretations of tax laws, including pending tax law changes. In addition, in certain cases more than one state in which we operate has indicated an intent to attempt to tax the same assets and activities, which could

116


result in double taxation if successful. Unanticipated changes in our tax rates or exposure to additional income tax liabilities could affect our profitability.

The Tax Cuts and Jobs Act of 2017 was approved by Congress and signed into law in December 2017. This legislation made significant changes to the U.S. Internal Revenue Code. Such changes include a reduction in the corporate tax rate and limitations on certain corporate deductions and credits, among other changes. Certain of these changes could have a negative impact on our business. Moreover, further legislative and regulatory changes may be more likely in the current political environment, particularly to the extent that Congress and the U.S. presidency are controlled by the same political party and significant reform of the tax code has been described publicly as a legislative priority.
The U.S. Treasury Department, the Internal Revenue Service, and other standard-setting bodies could interpret or issue additional guidance on how provisions of the Tax Act or other provisions of the Code will be applied or otherwise administered that is different from our interpretations. As we continue our ongoing analysis of the Tax Act and recent regulations promulgated thereunder and the related interpretations, collect and prepare necessary data, and interpret any additional guidance, we may be required to make adjustments to amounts and positions that we have, or intend to, record that may adversely impact our business, results of operations and financial condition. In addition, further legislative action could be taken to address questions or issues caused by the Tax Act or the interpretations or guidance thereunder. State governments may also enact tax laws in response to the Tax Act that could result in further changes to our tax obligations and adversely impact our business, results of operations and financial condition.

We are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other local, state and foreign tax authorities. We regularly assess the likelihood of outcomes resulting from these examinations to determine the adequacy of our estimated income tax liabilities. The outcomes from these continuous examinations could adversely affect our provision for income taxes and estimated income tax liabilities.

The proposed Spin-Off of the Company's home health, hospice and senior living operations transaction may not be completed on the terms contemplated, or at all, may not result in the benefits expected, and will result in costs whether or not completed.

On May 6, 2019, we announced a proposed plan to separate our transitional and skilled nursing service operations, our home health, hospice and substantially all of our senior living operations into two separate, publicly traded companies through the proposed Spin-Off. The Spin-Off is a complex transaction, and its completion will require significant time, effort and expense. This could distract management from the day-to-day operations of our business, which could adversely affect our operations. The completion of the Spin-Off is subject to a number of conditions, and there is no assurance that the conditions will be satisfied and that the Spin-Off will be completed. In addition, we reserve the right to abandon, defer or modify the Spin-Off at any time if our board of directors so determines. If the Spin-Off is completed, it is possible that, due to unforeseen changes in market or economic conditions, or other events or circumstances, the two resulting companies may not achieve the full strategic and operational benefits expected from the Spin-Off, which could result in the combined market value of the stock of both companies being less than the market value of our common stock if the Spin-Off had not occurred. If the Spin-Off is not completed for any reason, the market price of our common stock may decline to the extent that the market price at that time reflects a market assumption that the Spin-Off will be completed. Whether or not the Spin-Off is completed, we will incur costs related to the transaction, including legal and accounting fees and certain fees payable to our financial advisors.

If the proposed Spin-Off is completed, the trading price of our common stock will decline.

The trading price of our common stock immediately following the Spin-Off of our home health, hospice and substantially all of our senior living operations is expected to be significantly lower than immediately prior to the Spin-Off because the value of our common stock will no longer reflect the spun-off business. The combined value of our common stock and the value of the common stock of the spun-off business following the completion of the Spin-Off may or may not be equal to or greater than the value of our common stock had we not separated the businesses pursuant to the Spin-Off.










117


The Spin-Off and related transactions may expose us to potential liabilities arising out of state and federal fraudulent conveyance laws and legal distribution requirements.

While we believe that we will be adequately capitalized immediately after the Spin-Off, the Spin-Off could be challenged under various state and federal fraudulent conveyance laws. An unpaid creditor could claim that we did not receive fair consideration or reasonably equivalent value in the Spin-Off, and that the Spin-Off left us insolvent, or with unreasonably small capital, or that we intended or believed it would incur debts beyond its ability to pay such debts as they mature. If a court were to agree with such a plaintiff, then such court could void the Spin-Off as a fraudulent transfer and could impose a number of different remedies, including without limitation, returning the assets or the shares in Pennant to us or providing us with a claim for money damages against the spun-off business in an amount equal to the difference between the consideration received by us and the fair market value of the spun-off business at the time of the Spin-Off.

Certain directors who serve on our Board of Directors will serve as directors of the spun-off business at and following the Spin-Off, and ownership of shares of common stock of the spun-off business at and following the Spin-Off by our directors and executive officers may create, or appear to create, conflicts of interest.

Certain of our directors who serve on our Board of Directors are expected to serve on the board of directors of the spun-off business. This may create, or appear to create, conflicts of interest when our, or the spun-off business’ management and directors face decisions that could have different implications for us and the spun-off business, including the resolution of any dispute regarding the terms of the agreements governing the Spin-Off and the relationship between us and the spun-off business after the Spin-Off or any other commercial agreements entered into in the future between us and the spun-off business and the allocation of such directors’ time between us and the spun-off business.

All or substantially all of our executive officers and some or all of our non-employee directors will own shares of the common stock of the spun-off business. The continued ownership of such common stock by our directors and executive officers following the Spin-Off creates, or may create, the appearance of a conflict of interest when these directors and executive officers are faced with decisions that could have different implications for us and the spun-off business.

If the distribution, together with certain related transactions, were to fail to qualify as a reorganization for U.S. federal income tax purposes under Sections 368(a)(1)(D) and 355 of the Code, then our stockholders, we and the spun-off business might be required to pay substantial U.S. federal income taxes (including as a result of indemnification under the tax matters agreement).

The distribution is conditioned upon our receipt of an opinion to the effect that, subject to the assumptions and limitations described therein, the distribution, together with certain related transactions, will qualify as a reorganization for U.S. federal income tax purposes under Sections 368(a)(1)(D) and 355 of the Code in which no gain or loss is recognized by us or our stockholders, except, in the case of our stockholders, for cash received in lieu of fractional shares. The opinion will be based on, among other things, certain assumptions, as well as on the continuing accuracy of certain factual representations and statements that we and the spun-off business make. If any of the representations or statements that we or the spun-off business make are, or become inaccurate or incomplete, or if we or the spun-off business breach any of our covenants, the distribution and such related transactions might not qualify for such tax treatment. The opinion will not be binding on the Internal Revenue Service or a court, and there can be no assurance that the Internal Revenue Service will not challenge the validity of the distribution and such related transactions as a reorganization for U.S. federal income tax purposes under Sections 368(a)(1)(D) and 355 of the Code eligible for tax-free treatment, or that any such challenge ultimately will not prevail.

If the Spin-Off or any other related transaction does not qualify as a tax-free transaction for any reason, including as a result of a breach of a representation or covenant, we or other members of our affiliated group would recognize a substantial gain attributable to the spun-off business for U.S. federal income tax purposes. In such case, under U.S. Treasury regulations, each member of the Ensign consolidated group at the time of the Spin-Off would be jointly and severally liable for the entire resulting amount of any U.S. federal income tax liability. Additionally, if the distribution of common stock of the spun-off business does not qualify as tax-free under Section 355 of the Code, our stockholders will be treated as having received a taxable distribution equal to the value of the spun-off business stock distributed, treated as a taxable dividend to the extent of our current and accumulated earnings and profits, and then would have a tax-free basis recovery up to the amount of their tax basis in their shares, and then would have taxable gain from the sale or exchange of the shares to the extent of any excess.

If the spin-off of our real estate business as a separate publicly traded company in 2014 was to fail to qualify as a tax-free transaction for U.S. federal income tax purposes, we could be subject to significant tax liabilities and, in certain circumstances, we could be required to indemnify CareTrust for material taxes pursuant to indemnification obligations under the Tax Matters Agreement that we entered into with CareTrust.


118


In June 2014, we completed the separation of our healthcare business and our real estate business into two separate and independent publicly traded companies through the distribution of all of the outstanding shares of common stock of CareTrust REIT, Inc. to Ensign stockholders on a pro rata basis (the CareTrust Spin-Off). We received a private letter ruling from the Internal Revenue Services (IRS), which provides substantially to the effect that, on the basis of certain facts presented and representations and assumptions set forth in the request submitted to the IRS, the CareTrust Spin-Off will qualify as tax-free under Sections 368(a)(1)(D) and 355 of the Internal Revenue Code (the IRS Ruling). The IRS Ruling does not address certain requirements for tax-free treatment of the CareTrust Spin-Off under Section 355 of the Code, and we received tax opinions from our tax advisor and counsel, substantially to the effect that, with respect to such requirements on which the IRS will not rule, such requirements have been satisfied. The IRS Ruling, and the tax opinions that we received from our tax advisor and counsel, rely on, among other things, certain facts, representations, assumptions and undertakings, including those relating to the past and future conduct of our and CareTrust’s businesses, and the IRS Ruling and the tax opinions would not be valid if such facts, representations, assumptions and undertakings were incorrect in any material respect. Notwithstanding the IRS Ruling and the tax opinions, the IRS could determine the CareTrust Spin-Off should be treated as a taxable transaction for U.S. federal income tax purposes if it determines any of the facts, representations, assumptions or undertakings that were included in the request for the IRS Ruling are false or have been violated or if it disagrees with the conclusions in the opinions that are not covered by the IRS Ruling.

If the CareTrust Spin-Off ultimately is determined to be taxable, we would recognize taxable gain in an amount equal to the excess, if any, of the fair market value of the shares of CareTrust common stock held by us on the distribution date over our tax basis in such shares. Such taxable gain and resulting tax liability would be substantial.
In addition, under the terms of the Tax Matters Agreement that we entered into with CareTrust in connection with the CareTrust Spin-Off, we generally are responsible for any taxes imposed on CareTrust that arise from the failure of the CareTrust Spin-Off to qualify as tax-free for U.S. federal income tax purposes, within the meaning of Sections 368(a)(1)(D) and 355 of the Code, to the extent such failure to qualify is attributable to certain actions, events or transactions relating to our stock, assets or business, or a breach of the relevant representations or any covenants made by us in the Tax Matters Agreement, the materials submitted to the IRS in connection with the request for the IRS Ruling or the representation letter provided in connection with the tax opinion relating to the CareTrust Spin-Off. Our indemnification obligations to CareTrust and its subsidiaries, officers and directors are not limited by any maximum amount. If we are required to indemnify CareTrust under the circumstance set forth in the Tax Matters Agreement, we may be subject to substantial tax liabilities.

In connection with the CareTrust Spin-Off, CareTrust will indemnify us and we will indemnify CareTrust for certain liabilities. There can be no assurance that the indemnities from CareTrust will be sufficient to insure us against the full amount of such liabilities, or that CareTrust’s ability to satisfy its indemnification obligation will not be impaired in the future.
Pursuant to the Separation and Distribution Agreement that we entered into with CareTrust in connection with the CareTrust Spin-Off, the Tax Matters Agreement and other agreements we entered into in connection with the CareTrust Spin-Off, CareTrust agreed to indemnify us for certain liabilities, and we agreed to indemnify CareTrust for certain liabilities. However, third parties might seek to hold us responsible for liabilities that CareTrust agreed to retain under these agreements, and there can be no assurance that CareTrust will be able to fully satisfy its indemnification obligations under these agreements. Moreover, even if we ultimately succeed in recovering from CareTrust any amounts for which we are held liable to a third party, we may be temporarily required to bear these losses while seeking recovery from CareTrust. In addition, indemnities that we may be required to provide to CareTrust could be significant and could adversely affect our business.
Risks Related to Ownership of our Common Stock

We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for our beds, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. In addition, the revolving credit facility portion of the Credit Facility restricts our ability to pay dividends to stockholders if we receive notice that we are in default under this agreement. The failure to pay or maintain dividends could adversely affect our stock price.

The market price and trading volume of our common stock may be volatile, which could result in rapid and substantial losses for our stockholders.


119


The market price of our common stock may be highly volatile and could be subject to wide fluctuations. In addition, the trading volume in our common stock may fluctuate and cause significant price variations to occur. We cannot assure you that the market price of our common stock will not fluctuate or decline significantly in the future. The trading price of our common stock may fluctuate depending upon many factors, some of which may be beyond our control including the Spin-Off. On some occasions in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us due to volatility in the market price of our common stock, we could incur substantial costs defending or settling the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business.

Future offerings of debt or equity securities by us may adversely affect the market price of our common stock.

In February 2015, we completed a common stock offering, issuing approximately 5.5 million shares at approximately $20.50 per share and used a portion of the net proceeds of the offering to pay off outstanding amounts under our credit facility.

In the future, we may attempt to increase our capital resources by offering debt or additional equity securities, including commercial paper, medium-term notes, senior or subordinated notes, preferred shares or shares of our common stock. Upon liquidation, holders of our debt securities and preferred shares, and lenders with respect to other borrowings, would receive a distribution of our available assets prior to any distribution to the holders of our common stock. Additional equity offerings may dilute the economic and voting rights of our existing stockholders or reduce the market price of our common stock, or both. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, holders of our common stock bear the risk of our future offerings reducing the market price of our common stock and diluting their shareholdings in us. We also intend to continue to actively pursue acquisitions of facilities and may issue shares of stock in connection with these acquisitions.

Any shares issued in connection with our acquisitions, the exercise of outstanding stock options or otherwise would dilute the holdings of the investors who purchase our shares.

Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could result in a restatement of our financial statements, cause investors to lose confidence in our financial statements and our company and have a material adverse effect on our business and stock price.

We produce our consolidated financial statements in accordance with the requirements of GAAP. Effective internal controls are necessary for us to provide reliable financial reports to help mitigate the risk of fraud and to operate successfully as a publicly traded company. As a public company, we are required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, which requires annual management assessments of the effectiveness of our internal controls over financial reporting.

Testing and maintaining internal controls can divert our management's attention from other matters that are important to our business. We may not be able to conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 or our independent registered public accounting firm may not be able or willing to issue an unqualified report if we conclude that our internal controls over financial reporting are not effective. If either we are unable to conclude that we have effective internal controls over financial reporting or our independent registered public accounting firm is unable to provide us with an unqualified report as required by Section 404, investors could lose confidence in our reported financial information and our company, which could result in a decline in the market price of our common stock, and cause us to fail to meet our reporting obligations in the future, which in turn could impact our ability to raise additional financing if needed in the future.

Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include:

our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as “blank check” preferred stock, with rights senior to those of common stock;

120



advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;

our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;

stockholder action by written consent is limited;

special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;

stockholders are not permitted to cumulate their votes for the election of directors;

newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;

our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and

stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.
We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.

Item 2.         Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.         Defaults Upon Senior Securities

None.

Item 4.        Mine Safety Disclosures

None.

Item 5. Other Information

None.


121


Item 6.        Exhibits

EXHIBIT INDEX
Exhibit
 
Description
 
 
 
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
 
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
101.INS
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
101.SCH
 
Inline XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF
 
Inline XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB
 
Inline XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document


122


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
THE ENSIGN GROUP, INC.
 
 
 
August 1, 2019
BY: 
/s/ SUZANNE D. SNAPPER  
 
 
Suzanne D. Snapper 
 
 
Chief Financial Officer and Executive Vice President (Principal Financial Officer and Duly Authorized Officer) 

 


 


 

 

123


EXHIBIT INDEX
Exhibit
 
Description
 
 
 
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
 
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
101.INS
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
101.SCH
 
Inline XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF
 
Inline XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB
 
Inline XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document


124
EX-31.1 2 ensgq22019ex311.htm EXHIBIT 31.1 Wdesk | Exhibit


EXHIBIT 31.1

I, Barry R. Port, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of The Ensign Group, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2019 
 
 
 
 
 
 
/s/ Barry R. Port  
 
 
Name:  
Barry R. Port
 
 
Title:  
Chief Executive Officer  
 




EX-31.2 3 ensgq22019ex312.htm EXHIBIT 31.2 Wdesk | Exhibit


EXHIBIT 31.2

I, Suzanne D. Snapper, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of The Ensign Group, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 1, 2019
 
 
 
 
 
 
/s/ Suzanne D. Snapper  
 
 
Name:  
Suzanne D. Snapper 
 
 
Title:  
Chief Financial Officer and Executive Vice President
 



EX-32.1 4 ensg063019ex321.htm EXHIBIT 32.1 Wdesk | Exhibit


EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Barry R. Port, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 
1
 
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
 
 
 
2
 
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
/s/ Barry R. Port
 
 
Name:  
Barry R. Port 
 
 
Title:  
Chief Executive Officer  
 
 
 
August 1, 2019
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



EX-32.2 5 ensg063019ex322.htm EXHIBIT 32.2 Wdesk | Exhibit


EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 
1
 
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
 
 
 
2
 
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
/s/ Suzanne D. Snapper  
 
 
Name:  
Suzanne D. Snapper 
 
 
Title:  
Chief Financial Officer and Executive Vice President
 
 
 
August 1, 2019
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 



EX-101.SCH 6 ensg-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2134100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2434404 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2434403 - Disclosure - Acquisitions Prior Period Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2434402 - Disclosure - Acquisitions Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2334301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Business Segments (Details) link:presentationLink link:calculationLink link:definitionLink 2428403 - Disclosure - Business Segments Revenue by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2428404 - Disclosure - Business Segments Schedule of Segment Reporting Information, by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2428404 - Disclosure - Business Segments Schedule of Segment Reporting Information, by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2150100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2450406 - Disclosure - Commitments and Contingencies Cash in Excess of FDIC Limits (Details) link:presentationLink link:calculationLink link:definitionLink 2450405 - Disclosure - Commitments and Contingencies Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 2450402 - Disclosure - Commitments and Contingencies General Liability Claim (Details) link:presentationLink link:calculationLink link:definitionLink 2450401 - Disclosure - Commitments and Contingencies Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 2450404 - Disclosure - Commitments and Contingencies Other Matters (Details) link:presentationLink link:calculationLink link:definitionLink 2450403 - Disclosure - Commitments and Contingencies Revenue Recoupments (Details) link:presentationLink link:calculationLink link:definitionLink 2151100 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 2451401 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Computation of Net Income Per Common Share link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Computation of Net Income Per Common Share Antidilutive Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Computation of Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Computation of Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Consolidated Balance Sheets Balance Sheet (Paranthetical) link:presentationLink link:calculationLink link:definitionLink 1005001 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statement of Stockholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2147100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2447403 - Disclosure - Debt Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2447402 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2447405 - Disclosure - Debt Future Principal Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2447404 - Disclosure - Debt Other Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2347301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2153100 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 2453402 - Disclosure - Defined Contribution Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2353301 - Disclosure - Defined Contribution Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Description of Business Proposed Spin-Off Transaction (Details) link:presentationLink link:calculationLink link:definitionLink 2154100 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 2454402 - Disclosure - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 2354301 - Disclosure - Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2425403 - Disclosure - Fair Value Measurements Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2141100 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2441402 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2441403 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) link:presentationLink link:calculationLink link:definitionLink 2341301 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2146100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2446404 - Disclosure - Income Taxes Deferred (Details) link:presentationLink link:calculationLink link:definitionLink 2446402 - Disclosure - Income Taxes Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2446405 - Disclosure - Income Taxes Other Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2446403 - Disclosure - Income Taxes Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2346301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - Intangible Assets - Net link:presentationLink link:calculationLink link:definitionLink 2440403 - Disclosure - Intangible Assets - Net Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2440402 - Disclosure - Intangible Assets - Net (Details) link:presentationLink link:calculationLink link:definitionLink 2440404 - Disclosure - Intangible Assets - Net Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2340301 - Disclosure - Intangible Assets - Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2149100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2449407 - Disclosure - Leases Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2449403 - Disclosure - Leases Balance Sheet Impact on New Lease Guidance (Details) link:presentationLink link:calculationLink link:definitionLink 2449402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2449406 - Disclosure - Leases Future minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 2449404 - Disclosure - Leases Income Statement Impact on New Lease Guidance (Details) link:presentationLink link:calculationLink link:definitionLink 2449405 - Disclosure - Leases Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2449408 - Disclosure - Leases Sale Leaseback Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2349301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2148100 - Disclosure - Options and Awards link:presentationLink link:calculationLink link:definitionLink 2448409 - Disclosure - Options and Awards Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2448404 - Disclosure - Options and Awards Exercise Price and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2448410 - Disclosure - Options and Awards Intrinsic Values (Details) link:presentationLink link:calculationLink link:definitionLink 2448402 - Disclosure - Options and Awards Lead Paragraphs (Details) link:presentationLink link:calculationLink link:definitionLink 2448406 - Disclosure - Options and Awards Options Outstanding by Exercise Price (Details) link:presentationLink link:calculationLink link:definitionLink 2448405 - Disclosure - Options and Awards Options Outstanding Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2448408 - Disclosure - Options and Awards Restricted Award Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2448407 - Disclosure - Options and Awards Restricted Awards Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2448413 - Disclosure - Options and Awards Sale of Stock by Subsidiary (Details) link:presentationLink link:calculationLink link:definitionLink 2448411 - Disclosure - Options and Awards Subsidiary Common Stock Shares and Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2448412 - Disclosure - Options and Awards Subsidiary Equity Plan Share-based Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2348301 - Disclosure - Options and Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 2448403 - Disclosure - Options and Awards Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2145100 - Disclosure - Other Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2445402 - Disclosure - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2345301 - Disclosure - Other Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2437403 - Disclosure - Property and Equipment Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2437402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2337301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Proposed Spin-Off of Subsidiaries link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Proposed Spin-Off of Subsidiaries (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Proposed Spin-Off of Subsidiaries (Tables) link:presentationLink link:calculationLink link:definitionLink 2142100 - Disclosure - Restricted and Other Assets link:presentationLink link:calculationLink link:definitionLink 2442403 - Disclosure - Restricted and Other Assets Additional (Details) link:presentationLink link:calculationLink link:definitionLink 2442402 - Disclosure - Restricted and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2342301 - Disclosure - Restricted and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Revenue and Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Revenue and Accounts Receivable Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Revenue and Accounts Receivable Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Revenue and Accounts Receivable Impact of New Revenue Guidance (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Revenue and Accounts Receivable Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Revenue and Accounts Receivable Revenue from Medicare and Medicaid Programs (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Revenue and Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 2152100 - Disclosure - Self-Insurance Reserves link:presentationLink link:calculationLink link:definitionLink 2452402 - Disclosure - Self-Insurance Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 2352301 - Disclosure - Self-Insurance Reserves (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2413413 - Disclosure - Significant Accounting Policies Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Significant Accounting Policies Divestiture (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Significant Accounting Policies Impairment (Details) link:presentationLink link:calculationLink link:definitionLink 2413414 - Disclosure - Significant Accounting Policies Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Significant Accounting Policies Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2213201 - Disclosure - Significant Accounting Policies Level 2 (Policies) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Significant Accounting Policies Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2413415 - Disclosure - Significant Accounting Policies Recent Accounting Standards Adopted (Details) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Significant Accounting Policies Revenue and Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Significant Accounting Policies Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2413409 - Disclosure - Significant Accounting Policies Self-Insurance General and Professional (Details) link:presentationLink link:calculationLink link:definitionLink 2413412 - Disclosure - Significant Accounting Policies Self-Insurance Health Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - Significant Accounting Policies Self Insurance Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2413411 - Disclosure - Significant Accounting Policies Self Insurance Recoveries (Details) link:presentationLink link:calculationLink link:definitionLink 2413410 - Disclosure - Significant Accounting Policies Self-Insurance Workers' Compensation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ensg-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ensg-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ensg-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Segment Reporting [Abstract] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Medicaid Medicaid [Member] Revenue from Medicaid for custodial services [Member] Medicare Medicare [Member] Revenue from Medicare [Member] Medicaid — skilled Medicaid-skilled [Member] Revenue from Medicaid for skilled services [Member] Total Medicaid and Medicare Total Medicaid and Medicare Revenue [Member] Total revenue from Medicaid and Medicare [Member] Managed care Managed Care [Member] Revenue from managed care payors [Member] Private and other payors(1) Private Pay and Other [Member] Revenue from self-pay and Other payors [Member] Home Health and Hospice Agencies [Axis] Home Health and Hospice Agencies [Axis] Home Health and Hospice Agencies [Axis] Home Health and Hospice Agencies [Domain] Home Health and Hospice Agencies [Domain] [Domain] for Home Health and Hospice Agencies [Axis] skilled nursing, assisted living and independent living facilities [Axis] Transitional and Skilled Service Facilities [Axis] Transitional and skilled service facilities [Axis] Skilled nursing, assisted living and independent living facilities [Domain] Transitional and Skilled Service facilities [Domain] Transitional and skilled service facilities [Domain] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Transitional and Skilled Services Segment Transitional and Skilled Services Segment [Member] Transitional and Skilled Services Segment Senior Living Services Segment Senior Living Services Segment [Member] Assisted and Independent Living Services Segment [Member] Home Health and Hospice Services Home Health and Hospice Segment [Member] Home Health and Hospice Segment All Other All Other [Member] All Other Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer by Payor as a Percent of Total Revenue Revenue from Contract with Customer by Payor as a Percent of Total Revenue Revenue from Contract with Customer by Payor as a Percent of Total Revenue Balance Sheet Paranthetical [Abstract] Balance Sheet Paranthetical [Abstract] Current assets: Assets, Current [Abstract] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Common stock in treasury, at cost Treasury Stock, Shares Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation and Significant Accounting Policies [Text Block] Commitments and Contingencies Disclosure [Abstract] Cash in Excess of FDIC limits [Table] Cash in Excess of FDIC limits [Table] Cash in Excess of FDIC limits [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Cash in Excess of FDIC limits [Line Items] Cash in Excess of FDIC limits [Line Items] [Line Items] for Cash in Excess of FDIC limits [Table] Cash, Uninsured Amount Cash, Uninsured Amount Cash, FDIC Insured Amount Cash, FDIC Insured Amount Proposed Spin-Off [Abstract] Proposed Spin-Off [Abstract] Proposed Spin-Off [Text Block] Proposed Spin-Off [Text Block] Proposed Spin-Off [Text Block] Leases [Abstract] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Lease Initial Application Period Cumulative Effect Transition [Axis] Lease Initial Application Period Cumulative Effect Transition [Axis] Lease information about effect of transition method for cumulative effect in initial period of application. Lease Initial Application Period Cumulative Effect Transition [Domain] Lease Initial Application Period Cumulative Effect Transition [Domain] [Domain] for Lease information about effect of transition method for cumulative effect in initial period of application. Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract] COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract] Earnings Per Share, Diluted, Other Disclosures [Abstract] Earnings Per Share, Diluted, Other Disclosures [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Options and Awards [Abstract] Options and Awards [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract] Options Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Fair Value of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Intrinsic Value of Options Granted on Grant Date [Abstract] Intrinsic Value of Options Granted on Grant Date [Abstract] Intrinsic Value of Options Granted on Grant Date [Abstract] Grant Date Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value Business Combinations [Abstract] Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Common Stock [Abstract] Common Stock [Abstract] Common stock [Text Block] Common stock [Text Block] Common stock Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Leases and Leasehold Improvements Lessee, Leases [Policy Text Block] Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Self-Insurance Liability Reserve Estimate, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Noncontrolling Interest Noncontrolling Interest [Policy Text Block] The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Stock Options granted [Table] Stock Options granted [Table] Stock Options granted [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock Awards Restricted Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2017 Plan [Member] 2017 Plan [Member] 2017 Plan Title of Individual [Axis] Title of Individual [Axis] Title of Individual [Domain] Title of Individual [Domain] Director [Member] Director [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Stock Options granted [Line Items] Stock Options granted [Line Items] [Line Items] for Stock Options granted [Table] Number of Option Plans Number of Option Plans Number of Option Plans Shares Granted or Issued, Share-based Payment Arrangement [Abstract] Shares Granted or Issued, Share-based Payment Arrangement [Abstract] Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Conversion to Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability Other than Options, Conversion to Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Conversion to Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Conversion to Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Award Requisite Service Period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Expiration Period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Nonvested Restricted Awards, Granted Stock Issued During Period, Shares, Restricted Stock Award, Gross Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Insurance Policy [Axis] Product and Service [Axis] Insurance Policy [Domain] Product and Service [Domain] Workers' Compensation [Member] Workers' Compensation Insurance [Member] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Stop-Loss Insurance limit per claim [Member] Stop-Loss Insurance limit per claim [Member] Stop-Loss Insurance limit per claim[Member] Loss-Sensitive limit per claim [Member] [Member] Loss-Sensitive limit per claim [Member] [Member] Loss-Sensitive limit per claim Location, State [Axis] Location, State [Axis] Location, State [Axis] Location, State [Domain] Location, State [Domain] Location, State [Domain] TEXAS TEXAS Other states, except California, Texas and Washington [Domain] Other states, except California, Texas and Washington [Domain] Other states, except California, Texas and Washington Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Self Insurance Reserve Self Insurance Reserve Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets Disclosure [Text Block] Intangible Assets Disclosure [Text Block] Fair Value Disclosures [Abstract] Statement [Table] Statement [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Cash and cash equivalents Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Statement [Line Items] Statement [Line Items] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure DESCRIPTION OF BUSINESS [Abstract] DESCRIPTION OF BUSINESS [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Spinoff [Member] Spinoff [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Public Companies Created Public Companies Created Public companies created due to the proposed spin-off transaction Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Real Estate [Domain] Real Estate [Domain] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Real Estate Property Ownership [Axis] Real Estate Property Ownership [Axis] Real Estate Properties [Domain] Real Estate Properties [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Debt Disclosure [Abstract] Long-Term Debt Additional Disclosures [Table] Long-Term Debt Additional Disclosures [Table] Long-Term Debt Additional Disclosures [Table] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] SunTrust Bank [Member] SunTrust Bank [Member] SunTrust Bank [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Second Amended Credit Facility [Member] Second Amended Credit Facility [Member] Second Amended Credit Facility with a Lending Consortium Arranged by SunTrust (the Second Amended Credit Facility) [Member] Collateralized Debt Obligations [Member] Collateralized Debt Obligations [Member] Secured Debt [Member] Secured Debt [Member] Senior Debt Obligations [Member] Senior Debt Obligations [Member] Notes Payable to Banks [Member] Notes Payable to Banks [Member] Notes Payable, Other Payables [Member] Notes Payable, Other Payables [Member] Mortgages [Member] Mortgages [Member] Long-Term Debt Additional Disclosures [Line Items] Long-Term Debt Additional Disclosures [Line Items] [Line Items] for Long-Term Debt Additional Disclosures [Table] Increase in Letters of Credit Increase in Letters of Credit Increase in Letters of Credit Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities Term Loan, Amount Outstanding, Current Term Loan, Amount Outstanding, Current Term Loan, Amount Outstanding, Current Term Loan, Amount Outstanding, Noncurrent Term Loan, Amount Outstanding, Noncurrent Term Loan, Amount Outstanding, Noncurrent Revolving credit facility with SunTrust Line of Credit Facility, Fair Value of Amount Outstanding Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Long-term Line of Credit Long-term Line of Credit Term Loan, Borrowing Capacity Term Loan, Borrowing Capacity Borrowing capacity under the term loan Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Interest Rate, Additional Margin Line of Credit Facility, Interest Rate, Additional Margin Interest rate margin added to a specified base rate to determine total interest rate on borrowings. Line of Credit Facility, Interest Rate, LIBOR Line of Credit Facility, Interest Rate, LIBOR Interest rate margin added to the LIBOR rate to determine total interest rate on borrowings. Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Total Net Debt Ratio, Maximum Total Net Debt Ratio, Maximum Total Net Debt Ratio, Maximum Total Net Debt Ratio, Minimum Total Net Debt Ratio, Minimum Total Net Debt Ratio, Minimum EBITDA Ratio, Maximum EBITDA Ratio, Maximum EBITDA Ratio, Maximum EBITDA Ratio, Minimum EBITDA Ratio, Minimum EBITDA Ratio, Minimum Total Net Debt Ratio, Default Total Net Debt Ratio, Default Total Net Debt Ratio, Default EBITDA Ratio, Default EBITDA Ratio, Default EBITDA Ratio, Default Aggregate Revolving Commitment Percentage Aggregate Revolving Commitment Percentage Aggregate Revolving Commitment Percentage Term Loan and Line of Credit Facility, Amount Outstanding Term Loan and Line of Credit Facility, Amount Outstanding Term loan and line of credit facility outstanding amount for current and noncurrent Term loan with SunTrust Term Loan, Amount Outstanding Including the current and noncurrent portions of the outstanding balance for the term loan. Indefinite-Lived Intangible Assets (Including Goodwill) [Abstract] GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS [Abstract] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Trade name Trade Names [Member] Medicare and Medicaid licenses Medicare and Medicaid Licenses [Member] Medicare licenses for home health and hospice segment and all other segment. Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Other indefinite-lived intangibles Indefinite-lived Intangible Assets (Excluding Goodwill) Litigation [Table] Litigation [Table] Litigation [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] Litigation [Line Items] Litigation [Line Items] [Line Items] for Litigation [Table] Litigation Settlement, Amount Awarded to Other Party Litigation Settlement, Amount Awarded to Other Party Payments for Legal Settlements Payments for Legal Settlements Litigation Settlement, Return of Unclaimed Settlement Litigation Settlement, Return of Unclaimed Settlement Amount was returned as unclaimed settlement funds REVENUE AND ACCOUNTS RECEIVABLE [Abstract] REVENUE AND ACCOUNTS RECEIVABLE [Abstract] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Mortgage loans and promissory note Notes Payable Long-term Debt, Gross Long-term Debt, Gross Current maturities of long-term debt Long-term Debt, Current Maturities Less: debt issuance costs Debt Issuance Costs, Line of Credit Arrangements, Net Long Term Debt, net of Current Maturities and Debt Discount Long Term Debt, net of Current Maturities and Debt Discount Long Term Debt, net of Current Maturities and Debt Discount Goodwill & Indefinite-lived Intangible Assets [Member] Goodwill & Indefinite-lived Intangible Assets [Member] Asset representing future economic benefits arising from other assets acquired in a business combination and assets that lack physical substance, having a projected indefinite period of benefit. Senior Living Facilities [Member] Senior Living Facilities [Member] Assisted Living Facilities [Member] Business Acquisition Type [Axis] Accounting Acquisition Type [Axis] Accounting Acquisition Type [Axis] Business Acquisition Type [Domain] Business Acquisition Type [Domain] Business Acquisition Type [Domain] Asset Acquisition [Member] Asset Acquisition [Member] These acquisitions were classified as asset acquisitions in accordance with ASC 805. 8051 Services, Skilled Nursing Care Facilities [Member] 8051 Services, Skilled Nursing Care Facilities [Member] Business Combination [Member] Business Combination [Member] These acquisitions were classified as business acquisitions in accordance with ASC 805. Transitional and Skilled Services and Senior Living Campuses [Member] Transitional and Skilled Services and Senior Living Campuses [Member] Transitional and Skilled Services and Senior Living Campuses [Member] 621610 Home Health Care Services [Member] 621610 Home Health Care Services [Member] Hospice Agencies [Member] Hospice Agencies [Member] Hospice Agencies Home Care Agency [Member] Home Care Agency [Member] Home Care Agency [Member] Number of Businesses Acquired Number of Businesses Acquired Cash payments for asset acquisitions (Note 8) Payments to Acquire Asset Acquisitions Cash paid to acquire acquisitions. Payments to Acquire Business and Asset Acquisitions Payments to Acquire Business and Asset Acquisitions Cash paid to acquire acquisitions. Operational Skilled Nursing Beds Operational Skilled Nursing Beds Number of skilled nursing beds available for use at a skilled nursing facility Operational Senior Living Units Operational Senior Living Units Operational Assisted Living and Independent Living Units Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Various Landlords [Member] [Member] Various Landlords [Member] [Member] Various Landlords[Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Stock Options Share-based Payment Arrangement, Option [Member] Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement [Text Block] Self-Insurance Reserves [Abstract] Self-Insurance Reserves [Abstract] Schedule of Self-Insurance Reserves [Table] Schedule of Self-Insurance Reserves [Table] Schedule of Self-Insurance Reserves [Table] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Schedule of Self-Insurance Reserves [Line Items] Schedule of Self-Insurance Reserves [Line Items] [Line Items] for Schedule of Self-Insurance Reserves [Table] Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Favorable leases Off-Market Favorable Lease [Member] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Right-of-use assets Operating Lease, Right-of-Use Asset Net of Lease Liability Operating Lease, Liability Cumulative Effect on Retained Earnings, Net of Tax Cumulative Effect on Retained Earnings, Net of Tax Sale Leaseback Transaction, Deferred Gain Sale Leaseback Transaction, Current Period Gain Recognized Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Accrued Liabilities [Abstract] Quality assurance fee Quality Assurance Fee Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days Refunds payable Resident Refunds Payable Resident refunds payable includes amounts due to residents for overpayments and duplicate payments Resident advances Contract with Customer, Liability, Current Cash held in trust for patients Cash Held in Trust for Residents Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds. Resident deposits Resident Deposits Resident Deposits Dividends payable Dividends Payable Property taxes Accrual for Taxes Other than Income Taxes Other Other Liabilities, Noncurrent Other accrued liabilities Other Accrued Liabilities Restricted Stock Rollforward [Table] Restricted Stock Rollforward [Table] Restricted Stock Rollforward [Table] Restricted Stock Rollforward [Line Items] Restricted Stock Rollforward [Line Items] [Line Items] for Restricted Stock Rollforward [Table] Nonvested Restricted Awards, Nonvested at January 1, Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Weighted Average Grant Date Fair Value, Nonvested at January 1, Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Restricted Awards Granted in the Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Nonvested Restricted Awards, Vested in the Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Weighted Average Grant Date Fair Value, Restricted Awards Vested in the Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Nonvested Restricted Awards, Forfeited in the Period Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Weighted Average Grant Date Fair Value, Restricted Awards Forfeited in the Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested Restricted Awards, Nonvested at June 30, Weighted Average Grant Date Fair Value, Nonvested at June 30, Other Assets [Abstract] Right-of-Use Asset [Member] Right-of-Use Asset [Member] Amount of lessee's right to use underlying asset under operating lease. Deposits with Landlords [Member] Deposits with Landlords [Member] Deposits with landlords located within restricted and other assets on the balance sheet. Prepaid Rent Prepaid Rent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Amortization of Intangible Assets Amortization of Intangible Assets Right-of-use assets (Note 17) Assembled occupancy Assembled occupancy acquired [Member] Assembled occupancy acquired [Member] Customer relationships Customer Relationships [Member] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Goodwill and intangible asset impairment Goodwill and Intangible Asset Impairment Income Statement [Abstract] Product and Service [Axis] Product and Service [Domain] Litigation Case [Domain] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Expense Costs and Expenses [Abstract] Cost of services Cost of Goods and Services Sold Return of unclaimed class action settlement (Note 18) Gain (Loss) Related to Litigation Settlement Rent—cost of services (Note 17) Operating Lease, Expense General and administrative expense General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization Total expenses Costs and Expenses Income from operations Operating Income (Loss) Other income (expense): Other Nonoperating Income (Expense) [Abstract] Interest expense Interest Expense Interest income Investment Income, Interest Other expense, net Other Nonoperating Income (Expense) Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less: net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net income attributable to The Ensign Group, Inc. Net Income (Loss) Attributable to Parent Net income per share attributable to The Ensign Group, Inc.: Income Amounts Attributable to Parent, Disclosures [Abstract] Net income per share: Basic: Earnings Per Share, Basic [Abstract] Basic net income per common share attributable to The Ensign Group, Inc. Earnings Per Share, Basic Diluted: Earnings Per Share, Diluted [Abstract] Diluted net income per common share attributable to The Ensign Group, Inc. Earnings Per Share, Diluted Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic Weighted Average Number of Shares Outstanding, Basic Diluted Weighted Average Number of Shares Outstanding, Diluted Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Health Liability Insurance [Member] Health Liability Insurance [Member] Health Liability Insurance [Member] Stop Loss Deductible [Member] Stop Loss Deductible [Member] Stop Loss Deductible [Member] Schedule of Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block] Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block] Sale Leaseback Transactions [Abstract] Sale Leaseback Transactions [Abstract] Sale Leaseback Transaction [Table] Sale Leaseback Transaction [Table] Sale Leaseback Transaction, Description [Axis] Sale Leaseback Transaction, Description [Axis] Sale Leaseback Transaction, Name [Domain] Sale Leaseback Transaction, Name [Domain] Sale Leaseback Transaction [Line Items] Sale Leaseback Transaction [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Operating Segments [Member] Operating Segments [Member] Consolidation, Eliminations [Member] Consolidation, Eliminations [Member] Transitional and skilled services, assisted and independent living services and home health and hospice services segments [Member] Transitional and skilled services, assisted and independent living services and home health and hospice services segments [Member] Transitional and skilled services, assisted and independent living services and home health and hospice services segments. Elimination Intersegment Eliminations [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Revenue from external customers Intersegment revenue (1) Intersegment revenue Intersegment revenue Intersegment Expense Intersegment Expense Intersegment Expense Operating Income & Intersegment Expense Operating Income & Intersegment Expense The net result for the period of deducting operating expenses and intercompany expense from operating revenues. Total revenue Revenue from Contract with Customer Including Intersegment Revenue Revenue from Contract with Customer Including Intersegment Revenue Segment Income (Loss) Interest expense, net of interest income Income before provision for income taxes Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Private Pay and Other Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Receivable Accounts Receivable, before Allowance for Credit Loss Less: allowance for doubtful accounts Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Percentage of revenue Income Tax Disclosure [Abstract] Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Adjustments Due to ASC 842 [Member] Adjustments Due to ASC 842 [Member] Difference between Lease Guidance in Effect before and after Topic 842 Calculated under New Lease Guidance in Effect [Member] Calculated under New Lease Guidance in Effect [Member] Calculated under guidance for leases in effect for ASC 842. Assets Assets Liabilities Liabilities Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Common Class A [Member] Options outstanding January 1, Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Weighted average exercise price January 1, Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options vested January 1, Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number As of the balance sheet date, the number of shares into which fully vested stock options outstanding can be converted under the option plan. Weighted Average Exercise Price of Options Vested January 1, Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Options Granted Options Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Weighted Average Exercise Price, Options Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options Exercised in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted Average Exercise Price, Options Exercised in Period Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options outstanding June 30, Weighted average exercise price June 30, Options vested June 30, Weighted Average Exercise Price of Options Vested June 30, Earnings Per Share [Text Block] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] 2019 (remainder) Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Variable Rent Lessee, Operating Lease, Liability, Variable Rent Lessee, Operating Lease, Liability, Variable Rent Present value of total lease liabilities Less: current lease liabilities Operating Lease, Liability, Current Long-term operating lease liabilities Operating Lease, Liability, Noncurrent 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total lease payments Operating Leases, Future Minimum Payments Due Schedule of Other Assets [Table Text Block] Schedule of Other Assets [Table Text Block] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Office Building [Member] Office Building [Member] Building and improvements Building and Building Improvements [Member] Land Land [Member] Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Payments to Acquire Asset Acquisitions Note payable due to seller from business acquisition Notes Issued Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] January 1, Goodwill Additions Goodwill, Acquired During Period June 30, Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2019 (remainder) Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Intangible assets, net Finite-Lived Intangible Assets, Net Statement of Stockholders' Equity [Abstract] Dividends Per Share Common Stock, Dividends, Per Share, Declared Lessee, Operating Leases [Text Block] Lessee, Operating Leases [Text Block] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Stock awards Stock awards [Member] Stock awards [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based compensation expense Share-based Payment Arrangement, Expense Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract] Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Nonvested Awards Employee Service Share-based Compensation, Nonvested Awards Employee Service Share-based Compensation, Nonvested Awards Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Common Stock Transactions [Table] Common Stock Transactions [Table] Common Stock Transactions [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Common Stock [Member] Common Stock [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Common Stock Transactions [Line Items] Common Stock Transactions [Line Items] [Line Items] for Common Stock Transactions [Table] Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Period in Force Stock Repurchase Program, Period in Force Stock Repurchase Program Expiration Date Stock Repurchase Program Expiration Date Goodwill and Other Indefinite-Lived Intangibles [Text Block] Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Net income Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net income attributable to The Ensign Group, Inc. Denominator: Weighted average shares outstanding for basic net income per share Plus: incremental shares from assumed conversion (1) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Adjusted weighted average common shares outstanding Basic net income (loss) per common share: Diluted net (loss) income per common share: Other Assets Disclosure [Text Block] Other Assets Disclosure [Text Block] Revenue and Accounts receivable [Text Block] Revenue and Accounts receivable [Text Block] Revenue and accounts receivable [Text Block] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Retained Earnings [Member] Treasury Stock [Member] Treasury Stock [Member] Noncontrolling Interest [Member] Noncontrolling Interest [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance - January 1, Balance - January 1 (in shares) Balance - January 1 (in treasury shares) Shares, Outstanding Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares) Stock Issued During Period, Shares, New Issues Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards Stock Issued During Period, Value, New Issues Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Repurchase of shares of common stock to satisfy tax withholding obligations Payment, Tax Withholding, Share-based Payment Arrangement Dividends declared Dividends Employee stock award compensation Noncontrolling interest attributable to subsidiary equity plan (Note 16) Noncontrolling Interest, Increase from Subsidiary Equity Issuance Cumulative effect of new accounting change, net of tax Cumulative Effect of New Accounting Principle in Period of Adoption Distribution to noncontrolling interest holder Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Net income attributable to noncontrolling interest Net Income (Loss) Attributable to the Ensign Group, Inc. Balance - June 30, Balance - June 30 (in shares) Balance - June 30 (in treasury shares) Debt Securities, Held-to-maturity [Table] Debt Securities, Held-to-maturity [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Debt Security, Corporate, US [Member] Debt Security, Corporate, US [Member] Schedule of Held-to-maturity Securities [Line Items] Schedule of Held-to-maturity Securities [Line Items] Debt Securities, Held-to-maturity Debt Securities, Held-to-maturity Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Number of Operating Subsidiaries Number of Operating Subsidiaries Number of operating subsidiaries entered into mortgage loans that are insured with HUD. Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Prepayment Penalty Reduced Rate During First Three Years Prepayment Penalty Reduced Rate During First Three Years Percentage that the prepayment penalty percentage is reduced during the first three years. Prepayment Penalty Reduced Rate During the Fourth Year Prepayment Penalty Reduced Rate During the Fourth Year Percentage that the prepayment penalty percentage is reduced during the fourth year. Prepayment Penalty Reduced Rate for the Fifth through Tenth Years Prepayment Penalty Reduced Rate for the Fifth through Tenth Years Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years. Prepayment penalty reduced rate Prepayment penalty reduced rate Percentage that the prepayment penalty percentage is reduced over time Debt Instrument, pre-payment fee reduction, term Debt Instrument, pre-payment fee reduction, term Debt Instrument, pre-payment fee reduction, term Debt Instrument, Term Debt Instrument, Term Notes Payable Notes Payable, Current Notes Payable, Current Notes Payable, Noncurrent Notes Payable, Noncurrent Divestiture [Abstract] Divestiture [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Senior Living Facility Senior Living Facility Sale of a senior living facility Sale Price from Divestiture of Businesses Sale Price from Divestiture of Businesses The price associated with the amount received from the sale of a portion of the Company's businesses. Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Other Commitments [Table] Other Commitments [Table] CALIFORNIA CALIFORNIA Other Commitments [Line Items] Other Commitments [Line Items] Litigation Settlement Paid to U.S. Government Litigation Settlement Paid to U.S. Government Litigation Settlement Paid to U.S. Government Self-insurance retention per claim [Member] Self-insurance retention per claim [Member] Self-insurance retention per claim [Member] Aggregate Deductible [Member] Aggregate Deductible [Member] Aggregate Deductible [Member] Blanket Aggregate [Member] Blanket Aggregate [Member] Blanket Aggregate [Member] Per Facility [Member] Per Facility [Member] Per Facility [Member] Per Occurence [Member] Per Occurence [Member] Per Occurence [Member] Payor [Axis] Payor [Axis] Payor [Axis] Payor [Domain] Payor [Domain] Payor [Domain] Parent Company [Member] Parent Company [Member] Third-Party Payor [Member] 524292 Third Party Administration of Insurance and Pension Funds [Member] Non-California [Domain] Non-California [Domain] Non-California [Domain] All States Except Colorado [Domain] All States Except Colorado [Domain] All States Except Colorado [Domain] COLORADO COLORADO General and Professional Liability Insurance [Member] General Liability [Member] General and Professional Liability Insurance [Member] Professional Liability Insurance [Member] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Exercise Price Range [Axis] Exercise Price Range [Axis] Exercise Price Range [Domain] Exercise Price Range [Domain] 2009 Exercise Price Range [Member] Exercise Price Range 2010 Exercise Price Range One [Member] Exercise Price Range One [Member] 2011 Exercise Price Range Two [Member] Exercise Price Range Two [Member] 2012 Exercise Price Range Three [Member] Exercise Price Range Three [Member] 2013 Exercise Price Range Four [Member] Exercise Price Range Four [Member] 2014 Exercise Price Range Five [Member] Exercise Price Range Five [Member] 2015 Exercise Price Range Six [Member] Exercise Price Range Six [Member] 2016 Exercise Price Range Seven [Member] Exercise Price Range Seven [Member] 2017 Exercise Price Range Eight [Member] Exercise Price Range Eight [Member] 2018 Exercise Price Range Nine [Member] Exercise Price Range Nine [Member] 2019 Exercise Price Range Ten [Member] Exercise Price Range Ten [Member] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise Price, Lower Range Limit Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Exercise Price, Upper Range Limit Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Number of Outstanding Options Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Black-Scholes Fair Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range Remaining Contractual Life (Years) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Stock Options Vested and Exercisable Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Long-term insurance losses recoverable asset Estimated Insurance Recoveries Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Property, Plant and Equipment [Abstract] Schedule of Property, Plant and Equipment [Table] Equipment Equipment [Member] Furniture and fixtures Furniture and Fixtures [Member] Leasehold improvements Leasehold Improvements [Member] Construction in progress Construction in Progress [Member] Property and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Statement of Financial Position [Abstract] Cash and cash equivalents Fair Value Hierarchy and NAV [Domain] Assets Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable—less allowance for doubtful accounts of $3,726 and $2,886 at June 30, 2019 and December 31, 2018, respectively Accounts Receivable, after Allowance for Credit Loss, Current Investments—current Short-term Investments Prepaid income taxes Prepaid Taxes Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Assets held for sale - current Assets Held-for-sale, Not Part of Disposal Group, Current Total current assets Assets, Current Property and equipment, net Insurance subsidiary deposits and investments Insurance subsidiary deposits and investments Captive insurance subidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity. Escrow deposits Deposits Assets, Noncurrent Deferred tax assets Deferred Tax Assets, Net Restricted and other assets (Note 17) Other Restricted Assets, Noncurrent Intangible assets, net (Note 17) Goodwill Total assets Liabilities and equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued wages and related liabilities Employee-related Liabilities, Current Lease liabilities—current (Note 17) Accrued self-insurance liabilities—current Self Insurance Reserve, Current Other accrued liabilities Other Liabilities, Current Current maturities of long-term debt Total current liabilities Liabilities, Current Long-term debt—less current maturities Long-term Debt, Excluding Current Maturities Long-term lease liabilities—less current portion (Note 17) Accrued self-insurance liabilities—less current portion Self Insurance Reserve, Noncurrent Other long-term liabilities Deferred rent and other long-term liabilities Rental expense in excess of actual rental payments and other long-term liabilities Deferred gain related to sale-leaseback (Note 17) Sale Leaseback Transaction, Deferred Gain, Net Total liabilities Commitments and contingencies (Notes 15, 17 and 18) Commitments and Contingencies Equity: Equity [Abstract] Equity: Common stock; $0.001 par value; 100,000 shares authorized; 55,809 and 53,272 shares issued and outstanding at June 30, 2019, respectively, and 55,089 and 52,584 shares issued and outstanding at December 31, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Common stock in treasury, at cost, 1,941 and 1,932 shares at June 30, 2019 and December 31, 2018, respectively Treasury Stock, Value Total Ensign Group, Inc. stockholders' equity Stockholders' Equity Attributable to Parent Non-controlling interest Stockholders' Equity Attributable to Noncontrolling Interest Total equity Total liabilities and equity Liabilities and Equity Impairment of Long-Lived Assets to be Disposed of Impairment of Long-Lived Assets to be Disposed of Concentration Risk [Table] Concentration Risk [Table] Concentration Risk [Line Items] Concentration Risk [Line Items] Accounts receivable by payor as a percent of total accounts receivable Accounts receivable by payor as a percent of total accounts receivable Accounts receivable by payor as a percent of total accounts receivable % of Revenue Revenue by payor as a percent of total revenue Revenue by payor as a percent of total revenue [Line Items] Restricted awards granted [Table] Restricted awards granted [Table] Restricted awards granted [Table] Grant Class [Axis] Grant Class [Axis] Grant Class [Axis] Grant Class [Domain] Grant Class [Domain] [Domain] for Grant Class [Axis] Restricted awards granted [Line Items] Restricted awards granted [Line Items] [Line Items] for Restricted awards granted [Table] Restricted Awards Grant Date Fair Value Range, Minimum Restricted Awards Grant Date Fair Value Range, Minimum Restricted Awards Grant Date Fair Value Range, Minimum Restricted Awards Grant Date Fair Value Range, Maximum Restricted Awards Grant Date Fair Value Range, Maximum Restricted Awards Grant Date Fair Value Range, Maximum Options Granted to Non-employee Directors Options Granted to Non-employee Directors Options granted to non-employee directors Share-based Compensation, Restricted Awards, Exercise Price Share-based Compensation, Restricted Awards, Exercise Price Share-based Compensation, Restricted Awards, Exercise Price Issuance of restricted stock to employees (in shares) Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Lease acquisition costs Leases, Acquired-in-Place [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Weighted Average Life (Years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Amortization [Abstract] Amortization [Abstract] Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Tax Period [Axis] Tax Period [Axis] Tax Period [Domain] Tax Period [Domain] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Cumulative Effect on Retained Earnings, Tax Cumulative Effect on Retained Earnings, Tax Debt Disclosure [Text Block] Debt Disclosure [Text Block] Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment Disclosure [Text Block] Other Liabilities Disclosure [Text Block] Other Liabilities Disclosure [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General and Administrative Expense [Member] General and Administrative Expense [Member] Amortization of deferred rent Amortization of Deferred Rent Amortization of deferred rent Operating Lease, Cost Operating Lease, Cost Cost of Sales and General and Administrative Expense [Member] Cost of Sales and General and Administrative Expense [Member] Primary financial statement caption encompassing cost of services and general and administrative expense CareTrust REIT [Member] CareTrust REIT [Member] CareTrust REIT [Member] Skilled Nursing, Assisted Living and Independent Living Facilities Skilled Nursing, Assisted Living and Independent Living Facilities Skilled Nursing, Assisted Living and Independent Living Facilities Master Lease Agreements Master Lease Agreements Master Lease agreements Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms Lessee, Operating Lease, Renewal Term Lessee, Operating Lease, Renewal Term Operating Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate Operating Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate Payments for Rent Payments for Rent Average Term of Non-Cancellable Equipment Leases Average Term of Non-Cancellable Equipment Leases Average term of non-cancellable equipment leases Rent Operating Leases, Rent Expense Facilities under Master Lease Arrangement Facilities under Master Lease Arrangement Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block] Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block] Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block] Probe Reviews [Abstract] Medicare Probe Reviews [Abstract] Medicare Probe Reviews [Abstract] Facilities under Medicare Probe Reviews Facilities under Medicare Probe Reviews Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Consolidated Entities [Axis] Consolidated Entities [Axis] Consolidated Entities [Domain] Consolidated Entities [Domain] Subsidiaries [Member] Subsidiaries [Member] Award Type [Domain] Subsidiaries Stock awards [Member] Subsidiaries Stock awards [Member] Subsidiaries Stock awards [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Stock Repurchased During Period, Shares Stock Repurchased During Period, Shares Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Spin-Off Transaction Company [Member] Spin-Off Transaction Company [Member] Operated by the Spin-off company Remaining Company [Member] Remaining Company [Member] The Ensign Group, Inc. Home Health, Hospice and Home Care Operations Home Health, Hospice and Home Care Operations Home Health, Hospice and Home Care Operations Senior Living Facilities Senior Living Facilities Number of Assisted and Independent Living Facilities Stockholders' Equity Note, Stock Split, Conversion Ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Line Items] Class of Stock [Line Items] Common Stock Required to Settle Subsidiary Shares Common Stock Required to Settle Subsidiary Shares Common Stock Required to Settle Subsidiary Shares Total Medicare and Medicaid Revenue by payor as a percent of total revenue Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment [Table Text Block] Summary of Business Operations [Table] Summary of Business Operations [Table] Summary of Business Operations [Table] Skilled Nursing, Assisted Living and Independent living Facilities [Axis] Skilled Nursing and Senior living Facilities [Axis] Skilled Nursing, Assisted Living and Independent living Facilities [Axis] Skilled Nursing, Assisted Living and Independent living Facilities [Domain] Skilled Nursing and Senior living Facilities [Domain] [Domain] for Skilled Nursing, Assisted Living and Independent living Facilities [Axis] Summary of Business Operations [Line Items] Summary of Business Operations [Line Items] [Line Items] for Summary of Business Operations [Table] Skilled nursing, assisted living and independent living facilities [Abstract] Skilled nursing, assisted living and independent living facilities [Abstract] Skilled nursing, assisted living and independent living facilities [Abstract] Number of Real Estate Properties Number of Real Estate Properties Number of Real Estate Properties Leased Number of Real Estate Properties Leased Number of Real Estate Properties Leased Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Operated Number of Real Estate Properties Operated Number of Properties Operated Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract] Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract] Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract] Divestitures [Abstract] Divestitures [Abstract] Debt issuance costs, net Debt Issuance Costs, Net Deposits with landlords Security Deposit Capital improvement reserves with landlords and lenders Other Restricted Assets Note receivable from sale of ancillary business Notes Receivable, Fair Value Disclosure Restricted and other assets Other Assets, Noncurrent Subsidiary Equity Plan [Abstract] Subsidiary Equity Plan [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Segment Reporting Disclosure [Text Block] Segment Reporting Disclosure [Text Block] Fair Value Assumptions and Methodology Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted Average Risk-Free Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected Life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Weighted Average Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Weighted Average Dividend Yield Weighted Average Dividend Yield Weighted Average Dividend Yield Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Impairment of long-lived assets Amortization of deferred financing fees Amortization of Debt Issuance Costs and Discounts Amortization of deferred gain on sale-leaseback (Note 17) Non-cash leasing arrangement (Note 17) Non-cash Lease Expense Non-cash Lease Expense Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Share-based compensation Share-based Payment Arrangement, Noncash Expense Cash received from insurance proceeds related to replacement properties and business interruptions Proceeds from Insurance Settlement, Operating Activities Income tax refund Proceeds from Income Tax Refunds Change in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid income taxes Increase (Decrease) in Prepaid Taxes Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Insurance subsidiary deposits Increase (Decrease) in Insurance subsidiary deposits and investments Change in captive insurance subsidiary cash and cash equivalents and debt security investements Operating lease obligations Increase (Decrease) in Operating Right-of-Use Asset Increase (Decrease) in Operating Right-of-Use Asset Accounts payable Increase (Decrease) in Accounts Payable Accrued wages and related liabilities Increase (Decrease) in Employee Related Liabilities Other accrued liabilities Increase (Decrease) in Other Operating Liabilities Accrued self-insurance liabilities Increase (Decrease) in Self Insurance Reserve Other long-term liability Increase (Decrease) in Other Deferred Liability Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Cash payments for business acquisitions (Note 8) Payments to Acquire Businesses, Net of Cash Acquired Escrow deposits Payments for (Proceeds from) Deposits on Real Estate Acquisitions Escrow deposits used to fund acquisitions Escrow Deposits used to Fund Acquisitions Outflow of cash previously included in escrow deposits used to fund business and asset acquisitions in the current period. Cash proceeds from the sale of assets and insurance proceeds Proceeds from Sales of Assets, Investing Activities Investments and change in other assets Increase (Decrease) in Other Noncurrent Assets Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from revolving credit facility and other debt (Note 15) Proceeds from Issuance of Secured Debt Payments on revolving credit facility and other debt (Note 15) Repayments of Long-term Debt Issuance of common stock upon exercise of options Proceeds from Stock Options Exercised Proceeds from sale of subsidiary shares (Note 16) Repurchase of shares of common stock and subsidiary shares (Note 16) Dividends paid Payments of Dividends Non-controlling interest distribution Proceeds from (Payments to) Noncontrolling Interests Payments of deferred financing costs Payments of Financing Costs Net cash provided by/(used in) financing activities Net Cash Provided by (Used in) Financing Activities Net increase/(decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents beginning of period Cash and cash equivalents end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Additional Cash Flow Elements, Operating Activities [Abstract] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Income taxes Income Taxes Paid Lease liabilities Operating Lease, Payments Non-cash financing and investing activity: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Accrued dividends declared Note receivable from sale of ancillary business Noncash or Part Noncash Divestiture, Amount of Consideration Received Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Entity Information [Abstract] Entity Information [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Number of Reportable Segments Number of Reportable Segments Transitional and Skilled Service Facilities Transitional and Skilled Service Facilities Transitional and Skilled Service Facilities Transitional and Skilled Services and Senior Living Campuses Transitional and Skilled Services and Senior Living Campuses Transitional and Skilled Services and Assistant and Independent Living Campuses EX-101.PRE 10 ensg-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 ensg0630201910q_htm.xml IDEA: XBRL DOCUMENT 0001125376 2019-01-01 2019-06-30 0001125376 2019-07-31 0001125376 2019-06-30 0001125376 2018-12-31 0001125376 2019-04-01 2019-06-30 0001125376 2018-04-01 2018-06-30 0001125376 2018-01-01 2018-06-30 0001125376 2019-03-31 0001125376 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001125376 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0001125376 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001125376 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001125376 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001125376 2019-01-01 2019-03-31 0001125376 us-gaap:CommonStockMember 2019-03-31 0001125376 us-gaap:RetainedEarningsMember 2019-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001125376 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001125376 us-gaap:TreasuryStockMember 2018-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001125376 us-gaap:TreasuryStockMember 2019-06-30 0001125376 us-gaap:CommonStockMember 2019-06-30 0001125376 us-gaap:CommonStockMember 2018-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001125376 us-gaap:TreasuryStockMember 2019-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2019-06-30 0001125376 us-gaap:RetainedEarningsMember 2019-06-30 0001125376 us-gaap:RetainedEarningsMember 2018-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2019-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2017-12-31 0001125376 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001125376 2018-01-01 2018-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-04-01 2018-06-30 0001125376 us-gaap:CommonStockMember 2017-12-31 0001125376 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001125376 us-gaap:RetainedEarningsMember 2018-06-30 0001125376 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001125376 us-gaap:TreasuryStockMember 2018-06-30 0001125376 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001125376 2018-06-30 0001125376 us-gaap:CommonStockMember 2018-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001125376 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001125376 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001125376 us-gaap:TreasuryStockMember 2017-12-31 0001125376 us-gaap:CommonStockMember 2018-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001125376 us-gaap:RetainedEarningsMember 2017-12-31 0001125376 us-gaap:TreasuryStockMember 2018-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001125376 2018-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2018-03-31 0001125376 us-gaap:RetainedEarningsMember 2018-03-31 0001125376 2017-12-31 0001125376 us-gaap:SpinoffMember 2019-05-06 0001125376 us-gaap:SpinoffMember us-gaap:CommonStockMember ensg:SpinOffTransactionCompanyMember 2019-05-06 2019-05-06 0001125376 us-gaap:SpinoffMember us-gaap:CommonStockMember ensg:RemainingCompanyMember 2019-05-06 2019-05-06 0001125376 us-gaap:SpinoffMember ensg:RemainingCompanyMember 2019-05-06 0001125376 us-gaap:SpinoffMember ensg:SpinOffTransactionCompanyMember 2019-05-06 0001125376 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0001125376 srt:MaximumMember 2019-01-01 2019-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:PerOccurenceMember stpr:CO naics:ZZ524292 2019-06-30 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2019-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2019-06-30 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2019-01-01 2019-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2019-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2019-06-30 0001125376 us-gaap:ProfessionalLiabilityInsuranceMember 2019-06-30 0001125376 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001125376 us-gaap:ProfessionalLiabilityInsuranceMember 2018-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember stpr:TX 2019-06-30 0001125376 us-gaap:AccountingStandardsUpdate201602Member us-gaap:OffMarketFavorableLeaseMember 2019-01-01 0001125376 ensg:HealthLiabilityInsuranceMember 2019-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AggregateDeductibleMember stpr:CA srt:ParentCompanyMember 2019-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AggregateDeductibleMember ensg:NonCaliforniaDomain srt:ParentCompanyMember 2019-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:PerOccurenceMember ensg:AllStatesExceptColoradoDomain naics:ZZ524292 2019-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:PerFacilityMember stpr:CO naics:ZZ524292 2019-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:LossSensitivelimitperclaimMemberMember ensg:OtherstatesexceptCaliforniaTexasandWashingtonDomain 2019-06-30 0001125376 us-gaap:TradeNamesMember 2019-01-01 2019-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:BlanketAggregateMember ensg:AllStatesExceptColoradoDomain naics:ZZ524292 2019-06-30 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossDeductibleMember 2019-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2018-12-31 0001125376 ensg:HealthLiabilityInsuranceMember 2018-12-31 0001125376 us-gaap:GeneralLiabilityMember ensg:PerFacilityMember ensg:AllStatesExceptColoradoDomain naics:ZZ524292 2019-06-30 0001125376 srt:MinimumMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember 2019-06-30 0001125376 ensg:ManagedCareMember 2018-12-31 0001125376 ensg:PrivatePayAndOtherMember 2019-06-30 0001125376 ensg:MedicaidMember 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember 2018-12-31 0001125376 ensg:MedicaidMember 2018-12-31 0001125376 ensg:MedicareMember 2018-12-31 0001125376 ensg:MedicareMember 2019-06-30 0001125376 us-gaap:CommonClassAMember 2018-04-01 2018-06-30 0001125376 us-gaap:CommonClassAMember 2019-04-01 2019-06-30 0001125376 us-gaap:CommonClassAMember 2019-01-01 2019-06-30 0001125376 us-gaap:CommonClassAMember 2018-01-01 2018-06-30 0001125376 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001125376 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001125376 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001125376 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001125376 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001125376 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2019-06-30 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2018-12-31 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-01-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2019-01-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:HomeHealthandHospiceSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember 2019-04-01 2019-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2018-01-01 2018-06-30 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicareMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicareMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:ManagedCareMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:AllOtherMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:PrivatePayAndOtherMember ensg:TransitionalandSkilledServicesSegmentMember 2018-04-01 2018-06-30 0001125376 ensg:MedicaidMember ensg:SeniorLivingServicesSegmentMember 2018-04-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2019-04-01 2019-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:TransitionalandSkilledServicesSegmentMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:AllOtherMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:IntersegmentEliminationMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:SeniorLivingServicesSegmentMember 2018-01-01 2018-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:IntersegmentEliminationMember 2018-01-01 2018-06-30 0001125376 sic:Z8051 us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SubsequentEventMember 2019-07-01 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingFacilitiesMember 2019-06-30 0001125376 sic:Z8051 2019-06-30 0001125376 ensg:BusinessCombinationMember 2019-01-01 2019-06-30 0001125376 srt:OfficeBuildingMember 2018-01-01 2018-06-30 0001125376 ensg:GoodwillIndefinitelivedIntangibleAssetsMember 2019-01-01 2019-06-30 0001125376 sic:Z8051 us-gaap:SubsequentEventMember 2019-07-01 0001125376 sic:Z8051 2019-01-01 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesandSeniorLivingCampusesMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0001125376 ensg:HospiceAgenciesMember 2019-01-01 2019-06-30 0001125376 ensg:AssetAcquisitionMember 2019-01-01 2019-06-30 0001125376 us-gaap:LandMember 2019-01-01 2019-06-30 0001125376 naics:ZZ621610 2019-01-01 2019-06-30 0001125376 ensg:HomeCareAgencyMember 2019-01-01 2019-06-30 0001125376 ensg:SeniorLivingFacilitiesMember 2019-01-01 2019-06-30 0001125376 us-gaap:EquipmentMember 2018-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2019-06-30 0001125376 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001125376 us-gaap:ConstructionInProgressMember 2019-06-30 0001125376 us-gaap:ConstructionInProgressMember 2018-12-31 0001125376 us-gaap:LandMember 2018-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2019-06-30 0001125376 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001125376 us-gaap:LandMember 2019-06-30 0001125376 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001125376 us-gaap:EquipmentMember 2019-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2019-06-30 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2018-12-31 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2019-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2018-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2019-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2019-06-30 0001125376 us-gaap:TradeNamesMember 2019-06-30 0001125376 us-gaap:TradeNamesMember 2018-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2018-12-31 0001125376 us-gaap:OffMarketFavorableLeaseMember 2019-01-01 2019-06-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2019-01-01 2019-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2018-12-31 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2019-01-01 2019-06-30 0001125376 us-gaap:TradeNamesMember 2019-06-30 0001125376 us-gaap:TradeNamesMember 2018-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2018-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2019-06-30 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2018-12-31 0001125376 ensg:AllOtherMember 2018-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2019-06-30 0001125376 ensg:HomeHealthandHospiceSegmentMember 2018-12-31 0001125376 ensg:AllOtherMember 2019-06-30 0001125376 ensg:SeniorLivingServicesSegmentMember 2018-12-31 0001125376 us-gaap:AccountingStandardsUpdate201602Member ensg:RightofUseAssetMember 2019-01-01 0001125376 us-gaap:AccountingStandardsUpdate201602Member ensg:DepositswithLandlordsMember 2018-12-31 0001125376 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-03-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2018-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2019-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2019-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2018-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2019-06-30 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2018-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2017-12-27 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2016-07-19 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 2016-02-05 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember us-gaap:SubsequentEventMember 2019-07-30 0001125376 srt:MaximumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2017-10-30 2017-12-27 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 2016-02-05 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 0001125376 srt:MinimumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 0001125376 us-gaap:SeniorDebtObligationsMember us-gaap:SecuredDebtMember 2019-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2014-05-30 0001125376 us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2017-12-27 0001125376 srt:MaximumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 2014-12-31 0001125376 srt:MaximumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 0001125376 srt:MinimumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2014-12-31 2014-12-31 0001125376 srt:MinimumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2017-10-30 2017-12-27 0001125376 ensg:ExercisePriceRangeOneMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeSixMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeTenMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeSixMember 2019-06-30 0001125376 ensg:ExercisePriceRangeFourMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeThreeMember 2019-06-30 0001125376 ensg:ExercisePriceRangeMember 2019-06-30 0001125376 ensg:ExercisePriceRangeTwoMember 2019-06-30 0001125376 ensg:ExercisePriceRangeSevenMember 2019-06-30 0001125376 ensg:ExercisePriceRangeTwoMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeTenMember 2019-06-30 0001125376 ensg:ExercisePriceRangeFiveMember 2019-06-30 0001125376 ensg:ExercisePriceRangeFiveMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeSevenMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeNineMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeThreeMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeOneMember 2019-06-30 0001125376 ensg:ExercisePriceRangeEightMember 2019-06-30 0001125376 ensg:ExercisePriceRangeNineMember 2019-06-30 0001125376 ensg:ExercisePriceRangeEightMember 2019-01-01 2019-06-30 0001125376 ensg:ExercisePriceRangeFourMember 2019-06-30 0001125376 ensg:A2017PlanMember 2017-05-25 2017-05-25 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2019-04-01 2019-06-30 0001125376 ensg:A2017PlanMember 2017-05-25 0001125376 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001125376 srt:DirectorMember 2019-04-01 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2019-01-01 2019-06-30 0001125376 srt:DirectorMember ensg:A2017PlanMember 2017-05-25 2017-05-25 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2019-06-30 0001125376 srt:SubsidiariesMember srt:MaximumMember ensg:SubsidiariesStockawardsMember 2019-01-01 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2019-06-30 0001125376 srt:DirectorMember 2019-01-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2018-01-01 2018-06-30 0001125376 ensg:A2017PlanMember 2019-06-30 0001125376 srt:SubsidiariesMember ensg:SubsidiariesStockawardsMember 2018-04-01 2018-06-30 0001125376 ensg:StockAwardsMember 2018-04-01 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001125376 ensg:StockAwardsMember 2019-01-01 2019-06-30 0001125376 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0001125376 ensg:StockAwardsMember 2018-01-01 2018-06-30 0001125376 ensg:StockAwardsMember 2019-04-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001125376 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2018-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001125376 srt:SubsidiariesMember srt:MinimumMember ensg:SubsidiariesStockawardsMember 2019-01-01 2019-06-30 0001125376 ensg:VariousLandlordsMemberMember srt:MaximumMember 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2019-01-01 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2018-01-01 2018-06-30 0001125376 ensg:CareTrustREITMember 2019-01-01 2019-06-30 0001125376 ensg:CareTrustREITMember 2014-06-01 0001125376 ensg:VariousLandlordsMemberMember srt:MaximumMember 2019-01-01 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2018-04-01 2018-06-30 0001125376 ensg:CareTrustREITMember srt:MaximumMember 2014-06-01 0001125376 ensg:CareTrustREITMember 2019-04-01 2019-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2019-04-01 2019-06-30 0001125376 ensg:CareTrustREITMember 2018-04-01 2018-06-30 0001125376 ensg:CareTrustREITMember srt:MinimumMember 2014-06-01 0001125376 ensg:VariousLandlordsMemberMember 2019-06-30 0001125376 ensg:CareTrustREITMember 2018-01-01 2018-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2018-01-01 2018-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2019-04-01 2019-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001125376 us-gaap:OffMarketFavorableLeaseMember 2018-04-01 2018-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001125376 us-gaap:AccountingStandardsUpdate201602Member ensg:CalculatedunderNewLeaseGuidanceinEffectMember 2019-01-01 0001125376 us-gaap:AccountingStandardsUpdate201602Member ensg:AdjustmentsDuetoASC842Member 2019-01-01 0001125376 ensg:VariousLandlordsMemberMember srt:MinimumMember 2019-01-01 2019-06-30 0001125376 ensg:VariousLandlordsMemberMember srt:MinimumMember 2019-06-30 0001125376 2017-01-01 2017-03-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2019-06-30 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2018-12-31 0001125376 2013-01-01 2013-12-31 0001125376 us-gaap:SubsequentEventMember 2019-07-30 0001125376 us-gaap:CommonStockMember 2018-04-03 0001125376 2018-04-03 2018-04-03 ensg:Segments utreg:Rate shares ensg:business iso4217:USD shares ensg:Beds ensg:facilities pure iso4217:USD ensg:Agreements ensg:Renewals ensg:Operations ensg:installment false --12-31 Q2 2019 0001125376 P3Y0M P11Y0M P3Y0M P10Y0M P5Y0M 0.680 0.0450 0.0475 0.001 0.001 75000000 100000000 55089000 55809000 52584000 53272000 P12Y0M P30Y0M P3Y11M 0 0 0 0 P5Y0M P5Y0M P15Y0M P5Y0M P12Y0M 5220000 P3Y0M0D P3Y0M 976000 0 0 1932000 1941000 10-Q true 2019-06-30 false 001-33757 ENSIGN GROUP, INC DE 33-0861263 29222 Rancho Viejo Road, Suite 127 San Juan Capistrano CA 92675 949 487-9500 Common Stock, par value $0.001 per share ENSG NASDAQ Yes Yes Large Accelerated Filer false false false 53386352 39042000 31083000 296935000 276099000 8003000 8682000 5934000 6219000 25632000 24130000 0 1859000 375546000 348072000 674892000 618874000 1074449000 0 38929000 36168000 0 7271000 8603000 11650000 16943000 20844000 3829000 31000000 97408000 80477000 30922000 27602000 2321521000 1181958000 44694000 44236000 116018000 119656000 59686000 0 26981000 25446000 69816000 69784000 10153000 10105000 327348000 269227000 268179000 233135000 988145000 0 57565000 54605000 2977000 11234000 0 11417000 1644214000 579618000 55000 55000 298891000 284384000 401996000 344901000 38890000 38405000 662052000 590935000 15255000 11405000 677307000 602340000 2321521000 1181958000 575651000 496386000 1124865000 988520000 457000000 396132000 887002000 786375000 0 0 0 1664000 37060000 34472000 72846000 68322000 30561000 22386000 63585000 47490000 13184000 11621000 25782000 23243000 537805000 464611000 1049215000 923766000 37846000 31775000 75650000 64754000 3941000 3869000 7613000 7482000 572000 562000 1147000 1010000 -3369000 -3307000 -6466000 -6472000 34477000 28468000 69184000 58282000 5552000 6142000 12652000 12663000 28925000 22326000 56532000 45619000 316000 315000 551000 476000 28609000 22011000 55981000 45143000 0.54 0.42 1.05 0.87 0.51 0.41 1.00 0.84 53408000 51880000 53246000 51733000 56078000 54251000 55896000 53909000 52584000 55000 284384000 344901000 1932000 -38405000 11405000 602340000 371000 0 5616000 0 0 5616000 2543000 2543000 2612000 2612000 -317000 658000 341000 9030000 9030000 235000 235000 27372000 27372000 52955000 55000 292612000 378443000 1932000 -38405000 12298000 645003000 326000 0 3213000 0 0 3213000 -9000 9000 485000 485000 2559000 2559000 3066000 3066000 -2497000 2733000 236000 92000 92000 316000 316000 28609000 28609000 53272000 55000 298891000 401996000 1941000 -38890000 15255000 677307000 51360000 53000 266058000 264691000 1932000 -38405000 7662000 500059000 404000 1000 2919000 0 0 2920000 2346000 2346000 1971000 1971000 -79000 417000 338000 292000 292000 161000 161000 23132000 23132000 51764000 54000 270948000 285398000 1932000 -38405000 7948000 525943000 269000 0 1857000 0 0 1857000 2367000 2367000 2177000 2177000 -1885000 2228000 343000 315000 315000 22011000 22011000 52033000 54000 274982000 303157000 1932000 -38405000 10491000 550279000 56532000 45619000 25782000 23243000 0 860000 583000 588000 0 329000 688000 0 1155000 972000 6255000 4829000 638000 0 0 11000000 22716000 -13476000 -229000 129000 -3332000 3454000 0 -2571000 -2248000 0 356000 -74000 -355000 -1046000 -1566000 2531000 3717000 5349000 1272000 376000 72278000 101240000 35762000 24295000 21262000 0 43176000 55546000 0 2652000 7271000 228000 2575000 1610000 7902000 589000 -98256000 -81244000 535000000 405000000 500965000 439922000 5547000 4778000 485000 0 2293000 0 2293000 0 5068000 4695000 -92000 -292000 0 18000 33937000 -35149000 7959000 -15153000 31083000 42337000 39042000 27184000 7500000 7321000 12375000 12925000 73748000 0 3600000 3600000 2559000 2367000 0 282000 47748000 0 DESCRIPTION OF BUSINESS<div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Company - </span><span style="font-family:inherit;font-size:10pt;">The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company operated </span><span style="font-family:inherit;font-size:10pt;"><span>254</span></span><span style="font-family:inherit;font-size:10pt;"> facilities, </span><span style="font-family:inherit;font-size:10pt;"><span>62</span></span><span style="font-family:inherit;font-size:10pt;"> home health, hospice and home care agencies and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington, Wisconsin and Wyoming. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living, home health, hospice, home care and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>20,700</span></span><span style="font-family:inherit;font-size:10pt;"> operational skilled nursing beds and </span><span style="font-family:inherit;font-size:10pt;"><span>5,900</span></span><span style="font-family:inherit;font-size:10pt;"> senior living units. As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company owned </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>77</span></span><span style="font-family:inherit;font-size:10pt;"> of its </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>254</span></span><span style="font-family:inherit;font-size:10pt;"> affiliated facilities and leased an additional </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>177</span></span><span style="font-family:inherit;font-size:10pt;"> facilities through long-term lease arrangements and had options to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> of those </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>177</span></span><span style="font-family:inherit;font-size:10pt;"> facilities. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company owned </span><span style="font-family:inherit;font-size:10pt;"><span>72</span></span><span style="font-family:inherit;font-size:10pt;"> of its </span><span style="font-family:inherit;font-size:10pt;"><span>244</span></span><span style="font-family:inherit;font-size:10pt;"> affiliated facilities and leased an additional </span><span style="font-family:inherit;font-size:10pt;"><span>172</span></span><span style="font-family:inherit;font-size:10pt;"> facilities through long-term lease arrangements and had options to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> of those </span><span style="font-family:inherit;font-size:10pt;"><span>172</span></span><span style="font-family:inherit;font-size:10pt;"> facilities. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide certain accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Report is not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Proposed Spin-Off Transaction —</span><span style="font-family:inherit;font-size:10pt;"> On May 6, 2019, the Company announced a proposed plan to separate its transitional and skilled nursing services, its home health and hospice operations and substantially all of its senior living operations into </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> separate, publicly traded companies. See Note 2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Proposed Spin-Off of Subsidiaries</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Information —</span><span style="font-family:inherit;font-size:10pt;"> The accompanying condensed consolidated financial statements as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> which are included in the Company’s annual report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.</span></div> 254 62 20700 5900 77 254 177 12 177 72 244 172 12 172 2 PROPOSED SPIN-OFF OF SUBSIDIARIES<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 6, 2019, the Company announced a proposed plan to separate its transitional and skilled nursing services, its home health and hospice operations and substantially all of its senior living operations into </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> separate, publicly traded companies:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ensign, which will include transitional and skilled services, rehabilitative care services, healthcare campuses, post-acute-related new business ventures and real estate investments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Pennant Group, Inc. ("Pennant"), which will be a holding company of operating subsidiaries that provide home health, hospice and senior living.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company intends to accomplish the proposed separation through a spin-off (the Spin-Off), in which it expects to distribute shares of Pennant common stock to the Company’s stockholders, on a pro rata basis. The Company anticipates that at the time of the Spin-Off, Pennant, which is currently a wholly-owned subsidiary of the Company, will consists of </span><span style="font-family:inherit;font-size:10pt;"><span>62</span></span><span style="font-family:inherit;font-size:10pt;"> home health, hospice and home care agencies and </span><span style="font-family:inherit;font-size:10pt;"><span>51</span></span><span style="font-family:inherit;font-size:10pt;"> senior living communities as of June 30, 2019. Ensign affiliates will retain ownership of the real estate at </span><span style="font-family:inherit;font-size:10pt;"><span>28</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>51</span></span><span style="font-family:inherit;font-size:10pt;"> senior living operations that are being contributed to Pennant. The Company anticipates that after the Spin-Off, all of these properties will be leased to Pennant on a triple-net basis, under which Pennant affiliates will be responsible for all costs at the properties, including property taxes, insurance and maintenance and repair costs. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with Accounting Standards Codification (ASC) 505-60, Equity-Spinoffs and Reverse Spinoffs, the accounting for the separation of the Company follows its legal form, with Ensign as the legal and accounting spinnor and Pennant as the legal and accounting spinnee, due to the relative significance of Ensign’s healthcare business, the relative fair values of the respective companies, the retention of all senior management, and other relevant indicators.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the adoption of the stockholder rights plan, the Company anticipates that the board of directors will declare a dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> share of Pennant common stock for every </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock held by stockholders as of the record date. Pennant is also anticipating that awards of equity of Pennant subsidiaries granted to certain individuals will be exchanged for Pennant common stock immediately prior to the distribution. The number of shares of Ensign common stock each stockholder owns and the related proportionate interest in Ensign will not change as a result of the proposed Spin-Off. Each Ensign stockholder will receive only whole shares of Pennant common stock in the distribution, as well as cash in lieu of any fractional shares. The proposed Spin-Off is subject to customary conditions, including receipt of a tax opinion from counsel, effectiveness of the registration statement filed with the Securities and Exchange Commission, execution of third-party agreements and final approval by Ensign’s board of directors. </span></div> 2 62 51 28 51 1 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation —</span><span style="font-family:inherit;font-size:10pt;"> The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and senior living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company completed the sale of </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> of its senior living operations for a sale price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,838</span></span><span style="font-family:inherit;font-size:10pt;"> during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results. The Company presented property and equipment assets of the senior living operation sold as held for sale in the consolidated balance sheet as of December 31, 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Estimates and Assumptions —</span><span style="font-family:inherit;font-size:10pt;"> The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, intangible assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments —</span><span style="font-family:inherit;font-size:10pt;">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition — </span><span style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </span><span style="font-family:inherit;font-size:10pt;">(ASC 606) applying the modified retrospective method. The adoption of ASC 606 did not have a material impact on the measurement nor on the recognition of revenue of contracts, for which all revenue had not been recognized, as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of retained earnings at the beginning of 2018. See Note 4, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue and Accounts Receivable</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable and Allowance for Doubtful Accounts —</span><span style="font-family:inherit;font-size:10pt;"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence. See Note 4, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue and Accounts Receivable</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment —</span><span style="font-family:inherit;font-size:10pt;"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>59 years</span></span><span style="font-family:inherit;font-size:10pt;">). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets — </span><span style="font-family:inherit;font-size:10pt;">The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$705</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$860</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The Company did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t record an impairment charge during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases and Leasehold Improvements</span><span style="font-family:inherit;font-size:10pt;"> - The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases </span><span style="font-family:inherit;font-size:10pt;">(ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company estimates this rate based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term excludes lease renewals as the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably assured that the Company will exercise the extension options. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. See further discussion at Note 17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill —</span><span style="font-family:inherit;font-size:10pt;"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Trade names at affiliated facilities are amortized over </span><span style="font-family:inherit;font-size:10pt;"><span>30 years</span></span><span style="font-family:inherit;font-size:10pt;"> and customer relationships are amortized over a period of up to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t identify any goodwill or intangible assets impairment during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">. See further discussion at Note 11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Other Indefinite-Lived Intangible Assets</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Self-Insurance</span><span style="font-family:inherit;font-size:10pt;"> — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$500</span></span><span style="font-family:inherit;font-size:10pt;"> per claim, subject to an additional one-time deductible of </span><span style="font-family:inherit;font-size:10pt;"><span>$750</span></span><span style="font-family:inherit;font-size:10pt;"> for California affiliated operations and a separate, one-time, deductible of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> per claim, </span><span style="font-family:inherit;font-size:10pt;"><span>$3,000</span></span><span style="font-family:inherit;font-size:10pt;"> per operation, with a </span><span style="font-family:inherit;font-size:10pt;"><span>$5,000</span></span><span style="font-family:inherit;font-size:10pt;"> blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> per claim and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$3,000</span></span><span style="font-family:inherit;font-size:10pt;"> per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas, Washington and Wyoming for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were </span><span style="font-family:inherit;font-size:10pt;"><span>$45,106</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$42,635</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:1pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$500</span></span><span style="font-family:inherit;font-size:10pt;"> per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$750</span></span><span style="font-family:inherit;font-size:10pt;"> per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington and Wyoming, are under a loss sensitive plan that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$350</span></span><span style="font-family:inherit;font-size:10pt;"> per occurrence. In Washington and Wyoming, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas, Washington and Wyoming, the Company has purchased insurance coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$350</span></span><span style="font-family:inherit;font-size:10pt;"> per accident. In all states except Washington and Wyoming, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were </span><span style="font-family:inherit;font-size:10pt;"><span>$25,317</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24,624</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the Company has recorded an asset and equal liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$7,747</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6,969</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted and Other Assets.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$300</span></span><span style="font-family:inherit;font-size:10pt;"> for each covered person with an additional one-time aggregate individual stop loss deductible of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$75</span></span><span style="font-family:inherit;font-size:10pt;">. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of </span><span style="font-family:inherit;font-size:10pt;"><span>$75</span></span><span style="font-family:inherit;font-size:10pt;">. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was </span><span style="font-family:inherit;font-size:10pt;"><span>$6,376</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5,823</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noncontrolling Interest — </span><span style="font-family:inherit;font-size:10pt;">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Compensation — </span><span style="font-family:inherit;font-size:10pt;">The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements —</span><span style="font-family:inherit;font-size:10pt;"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB established Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted the standard as of January 1, 2019, electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings, if applicable. The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows the Company to carry forward the historical lease classification. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has made an accounting policy to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. The Company has also elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adoption of this standard resulted in recognition of right-of-use assets and lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,051,148</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,029,240</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, on its condensed consolidated balance sheets as of January 1, 2019. The Company recorded an adjustment, net of tax, of </span><span style="font-family:inherit;font-size:10pt;"><span>$9,030</span></span><span style="font-family:inherit;font-size:10pt;"> to retained earnings, on the adoption date, related to a deferred gain on a previous sale-leaseback transaction, which resulted in an increase in rent expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$658</span></span><span style="font-family:inherit;font-size:10pt;"> annually, as we are no longer able to recognize the gain in our consolidated statement of income as a result of the new lease standard. In addition, initial direct costs associated with its lease agreements and favorable lease assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$26,939</span></span><span style="font-family:inherit;font-size:10pt;"> were classified into right-of-use assets on the adoption date. The standard does not materially affect the Company's consolidated net earnings or have a notable impact on liquidity or debt-covenant compliance under the current agreements. See further discussion at Note 17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 842, the Company recognized revenue related to its senior living residency agreements in accordance with the provisions of ASC 840, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> ("ASC 840").  Subsequent to the adoption of ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of ASC 842 and the non-lease components utilizing the provisions of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with ASC 840 prior to the adoption of ASU 2016-02 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of ASC 606 subsequent to the adoption of ASU 2016-02. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of ASU 2016-02 for changes to amounts recognized for these certain components for the transition from ASC 840 to ASC 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of ASC 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of ASU 2016-02 and ASU 2018-11, the Company elected the lessor practical expedient within ASU 2018-11.  The Company recognizes revenue under these resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under ASC Topic 842 and ASC Topic 606. The Company has concluded that the non-lease components of the agreements with respect to its senior living communities are the predominant component of the contract, therefore, the Company recognizes revenue for these residents agreements under ASC Topic 606. The timing and pattern of revenue recognition is substantially the same as that prior to the adoption of these standards. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The Company adopted this guidance effective January 1, 2019. The adoption of this guidance did not have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13 “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">”, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for fiscal year beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption is permitted. The Company has not yet determined the effect of the ASU on its results of operations, financial condition or cash flows.</span></div> <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation —</span><span style="font-family:inherit;font-size:10pt;"> The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and senior living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company completed the sale of </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> of its senior living operations for a sale price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,838</span></span><span style="font-family:inherit;font-size:10pt;"> during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results. The Company presented property and equipment assets of the senior living operation sold as held for sale in the consolidated balance sheet as of December 31, 2018.</span></div> 1 1838000 <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Estimates and Assumptions —</span><span style="font-family:inherit;font-size:10pt;"> The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, intangible assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span></div> <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments —</span><span style="font-family:inherit;font-size:10pt;">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. </span></div> <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition — </span><span style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </span><span style="font-family:inherit;font-size:10pt;">(ASC 606) applying the modified retrospective method. The adoption of ASC 606 did not have a material impact on the measurement nor on the recognition of revenue of contracts, for which all revenue had not been recognized, as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of retained earnings at the beginning of 2018. See Note 4, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue and Accounts Receivable</span><span style="font-family:inherit;font-size:10pt;">. </span></div> <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable and Allowance for Doubtful Accounts —</span><span style="font-family:inherit;font-size:10pt;"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence. See Note 4, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue and Accounts Receivable</span><span style="font-family:inherit;font-size:10pt;">. </span></div> <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment —</span><span style="font-family:inherit;font-size:10pt;"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>59 years</span></span><span style="font-family:inherit;font-size:10pt;">). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets — </span><span style="font-family:inherit;font-size:10pt;">The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$705</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$860</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The Company did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t record an impairment charge during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P59Y 705000 860000 0 <div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases and Leasehold Improvements</span><span style="font-family:inherit;font-size:10pt;"> - The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases </span><span style="font-family:inherit;font-size:10pt;">(ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company estimates this rate based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term excludes lease renewals as the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably assured that the Company will exercise the extension options. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. See further discussion at Note 17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill —</span><span style="font-family:inherit;font-size:10pt;"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Trade names at affiliated facilities are amortized over </span><span style="font-family:inherit;font-size:10pt;"><span>30 years</span></span><span style="font-family:inherit;font-size:10pt;"> and customer relationships are amortized over a period of up to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t identify any goodwill or intangible assets impairment during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">. See further discussion at Note 11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Other Indefinite-Lived Intangible Assets</span><span style="font-family:inherit;font-size:10pt;">.</span></div> P30Y P20Y 0 <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Self-Insurance</span><span style="font-family:inherit;font-size:10pt;"> — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$500</span></span><span style="font-family:inherit;font-size:10pt;"> per claim, subject to an additional one-time deductible of </span><span style="font-family:inherit;font-size:10pt;"><span>$750</span></span><span style="font-family:inherit;font-size:10pt;"> for California affiliated operations and a separate, one-time, deductible of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> per claim, </span><span style="font-family:inherit;font-size:10pt;"><span>$3,000</span></span><span style="font-family:inherit;font-size:10pt;"> per operation, with a </span><span style="font-family:inherit;font-size:10pt;"><span>$5,000</span></span><span style="font-family:inherit;font-size:10pt;"> blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> per claim and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$3,000</span></span><span style="font-family:inherit;font-size:10pt;"> per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas, Washington and Wyoming for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were </span><span style="font-family:inherit;font-size:10pt;"><span>$45,106</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$42,635</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:1pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$500</span></span><span style="font-family:inherit;font-size:10pt;"> per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$750</span></span><span style="font-family:inherit;font-size:10pt;"> per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington and Wyoming, are under a loss sensitive plan that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$350</span></span><span style="font-family:inherit;font-size:10pt;"> per occurrence. In Washington and Wyoming, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas, Washington and Wyoming, the Company has purchased insurance coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$350</span></span><span style="font-family:inherit;font-size:10pt;"> per accident. In all states except Washington and Wyoming, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were </span><span style="font-family:inherit;font-size:10pt;"><span>$25,317</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24,624</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the Company has recorded an asset and equal liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$7,747</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6,969</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and December 31, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted and Other Assets.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$300</span></span><span style="font-family:inherit;font-size:10pt;"> for each covered person with an additional one-time aggregate individual stop loss deductible of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$75</span></span><span style="font-family:inherit;font-size:10pt;">. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of </span><span style="font-family:inherit;font-size:10pt;"><span>$75</span></span><span style="font-family:inherit;font-size:10pt;">. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was </span><span style="font-family:inherit;font-size:10pt;"><span>$6,376</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5,823</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.</span></div> 500000 750000 1000000 1000000 3000000 5000000 1000000 3000000 45106000 42635000 500000 750000 350000 350000 25317000 24624000 7747000 6969000 300000 75000 75000 6376000 5823000 <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Noncontrolling Interest — </span><span style="font-family:inherit;font-size:10pt;">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </span></div> <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Compensation — </span><span style="font-family:inherit;font-size:10pt;">The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span></div> <div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements —</span><span style="font-family:inherit;font-size:10pt;"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB established Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted the standard as of January 1, 2019, electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings, if applicable. The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows the Company to carry forward the historical lease classification. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has made an accounting policy to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. The Company has also elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adoption of this standard resulted in recognition of right-of-use assets and lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,051,148</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,029,240</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, on its condensed consolidated balance sheets as of January 1, 2019. The Company recorded an adjustment, net of tax, of </span><span style="font-family:inherit;font-size:10pt;"><span>$9,030</span></span><span style="font-family:inherit;font-size:10pt;"> to retained earnings, on the adoption date, related to a deferred gain on a previous sale-leaseback transaction, which resulted in an increase in rent expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$658</span></span><span style="font-family:inherit;font-size:10pt;"> annually, as we are no longer able to recognize the gain in our consolidated statement of income as a result of the new lease standard. In addition, initial direct costs associated with its lease agreements and favorable lease assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$26,939</span></span><span style="font-family:inherit;font-size:10pt;"> were classified into right-of-use assets on the adoption date. The standard does not materially affect the Company's consolidated net earnings or have a notable impact on liquidity or debt-covenant compliance under the current agreements. See further discussion at Note 17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the adoption of ASC 842, the Company recognized revenue related to its senior living residency agreements in accordance with the provisions of ASC 840, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> ("ASC 840").  Subsequent to the adoption of ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of ASC 842 and the non-lease components utilizing the provisions of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with ASC 840 prior to the adoption of ASU 2016-02 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of ASC 606 subsequent to the adoption of ASU 2016-02. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of ASU 2016-02 for changes to amounts recognized for these certain components for the transition from ASC 840 to ASC 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of ASC 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of ASU 2016-02 and ASU 2018-11, the Company elected the lessor practical expedient within ASU 2018-11.  The Company recognizes revenue under these resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under ASC Topic 842 and ASC Topic 606. The Company has concluded that the non-lease components of the agreements with respect to its senior living communities are the predominant component of the contract, therefore, the Company recognizes revenue for these residents agreements under ASC Topic 606. The timing and pattern of revenue recognition is substantially the same as that prior to the adoption of these standards. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The Company adopted this guidance effective January 1, 2019. The adoption of this guidance did not have a material impact on its consolidated financial statements and related disclosures.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13 “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">”, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for fiscal year beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption is permitted. The Company has not yet determined the effect of the ASU on its results of operations, financial condition or cash flows.</span></div> 1051148000 1029240000 9030000 658000 26939000 REVENUE AND ACCOUNTS RECEIVABLE<div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's revenue is derived primarily from providing healthcare services to its patients. Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in transitional and skilled, home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from the Medicare and Medicaid programs accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>68.0%</span></span><span style="font-family:inherit;font-size:10pt;"> the Company's revenue for both the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively and </span><span style="font-family:inherit;font-size:10pt;"><span>68.2%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>68.0%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Settlement with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue or Interim Financial Statements for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Disaggregation of Revenue</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in Note 7, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business Segments</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s service specific revenue recognition policies are as follows:</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Nursing Revenue</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Revenue</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has elected the lessor practical expedient within ASC 842, Leases ("ASC 842") and recognizes, measures, presents, and discloses the revenue for services under the Company's senior living residency agreements based upon the predominant component, either the lease or nonlease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements have the same timing and pattern of transfer. The Company recognizes revenue under ASC 606, Revenue Recognition from Contracts with Customers ("ASC 606") for its senior residency agreements for which it has estimated that the nonlease components of such residency agreements are the predominant component of the contract.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health Revenue</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Medicare Revenue</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and the Company’s estimate of the average percentage complete based on visits performed.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-Medicare Revenue</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Episodic Based Revenue -</span><span style="font-family:inherit;font-size:10pt;"> The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-episodic Based Revenue -</span><span style="font-family:inherit;font-size:10pt;"> Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Hospice Revenue</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care the Company delivers. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and increases to other accrued liabilities.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> is summarized in the following tables:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid — skilled</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Medicaid and Medicare</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,790</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>338,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other payors</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019 and 2018. </span></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of<br/>Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of<br/>Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340,794</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid — skilled</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Medicaid and Medicare</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764,964</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672,261</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other payors</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019 and 2018. </span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Balance Sheet Impact</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in the Company’s condensed consolidated balance sheet are contract assets, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, or activity during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is summarized in the following table:</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,994</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other payors</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,755</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278,985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,726</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,935</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276,099</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Practical Expedients and Exemptions</span></div><span style="font-family:inherit;font-size:10pt;">As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Assets and Deferred Costs</span>, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less. 0.680 0.682 0.680 <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> is summarized in the following tables:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid — skilled</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Medicaid and Medicare</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,790</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>338,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other payors</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019 and 2018. </span></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of<br/>Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">% of<br/>Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340,794</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid — skilled</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Medicaid and Medicare</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764,964</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672,261</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other payors</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019 and 2018. </span></div> 206811000 0.359 173169000 0.349 153187000 0.266 136813000 0.276 31792000 0.055 28298000 0.057 391790000 0.680 338280000 0.682 93690000 0.163 80150000 0.161 90171000 0.157 77956000 0.157 575651000 1.000 496386000 1.000 401814000 0.357 340794000 0.345 300907000 0.268 276127000 0.279 62243000 0.055 55340000 0.056 764964000 0.680 672261000 0.680 183538000 0.163 163866000 0.166 176363000 0.157 152393000 0.154 1124865000 1.000 988520000 1.000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is summarized in the following table:</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,994</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other payors</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,755</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278,985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,726</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296,935</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276,099</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 128069000 117984000 62605000 54682000 53232000 50994000 56755000 55325000 300661000 278985000 3726000 2886000 296935000 276099000 COMPUTATION OF NET INCOME PER COMMON SHARE<div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per share is computed by dividing income from continuing operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding for basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.54</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.87</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,733</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plus: incremental shares from assumed conversion</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,896</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:9pt;">(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were </span><span style="font-family:inherit;font-size:9pt;"><span>173</span></span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;"><span>322</span></span><span style="font-family:inherit;font-size:9pt;"> for the </span><span style="font-family:inherit;font-size:9pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:9pt;">, respectively, and </span><span style="font-family:inherit;font-size:9pt;"><span>196</span></span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;"><span>398</span></span><span style="font-family:inherit;font-size:9pt;"> for the </span><span style="font-family:inherit;font-size:9pt;">three and six months ended June 30, 2018</span>, respectively. <div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding for basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.54</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.87</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 28925000 22326000 56532000 45619000 316000 315000 551000 476000 28609000 22011000 55981000 45143000 53408000 51880000 53246000 51733000 0.54 0.42 1.05 0.87 <div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,733</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plus: incremental shares from assumed conversion</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,896</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share attributable to The Ensign Group, Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:9pt;">(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were </span><span style="font-family:inherit;font-size:9pt;"><span>173</span></span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;"><span>322</span></span><span style="font-family:inherit;font-size:9pt;"> for the </span><span style="font-family:inherit;font-size:9pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:9pt;">, respectively, and </span><span style="font-family:inherit;font-size:9pt;"><span>196</span></span><span style="font-family:inherit;font-size:9pt;"> and </span><span style="font-family:inherit;font-size:9pt;"><span>398</span></span><span style="font-family:inherit;font-size:9pt;"> for the </span><span style="font-family:inherit;font-size:9pt;">three and six months ended June 30, 2018</span>, respectively. 28925000 22326000 56532000 45619000 316000 315000 551000 476000 28609000 22011000 55981000 45143000 53408000 51880000 53246000 51733000 2670000 2371000 2650000 2176000 56078000 54251000 55896000 53909000 0.51 0.41 1.00 0.84 173000 322000 196000 398000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's non-financial assets, which includes goodwill, intangible assets and property and equipment, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. See Note 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> for further discussion of the Company's significant accounting policies.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt Security Investments - Held to Maturity</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$46,932</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$44,850</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the debt security investments were held in AA, A and BBB rated debt securities.</span></div> <div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 39042000 0 0 31083000 0 0 46932000 44850000 BUSINESS SEGMENTS<div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> reportable operating segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities; (2) senior living services, which includes the operation of assisted and independent living facilities; and (3) home health and hospice services, which includes the Company's home health, hospice and home care businesses. The Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, reviews financial information at the operating segment level.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also reports an “all other” category that includes results from its mobile diagnostics and other ancillary operations. These operations are neither significant individually nor in aggregate, and therefore do not constitute a reportable segment. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, transitional and skilled services included </span><span style="font-family:inherit;font-size:10pt;"><span>171</span></span><span style="font-family:inherit;font-size:10pt;"> wholly-owned affiliated skilled nursing operations and </span><span style="font-family:inherit;font-size:10pt;"><span>27</span></span><span style="font-family:inherit;font-size:10pt;"> campuses that provide skilled nursing and rehabilitative care services and senior living services. The Company provided room and board and social services through </span><span style="font-family:inherit;font-size:10pt;"><span>56</span></span><span style="font-family:inherit;font-size:10pt;"> wholly-owned affiliated senior living operations and </span><span style="font-family:inherit;font-size:10pt;"><span>27</span></span><span style="font-family:inherit;font-size:10pt;"> campuses as mentioned above. Home health, hospice and home care services were provided to patients through </span><span style="font-family:inherit;font-size:10pt;"><span>62</span></span><span style="font-family:inherit;font-size:10pt;"> affiliated agencies. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company held majority membership interests in other ancillary operations, which operating results are included in the "all other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. General and administrative expenses are not allocated to any segment for purposes of determining segment profit or loss, and are included in the "all other" category in the selected segment financial data that follows. The accounting policies of the reporting segments are the same as those described in Note 3</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, Summary of Significant Accounting Policies. </span><span style="font-family:inherit;font-size:10pt;">The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment revenues by major payor source were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192,545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343,144</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,333</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,313</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,790</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,713</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469,238</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298,119</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,677</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,484</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>338,280</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,956</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>408,518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2018. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,839</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>671,590</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,135</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,239</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764,964</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176,363</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>918,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,758</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340,794</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593,625</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,941</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,695</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672,261</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>815,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2018. </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth selected financial data consolidated by business segment:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,929</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,821</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30,933</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,019</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,907</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,184</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$780</span></span><span style="font-family:inherit;font-size:8pt;">. Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$6,526</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$2,149</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense are included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>408,518</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,757</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>409,163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,567</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,757</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,210</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,966</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,268</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,669</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,775</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,708</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$645</span></span><span style="font-family:inherit;font-size:8pt;">.  Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$5,623</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$1,112</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense is included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>918,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,861</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>919,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,416</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,859</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,174</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63,799</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,650</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,919</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>580</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$1,495</span></span><span style="font-family:inherit;font-size:8pt;">. Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$12,679</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines which are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$3,861</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense is included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>815,534</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,334</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,528</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>816,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,896</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,528</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,405</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,629</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,326</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,606</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,754</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,472</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$1,334</span></span><span style="font-family:inherit;font-size:8pt;">.  Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$10,992</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$2,194</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense is included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.</span></div><span style="font-family:inherit;font-size:10pt;">The Company completed the sale of </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> of its senior living operations for an aggregate sale price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,838</span></span> during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results. 3 171 27 56 27 62 <div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment revenues by major payor source were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192,545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>343,144</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,333</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,313</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,790</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93,690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,713</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,696</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469,238</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108,237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,298</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,298</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298,119</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,677</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,484</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>338,280</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,956</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>408,518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2018. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,839</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235,508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,907</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>671,590</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,135</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,239</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764,964</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176,363</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>918,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,758</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340,794</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276,127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid-skilled</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593,625</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,941</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,695</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672,261</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Managed care</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151,968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>815,534</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,702</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2018. </span></div> 192545000 10333000 3933000 0 206811000 0.359 118807000 0 34380000 0 153187000 0.266 31792000 0 0 0 31792000 0.055 343144000 10333000 38313000 0 391790000 0.680 86491000 0 7199000 0 93690000 0.163 39603000 31713000 4696000 14159000 90171000 0.157 469238000 42046000 50208000 14159000 575651000 1.000 161584000 8677000 2908000 0 173169000 0.349 108237000 0 28576000 0 136813000 0.276 28298000 0 0 0 28298000 0.057 298119000 8677000 31484000 0 338280000 0.682 74168000 0 5982000 0 80150000 0.161 36231000 28487000 3783000 9455000 77956000 0.157 408518000 37164000 41249000 9455000 496386000 1.000 373839000 20135000 7840000 0 401814000 0.357 235508000 0 65399000 0 300907000 0.268 62243000 0 0 0 62243000 0.055 671590000 20135000 73239000 0 764964000 0.680 169663000 0 13875000 0 183538000 0.163 77243000 62605000 9211000 27304000 176363000 0.157 918496000 82740000 96325000 27304000 1124865000 1.000 318095000 16941000 5758000 0 340794000 0.345 220190000 0 55937000 0 276127000 0.279 55340000 0 0 0 55340000 0.056 593625000 16941000 61695000 0 672261000 0.680 151968000 0 11898000 0 163866000 0.166 69941000 56336000 7414000 18702000 152393000 0.154 815534000 73277000 81007000 18702000 988520000 1.000 <div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth selected financial data consolidated by business segment:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,929</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,821</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30,933</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,019</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,907</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,184</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$780</span></span><span style="font-family:inherit;font-size:8pt;">. Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$6,526</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$2,149</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense are included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>408,518</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,757</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>409,163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,567</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,757</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,210</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,966</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,268</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,669</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,775</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,708</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$645</span></span><span style="font-family:inherit;font-size:8pt;">.  Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$5,623</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$1,112</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense is included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>918,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,861</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>919,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,740</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,416</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,859</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,174</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(63,799</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,650</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,919</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>580</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$1,495</span></span><span style="font-family:inherit;font-size:8pt;">. Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$12,679</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines which are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$3,861</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense is included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from external customers</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>815,534</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment revenue</span><span style="font-family:inherit;font-size:7pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,334</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,528</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>816,868</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,896</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,528</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income (loss)</span><span style="font-family:inherit;font-size:7pt;">(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,405</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,629</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,326</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46,606</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,754</span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,472</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,510</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of </span><span style="font-family:inherit;font-size:8pt;"><span>$1,334</span></span><span style="font-family:inherit;font-size:8pt;">.  Including these expenses, home health and hospice services segment income would be </span><span style="font-family:inherit;font-size:8pt;"><span>$10,992</span></span><span style="font-family:inherit;font-size:8pt;">. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of </span><span style="font-family:inherit;font-size:8pt;"><span>$2,194</span></span><span style="font-family:inherit;font-size:8pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) General and administrative expense is included in the "All Other" category. </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.</span></div> 469238000 42046000 50208000 14159000 0 575651000 780000 0 0 2149000 -2929000 0 470018000 42046000 50208000 16308000 -2929000 575651000 56652000 4821000 7306000 -30933000 0 37846000 -3369000 34477000 8938000 2019000 320000 1907000 0 13184000 780000 6526000 2149000 408518000 37164000 41249000 9455000 0 496386000 645000 0 0 1112000 -1757000 0 409163000 37164000 41249000 10567000 -1757000 496386000 43210000 4966000 6268000 -22669000 0 31775000 -3307000 28468000 7708000 1863000 281000 1769000 0 11621000 645000 5623000 1112000 918496000 82740000 96325000 27304000 0 1124865000 1495000 0 0 3861000 -5356000 0 919991000 82740000 96325000 31165000 -5356000 1124865000 115416000 9859000 14174000 -63799000 0 75650000 -6466000 69184000 17552000 3919000 580000 3731000 0 25782000 1495000 12679000 3861000 815534000 73277000 81007000 18702000 0 988520000 1334000 0 0 2194000 -3528000 0 816868000 73277000 81007000 20896000 -3528000 988520000 89405000 9629000 12326000 -46606000 0 64754000 -6472000 58282000 15510000 3460000 526000 3747000 0 23243000 1334000 10992000 2194000 1 1838000 ACQUISITIONS<div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The acquisition focus of the subsidiaries is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the accompanying Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, the affiliated operations will acquire facilities that have been operating under third-party leases.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company expanded its operations through a combination of a long-term lease and real estate purchases, with the addition of </span><span style="font-family:inherit;font-size:10pt;"><span>seven</span></span><span style="font-family:inherit;font-size:10pt;"> stand-alone skilled nursing operations, </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> stand-alone senior living operation, </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> campus operations, </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> home health agencies, </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> hospice agencies and </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> home care agencies. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of </span><span style="font-family:inherit;font-size:10pt;"><span>1,088</span></span><span style="font-family:inherit;font-size:10pt;"> operational skilled nursing beds and </span><span style="font-family:inherit;font-size:10pt;"><span>364</span></span><span style="font-family:inherit;font-size:10pt;"> operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. The aggregate purchase price for these acquisitions during the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$65,362</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of assets for </span><span style="font-family:inherit;font-size:10pt;"><span>eleven</span></span><span style="font-family:inherit;font-size:10pt;"> of the acquisitions was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions in accordance with Accounting Standards Codification Topic 805, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clarifying the Definition of a Business </span><span style="font-family:inherit;font-size:10pt;">(ASC 805). The purchase price for the </span><span style="font-family:inherit;font-size:10pt;"><span>eleven</span></span><span style="font-family:inherit;font-size:10pt;"> asset acquisitions was </span><span style="font-family:inherit;font-size:10pt;"><span>$43,176</span></span><span style="font-family:inherit;font-size:10pt;">, which mainly consisted of building and improvements of </span><span style="font-family:inherit;font-size:10pt;"><span>$33,900</span></span><span style="font-family:inherit;font-size:10pt;"> and land of </span><span style="font-family:inherit;font-size:10pt;"><span>$7,660</span></span><span style="font-family:inherit;font-size:10pt;">. The fair value of assets for the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>nine</span></span><span style="font-family:inherit;font-size:10pt;"> acquisitions was concentrated in goodwill and as such, these transactions were classified as business acquisitions in accordance with ASC 805. The purchase price for the </span><span style="font-family:inherit;font-size:10pt;"><span>nine</span></span><span style="font-family:inherit;font-size:10pt;"> business combinations was </span><span style="font-family:inherit;font-size:10pt;"><span>$22,186</span></span><span style="font-family:inherit;font-size:10pt;">, which mainly consisted of goodwill and indefinite-lived intangible assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$20,251</span></span><span style="font-family:inherit;font-size:10pt;">. The Company also entered into a note payable with the seller of </span><span style="font-family:inherit;font-size:10pt;"><span>$924</span></span><span style="font-family:inherit;font-size:10pt;">, which was subsequently paid off in the second quarter of 2019 and included in the payments on revolving credit facility and other debt line item in the consolidated statement of cash flow. As of the date of this filing, the preliminary allocation of the purchase price for the acquisitions in the second quarter was not finalized as necessary valuation information was not yet available.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, all of the fair value of the assets acquired were concentrated in property and equipment and as such, the transactions were classified as asset acquisitions in accordance with ASC 805. During the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the aggregate purchase price for those acquisitions was </span><span style="font-family:inherit;font-size:10pt;"><span>$55,546</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$31,500</span></span><span style="font-family:inherit;font-size:10pt;"> was related to an office building acquisition to accommodate its growing Service Center team. </span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The businesses acquired during the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were not material acquisitions to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These acquisitions have been included in the </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the dates the Company gained effective control.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Subsequent to </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company expanded its operations through long-term leases, with the addition of </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> stand-alone skilled nursing operation and </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> stand-alone senior living operation. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of </span><span style="font-family:inherit;font-size:10pt;"><span>27</span></span><span style="font-family:inherit;font-size:10pt;"> operational skilled nursing beds and </span><span style="font-family:inherit;font-size:10pt;"><span>91</span></span> operational senior living units to be operated by the Company's operating subsidiaries. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. 7 1 3 2 4 2 1088 364 65362000 11 11 43176000 33900000 7660000 9 9 22186000 20251000 924000 55546000 31500000 1 1 27 91 PROPERTY AND EQUIPMENT— Net<div style="line-height:120%;padding-top:13px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,081</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>411,096</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202,346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,079</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,729</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>881,251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182,731</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>674,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>618,874</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See also Note 8, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions </span><span style="font-family:inherit;font-size:10pt;">for information on acquisitions during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018.</span></div> <div style="line-height:120%;padding-top:13px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,081</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449,763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>411,096</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202,346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,079</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127,345</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,729</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>881,251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>801,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182,731</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>674,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>618,874</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 68081000 60420000 449763000 411096000 220402000 202346000 5465000 5079000 127345000 112935000 10195000 9729000 881251000 801605000 206359000 182731000 674892000 618874000 INTANGIBLE ASSETS — Net<div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:18%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease acquisition costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Favorable leases </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,724</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,926</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assembled occupancy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,936</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Facility trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(330</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(317</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>416</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,964</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$1,012</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,905</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$691</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,306</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Favorable leases and lease acquisition costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$26,939</span></span><span style="font-family:inherit;font-size:10pt;"> were reclassed to right-of-use assets as of January 1, 2019, as a part of the adoption of ASC 842. See Note 17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated amortization expense for each of the years ending December 31 is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (remainder)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,948</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:18%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease acquisition costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Favorable leases </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(316</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,724</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,926</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assembled occupancy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,936</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Facility trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(330</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(317</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>416</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,964</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P1Y8M12D 360000 240000 120000 843000 251000 592000 P2Y1M6D 534000 316000 218000 35650000 8724000 26926000 P0M12D 3180000 3056000 124000 2936000 2870000 66000 P30Y 733000 330000 403000 733000 317000 416000 P16Y8M12D 5110000 2146000 2964000 4670000 1670000 3000000 9917000 6088000 3829000 44832000 13832000 31000000 1012000 1905000 691000 1306000 26939000 <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated amortization expense for each of the years ending December 31 is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:89%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (remainder)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,948</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 567000 345000 249000 249000 237000 234000 1948000 3829000 GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of Accounting Standards Codification topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a "Step 0" analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs "Step 1" of the traditional two-step goodwill impairment test by comparing the net assets of each reporting unit to their respective fair values. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. In the event a unit's net assets exceed its fair value, an implied fair value of goodwill must be determined by assigning the unit's fair value to each asset and liability of the unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. An impairment loss is measured by the difference between the goodwill carrying value and the implied fair value. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. See further discussion of goodwill acquired at Note 8, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents activity in goodwill by segment as of and for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,477</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,931</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other indefinite-lived intangible assets consists of the following:</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare and Medicaid licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span style="font-family:inherit;font-size:10pt;">As of the date of this filing, the preliminary allocation of the purchase price for the acquisitions in the second quarter, mentioned in Note 8, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions</span>, was not finalized as necessary valuation information was not yet available. The final allocation could have an impact on the allocation of goodwill and indefinite-lived intangible assets related to these acquisitions. <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents activity in goodwill by segment as of and for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Living Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,477</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,431</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,931</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 45486000 3958000 27250000 3783000 80477000 0 0 11500000 5431000 16931000 45486000 3958000 38750000 9214000 97408000 <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other indefinite-lived intangible assets consists of the following:</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,373</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare and Medicaid licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 1373000 1217000 29549000 26385000 30922000 27602000 RESTRICTED AND OTHER ASSETS<div style="line-height:120%;padding-top:13px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted and other assets consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt issuance costs, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term insurance losses recoverable asset</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deposits with landlords</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital improvement reserves with landlords and lenders</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note receivable from sale of ancillary business</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted and other assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,844</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in restricted and other assets as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are anticipated insurance recoveries related to the Company's workers' compensation, general and professional liability claims that are recorded on a gross rather than net basis in accordance with an Accounting Standards Update issued by the FASB. Prepaid rent of </span><span style="font-family:inherit;font-size:10pt;"><span>$5,220</span></span><span style="font-family:inherit;font-size:10pt;">, previously included in deposits with landlords above, were reclassed to right-of-use assets as of January 1, 2019, as part of the adoption of ASC 842. See Note 17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:13px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted and other assets consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt issuance costs, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term insurance losses recoverable asset</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deposits with landlords</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital improvement reserves with landlords and lenders</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note receivable from sale of ancillary business</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted and other assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,844</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1442000 1892000 7747000 6969000 4148000 8694000 3535000 3196000 71000 93000 16943000 20844000 5220000 OTHER ACCRUED LIABILITIES<div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities consist of the following:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.71014492753623%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Quality assurance fee</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,375</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refunds payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,477</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Resident advances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash held in trust for patients</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,842</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Resident deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying condensed consolidated balance sheets. <div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities consist of the following:</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.71014492753623%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Quality assurance fee</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,639</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,375</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refunds payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,477</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Resident advances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash held in trust for patients</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,842</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Resident deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5639000 5375000 27477000 25118000 4607000 8495000 2842000 2824000 7753000 6665000 2559000 2525000 7669000 9426000 11270000 9356000 69816000 69784000 INCOME TAXES<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded income tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$12,652</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12,663</span></span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, or </span><span style="font-family:inherit;font-size:10pt;"><span>18.3%</span></span><span style="font-family:inherit;font-size:10pt;"> of earnings before income taxes for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;"><span>21.7%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The effective tax rate for both six month periods include excess tax benefits from stock-based compensation which were offset by non-deductible expenses including non-deductible compensation. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The Company is not currently under examination by any major income tax jurisdiction. During 2019, the statutes of limitations will lapse on the Company's 2015 Federal tax year and certain 2014 and 2015 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company implemented ASC 842 as described in the Summary of Significant Accounting Policies. The new lease standard reduced net deferred assets by </span><span style="font-family:inherit;font-size:10pt;"><span>$3,044</span></span>, which is reflected in retained earnings as day one accounting change adjustment. 12652000 12663000 0.183 0.217 3044000 DEBT<div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt consists of the following:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term loan with SunTrust</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving credit facility with SunTrust</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mortgage loans and promissory note</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,039</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,080</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,707</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>233,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Facility with a Lending Consortium Arranged by SunTrust </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains a credit facility with a lending consortium arranged by SunTrust (as amended to date, the Credit Facility). The Company originally entered into the Credit Facility in an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$150,000</span></span><span style="font-family:inherit;font-size:10pt;"> in May 2014. Under the Credit Facility, the Company could seek to obtain incremental revolving or term loans in an aggregate amount not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$75,000</span></span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 5, 2016, the Company amended its existing revolving credit facility to increase its aggregate principal amount available to </span><span style="font-family:inherit;font-size:10pt;"><span>$250,000</span></span><span style="font-family:inherit;font-size:10pt;"> (the Amended Credit Facility). Under the credit facility, the Company may seek to obtain incremental revolving or term loans in an aggregate amount not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$150,000</span></span><span style="font-family:inherit;font-size:10pt;">. The interest rates applicable to loans under the credit facility are, at the Company's option, equal to either a base rate plus a margin ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum or LIBOR plus a margin ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>2.75%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company pays a commitment fee on the unused portion of the commitments under the credit facility that will range from </span><span style="font-family:inherit;font-size:10pt;"><span>0.30%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.50%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is permitted to prepay all or any portion of the loans under the credit facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 19, 2016, the Company entered into the second amendment to the credit facility (Second Amended Credit Facility), which amended the existing credit agreement to increase the aggregate principal amount up to </span><span style="font-family:inherit;font-size:10pt;"><span>$450,000</span></span><span style="font-family:inherit;font-size:10pt;">. The Second Amended Credit Facility is comprised of a </span><span style="font-family:inherit;font-size:10pt;"><span>$300,000</span></span><span style="font-family:inherit;font-size:10pt;"> revolving credit facility and a </span><span style="font-family:inherit;font-size:10pt;"><span>$150,000</span></span><span style="font-family:inherit;font-size:10pt;"> term loan. Borrowings under the term loan portion of the Second Amended Credit Facility mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>5.00%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum of the original principal amount. The interest rates and commitment fee applicable to the Second Amended Credit Facility are similar to the Amended Credit Facility discussed below. Except as set forth in the Second Amended Credit Facility, all other terms and conditions of the Amended Credit Facility remained in full force and effect as described below.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The credit facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to consolidated EBITDA ratio (which shall be increased to </span><span style="font-family:inherit;font-size:10pt;"><span>3.50</span></span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span><span style="font-family:inherit;font-size:10pt;"> for the first fiscal quarter and the immediate following </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> fiscal quarters), and a minimum interest/rent coverage ratio (which cannot be below </span><span style="font-family:inherit;font-size:10pt;"><span>1.50</span></span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span><span style="font-family:inherit;font-size:10pt;">). The majority of lenders can require that the Company and its operating subsidiaries mortgage certain of its real property assets to secure the Amended Credit Facility if an event of default occurs, the Consolidated Total Net Debt to consolidated EBITDA ratio is above </span><span style="font-family:inherit;font-size:10pt;"><span>2.75</span></span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> consecutive fiscal quarters, or its liquidity is equal or less than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Aggregate Revolving Commitment Amount (as defined in the agreement) for </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;"> consecutive business days, provided that such mortgages will no longer be required if the event of default is cured, the Consolidated Total Net Debt to consolidated EBITDA ratio is below </span><span style="font-family:inherit;font-size:10pt;"><span>2.75</span></span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;"><span>1.00</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> consecutive fiscal quarters, or its liquidity is above </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Aggregate Revolving Commitment Amount (as defined in the agreement) or </span><span style="font-family:inherit;font-size:10pt;">ninety</span><span style="font-family:inherit;font-size:10pt;"> consecutive days, as applicable. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company's operating subsidiaries had </span><span style="font-family:inherit;font-size:10pt;"><span>$159,375</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under the Credit Facility. The outstanding balance on the term loan was </span><span style="font-family:inherit;font-size:10pt;"><span>$109,375</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$7,500</span></span><span style="font-family:inherit;font-size:10pt;"> is classified as short-term and the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$101,875</span></span><span style="font-family:inherit;font-size:10pt;"> is classified as long-term. The outstanding balance on the revolving Credit Facility was </span><span style="font-family:inherit;font-size:10pt;"><span>$50,000</span></span><span style="font-family:inherit;font-size:10pt;">, which is classified as long-term. The Company was in compliance with all loan covenants as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">July 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$111,250</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under the Revolving Credit Facility.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Mortgage Loans and Promissory Note</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>17</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's subsidiaries entered into mortgage loans in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$112,000</span></span><span style="font-family:inherit;font-size:10pt;">. The mortgage loans are insured with Department of Housing and Urban Development (HUD), which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans and note bear fixed interest rates of </span><span style="font-family:inherit;font-size:10pt;"><span>3.3%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. During the first three years, the prepayment fee is </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> and is reduced by </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> in the fourth year of the loan, and reduced by </span><span style="font-family:inherit;font-size:10pt;"><span>1.0%</span></span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">per year for years </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;"> of the loan. There is no prepayment penalty after year </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;">. The terms of the mortgage loans are </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>35 years</span></span><span style="font-family:inherit;font-size:10pt;">. The borrowings were arranged by Lancaster Pollard Mortgage Company, LLC, and insured by HUD. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, to renovate and upgrade existing and future facilities, to cover working capital needs and for other business purposes.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the HUD mortgage loans above, the Company had outstanding indebtedness under mortgage loans insured with HUD and a promissory note issued in connection with various acquisitions. These mortgage loans and note bear fixed interest rates between </span><span style="font-family:inherit;font-size:10pt;"><span>2.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>5.3%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum. Amounts borrowed under the mortgage loans may be prepaid starting after the second anniversary of the notes subject to prepayment fees of the principal balance on the date of prepayment. These prepayment fees are reduced by </span><span style="font-family:inherit;font-size:10pt;"><span>1.0%</span></span><span style="font-family:inherit;font-size:10pt;"> per year for years </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;"> of the loan. There is no prepayment penalty after year </span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;">. The term of the mortgage loans and the note is between </span><span style="font-family:inherit;font-size:10pt;">12</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>33 years</span></span><span style="font-family:inherit;font-size:10pt;">. The mortgage loans and note are secured by the real property comprising the facilities and the rents, issues and profits thereof, as well as all personal property used in the operation of the facilities. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company's operating subsidiaries had </span><span style="font-family:inherit;font-size:10pt;"><span>$121,664</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under the mortgage loans and note, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$2,653</span></span><span style="font-family:inherit;font-size:10pt;"> is classified as short-term and the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$119,011</span></span><span style="font-family:inherit;font-size:10pt;"> is classified as long-term. The Company was in compliance with all loan covenants as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company increased its outstanding letters of credit by </span><span style="font-family:inherit;font-size:10pt;"><span>$560</span></span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">As of June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5,342</span></span> on the credit facility of borrowing capacity pledged as collateral to secure outstanding letters of credit. <div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt consists of the following:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term loan with SunTrust</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving credit facility with SunTrust</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mortgage loans and promissory note</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281,039</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,080</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,707</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>233,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 109375000 113125000 50000000 10000000 121664000 122955000 281039000 246080000 10153000 10105000 2707000 2840000 268179000 233135000 150000000 75000000 250000000 150000000 0.0075 0.0175 0.0175 0.0275 0.0030 0.0050 450000000 300000000 150000000 0.0500 3.50 1.00 1.50 1.00 2.75 1.00 0.10 2.75 1.00 0.10 159375000 109375000 7500000 101875000 50000000 111250000 17 112000000 0.033 0.10 0.03 0.010 P35Y 0.026 0.053 0.010 P33Y 121664000 2653000 119011000 560000 5342000 OPTIONS AND AWARDS<div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense consists of share-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Omnibus Incentive Plan</span><span style="font-family:inherit;font-size:10pt;"> - The Company has </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> active stock incentive plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The 2017 Plan provides for the issuance of </span><span style="font-family:inherit;font-size:10pt;"><span>6,881</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. The number of shares available to be issued under the 2017 Plan will be reduced by (i) </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> share for each share that relates to an option or stock appreciation right award and (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span><span style="font-family:inherit;font-size:10pt;"> shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> equal annual installments, or the length of the term if less than </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;">, on the completion of each year of service measured from the grant date. All other options generally vest over </span><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> per year on the anniversary of the grant date. Options expire </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of grant. At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>3,908</span></span><span style="font-family:inherit;font-size:10pt;"> unissued shares of common stock available for issuance under this plan. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for all share-based payment awards. Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the grant date requires considerable judgment, including estimating stock price volatility, expected option life and forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>399</span></span><span style="font-family:inherit;font-size:10pt;"> options and </span><span style="font-family:inherit;font-size:10pt;"><span>194</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards from the 2017 Plan during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company used the following assumptions for stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Risk-Free Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Dividend Yield</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company used the following assumptions for stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Risk-Free Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Dividend Yield</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.9%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Fair Value of Options</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> and therefore, the intrinsic value was </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;"> at the date of grant. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the employee stock option activity during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">of Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,188</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(531</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summary information reflects stock options outstanding, vested and related details as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:2%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="12" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Vested</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Black-Scholes Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Remaining Contractual Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested and Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year of Grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2009</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$4.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$4.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.77</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.96</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2011</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2012</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.56</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.96</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2013</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.55</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.94</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.79</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.89</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.59</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$53.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$53.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,724</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Awards</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>89</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>194</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>217</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>274</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards during the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. All awards were granted at an issued price of </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;"> and generally vest over </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. The fair value per share of restricted awards granted during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> ranged from </span><span style="font-family:inherit;font-size:10pt;"><span>$41.68</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$53.99</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$23.61</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$36.61</span></span><span style="font-family:inherit;font-size:10pt;"> respectively. The fair value per share includes quarterly stock awards to non-employee directors. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's non-vested restricted stock awards as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>596</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>8</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards ranged from </span><span style="font-family:inherit;font-size:10pt;"><span>$41.68</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$51.78</span></span><span style="font-family:inherit;font-size:10pt;"> based on the market price on the grant date. </span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense recognized for the Company's equity incentive plans for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,508</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to restricted stock awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,177</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,678</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In future periods, the Company expects to recognize approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$17,760</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$18,860</span></span><span style="font-family:inherit;font-size:10pt;"> in share-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Future share-based compensation expense will be recognized over </span><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span><span style="font-family:inherit;font-size:10pt;"> weighted average years for both unvested options and restricted stock awards. There were </span><span style="font-family:inherit;font-size:10pt;"><span>1,622</span></span><span style="font-family:inherit;font-size:10pt;"> unvested and outstanding options at </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>1,517</span></span><span style="font-family:inherit;font-size:10pt;"> are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest at </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>6.1</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,806</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Instrument Denominated in the Shares of a Subsidiary</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 26, 2016, the Company implemented a management equity plan and granted stock options and restricted stock awards of a subsidiary of the Company to employees and management of that subsidiary (Subsidiary Equity Plan). The Company did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t grant any new restricted shares during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">. These awards generally vest over a period of </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, or upon the occurrence of certain prescribed events. During both the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>976</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards vested. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>221</span></span><span style="font-family:inherit;font-size:10pt;"> stock options during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The Company did </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;">t grant any new stock options during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The value of the stock options and restricted stock awards is tied to the value of the common stock of the subsidiary. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. </span></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant-date fair value of the awards is recognized as compensation expense over the relevant vesting periods, with a corresponding adjustment to noncontrolling interests. The grant value was determined based on an independent valuation of the subsidiary shares. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company expensed </span><span style="font-family:inherit;font-size:10pt;"><span>$236</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$577</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in share-based compensation related to the Subsidiary Equity Plan. For the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company expensed </span><span style="font-family:inherit;font-size:10pt;"><span>$343</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$681</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in share-based compensation related to the Subsidiary Equity Plan. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate number of the Company's common shares that would be required to settle these awards at current estimated fair values, including vested and unvested awards, at </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>328</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>235</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, the Company repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>469</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock under the Subsidiary Equity Plan for </span><span style="font-family:inherit;font-size:10pt;"><span>$2,293</span></span><span style="font-family:inherit;font-size:10pt;">. The Company subsequently sold the shares and received net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$2,293</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div> 1 6881000 1 2.5 3 P3Y P5Y 0.20 P10Y 3908000 399000 194000 <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company used the following assumptions for stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Risk-Free Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Dividend Yield</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company used the following assumptions for stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Risk-Free Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Dividend Yield</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.9%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 258000 0.021 P6Y3M18D 0.340 0.004 227000 0.027 P6Y2M12D 0.320 0.005 399000 0.022 P6Y3M18D 0.339 0.003 395000 0.027 P6Y2M12D 0.320 0.006 <div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;">, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Fair Value of Options</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 399000 53.67 19.35 395000 32.33 11.15 0 <div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table represents the employee stock option activity during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">of Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,188</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(531</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4188000 17.35 2431000 12.37 399000 53.67 27000 26.16 531000 10.45 4029000 21.80 2407000 13.88 <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summary information reflects stock options outstanding, vested and related details as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:2%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="12" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Vested</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Black-Scholes Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Remaining Contractual Life (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested and Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year of Grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2009</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$4.06</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$4.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.77</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.96</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2011</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2012</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.56</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.96</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2013</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.55</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.94</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.79</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.89</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.59</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$53.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$53.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,724</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4.06 4.56 40000 83000 P0Y 40000 4.77 4.96 50000 122000 P1Y 50000 5.90 7.99 80000 274000 P2Y 80000 6.56 7.96 217000 797000 P3Y 217000 7.98 11.49 355000 1712000 P4Y 355000 10.55 18.94 1049000 5953000 P5Y 1025000 21.47 25.24 431000 3926000 P6Y 272000 18.79 19.89 381000 2652000 P7Y 180000 18.64 22.90 420000 2931000 P8Y 118000 26.53 38.59 607000 7346000 P9Y 70000 53.50 53.99 399000 7724000 P10Y 0 4029000 33520000 2407000 89000 194000 217000 274000 0 P5Y 41.68 53.99 23.61 36.61 <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's non-vested restricted stock awards as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>596</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 573000 29.31 194000 52.16 166000 38.79 5000 28.67 596000 34.13 8000 14000 41.68 51.78 <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense recognized for the Company's equity incentive plans for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019 and 2018</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,822</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,508</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to restricted stock awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,177</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,678</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1479000 1292000 2822000 2508000 1199000 675000 2197000 1253000 388000 210000 659000 387000 3066000 2177000 5678000 4148000 17760000 18860000 P3Y10M24D 1622000 1517000 P6Y1M6D <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,806</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103,589</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 141531000 89806000 103589000 64222000 32597000 22963000 21118000 27646000 0 P5Y 976000 221000 0 236000 577000 343000 681000 328000 235000 469000 2293000 2293000 LEASES<div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with </span><span style="font-family:inherit;font-size:10pt;"><span>93</span></span><span style="font-family:inherit;font-size:10pt;"> affiliated skilled nursing, senior living facilities used in the Company’s operations under </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from </span><span style="font-family:inherit;font-size:10pt;">12</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;">. At the Company’s option, the Master Leases may be extended for </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commencing the third year, the rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;">. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Total rent expense under the Master Leases was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$15,057</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$29,896</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$14,538</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$28,956</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is not aware of any defaults as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is </span><span style="font-family:inherit;font-size:10pt;">15 years</span><span style="font-family:inherit;font-size:10pt;"> with </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense, inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was </span><span style="font-family:inherit;font-size:10pt;"><span>$37,211</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$73,181</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$34,476</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$68,640</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>Thirty-nine</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under </span><span style="font-family:inherit;font-size:10pt;"><span>seven</span></span><span style="font-family:inherit;font-size:10pt;"> separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impact of New Leases Guidance </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described further in Note 3, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;">, the Company adopted Topic 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, as of January 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under Topic 840. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All of the Company's leases are classified as operating leases. The components of lease assets and liabilities are included in the condensed consolidated balance sheets. The following tables summarize the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the condensed consolidated statement of income for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, as if the previous accounting guidance was in effect for comparison purposes. There was no impact to the condensed consolidated statement of cash flows for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments due to new lease guidance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,181,958</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,015,937</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,321,521</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>579,618</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,006,907</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,586,525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,644,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>611,370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>677,307</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Adjustment in assets includes the reclassification of intangible assets, prepaid rent and deferred rent into right-of-use assets and the decrease in deferred tax assets due to the removal of deferred gain related to sale-leaseback as of January 1, 2019.</span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Adjustment in liabilities includes the reclassification of other liabilities into lease liabilities and the removal of deferred gain related to sale-lease back as of January 1, 2019.</span></div><div style="line-height:120%;padding-top:13px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of operating lease expense</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">, are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent - cost of services</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:8pt;">(1) Operating lease expenses include short-term leases and variable lease costs, which are immaterial.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Rent- cost of services includes the amortization of deferred rent of </span><span style="font-family:inherit;font-size:8pt;"><span>$434</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$688</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:8pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments for all leases as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (remainder)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,865</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,083</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>912,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719,234</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: present value adjustment </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(646,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: variable rent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of total lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,047,831</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,686</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments for all leases as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,349</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,667,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span>12 years</span></span><span style="font-family:inherit;font-size:10pt;"> and the weighted average discount rate used to determine the operating lease liability is </span><span style="font-family:inherit;font-size:10pt;"><span>8.66%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div> 93 8 P20Y 2 3 0.025 15057000 29896000 14538000 28956000 P20Y 2 P5Y 37211000 73181000 34476000 68640000 39 7 <div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments due to new lease guidance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,181,958</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,015,937</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,197,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,321,521</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>579,618</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,006,907</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,586,525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,644,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>611,370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>677,307</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Adjustment in assets includes the reclassification of intangible assets, prepaid rent and deferred rent into right-of-use assets and the decrease in deferred tax assets due to the removal of deferred gain related to sale-leaseback as of January 1, 2019.</span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Adjustment in liabilities includes the reclassification of other liabilities into lease liabilities and the removal of deferred gain related to sale-lease back as of January 1, 2019.</span></div> 1181958000 1015937000 2197895000 2321521000 579618000 1006907000 1586525000 1644214000 602340000 9030000 611370000 677307000 <div style="line-height:120%;padding-top:13px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of operating lease expense</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span><span style="font-family:inherit;font-size:10pt;">, are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent - cost of services</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:8pt;">(1) Operating lease expenses include short-term leases and variable lease costs, which are immaterial.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) Rent- cost of services includes the amortization of deferred rent of </span><span style="font-family:inherit;font-size:8pt;"><span>$434</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$688</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:8pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(3) Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div> 37060000 34472000 72846000 68322000 151000 168000 335000 318000 495000 495000 990000 990000 37706000 35135000 74171000 69630000 434000 688000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments for all leases as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (remainder)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,865</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149,083</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>912,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719,234</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: present value adjustment </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(646,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: variable rent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of total lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,047,831</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,686</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments for all leases as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,536</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,349</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,667,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 74865000 149083000 148086000 146540000 144852000 142880000 912928000 1719234000 646138000 25265000 1047831000 59686000 988145000 142497000 141536000 140524000 139018000 137349000 967027000 1667951000 P12Y 0.0866 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Regulatory Matters —</span><span style="font-family:inherit;font-size:10pt;"> Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information. In late December of 2016, the Company learned of a potential issue at one of its independent operating entities in Arizona which involved the limited and inadvertent disclosure of certain confidential information. The issue has been internally investigated, addressed and disclosed as is required by law. The Company believes that it is presently in compliance in all material respects with applicable HIPAA laws and regulations. As of June 30, 2019, this matter has been resolved. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost-Containment Measures —</span><span style="font-family:inherit;font-size:10pt;"> Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Indemnities —</span><span style="font-family:inherit;font-size:10pt;"> From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer by the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Department of Justice Civil Investigative Demand - </span><span style="font-family:inherit;font-size:10pt;">On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether the Company has violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of the Company’s independently operated skilled nursing facilities and persons who served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 to the present, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 to the present, relating to the same topic. As a general matter, the Company’s independent operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company is fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information. However, the Company cannot predict when the investigation will be resolved, the outcome of the investigation, or its potential impact on the Company.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation —</span><span style="font-family:inherit;font-size:10pt;"> The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act (FCA) and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of minimum staffing requirements for skilled nursing facilities in those states which have enacted such requirements. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with the requirements of participation under certain state and federal healthcare programs; it may also subject the facility to a deficiency, a citation, a civil money penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its independent operating subsidiaries have in the past been subject to class action litigation involving claims of alleged violations of regulatory requirements related to staffing. While the Company has been able to settle these claims without a material ongoing adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. For example, the Company has been subjected to, and is currently involved in, class action litigation alleging violations of state and federal wage and hour law as related to the alleged failure to pay wages and to timely provide and authorize meal and rest breaks. The Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s business, cash flows, financial condition or results of operations. A significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment, as well as employment related claims. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In August of 2011, the Company was named as a Defendant in a class action litigation alleging violations of state and federal wage and hour law. In January of 2017, the Company participated in an initial mediation session with plaintiffs' counsel. As a result of this discussion and due to (i) the fact no class had been certified (ii) the lack of specificity as to legal theories put forth by the plaintiffs (iii) the nature of the remedies sought and (iv) the lack of any basis on which to compute estimated compensatory and/or exemplary damages, the Company could not predict what the outcome of the pending class action lawsuit would be, what the timing of the ultimate resolution of this lawsuit would be, or an estimate and/or range of possible loss related to it. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March of 2017, the Company was invited to engage in further settlement discussions to determine whether a resolution of the case was possible in advance of a decision on class certification. In April of 2017, the Company reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court.  Based upon the change in case status, the Company recorded an accrual for estimated probable losses of </span><span style="font-family:inherit;font-size:10pt;"><span>$11,000</span></span><span style="font-family:inherit;font-size:10pt;">, exclusive of legal fees, in the first quarter of 2017. The Company funded the settlement amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$11,000</span></span><span style="font-family:inherit;font-size:10pt;"> in December of 2017, and the funds were distributed to the class members in the first quarter of 2018. The Company received back </span><span style="font-family:inherit;font-size:10pt;"><span>$1,664</span></span><span style="font-family:inherit;font-size:10pt;"> related to unclaimed class settlement funds remaining after completion of the settlement process, and the recoveries were recorded in the first quarter of 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other claims and suits continue to be filed against the Company, its independent operating entities, and other post-acute care providers. In addition, professional negligence claims have been filed and will likely continue to be filed against the Company's independent operating entities by residents or responsible parties.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:28px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any litigation were to proceed through trial, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar State and Federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its subsidiaries going forward under a corporate integrity agreement and/or other arrangements.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Revenue Recoupments —</span><span style="font-family:inherit;font-size:10pt;"> The Company's independent operating entities are subject to regulatory reviews relating to Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC), Unified Program Integrity Contractors (UPIC) and Medicaid Integrity Contributors (MIC) programs collectively referred to as Reviews. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>ten</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process, both pre- and post-payment. The Company anticipates that these Reviews will increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company's independent operating subsidiaries have responded to the requests and the related claims are currently under Review, on appeal or in a dispute resolution process. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Government Inquiry and Corporate Integrity Agreement —</span><span style="font-family:inherit;font-size:10pt;"> In October 2013, the Company and its independent operating entities completed and executed a settlement agreement (the Settlement Agreement) with the DOJ, which received the final approval of the Office of Inspector General-HHS and the United States District Court for the Central District of California. Pursuant to the Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$48,000</span></span><span style="font-family:inherit;font-size:10pt;"> in October 2013. The Company and its independent operating entities have denied engaging in any illegal conduct and agreed to the settlement amount without any admission of wrongdoing in order to resolve the allegations and to avoid the uncertainty and expense of protracted litigation.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the settlement and effective as of October 1, 2013, the Company and its independent operating entities entered into a five-year corporate integrity agreement (the CIA) with the Office of Inspector General-HHS. CMS acknowledged the existence of the Company’s current compliance program, which is in accord with the Office of the Inspector General (OIG)’s guidance related to an effective compliance program, and required that the Company and its independent operating entities continue during the term of the CIA to maintain a program designed to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs. </span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2019, the Company received notice from the OIG that the Company’s five-year CIA with the OIG has been completed. Upon receipt of the Company’s fifth and final annual report, the OIG confirmed that the term of the CIA is concluded. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Credit Risk</span><span style="font-family:inherit;font-size:10pt;"> — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>60.3%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>60.6%</span></span><span style="font-family:inherit;font-size:10pt;"> of its total accounts receivable as of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>68.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's revenue for both the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>68.2%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>68.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's revenue for the </span><span style="font-family:inherit;font-size:10pt;">three and six months ended June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash in Excess of FDIC Limits</span><span style="font-family:inherit;font-size:10pt;"> — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to </span><span style="font-family:inherit;font-size:10pt;"><span>$250</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of </span><span style="font-family:inherit;font-size:10pt;">July 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,066</span></span><span style="font-family:inherit;font-size:10pt;"> in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.</span></div> 11000000 11000000 1664000 10 48000000 0.603 0.606 0.680 0.682 0.680 250000 1066000 COMMON STOCK <div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As approved by the Board of Directors on April 3, 2018, the Company entered into a stock repurchase program pursuant to which the Company may repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$30,000</span></span><span style="font-family:inherit;font-size:10pt;"> of its common stock under the program for a period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11 months</span></span><span style="font-family:inherit;font-size:10pt;">. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The stock repurchase program expired on </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">February 20, 2019</span></span></span><span style="font-family:inherit;font-size:10pt;">. The Company did not purchase any shares pursuant to this stock repurchase program.</span></div> 30000000 P11Y 2019-02-20 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Cover Page - shares
6 Months Ended
Jun. 30, 2019
Jul. 31, 2019
Entity Information [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2019  
Document Transition Report false  
Entity File Number 001-33757  
Entity Registrant Name ENSIGN GROUP, INC  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 33-0861263  
Entity Address, Address Line One 29222 Rancho Viejo Road, Suite 127  
Entity Address, City or Town San Juan Capistrano  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92675  
City Area Code 949  
Local Phone Number 487-9500  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol ENSG  
Security Exchange Name NASDAQ  
Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   53,386,352
Entity Central Index Key 0001125376  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 39,042 $ 31,083
Accounts receivable—less allowance for doubtful accounts of $3,726 and $2,886 at June 30, 2019 and December 31, 2018, respectively 296,935 276,099
Investments—current 8,003 8,682
Prepaid income taxes 5,934 6,219
Prepaid expenses and other current assets 25,632 24,130
Assets held for sale - current 0 1,859
Total current assets 375,546 348,072
Property and equipment, net 674,892 618,874
Right-of-use assets (Note 17) 1,074,449 0
Insurance subsidiary deposits and investments 38,929 36,168
Escrow deposits 0 7,271
Deferred tax assets 8,603 11,650
Restricted and other assets (Note 17) 16,943 20,844
Intangible assets, net (Note 17) 3,829 31,000
Goodwill 97,408 80,477
Other indefinite-lived intangibles 30,922 27,602
Total assets 2,321,521 1,181,958
Current liabilities:    
Accounts payable 44,694 44,236
Accrued wages and related liabilities 116,018 119,656
Lease liabilities—current (Note 17) 59,686 0
Accrued self-insurance liabilities—current 26,981 25,446
Other accrued liabilities 69,816 69,784
Current maturities of long-term debt 10,153 10,105
Total current liabilities 327,348 269,227
Long-term debt—less current maturities 268,179 233,135
Long-term lease liabilities—less current portion (Note 17) 988,145 0
Accrued self-insurance liabilities—less current portion 57,565 54,605
Other long-term liabilities 2,977 11,234
Deferred gain related to sale-leaseback (Note 17) 0 11,417
Total liabilities 1,644,214 579,618
Commitments and contingencies (Notes 15, 17 and 18)
Equity:    
Common stock; $0.001 par value; 100,000 shares authorized; 55,809 and 53,272 shares issued and outstanding at June 30, 2019, respectively, and 55,089 and 52,584 shares issued and outstanding at December 31, 2018, respectively 55 55
Additional paid-in capital 298,891 284,384
Retained earnings 401,996 344,901
Common stock in treasury, at cost, 1,941 and 1,932 shares at June 30, 2019 and December 31, 2018, respectively (38,890) (38,405)
Total Ensign Group, Inc. stockholders' equity 662,052 590,935
Non-controlling interest 15,255 11,405
Total equity 677,307 602,340
Total liabilities and equity $ 2,321,521 $ 1,181,958
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Balance Sheets Balance Sheet (Paranthetical) - USD ($)
shares in Thousands, $ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Allowance for doubtful accounts $ 3,726 $ 2,886
Equity:    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000 75,000
Common stock, shares issued 55,809 55,089
Common stock, shares outstanding 53,272 52,584
Common stock in treasury, at cost 1,941 1,932
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue $ 575,651 $ 496,386 $ 1,124,865 $ 988,520
Expense        
Cost of services 457,000 396,132 887,002 786,375
Return of unclaimed class action settlement (Note 18) 0 0 0 (1,664)
Rent—cost of services (Note 17) 37,060 34,472 72,846 68,322
General and administrative expense 30,561 22,386 63,585 47,490
Depreciation and amortization 13,184 11,621 25,782 23,243
Total expenses 537,805 464,611 1,049,215 923,766
Income from operations 37,846 31,775 75,650 64,754
Other income (expense):        
Interest expense (3,941) (3,869) (7,613) (7,482)
Interest income 572 562 1,147 1,010
Other expense, net (3,369) (3,307) (6,466) (6,472)
Income before provision for income taxes 34,477 28,468 69,184 58,282
Provision for income taxes 5,552 6,142 12,652 12,663
Net income 28,925 22,326 56,532 45,619
Less: net income attributable to noncontrolling interests 316 315 551 476
Net income attributable to The Ensign Group, Inc. $ 28,609 $ 22,011 $ 55,981 $ 45,143
Basic:        
Basic net income per common share attributable to The Ensign Group, Inc. $ 0.54 $ 0.42 $ 1.05 $ 0.87
Diluted:        
Diluted net income per common share attributable to The Ensign Group, Inc. $ 0.51 $ 0.41 $ 1.00 $ 0.84
Weighted average common shares outstanding:        
Basic 53,408 51,880 53,246 51,733
Diluted 56,078 54,251 55,896 53,909
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statement of Stockholders' Equity Statement - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock [Member]
Noncontrolling Interest [Member]
Balance - January 1, at Dec. 31, 2017 $ 500,059 $ 53 $ 266,058 $ 264,691 $ (38,405) $ 7,662
Balance - January 1 (in shares) at Dec. 31, 2017   51,360        
Balance - January 1 (in treasury shares) at Dec. 31, 2017         1,932  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   404     0  
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards 2,920 $ 1 2,919   $ 0  
Dividends declared (2,346)     (2,346)    
Employee stock award compensation 1,971   1,971      
Noncontrolling interest attributable to subsidiary equity plan (Note 16) 338     (79)   417
Distribution to noncontrolling interest holder (292)         (292)
Net income attributable to noncontrolling interest 161         161
Net Income (Loss) Attributable to the Ensign Group, Inc. 23,132     23,132    
Balance - June 30, at Mar. 31, 2018 525,943 $ 54 270,948 285,398 $ (38,405) 7,948
Balance - June 30 (in shares) at Mar. 31, 2018   51,764        
Balance - June 30 (in treasury shares) at Mar. 31, 2018         1,932  
Balance - January 1, at Dec. 31, 2017 500,059 $ 53 266,058 264,691 $ (38,405) 7,662
Balance - January 1 (in shares) at Dec. 31, 2017   51,360        
Balance - January 1 (in treasury shares) at Dec. 31, 2017         1,932  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Repurchase of shares of common stock to satisfy tax withholding obligations 0          
Dividends declared (2,367)          
Employee stock award compensation 4,148          
Net income attributable to noncontrolling interest 476          
Net Income (Loss) Attributable to the Ensign Group, Inc. 45,143          
Balance - June 30, at Jun. 30, 2018 550,279 $ 54 274,982 303,157 $ (38,405) 10,491
Balance - June 30 (in shares) at Jun. 30, 2018   52,033        
Balance - June 30 (in treasury shares) at Jun. 30, 2018         1,932  
Balance - January 1, at Mar. 31, 2018 525,943 $ 54 270,948 285,398 $ (38,405) 7,948
Balance - January 1 (in shares) at Mar. 31, 2018   51,764        
Balance - January 1 (in treasury shares) at Mar. 31, 2018         1,932  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   269     0  
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards 1,857 $ 0 1,857   $ 0  
Dividends declared (2,367)     (2,367)    
Employee stock award compensation 2,177   2,177      
Noncontrolling interest attributable to subsidiary equity plan (Note 16) 343     (1,885)   2,228
Net income attributable to noncontrolling interest 315         315
Net Income (Loss) Attributable to the Ensign Group, Inc. 22,011     22,011    
Balance - June 30, at Jun. 30, 2018 550,279 $ 54 274,982 303,157 $ (38,405) 10,491
Balance - June 30 (in shares) at Jun. 30, 2018   52,033        
Balance - June 30 (in treasury shares) at Jun. 30, 2018         1,932  
Balance - January 1, at Dec. 31, 2018 $ 602,340 $ 55 284,384 344,901 $ (38,405) 11,405
Balance - January 1 (in shares) at Dec. 31, 2018 52,584 52,584        
Balance - January 1 (in treasury shares) at Dec. 31, 2018         1,932  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   371     0  
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards $ 5,616 $ 0 5,616   $ 0  
Dividends declared (2,543)     (2,543)    
Employee stock award compensation 2,612   2,612      
Noncontrolling interest attributable to subsidiary equity plan (Note 16) 341     (317)   658
Net income attributable to noncontrolling interest 235         235
Net Income (Loss) Attributable to the Ensign Group, Inc. 27,372     27,372    
Balance - June 30, at Mar. 31, 2019 645,003 $ 55 292,612 378,443 $ (38,405) 12,298
Balance - June 30 (in shares) at Mar. 31, 2019   52,955        
Balance - June 30 (in treasury shares) at Mar. 31, 2019         1,932  
Balance - January 1, at Dec. 31, 2018 $ 602,340 $ 55 284,384 344,901 $ (38,405) 11,405
Balance - January 1 (in shares) at Dec. 31, 2018 52,584 52,584        
Balance - January 1 (in treasury shares) at Dec. 31, 2018         1,932  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Repurchase of shares of common stock to satisfy tax withholding obligations $ (485)          
Dividends declared (2,559)          
Employee stock award compensation 5,678          
Net income attributable to noncontrolling interest 551          
Net Income (Loss) Attributable to the Ensign Group, Inc. 55,981          
Balance - June 30, at Jun. 30, 2019 $ 677,307 $ 55 298,891 401,996 $ (38,890) 15,255
Balance - June 30 (in shares) at Jun. 30, 2019 53,272 53,272        
Balance - June 30 (in treasury shares) at Jun. 30, 2019         1,941  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Cumulative effect of new accounting change, net of tax $ 9,030     9,030    
Balance - January 1, at Mar. 31, 2019 645,003 $ 55 292,612 378,443 $ (38,405) 12,298
Balance - January 1 (in shares) at Mar. 31, 2019   52,955        
Balance - January 1 (in treasury shares) at Mar. 31, 2019         1,932  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)   326     0  
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards 3,213 $ 0 3,213   $ 0  
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation   (9)     9  
Repurchase of shares of common stock to satisfy tax withholding obligations (485)       $ (485)  
Dividends declared (2,559)     (2,559)    
Employee stock award compensation 3,066   3,066      
Noncontrolling interest attributable to subsidiary equity plan (Note 16) 236     (2,497)   2,733
Distribution to noncontrolling interest holder (92)         (92)
Net income attributable to noncontrolling interest 316         316
Net Income (Loss) Attributable to the Ensign Group, Inc. 28,609     28,609    
Balance - June 30, at Jun. 30, 2019 $ 677,307 $ 55 $ 298,891 $ 401,996 $ (38,890) $ 15,255
Balance - June 30 (in shares) at Jun. 30, 2019 53,272 53,272        
Balance - June 30 (in treasury shares) at Jun. 30, 2019         1,941  
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statement of Stockholders' Equity (Parenthetical) - $ / shares
3 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Statement of Stockholders' Equity [Abstract]    
Dividends Per Share $ 0.0475 $ 0.0450
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Cash flows from operating activities:    
Net income $ 56,532 $ 45,619
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 25,782 23,243
Impairment of long-lived assets 0 860
Amortization of deferred financing fees 583 588
Amortization of deferred gain on sale-leaseback (Note 17) 0 (329)
Non-cash leasing arrangement (Note 17) (688) 0
Provision for doubtful accounts 1,155 972
Share-based compensation 6,255 4,829
Cash received from insurance proceeds related to replacement properties and business interruptions 638 0
Income tax refund 0 11,000
Change in operating assets and liabilities    
Accounts receivable (22,716) 13,476
Prepaid income taxes 229 (129)
Prepaid expenses and other assets 3,332 (3,454)
Insurance subsidiary deposits 0 (2,571)
Operating lease obligations (2,248) 0
Accounts payable 356 (74)
Accrued wages and related liabilities (355) (1,046)
Other accrued liabilities (1,566) 2,531
Accrued self-insurance liabilities 3,717 5,349
Other long-term liability 1,272 376
Net cash provided by operating activities 72,278 101,240
Cash flows from investing activities:    
Purchase of property and equipment (35,762) (24,295)
Cash payments for business acquisitions (Note 8) (21,262) 0
Cash payments for asset acquisitions (Note 8) (43,176) (55,546)
Escrow deposits 0 (2,652)
Escrow deposits used to fund acquisitions 7,271 228
Cash proceeds from the sale of assets and insurance proceeds 2,575 1,610
Investments and change in other assets (7,902) (589)
Net cash used in investing activities (98,256) (81,244)
Cash flows from financing activities:    
Proceeds from revolving credit facility and other debt (Note 15) 535,000 405,000
Payments on revolving credit facility and other debt (Note 15) (500,965) (439,922)
Issuance of common stock upon exercise of options 5,547 4,778
Repurchase of shares of common stock to satisfy tax withholding obligations (485) 0
Proceeds from sale of subsidiary shares (Note 16) 2,293 0
Repurchase of shares of common stock and subsidiary shares (Note 16) (2,293) 0
Dividends paid (5,068) (4,695)
Non-controlling interest distribution (92) (292)
Payments of deferred financing costs 0 (18)
Net cash provided by/(used in) financing activities 33,937 (35,149)
Net increase/(decrease) in cash and cash equivalents 7,959 (15,153)
Cash and cash equivalents beginning of period 31,083 42,337
Cash and cash equivalents end of period 39,042 27,184
Cash paid during the period for:    
Interest 7,500 7,321
Income taxes 12,375 12,925
Lease liabilities 73,748 0
Non-cash financing and investing activity:    
Accrued capital expenditures 3,600 3,600
Accrued dividends declared 2,559 2,367
Note receivable from sale of ancillary business 0 282
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 47,748 $ 0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Description of Business
6 Months Ended
Jun. 30, 2019
DESCRIPTION OF BUSINESS [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] DESCRIPTION OF BUSINESS

The Company - The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum. As of June 30, 2019, the Company operated 254 facilities, 62 home health, hospice and home care agencies and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington, Wisconsin and Wyoming. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living, home health, hospice, home care and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately 20,700 operational skilled nursing beds and 5,900 senior living units. As of June 30, 2019, the Company owned 77 of its 254 affiliated facilities and leased an additional 177 facilities through long-term lease arrangements and had options to purchase 12 of those 177 facilities. As of December 31, 2018, the Company owned 72 of its 244 affiliated facilities and leased an additional 172 facilities through long-term lease arrangements and had options to purchase 12 of those 172 facilities.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide certain accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities.
Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Report is not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.

Proposed Spin-Off Transaction — On May 6, 2019, the Company announced a proposed plan to separate its transitional and skilled nursing services, its home health and hospice operations and substantially all of its senior living operations into two separate, publicly traded companies. See Note 2, Proposed Spin-Off of Subsidiaries.

Other Information — The accompanying condensed consolidated financial statements as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2018 which are included in the Company’s annual report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Proposed Spin-Off of Subsidiaries
6 Months Ended
Jun. 30, 2019
Proposed Spin-Off [Abstract]  
Proposed Spin-Off [Text Block] PROPOSED SPIN-OFF OF SUBSIDIARIES

On May 6, 2019, the Company announced a proposed plan to separate its transitional and skilled nursing services, its home health and hospice operations and substantially all of its senior living operations into two separate, publicly traded companies:

Ensign, which will include transitional and skilled services, rehabilitative care services, healthcare campuses, post-acute-related new business ventures and real estate investments; and
The Pennant Group, Inc. ("Pennant"), which will be a holding company of operating subsidiaries that provide home health, hospice and senior living.

The Company intends to accomplish the proposed separation through a spin-off (the Spin-Off), in which it expects to distribute shares of Pennant common stock to the Company’s stockholders, on a pro rata basis. The Company anticipates that at the time of the Spin-Off, Pennant, which is currently a wholly-owned subsidiary of the Company, will consists of 62 home health, hospice and home care agencies and 51 senior living communities as of June 30, 2019. Ensign affiliates will retain ownership of the real estate at 28 of the 51 senior living operations that are being contributed to Pennant. The Company anticipates that after the Spin-Off, all of these properties will be leased to Pennant on a triple-net basis, under which Pennant affiliates will be responsible for all costs at the properties, including property taxes, insurance and maintenance and repair costs.

In accordance with Accounting Standards Codification (ASC) 505-60, Equity-Spinoffs and Reverse Spinoffs, the accounting for the separation of the Company follows its legal form, with Ensign as the legal and accounting spinnor and Pennant as the legal and accounting spinnee, due to the relative significance of Ensign’s healthcare business, the relative fair values of the respective companies, the retention of all senior management, and other relevant indicators.

In connection with the adoption of the stockholder rights plan, the Company anticipates that the board of directors will declare a dividend of one share of Pennant common stock for every two shares of the Company's common stock held by stockholders as of the record date. Pennant is also anticipating that awards of equity of Pennant subsidiaries granted to certain individuals will be exchanged for Pennant common stock immediately prior to the distribution. The number of shares of Ensign common stock each stockholder owns and the related proportionate interest in Ensign will not change as a result of the proposed Spin-Off. Each Ensign stockholder will receive only whole shares of Pennant common stock in the distribution, as well as cash in lieu of any fractional shares. The proposed Spin-Off is subject to customary conditions, including receipt of a tax opinion from counsel, effectiveness of the registration statement filed with the Securities and Exchange Commission, execution of third-party agreements and final approval by Ensign’s board of directors.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies
6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and senior living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.
The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three and six months ended June 30, 2019 and 2018.
The Company completed the sale of one of its senior living operations for a sale price of $1,838 during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results. The Company presented property and equipment assets of the senior living operation sold as held for sale in the consolidated balance sheet as of December 31, 2018.
Estimates and Assumptions — The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, intangible assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.

Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.

Revenue Recognition — On January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) applying the modified retrospective method. The adoption of ASC 606 did not have a material impact on the measurement nor on the recognition of revenue of contracts, for which all revenue had not been recognized, as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of retained earnings at the beginning of 2018. See Note 4, Revenue and Accounts Receivable.
Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence. See Note 4, Revenue and Accounts Receivable.
Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of $705 and $860 during the three and six months ended June 30, 2018. The Company did not record an impairment charge during the three and six months ended June 30, 2019.

Leases and Leasehold Improvements - The Company leases skilled nursing facilities, senior living facilities and commercial office space. On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company estimates this rate based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term excludes lease renewals as the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably assured that the Company will exercise the extension options. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.

The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. See further discussion at Note 17, Leases.
Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible assets impairment during the three and six months ended June 30, 2019 and 2018. See further discussion at Note 11, Goodwill and Other Indefinite-Lived Intangible Assets.
Self-Insurance — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas, Washington and Wyoming for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $45,106 and $42,635 as of June 30, 2019 and December 31, 2018, respectively.
 The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington and Wyoming, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington and Wyoming, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas, Washington and Wyoming, the Company has purchased insurance coverage that insures individual claims that exceed $350 per accident. In all states except Washington and Wyoming, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,317 and $24,624 as of June 30, 2019 and December 31, 2018, respectively.
In addition, the Company has recorded an asset and equal liability of $7,747 and $6,969 at June 30, 2019 and December 31, 2018, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $300 for each covered person with an additional one-time aggregate individual stop loss deductible of $75. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of $75. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $6,376 and $5,823 as of June 30, 2019 and December 31, 2018, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific
and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.

Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Share-Based Compensation — The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

Recent Accounting Pronouncements — Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In February 2016, the FASB established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines.

The Company adopted the standard as of January 1, 2019, electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings, if applicable. The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows the Company to carry forward the historical lease classification. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has made an accounting policy to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. The Company has also elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.

The adoption of this standard resulted in recognition of right-of-use assets and lease liabilities of $1,051,148 and $1,029,240, respectively, on its condensed consolidated balance sheets as of January 1, 2019. The Company recorded an adjustment, net of tax, of $9,030 to retained earnings, on the adoption date, related to a deferred gain on a previous sale-leaseback transaction, which resulted in an increase in rent expense of $658 annually, as we are no longer able to recognize the gain in our consolidated statement of income as a result of the new lease standard. In addition, initial direct costs associated with its lease agreements and favorable lease assets of $26,939 were classified into right-of-use assets on the adoption date. The standard does not materially affect the Company's consolidated net earnings or have a notable impact on liquidity or debt-covenant compliance under the current agreements. See further discussion at Note 17, Leases.

Prior to the adoption of ASC 842, the Company recognized revenue related to its senior living residency agreements in accordance with the provisions of ASC 840, Leases ("ASC 840").  Subsequent to the adoption of ASU 2016-02, Leases, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of ASC 842 and the non-lease components utilizing the provisions of ASC 606, Revenue from Contracts with Customers. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with ASC 840 prior to the adoption of ASU 2016-02 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of ASC 606 subsequent to the adoption of ASU 2016-02. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of ASU 2016-02 for changes to amounts recognized for these certain components for the transition from ASC 840 to ASC 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, Leases, allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of ASC 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions.

Upon adoption of ASU 2016-02 and ASU 2018-11, the Company elected the lessor practical expedient within ASU 2018-11.  The Company recognizes revenue under these resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under ASC Topic 842 and ASC Topic 606. The Company has concluded that the non-lease components of the agreements with respect to its senior living communities are the predominant component of the contract, therefore, the Company recognizes revenue for these residents agreements under ASC Topic 606. The timing and pattern of revenue recognition is substantially the same as that prior to the adoption of these standards.

In June 2018, the FASB issued ASU 2018-07, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The Company adopted this guidance effective January 1, 2019. The adoption of this guidance did not have a material impact on its consolidated financial statements and related disclosures.

Accounting Standards Recently Issued But Not Yet Adopted by the Company

In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of credit Losses on Financial Instruments”, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for fiscal year beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption is permitted. The Company has not yet determined the effect of the ASU on its results of operations, financial condition or cash flows.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue and Accounts Receivable
6 Months Ended
Jun. 30, 2019
REVENUE AND ACCOUNTS RECEIVABLE [Abstract]  
Revenue and Accounts receivable [Text Block] REVENUE AND ACCOUNTS RECEIVABLE

The Company's revenue is derived primarily from providing healthcare services to its patients. Revenues are recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in transitional and skilled, home health and hospice patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.
Revenue from the Medicare and Medicaid programs accounted for 68.0% the Company's revenue for both the three and six months ended June 30, 2019, respectively and 68.2% and 68.0% for the three and six months ended June 30, 2018, respectively. Settlement with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue or Interim Financial Statements for the three and six months ended June 30, 2019 and 2018.
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by reportable operating segments and payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A reconciliation of disaggregated revenue to segment revenue as well as revenue by payor is provided in Note 7, Business Segments.
The Company’s service specific revenue recognition policies are as follows:


Transitional and Skilled Nursing Revenue
The Company’s revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.
Senior Living Revenue
The Company's senior living revenue consists of fees for basic housing and assisted living care. Accordingly, we record revenue when services are rendered on the date services are provided at amounts billable to individual residents. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For residents under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rates on a per resident, daily basis or as services are rendered.

The Company has elected the lessor practical expedient within ASC 842, Leases ("ASC 842") and recognizes, measures, presents, and discloses the revenue for services under the Company's senior living residency agreements based upon the predominant component, either the lease or nonlease component, of the contracts. The Company has determined that the services included under the Company’s senior living residency agreements have the same timing and pattern of transfer. The Company recognizes revenue under ASC 606, Revenue Recognition from Contracts with Customers ("ASC 606") for its senior residency agreements for which it has estimated that the nonlease components of such residency agreements are the predominant component of the contract.
Home Health Revenue
Medicare Revenue
Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if the patient’s care was unusually costly; (b) a low utilization adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or transferred from another provider before completing the episode; (d) a payment adjustment based upon the level of covered therapy services; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.
The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.
In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and the Company’s estimate of the average percentage complete based on visits performed.
Non-Medicare Revenue
Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.
Non-episodic Based Revenue - Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per visit rates, as applicable.


Hospice Revenue
Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care the Company delivers. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and increases to other accrued liabilities.
Revenue for the three and six months ended June 30, 2019 and 2018 is summarized in the following tables:
 
Three Months Ended June 30,
 
2019
 
2018
 
Revenue
 
% of
Revenue
 
Revenue
 
% of
Revenue
Medicaid
$
206,811

 
35.9
%
 
$
173,169

 
34.9
%
Medicare
153,187

 
26.6

 
136,813

 
27.6

Medicaid — skilled
31,792

 
5.5

 
28,298

 
5.7

Total Medicaid and Medicare
391,790

 
68.0

 
338,280

 
68.2

Managed care
93,690

 
16.3

 
80,150

 
16.1

Private and other payors(1)
90,171

 
15.7

 
77,956

 
15.7

Revenue
$
575,651

 
100.0
%
 
$
496,386

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019 and 2018.
 
Six Months Ended June 30,
 
2019
 
2018
 
Revenue
 
% of
Revenue
 
Revenue
 
% of
Revenue
Medicaid
$
401,814

 
35.7
%
 
$
340,794

 
34.5
%
Medicare
300,907

 
26.8

 
276,127

 
27.9

Medicaid — skilled
62,243

 
5.5

 
55,340

 
5.6

Total Medicaid and Medicare
764,964

 
68.0

 
672,261

 
68.0

Managed care
183,538

 
16.3

 
163,866

 
16.6

Private and other payors(1)
176,363

 
15.7

 
152,393

 
15.4

Revenue
$
1,124,865

 
100.0
%
 
$
988,520

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019 and 2018.
Balance Sheet Impact
Included in the Company’s condensed consolidated balance sheet are contract assets, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities as of June 30, 2019 and December 31, 2018, or activity during the three and six months ended June 30, 2019 and 2018.

Accounts receivable as of June 30, 2019 and December 31, 2018 is summarized in the following table:
 
June 30, 2019
 
December 31, 2018
Medicaid
$
128,069

 
$
117,984

Managed care
62,605

 
54,682

Medicare
53,232

 
50,994

Private and other payors
56,755

 
55,325

 
300,661

 
278,985

Less: allowance for doubtful accounts
(3,726
)
 
(2,886
)
Accounts receivable, net
$
296,935

 
$
276,099


Practical Expedients and Exemptions
As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Computation of Net Income Per Common Share
6 Months Ended
Jun. 30, 2019
COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract]  
Earnings Per Share [Text Block] COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from continuing operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net income
$
28,925

 
$
22,326

 
$
56,532

 
$
45,619

Less: net income attributable to noncontrolling interests
316

 
315

 
551

 
476

Net income attributable to The Ensign Group, Inc.
$
28,609

 
$
22,011

 
$
55,981

 
$
45,143

 
 
 
 
 
 
 
 
Denominator:

 
 
 
 
 
 
Weighted average shares outstanding for basic net income per share
53,408

 
51,880

 
53,246

 
51,733

Basic net income per common share attributable to The Ensign Group, Inc.
$
0.54

 
$
0.42

 
$
1.05

 
$
0.87



A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net income
$
28,925

 
$
22,326

 
$
56,532

 
$
45,619

Less: net income attributable to noncontrolling interests
316

 
315

 
551

 
476

Net income attributable to The Ensign Group, Inc.
$
28,609

 
$
22,011

 
$
55,981

 
$
45,143

 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average common shares outstanding
53,408

 
51,880

 
53,246

 
51,733

Plus: incremental shares from assumed conversion (1)
2,670

 
2,371

 
2,650

 
2,176

Adjusted weighted average common shares outstanding
56,078


54,251

 
55,896

 
53,909

Diluted net income per common share attributable to The Ensign Group, Inc.
$
0.51

 
$
0.41

 
$
1.00

 
$
0.84


(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 173 and 322 for the three and six months ended June 30, 2019, respectively, and 196 and 398 for the three and six months ended June 30, 2018, respectively.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS
Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018:
 
 
June 30, 2019
 
December 31, 2018
 
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
Cash and cash equivalents
 
$
39,042

 
$

 
$

 
$
31,083

 
$

 
$



The Company's non-financial assets, which includes goodwill, intangible assets and property and equipment, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. See Note 3, Summary of Significant Accounting Policies for further discussion of the Company's significant accounting policies.

Debt Security Investments - Held to Maturity

At June 30, 2019 and December 31, 2018, the Company had approximately $46,932 and $44,850, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of June 30, 2019, the debt security investments were held in AA, A and BBB rated debt securities.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Business Segments
6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block] BUSINESS SEGMENTS

The Company has three reportable operating segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities; (2) senior living services, which includes the operation of assisted and independent living facilities; and (3) home health and hospice services, which includes the Company's home health, hospice and home care businesses. The Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, reviews financial information at the operating segment level.

The Company also reports an “all other” category that includes results from its mobile diagnostics and other ancillary operations. These operations are neither significant individually nor in aggregate, and therefore do not constitute a reportable segment. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations.

As of June 30, 2019, transitional and skilled services included 171 wholly-owned affiliated skilled nursing operations and 27 campuses that provide skilled nursing and rehabilitative care services and senior living services. The Company provided room and board and social services through 56 wholly-owned affiliated senior living operations and 27 campuses as mentioned above. Home health, hospice and home care services were provided to patients through 62 affiliated agencies. As of June 30, 2019, the Company held majority membership interests in other ancillary operations, which operating results are included in the "all other" category.

The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. General and administrative expenses are not allocated to any segment for purposes of determining segment profit or loss, and are included in the "all other" category in the selected segment financial data that follows. The accounting policies of the reporting segments are the same as those described in Note 3, Summary of Significant Accounting Policies. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

Segment revenues by major payor source were as follows:
 
 
Three Months Ended June 30, 2019
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
192,545

 
$
10,333

 
$
3,933

 
$

 
$
206,811

 
35.9
%
Medicare
 
118,807

 

 
34,380

 

 
153,187

 
26.6

Medicaid-skilled
 
31,792

 

 

 

 
31,792

 
5.5

Subtotal
 
343,144

 
10,333

 
38,313

 

 
391,790

 
68.0

Managed care
 
86,491

 

 
7,199

 

 
93,690

 
16.3

Private and other
 
39,603

 
31,713

 
4,696

 
14,159

(1)
90,171

 
15.7

Total revenue
 
$
469,238

 
$
42,046

 
$
50,208

 
$
14,159

 
$
575,651

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019.
 
 
Three Months Ended June 30, 2018
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
161,584

 
$
8,677

 
$
2,908

 
$

 
$
173,169

 
34.9
%
Medicare
 
108,237

 

 
28,576

 

 
136,813

 
27.6

Medicaid-skilled
 
28,298

 

 

 

 
28,298

 
5.7

Subtotal
 
298,119

 
8,677

 
31,484

 

 
338,280

 
68.2

Managed care
 
74,168

 

 
5,982

 

 
80,150

 
16.1

Private and other
 
36,231

 
28,487

 
3,783

 
9,455

(1)
77,956

 
15.7

Total revenue
 
$
408,518

 
$
37,164

 
$
41,249

 
$
9,455

 
$
496,386

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2018.
 
 
Six Months Ended June 30, 2019
 
 
Transitional and Skilled Services
 
Assisted and Independent Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
373,839

 
$
20,135

 
$
7,840

 
$

 
$
401,814

 
35.7
%
Medicare
 
235,508

 

 
65,399

 

 
300,907

 
26.8

Medicaid-skilled
 
62,243

 

 

 

 
62,243

 
5.5

Subtotal
 
671,590

 
20,135

 
73,239

 

 
764,964

 
68.0

Managed care
 
169,663

 

 
13,875

 

 
183,538

 
16.3

Private and other
 
77,243

 
62,605

 
9,211

 
27,304

(1)
176,363

 
15.7

Total revenue
 
$
918,496

 
$
82,740

 
$
96,325

 
$
27,304

 
$
1,124,865

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019.

 
 
Six Months Ended June 30, 2018
 
 
Transitional and Skilled Services
 
Assisted and Independent Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
318,095

 
$
16,941

 
$
5,758

 
$

 
$
340,794

 
34.5
%
Medicare
 
220,190

 

 
55,937

 

 
276,127

 
27.9

Medicaid-skilled
 
55,340

 

 

 

 
55,340

 
5.6

Subtotal
 
593,625

 
16,941

 
61,695

 

 
672,261

 
68.0

Managed care
 
151,968

 

 
11,898

 

 
163,866

 
16.6

Private and other
 
69,941

 
56,336

 
7,414

 
18,702

(1)
152,393

 
15.4

Total revenue
 
$
815,534

 
$
73,277

 
$
81,007

 
$
18,702

 
$
988,520

 
100.0
%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2018.

The following table sets forth selected financial data consolidated by business segment:
 
 
Three Months Ended June 30, 2019
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
469,238

 
$
42,046

 
$
50,208

 
$
14,159

 
$

 
$
575,651

Intersegment revenue(1)
 
780

 

 

 
2,149

 
(2,929
)
 

Total revenue
 
$
470,018

 
$
42,046

 
$
50,208

 
$
16,308

 
$
(2,929
)
 
$
575,651

Segment income (loss)(2)
 
$
56,652

 
$
4,821

 
$
7,306

 
$
(30,933
)
 
$

 
$
37,846

Interest expense, net of interest income
 

 

 

 

 
 
 
$
(3,369
)
Income before provision for income taxes
 

 

 

 

 
 
 
$
34,477

Depreciation and amortization
 
$
8,938

 
$
2,019

 
$
320

 
$
1,907

 
$

 
$
13,184

 
 
 
 
 
 
 
 
 
 
 
 
 

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $780. Including these expenses, home health and hospice services segment income would be $6,526. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $2,149.
(3) General and administrative expense are included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.

 
 
Three Months Ended June 30, 2018
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
408,518

 
$
37,164

 
$
41,249

 
$
9,455

 
$

 
$
496,386

Intersegment revenue(1)
 
645

 

 

 
1,112

 
(1,757
)
 

Total revenue
 
$
409,163

 
$
37,164

 
$
41,249

 
$
10,567

 
$
(1,757
)
 
$
496,386

Segment income (loss)(2)
 
$
43,210

 
$
4,966

 
$
6,268

 
$
(22,669
)
 
$

 
$
31,775

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(3,307
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
28,468

Depreciation and amortization
 
$
7,708

 
$
1,863

 
$
281

 
$
1,769

 
$

 
$
11,621

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $645.  Including these expenses, home health and hospice services segment income would be $5,623. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $1,112.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
 
 
Six Months Ended June 30, 2019
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
918,496

 
$
82,740

 
$
96,325

 
$
27,304

 
$

 
$
1,124,865

Intersegment revenue(1)
 
1,495

 

 

 
3,861

 
(5,356
)
 

Total revenue
 
$
919,991

 
$
82,740

 
$
96,325

 
$
31,165

 
$
(5,356
)
 
$
1,124,865

Segment income (loss)(2)
 
$
115,416

 
$
9,859

 
$
14,174

 
$
(63,799
)
 
$

 
$
75,650

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(6,466
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
69,184

Depreciation and amortization
 
$
17,552

 
$
3,919

 
$
580

 
$
3,731

 
$

 
$
25,782

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $1,495. Including these expenses, home health and hospice services segment income would be $12,679. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines which are included in the "All Other" category of $3,861.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.


 
 
Six Months Ended June 30, 2018
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
815,534

 
$
73,277

 
$
81,007

 
$
18,702

 
$

 
$
988,520

Intersegment revenue(1)
 
1,334

 

 

 
2,194

 
(3,528
)
 

Total revenue
 
$
816,868

 
$
73,277

 
$
81,007

 
$
20,896

 
$
(3,528
)
 
$
988,520

Segment income (loss)(2)
 
$
89,405

 
$
9,629

 
$
12,326

 
$
(46,606
)
 
$

 
$
64,754

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(6,472
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
58,282

Depreciation and amortization
 
$
15,510

 
$
3,460

 
$
526

 
$
3,747

 
$

 
$
23,243

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $1,334.  Including these expenses, home health and hospice services segment income would be $10,992. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $2,194.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
The Company completed the sale of one of its senior living operations for an aggregate sale price of $1,838 during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Acquisitions
6 Months Ended
Jun. 30, 2019
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block] ACQUISITIONS
The acquisition focus of the subsidiaries is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the accompanying Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, the affiliated operations will acquire facilities that have been operating under third-party leases.
During the six months ended June 30, 2019, the Company expanded its operations through a combination of a long-term lease and real estate purchases, with the addition of seven stand-alone skilled nursing operations, one stand-alone senior living operation, three campus operations, two home health agencies, four hospice agencies and two home care agencies. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of 1,088 operational skilled nursing beds and 364 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. The aggregate purchase price for these acquisitions during the six months ended June 30, 2019 was $65,362.
The fair value of assets for eleven of the acquisitions was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions in accordance with Accounting Standards Codification Topic 805, Clarifying the Definition of a Business (ASC 805). The purchase price for the eleven asset acquisitions was $43,176, which mainly consisted of building and improvements of $33,900 and land of $7,660. The fair value of assets for the remaining nine acquisitions was concentrated in goodwill and as such, these transactions were classified as business acquisitions in accordance with ASC 805. The purchase price for the nine business combinations was $22,186, which mainly consisted of goodwill and indefinite-lived intangible assets of $20,251. The Company also entered into a note payable with the seller of $924, which was subsequently paid off in the second quarter of 2019 and included in the payments on revolving credit facility and other debt line item in the consolidated statement of cash flow. As of the date of this filing, the preliminary allocation of the purchase price for the acquisitions in the second quarter was not finalized as necessary valuation information was not yet available.
During the second quarter of 2018, all of the fair value of the assets acquired were concentrated in property and equipment and as such, the transactions were classified as asset acquisitions in accordance with ASC 805. During the six months ended June 30, 2018, the aggregate purchase price for those acquisitions was $55,546, of which $31,500 was related to an office building acquisition to accommodate its growing Service Center team.

The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The businesses acquired during the six months ended June 30, 2019 were not material acquisitions to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These acquisitions have been included in the June 30, 2019 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the dates the Company gained effective control.

Subsequent to June 30, 2019, the Company expanded its operations through long-term leases, with the addition of one stand-alone skilled nursing operation and one stand-alone senior living operation. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The addition of these operations added a total of 27 operational skilled nursing beds and 91 operational senior living units to be operated by the Company's operating subsidiaries. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment
6 Months Ended
Jun. 30, 2019
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT— Net
Property and equipment, net consist of the following:
 
June 30, 2019
 
December 31, 2018
Land
$
68,081

 
$
60,420

Buildings and improvements
449,763

 
411,096

Equipment
220,402

 
202,346

Furniture and fixtures
5,465

 
5,079

Leasehold improvements
127,345

 
112,935

Construction in progress
10,195

 
9,729

 
881,251

 
801,605

Less: accumulated depreciation
(206,359
)
 
(182,731
)
Property and equipment, net
$
674,892

 
$
618,874



See also Note 8, Acquisitions for information on acquisitions during the six months ended June 30, 2019 and 2018.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets - Net
6 Months Ended
Jun. 30, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets Disclosure [Text Block] INTANGIBLE ASSETS — Net
 
 
Weighted Average Life (Years)
 
June 30, 2019
 
December 31, 2018
 
 
 
Gross Carrying Amount
 
Accumulated Amortization
 
 
 
Gross Carrying Amount
 
Accumulated Amortization
 
 
Intangible Assets
 
 
 
 
Net
 
 
 
Net
Lease acquisition costs
 
1.7
 
$
360

 
$
(240
)
 
120

 
$
843

 
$
(251
)
 
$
592

Favorable leases
 
2.1
 
534

 
(316
)
 
218

 
35,650

 
(8,724
)
 
26,926

Assembled occupancy
 
0.4
 
3,180

 
(3,056
)
 
124

 
2,936

 
(2,870
)
 
66

Facility trade name
 
30.0
 
733

 
(330
)
 
403

 
733

 
(317
)
 
416

Customer relationships
 
16.7
 
5,110

 
(2,146
)
 
2,964

 
4,670

 
(1,670
)
 
3,000

Total
 
 
 
$
9,917

 
$
(6,088
)
 
$
3,829

 
$
44,832

 
$
(13,832
)
 
$
31,000



Amortization expense was $1,012 and $1,905 for the three and six months ended June 30, 2019, respectively, and $691 and $1,306 for the three and six months ended June 30, 2018, respectively. Favorable leases and lease acquisition costs of $26,939 were reclassed to right-of-use assets as of January 1, 2019, as a part of the adoption of ASC 842. See Note 17, Leases.
Estimated amortization expense for each of the years ending December 31 is as follows:
Year
Amount
2019 (remainder)
$
567

2020
345

2021
249

2022
249

2023
237

2024
234

Thereafter
1,948

 
$
3,829



XML 29 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Other Indefinite-Lived Intangible Assets
6 Months Ended
Jun. 30, 2019
Indefinite-Lived Intangible Assets (Including Goodwill) [Abstract]  
Goodwill and Other Indefinite-Lived Intangibles [Text Block] GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS

The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of Accounting Standards Codification topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a "Step 0" analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs "Step 1" of the traditional two-step goodwill impairment test by comparing the net assets of each reporting unit to their respective fair values. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. In the event a unit's net assets exceed its fair value, an implied fair value of goodwill must be determined by assigning the unit's fair value to each asset and liability of the unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. An impairment loss is measured by the difference between the goodwill carrying value and the implied fair value.

The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of June 30, 2019. See further discussion of goodwill acquired at Note 8, Acquisitions.

The following table represents activity in goodwill by segment as of and for the six months ended June 30, 2019:
 
Goodwill
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total
January 1, 2019
$
45,486

 
$
3,958


$
27,250

 
$
3,783

 
$
80,477

Additions

 

 
11,500

 
5,431

 
16,931

June 30, 2019
$
45,486

 
$
3,958

 
$
38,750

 
$
9,214

 
$
97,408



Other indefinite-lived intangible assets consists of the following:
 
June 30, 2019

December 31, 2018
Trade name
$
1,373

 
$
1,217

Medicare and Medicaid licenses
29,549

 
26,385

 
$
30,922

 
$
27,602

As of the date of this filing, the preliminary allocation of the purchase price for the acquisitions in the second quarter, mentioned in Note 8, Acquisitions, was not finalized as necessary valuation information was not yet available. The final allocation could have an impact on the allocation of goodwill and indefinite-lived intangible assets related to these acquisitions.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Restricted and Other Assets
6 Months Ended
Jun. 30, 2019
Other Assets [Abstract]  
Other Assets Disclosure [Text Block] RESTRICTED AND OTHER ASSETS
Restricted and other assets consist of the following:
 
June 30, 2019
 
December 31, 2018
Debt issuance costs, net
$
1,442

 
$
1,892

Long-term insurance losses recoverable asset
7,747

 
6,969

Deposits with landlords
4,148

 
8,694

Capital improvement reserves with landlords and lenders
3,535

 
3,196

Note receivable from sale of ancillary business
71

 
93

Restricted and other assets
$
16,943

 
$
20,844



Included in restricted and other assets as of June 30, 2019 and December 31, 2018 are anticipated insurance recoveries related to the Company's workers' compensation, general and professional liability claims that are recorded on a gross rather than net basis in accordance with an Accounting Standards Update issued by the FASB. Prepaid rent of $5,220, previously included in deposits with landlords above, were reclassed to right-of-use assets as of January 1, 2019, as part of the adoption of ASC 842. See Note 17, Leases.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Other Accrued Liabilities
6 Months Ended
Jun. 30, 2019
Accrued Liabilities [Abstract]  
Other Liabilities Disclosure [Text Block] OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:
 
June 30, 2019
 
December 31, 2018
Quality assurance fee
$
5,639

 
$
5,375

Refunds payable
27,477

 
25,118

Resident advances
4,607

 
8,495

Cash held in trust for patients
2,842

 
2,824

Resident deposits
7,753

 
6,665

Dividends payable
2,559

 
2,525

Property taxes
7,669

 
9,426

Other
11,270

 
9,356

Other accrued liabilities
$
69,816

 
$
69,784



Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying condensed consolidated balance sheets.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Income Taxes
6 Months Ended
Jun. 30, 2019
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block] INCOME TAXES

The Company recorded income tax expense of $12,652 and $12,663 during the six months ended June 30, 2019 and 2018, respectively, or 18.3% of earnings before income taxes for the six months ended June 30, 2019, compared to 21.7% for the six months ended June 30, 2018. The effective tax rate for both six month periods include excess tax benefits from stock-based compensation which were offset by non-deductible expenses including non-deductible compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2019, the statutes of limitations will lapse on the Company's 2015 Federal tax year and certain 2014 and 2015 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the six months ended June 30, 2019 and 2018.

The Company implemented ASC 842 as described in the Summary of Significant Accounting Policies. The new lease standard reduced net deferred assets by $3,044, which is reflected in retained earnings as day one accounting change adjustment.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Debt
6 Months Ended
Jun. 30, 2019
Debt Disclosure [Abstract]  
Debt Disclosure [Text Block] DEBT
Long-term debt consists of the following:
 
June 30, 2019
 
December 31, 2018
Term loan with SunTrust
$
109,375

 
$
113,125

Revolving credit facility with SunTrust
50,000

 
10,000

Mortgage loans and promissory note
121,664

 
122,955

 
281,039

 
246,080

Less: current maturities
(10,153
)
 
(10,105
)
Less: debt issuance costs
(2,707
)
 
(2,840
)
 
$
268,179

 
$
233,135



Credit Facility with a Lending Consortium Arranged by SunTrust
The Company maintains a credit facility with a lending consortium arranged by SunTrust (as amended to date, the Credit Facility). The Company originally entered into the Credit Facility in an aggregate principal amount of $150,000 in May 2014. Under the Credit Facility, the Company could seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $75,000.

On February 5, 2016, the Company amended its existing revolving credit facility to increase its aggregate principal amount available to $250,000 (the Amended Credit Facility). Under the credit facility, the Company may seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $150,000. The interest rates applicable to loans under the credit facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.75% to 1.75% per annum or LIBOR plus a margin ranging from 1.75% to 2.75% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company pays a commitment fee on the unused portion of the commitments under the credit facility that will range from 0.30% to 0.50% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is permitted to prepay all or any portion of the loans under the credit facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders.

On July 19, 2016, the Company entered into the second amendment to the credit facility (Second Amended Credit Facility), which amended the existing credit agreement to increase the aggregate principal amount up to $450,000. The Second Amended Credit Facility is comprised of a $300,000 revolving credit facility and a $150,000 term loan. Borrowings under the term loan portion of the Second Amended Credit Facility mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to 5.00% per annum of the original principal amount. The interest rates and commitment fee applicable to the Second Amended Credit Facility are similar to the Amended Credit Facility discussed below. Except as set forth in the Second Amended Credit Facility, all other terms and conditions of the Amended Credit Facility remained in full force and effect as described below.

The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The credit facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to consolidated EBITDA ratio (which shall be increased to 3.50:1.00 for the first fiscal quarter and the immediate following three fiscal quarters), and a minimum interest/rent coverage ratio (which cannot be below 1.50:1.00). The majority of lenders can require that the Company and its operating subsidiaries mortgage certain of its real property assets to secure the Amended Credit Facility if an event of default occurs, the Consolidated Total Net Debt to consolidated EBITDA ratio is above 2.75:1.00 for two consecutive fiscal quarters, or its liquidity is equal or less than 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) for ten consecutive business days, provided that such mortgages will no longer be required if the event of default is cured, the Consolidated Total Net Debt to consolidated EBITDA ratio is below 2.75:1.00 for two consecutive fiscal quarters, or its liquidity is above 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) or ninety consecutive days, as applicable. As of June 30, 2019, the Company's operating subsidiaries had $159,375 outstanding under the Credit Facility. The outstanding balance on the term loan was $109,375, of which $7,500 is classified as short-term and the remaining $101,875 is classified as long-term. The outstanding balance on the revolving Credit Facility was $50,000, which is classified as long-term. The Company was in compliance with all loan covenants as of June 30, 2019.

As of July 30, 2019, there was approximately $111,250 outstanding under the Revolving Credit Facility.











Mortgage Loans and Promissory Note

In December 2017, 17 of the Company's subsidiaries entered into mortgage loans in the aggregate amount of $112,000. The mortgage loans are insured with Department of Housing and Urban Development (HUD), which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans and note bear fixed interest rates of 3.3% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. During the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms of the mortgage loans are 30 to 35 years. The borrowings were arranged by Lancaster Pollard Mortgage Company, LLC, and insured by HUD. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, to renovate and upgrade existing and future facilities, to cover working capital needs and for other business purposes.

In addition to the HUD mortgage loans above, the Company had outstanding indebtedness under mortgage loans insured with HUD and a promissory note issued in connection with various acquisitions. These mortgage loans and note bear fixed interest rates between 2.6% and 5.3% per annum. Amounts borrowed under the mortgage loans may be prepaid starting after the second anniversary of the notes subject to prepayment fees of the principal balance on the date of prepayment. These prepayment fees are reduced by 1.0% per year for years three through 11 of the loan. There is no prepayment penalty after year 11. The term of the mortgage loans and the note is between 12 and 33 years. The mortgage loans and note are secured by the real property comprising the facilities and the rents, issues and profits thereof, as well as all personal property used in the operation of the facilities.
As of June 30, 2019, the Company's operating subsidiaries had $121,664 outstanding under the mortgage loans and note, of which $2,653 is classified as short-term and the remaining $119,011 is classified as long-term. The Company was in compliance with all loan covenants as of June 30, 2019.
Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.

Off-Balance Sheet Arrangements

During the six months ended June 30, 2019, the Company increased its outstanding letters of credit by $560. As of June 30, 2019, the Company had approximately $5,342 on the credit facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards
6 Months Ended
Jun. 30, 2019
Options and Awards [Abstract]  
Share-based Payment Arrangement [Text Block] OPTIONS AND AWARDS
Stock-based compensation expense consists of share-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three and six months ended June 30, 2019 and 2018 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
Stock Options
2017 Omnibus Incentive Plan - The Company has one active stock incentive plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The 2017 Plan provides for the issuance of 6,881 shares of common stock. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over 5 years at 20% per year on the anniversary of the grant date. Options expire 10 years from the date of grant. At June 30, 2019, there were 3,908 unissued shares of common stock available for issuance under this plan.
The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for all share-based payment awards. Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the grant date requires considerable judgment, including estimating stock price volatility, expected option life and forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Company granted 399 options and 194 restricted stock awards from the 2017 Plan during the six months ended June 30, 2019.
The Company used the following assumptions for stock options granted during the three months ended June 30, 2019 and 2018:
Grant Year
 
Options Granted
 
Weighted Average Risk-Free Rate
 
Expected Life
 
Weighted Average Volatility
 
Weighted Average Dividend Yield
2019
 
258
 
2.1%
 
6.3 years
 
34.0%
 
0.4%
2018
 
227
 
2.7%
 
6.2 years
 
32.0%
 
0.5%


The Company used the following assumptions for stock options granted during the six months ended June 30, 2019 and 2018:
Grant Year
 
Options Granted
 
Weighted Average Risk-Free Rate
 
Expected Life
 
Weighted Average Volatility
 
Weighted Average Dividend Yield
2019
 
399

 
2.2%
 
6.3 years
 
33.9%
 
0.3%
2018
 
395

 
2.7%
 
6.2 years
 
32.0%
 
0.6%

For the six months ended June 30, 2019 and 2018, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant Year
 
Granted
 
Weighted Average Exercise Price
 
Weighted Average Fair Value of Options
2019
 
399

 
$
53.67

 
$
19.35

2018
 
395

 
$
32.33

 
$
11.15



The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended June 30, 2019 and 2018 and therefore, the intrinsic value was $0 at the date of grant.

The following table represents the employee stock option activity during the six months ended June 30, 2019:
 
Number of
Options
Outstanding
 
Weighted
Average
Exercise Price
 
Number of
Options Vested
 
Weighted
Average
Exercise Price
of Options
Vested
January 1, 2019
4,188

 
$
17.35

 
2,431

 
$
12.37

Granted
399

 
53.67

 
 
 
 
Forfeited
(27
)
 
26.16

 
 
 
 
Exercised
(531
)
 
10.45

 
 
 
 
June 30, 2019
4,029

 
$
21.80

 
2,407

 
$
13.88



The following summary information reflects stock options outstanding, vested and related details as of June 30, 2019:
 
 
Stock Options Outstanding
 
Stock Options Vested
 
 
 
 
 
 
 
Number Outstanding
 
Black-Scholes Fair Value
 
Remaining Contractual Life (Years)
 
Vested and Exercisable
Year of Grant
 
Exercise Price
 
 
 
 
2009
 
$4.06
-
$4.56
 
40

 
$
83

 
0
 
40

2010
 
4.77
-
4.96
 
50

 
122

 
1
 
50

2011
 
5.90
-
7.99
 
80

 
274

 
2
 
80

2012
 
6.56
-
7.96
 
217

 
797

 
3
 
217

2013
 
7.98
-
11.49
 
355

 
1,712

 
4
 
355

2014
 
10.55
-
18.94
 
1,049

 
5,953

 
5
 
1,025

2015
 
21.47
-
25.24
 
431

 
3,926

 
6
 
272

2016
 
18.79
-
19.89
 
381

 
2,652

 
7
 
180

2017
 
18.64
-
22.90
 
420

 
2,931

 
8
 
118

2018
 
26.53
-
38.59
 
607

 
7,346

 
9
 
70

2019
 
$53.50
-
$53.99
 
399

 
7,724


10


Total
 
 
 
 
 
4,029

 
$
33,520

 
 

2,407


Restricted Stock Awards
The Company granted 89 and 194 restricted stock awards during the three and six months ended June 30, 2019, respectively. The Company granted 217 and 274 restricted stock awards during the three and six months ended June 30, 2018, respectively. All awards were granted at an issued price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the six months ended June 30, 2019 and 2018 ranged from $41.68 to $53.99 and $23.61 to $36.61 respectively. The fair value per share includes quarterly stock awards to non-employee directors.
A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2019 and changes during the six months ended June 30, 2019 is presented below:
 
Non-Vested Restricted Awards
 
Weighted Average Grant Date Fair Value
Nonvested at January 1, 2019
573

 
$
29.31

Granted
194

 
52.16

Vested
(166
)
 
38.79

Forfeited
(5
)
 
28.67

Nonvested at June 30, 2019
596

 
$
34.13



During the three and six months ended June 30, 2019, the Company granted 8 and 14 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards ranged from $41.68 to $51.78 based on the market price on the grant date.

Share-based compensation expense recognized for the Company's equity incentive plans for the three and six months ended June 30, 2019 and 2018 was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Share-based compensation expense related to stock options
$
1,479

 
$
1,292

 
$
2,822

 
$
2,508

Share-based compensation expense related to restricted stock awards
1,199

 
675

 
2,197

 
1,253

Share-based compensation expense related to stock options and restricted stock awards to non-employee directors
388

 
210

 
659

 
387

Total
$
3,066

 
$
2,177

 
$
5,678


$
4,148



In future periods, the Company expects to recognize approximately $17,760 and $18,860 in share-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of June 30, 2019. Future share-based compensation expense will be recognized over 3.9 weighted average years for both unvested options and restricted stock awards. There were 1,622 unvested and outstanding options at June 30, 2019, of which 1,517 are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest at June 30, 2019 was 6.1 years.

The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of June 30, 2019 and December 31, 2018 is as follows:
Options
 
June 30, 2019
 
December 31, 2018
Outstanding
 
$
141,531

 
$
89,806

Vested
 
103,589

 
64,222

Expected to vest
 
32,597

 
22,963

Exercisable
 
21,118

 
27,646


The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options.
Equity Instrument Denominated in the Shares of a Subsidiary
On May 26, 2016, the Company implemented a management equity plan and granted stock options and restricted stock awards of a subsidiary of the Company to employees and management of that subsidiary (Subsidiary Equity Plan). The Company did not grant any new restricted shares during the six months ended June 30, 2019 and 2018. These awards generally vest over a period of three to five years, or upon the occurrence of certain prescribed events. During both the six months ended June 30, 2019 and 2018, 976 restricted stock awards vested.
The Company granted 221 stock options during the six months ended June 30, 2018. The Company did not grant any new stock options during the six months ended June 30, 2019. The value of the stock options and restricted stock awards is tied to the value of the common stock of the subsidiary. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination.
The grant-date fair value of the awards is recognized as compensation expense over the relevant vesting periods, with a corresponding adjustment to noncontrolling interests. The grant value was determined based on an independent valuation of the subsidiary shares. For the three and six months ended June 30, 2019, the Company expensed $236 and $577, respectively, in share-based compensation related to the Subsidiary Equity Plan. For the three and six months ended June 30, 2018, the Company expensed $343 and $681, respectively, in share-based compensation related to the Subsidiary Equity Plan.
The aggregate number of the Company's common shares that would be required to settle these awards at current estimated fair values, including vested and unvested awards, at June 30, 2019 and 2018 is 328 and 235, respectively.
During the second quarter of 2019, the Company repurchased 469 shares of common stock under the Subsidiary Equity Plan for $2,293. The Company subsequently sold the shares and received net proceeds of $2,293.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Leases
6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Lessee, Operating Leases [Text Block] LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 93 affiliated skilled nursing, senior living facilities used in the Company’s operations under eight “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
Commencing the third year, the rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Total rent expense under the Master Leases was approximately $15,057 and $29,896 for the three and six months ended June 30, 2019, respectively, and $14,538 and $28,956 for the three and six months ended June 30, 2018, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is not aware of any defaults as of June 30, 2019.
The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense, inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37,211 and $73,181 for the three and six months ended June 30, 2019, respectively, and $34,476 and $68,640 for the three and six months ended June 30, 2018, respectively.
Thirty-nine of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under seven separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.
Impact of New Leases Guidance
As described further in Note 3, Summary of Significant Accounting Policies, the Company adopted Topic 842, Leases, as of January 1, 2019. Prior period amounts have not been adjusted and continue to be reported in accordance with our historic accounting under Topic 840.
All of the Company's leases are classified as operating leases. The components of lease assets and liabilities are included in the condensed consolidated balance sheets. The following tables summarize the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of June 30, 2019 and the condensed consolidated statement of income for the three and six months ended June 30, 2019, as if the previous accounting guidance was in effect for comparison purposes. There was no impact to the condensed consolidated statement of cash flows for the six months ended June 30, 2019.
The following table summarizes the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of January 1, 2019.

 
 
Balance at December 31, 2018
 
Adjustments due to new lease guidance
 
January 1, 2019
 
Balance at June 30, 2019
Total assets(1)
 
$
1,181,958

 
$
1,015,937

 
$
2,197,895

 
$
2,321,521

Total liabilities(2)
 
579,618

 
1,006,907

 
1,586,525

 
1,644,214

Total equity
 
602,340

 
9,030

 
611,370

 
677,307

(1) Adjustment in assets includes the reclassification of intangible assets, prepaid rent and deferred rent into right-of-use assets and the decrease in deferred tax assets due to the removal of deferred gain related to sale-leaseback as of January 1, 2019.
(2) Adjustment in liabilities includes the reclassification of other liabilities into lease liabilities and the removal of deferred gain related to sale-lease back as of January 1, 2019.
The components of operating lease expense(1), are as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2019
 
2018
 
2019
 
2018
Rent - cost of services(2)
 
$
37,060

 
$
34,472

 
$
72,846

 
$
68,322

General and administrative expense
 
151

 
168

 
335

 
318

Depreciation and amortization(3)
 
495

 
495

 
990

 
990

 
 
$
37,706

 
$
35,135

 
$
74,171

 
$
69,630

(1) Operating lease expenses include short-term leases and variable lease costs, which are immaterial.
(2) Rent- cost of services includes the amortization of deferred rent of $434 and $688 for the three and six months ended June 30, 2019, respectively.
(3) Depreciation and amortization is related to the amortization of favorable and direct lease costs.

Future minimum lease payments for all leases as of June 30, 2019 are as follows:
Year
 
Amount
2019 (remainder)
 
$
74,865

2020
 
149,083

2021
 
148,086

2022
 
146,540

2023
 
144,852

2024
 
142,880

Thereafter
 
912,928

Total lease payments
 
1,719,234

Less: present value adjustment
 
(646,138
)
Less: variable rent
 
(25,265
)
Present value of total lease liabilities
 
1,047,831

Less: current lease liabilities
 
(59,686
)
Long-term operating lease liabilities
 
$
988,145

Future minimum lease payments for all leases as of December 31, 2018 were as follows:
Year
 
Amount
2019
 
$
142,497

2020
 
141,536

2021
 
140,524

2022
 
139,018

2023
 
137,349

Thereafter
 
967,027

Total lease payments
 
$
1,667,951



Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2019, the weighted average remaining lease term is 12 years and the weighted average discount rate used to determine the operating lease liability is 8.66%.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES
Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which requires healthcare providers (among other things) to safeguard the privacy and security of certain health information. In late December of 2016, the Company learned of a potential issue at one of its independent operating entities in Arizona which involved the limited and inadvertent disclosure of certain confidential information. The issue has been internally investigated, addressed and disclosed as is required by law. The Company believes that it is presently in compliance in all material respects with applicable HIPAA laws and regulations. As of June 30, 2019, this matter has been resolved.
Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.
Indemnities — From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer by the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.
U.S. Department of Justice Civil Investigative Demand - On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether the Company has violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of the Company’s independently operated skilled nursing facilities and persons who served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 to the present, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 to the present, relating to the same topic. As a general matter, the Company’s independent operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company is fully cooperating with the U.S. Department of Justice to promptly respond to the requests for information. However, the Company cannot predict when the investigation will be resolved, the outcome of the investigation, or its potential impact on the Company.
Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.
In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction
Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act (FCA) and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of minimum staffing requirements for skilled nursing facilities in those states which have enacted such requirements. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with the requirements of participation under certain state and federal healthcare programs; it may also subject the facility to a deficiency, a citation, a civil money penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.
The Company and its independent operating subsidiaries have in the past been subject to class action litigation involving claims of alleged violations of regulatory requirements related to staffing. While the Company has been able to settle these claims without a material ongoing adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. For example, the Company has been subjected to, and is currently involved in, class action litigation alleging violations of state and federal wage and hour law as related to the alleged failure to pay wages and to timely provide and authorize meal and rest breaks. The Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s business, cash flows, financial condition or results of operations. A significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.
The Company and its independent operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment, as well as employment related claims. A significant increase in the number of these claims, or an increase in the amounts due as a result of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.
In August of 2011, the Company was named as a Defendant in a class action litigation alleging violations of state and federal wage and hour law. In January of 2017, the Company participated in an initial mediation session with plaintiffs' counsel. As a result of this discussion and due to (i) the fact no class had been certified (ii) the lack of specificity as to legal theories put forth by the plaintiffs (iii) the nature of the remedies sought and (iv) the lack of any basis on which to compute estimated compensatory and/or exemplary damages, the Company could not predict what the outcome of the pending class action lawsuit would be, what the timing of the ultimate resolution of this lawsuit would be, or an estimate and/or range of possible loss related to it.
In March of 2017, the Company was invited to engage in further settlement discussions to determine whether a resolution of the case was possible in advance of a decision on class certification. In April of 2017, the Company reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court.  Based upon the change in case status, the Company recorded an accrual for estimated probable losses of $11,000, exclusive of legal fees, in the first quarter of 2017. The Company funded the settlement amount of $11,000 in December of 2017, and the funds were distributed to the class members in the first quarter of 2018. The Company received back $1,664 related to unclaimed class settlement funds remaining after completion of the settlement process, and the recoveries were recorded in the first quarter of 2018.

Other claims and suits continue to be filed against the Company, its independent operating entities, and other post-acute care providers. In addition, professional negligence claims have been filed and will likely continue to be filed against the Company's independent operating entities by residents or responsible parties.

The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any litigation were to proceed through trial, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar State and Federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its subsidiaries going forward under a corporate integrity agreement and/or other arrangements.
Medicare Revenue Recoupments — The Company's independent operating entities are subject to regulatory reviews relating to Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC), Unified Program Integrity Contractors (UPIC) and Medicaid Integrity Contributors (MIC) programs collectively referred to as Reviews. As of June 30, 2019, ten of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process, both pre- and post-payment. The Company anticipates that these Reviews will increase in frequency in the future. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. As of June 30, 2019, the Company's independent operating subsidiaries have responded to the requests and the related claims are currently under Review, on appeal or in a dispute resolution process.
U.S. Government Inquiry and Corporate Integrity Agreement — In October 2013, the Company and its independent operating entities completed and executed a settlement agreement (the Settlement Agreement) with the DOJ, which received the final approval of the Office of Inspector General-HHS and the United States District Court for the Central District of California. Pursuant to the Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $48,000 in October 2013. The Company and its independent operating entities have denied engaging in any illegal conduct and agreed to the settlement amount without any admission of wrongdoing in order to resolve the allegations and to avoid the uncertainty and expense of protracted litigation.

In connection with the settlement and effective as of October 1, 2013, the Company and its independent operating entities entered into a five-year corporate integrity agreement (the CIA) with the Office of Inspector General-HHS. CMS acknowledged the existence of the Company’s current compliance program, which is in accord with the Office of the Inspector General (OIG)’s guidance related to an effective compliance program, and required that the Company and its independent operating entities continue during the term of the CIA to maintain a program designed to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs.

In the first quarter of 2019, the Company received notice from the OIG that the Company’s five-year CIA with the OIG has been completed. Upon receipt of the Company’s fifth and final annual report, the OIG confirmed that the term of the CIA is concluded.

Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for approximately 60.3% and 60.6% of its total accounts receivable as of June 30, 2019 and December 31, 2018, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 68.0% of the Company's revenue for both the three and six months ended June 30, 2019, respectively, and 68.2% and 68.0% of the Company's revenue for the three and six months ended June 30, 2018, respectively.

Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of July 30, 2019, the Company had approximately $1,066 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Common Stock
6 Months Ended
Jun. 30, 2019
Common Stock [Abstract]  
Common stock [Text Block] COMMON STOCK
As approved by the Board of Directors on April 3, 2018, the Company entered into a stock repurchase program pursuant to which the Company may repurchase up to $30,000 of its common stock under the program for a period of approximately 11 months. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The stock repurchase program expired on February 20, 2019. The Company did not purchase any shares pursuant to this stock repurchase program.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Level 2 (Policies)
6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation — The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and senior living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.
The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the three and six months ended June 30, 2019 and 2018.
The Company completed the sale of one of its senior living operations for a sale price of $1,838 during the first quarter of 2019. The sale transaction does not meet the criteria of discontinued operations as it does not represent a strategic shift that has, or will have, a major effect on the Company's operations and financial results. The Company presented property and equipment assets of the senior living operation sold as held for sale in the consolidated balance sheet as of December 31, 2018.
Estimates and Assumptions
Estimates and Assumptions — The preparation of Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, intangible assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments
Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.
Revenue Recognition

Revenue Recognition — On January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606) applying the modified retrospective method. The adoption of ASC 606 did not have a material impact on the measurement nor on the recognition of revenue of contracts, for which all revenue had not been recognized, as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of retained earnings at the beginning of 2018. See Note 4, Revenue and Accounts Receivable.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration. The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts and other currently available evidence. See Note 4, Revenue and Accounts Receivable.
Property and Equipment
Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of $705 and $860 during the three and six months ended June 30, 2018. The Company did not record an impairment charge during the three and six months ended June 30, 2019.

Leases and Leasehold Improvements
Leases and Leasehold Improvements - The Company leases skilled nursing facilities, senior living facilities and commercial office space. On January 1, 2019, the Company adopted Accounting Standards Codification Topic 842, Leases (ASC 842), electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings. The Company determines if an arrangement is a lease at the inception of each lease. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheet. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company estimates this rate based on prevailing financial market conditions, comparable company and credit analysis, and management judgment. The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term excludes lease renewals as the renewal rents are not at a bargain, there are no economic penalties for the Company to renew the lease, and it is not reasonably assured that the Company will exercise the extension options. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.

The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheet. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. See further discussion at Note 17, Leases.
Intangible Assets and Goodwill
Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible assets impairment during the three and six months ended June 30, 2019 and 2018. See further discussion at Note 11, Goodwill and Other Indefinite-Lived Intangible Assets.
Self-Insurance
Self-Insurance — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas, Washington and Wyoming for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $45,106 and $42,635 as of June 30, 2019 and December 31, 2018, respectively.
 The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington and Wyoming, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington and Wyoming, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and benefit payments are managed through a state insurance pool. Outside of California, Texas, Washington and Wyoming, the Company has purchased insurance coverage that insures individual claims that exceed $350 per accident. In all states except Washington and Wyoming, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $25,317 and $24,624 as of June 30, 2019 and December 31, 2018, respectively.
In addition, the Company has recorded an asset and equal liability of $7,747 and $6,969 at June 30, 2019 and December 31, 2018, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $300 for each covered person with an additional one-time aggregate individual stop loss deductible of $75. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of $75. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $6,376 and $5,823 as of June 30, 2019 and December 31, 2018, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific
and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

Noncontrolling Interest
Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Share-Based Compensation
Share-Based Compensation — The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
Recent Accounting Pronouncements
Recent Accounting Pronouncements — Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In February 2016, the FASB established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases with terms longer than 12 months on the balance sheet and disclose key information about leasing arrangements. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The classification criteria for distinguishing between operating and finance (previously capital) leases are substantially similar to the previous lease guidance, but with no explicit bright lines.

The Company adopted the standard as of January 1, 2019, electing the transition method that allows it to apply the standard as of the adoption date and record a cumulative adjustment in retained earnings, if applicable. The Company has elected the package of practical expedients permitted under the transition guidance, which among other things, allows the Company to carry forward the historical lease classification. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company has made an accounting policy to keep leases with an initial term of 12 months or less off of the balance sheet and recognize those lease payments in the consolidated statements of income on a straight-line basis over the lease term. The Company has also elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.

The adoption of this standard resulted in recognition of right-of-use assets and lease liabilities of $1,051,148 and $1,029,240, respectively, on its condensed consolidated balance sheets as of January 1, 2019. The Company recorded an adjustment, net of tax, of $9,030 to retained earnings, on the adoption date, related to a deferred gain on a previous sale-leaseback transaction, which resulted in an increase in rent expense of $658 annually, as we are no longer able to recognize the gain in our consolidated statement of income as a result of the new lease standard. In addition, initial direct costs associated with its lease agreements and favorable lease assets of $26,939 were classified into right-of-use assets on the adoption date. The standard does not materially affect the Company's consolidated net earnings or have a notable impact on liquidity or debt-covenant compliance under the current agreements. See further discussion at Note 17, Leases.

Prior to the adoption of ASC 842, the Company recognized revenue related to its senior living residency agreements in accordance with the provisions of ASC 840, Leases ("ASC 840").  Subsequent to the adoption of ASU 2016-02, Leases, lessors are required to separately recognize and measure the lease component of a contract with a customer utilizing the provisions of ASC 842 and the non-lease components utilizing the provisions of ASC 606, Revenue from Contracts with Customers. To separately account for the components, the transaction price is allocated among the components based upon the estimated stand alone selling prices of the components. Additionally, certain components of a contract which were previously included within the lease element recognized in accordance with ASC 840 prior to the adoption of ASU 2016-02 (such as common area maintenance services, other basic services, and executory costs) are recognized as non-lease components subject to the provisions of ASC 606 subsequent to the adoption of ASU 2016-02. Entities are required to recognize a cumulative effect adjustment to beginning retained earnings as of the initial application date of ASU 2016-02 for changes to amounts recognized for these certain components for the transition from ASC 840 to ASC 606. However, entities are permitted to elect the practical expedient under ASU 2018-11, Leases, allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. Entities that elect to utilize the lease/non-lease component combination practical expedient under ASU 2018-11 upon initial application of ASC 842 are required to apply the practical expedient to all new and existing transactions within a class of underlying assets that qualify for the expedient as of the initial application date with a cumulative effect adjustment to beginning retained earnings as of the initial application date for any changes recognized related to existing transactions.

Upon adoption of ASU 2016-02 and ASU 2018-11, the Company elected the lessor practical expedient within ASU 2018-11.  The Company recognizes revenue under these resident agreements based upon the predominant component, either the lease or non-lease component, of the contracts rather than allocating the consideration and separately accounting for it under ASC Topic 842 and ASC Topic 606. The Company has concluded that the non-lease components of the agreements with respect to its senior living communities are the predominant component of the contract, therefore, the Company recognizes revenue for these residents agreements under ASC Topic 606. The timing and pattern of revenue recognition is substantially the same as that prior to the adoption of these standards.

In June 2018, the FASB issued ASU 2018-07, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation-Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The Company adopted this guidance effective January 1, 2019. The adoption of this guidance did not have a material impact on its consolidated financial statements and related disclosures.

Accounting Standards Recently Issued But Not Yet Adopted by the Company

In August 2018, the FASB issued amended guidance to simplify fair value measurement disclosure requirements. The new provisions eliminate the requirements to disclose (1) transfers between Level 1 and Level 2 of the fair value hierarchy, (2) policies related to valuation processes and the timing of transfers between levels of the fair value hierarchy, and (3) net asset value disclosure of estimates of timing of future liquidity events. The FASB also modified disclosure requirements of Level 3 fair value measurements. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The FASB also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of credit Losses on Financial Instruments”, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for fiscal year beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption is permitted. The Company has not yet determined the effect of the ASU on its results of operations, financial condition or cash flows.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue and Accounts Receivable (Tables)
6 Months Ended
Jun. 30, 2019
REVENUE AND ACCOUNTS RECEIVABLE [Abstract]  
Disaggregation of Revenue [Table Text Block]
Revenue for the three and six months ended June 30, 2019 and 2018 is summarized in the following tables:
 
Three Months Ended June 30,
 
2019
 
2018
 
Revenue
 
% of
Revenue
 
Revenue
 
% of
Revenue
Medicaid
$
206,811

 
35.9
%
 
$
173,169

 
34.9
%
Medicare
153,187

 
26.6

 
136,813

 
27.6

Medicaid — skilled
31,792

 
5.5

 
28,298

 
5.7

Total Medicaid and Medicare
391,790

 
68.0

 
338,280

 
68.2

Managed care
93,690

 
16.3

 
80,150

 
16.1

Private and other payors(1)
90,171

 
15.7

 
77,956

 
15.7

Revenue
$
575,651

 
100.0
%
 
$
496,386

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019 and 2018.
 
Six Months Ended June 30,
 
2019
 
2018
 
Revenue
 
% of
Revenue
 
Revenue
 
% of
Revenue
Medicaid
$
401,814

 
35.7
%
 
$
340,794

 
34.5
%
Medicare
300,907

 
26.8

 
276,127

 
27.9

Medicaid — skilled
62,243

 
5.5

 
55,340

 
5.6

Total Medicaid and Medicare
764,964

 
68.0

 
672,261

 
68.0

Managed care
183,538

 
16.3

 
163,866

 
16.6

Private and other payors(1)
176,363

 
15.7

 
152,393

 
15.4

Revenue
$
1,124,865

 
100.0
%
 
$
988,520

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019 and 2018.
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

Accounts receivable as of June 30, 2019 and December 31, 2018 is summarized in the following table:
 
June 30, 2019
 
December 31, 2018
Medicaid
$
128,069

 
$
117,984

Managed care
62,605

 
54,682

Medicare
53,232

 
50,994

Private and other payors
56,755

 
55,325

 
300,661

 
278,985

Less: allowance for doubtful accounts
(3,726
)
 
(2,886
)
Accounts receivable, net
$
296,935

 
$
276,099


XML 40 R29.htm IDEA: XBRL DOCUMENT v3.19.2
Computation of Net Income Per Common Share (Tables)
6 Months Ended
Jun. 30, 2019
COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract]  
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]
A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net income
$
28,925

 
$
22,326

 
$
56,532

 
$
45,619

Less: net income attributable to noncontrolling interests
316

 
315

 
551

 
476

Net income attributable to The Ensign Group, Inc.
$
28,609

 
$
22,011

 
$
55,981

 
$
45,143

 
 
 
 
 
 
 
 
Denominator:

 
 
 
 
 
 
Weighted average shares outstanding for basic net income per share
53,408

 
51,880

 
53,246

 
51,733

Basic net income per common share attributable to The Ensign Group, Inc.
$
0.54

 
$
0.42

 
$
1.05

 
$
0.87


Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]
A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019

2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net income
$
28,925

 
$
22,326

 
$
56,532

 
$
45,619

Less: net income attributable to noncontrolling interests
316

 
315

 
551

 
476

Net income attributable to The Ensign Group, Inc.
$
28,609

 
$
22,011

 
$
55,981

 
$
45,143

 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average common shares outstanding
53,408

 
51,880

 
53,246

 
51,733

Plus: incremental shares from assumed conversion (1)
2,670

 
2,371

 
2,650

 
2,176

Adjusted weighted average common shares outstanding
56,078


54,251

 
55,896

 
53,909

Diluted net income per common share attributable to The Ensign Group, Inc.
$
0.51

 
$
0.41

 
$
1.00

 
$
0.84


(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 173 and 322 for the three and six months ended June 30, 2019, respectively, and 196 and 398 for the three and six months ended June 30, 2018, respectively.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018:
 
 
June 30, 2019
 
December 31, 2018
 
 
Level 1
 
Level 2
 
Level 3
 
Level 1
 
Level 2
 
Level 3
Cash and cash equivalents
 
$
39,042

 
$

 
$

 
$
31,083

 
$

 
$


XML 42 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Business Segments (Tables)
6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]
Segment revenues by major payor source were as follows:
 
 
Three Months Ended June 30, 2019
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
192,545

 
$
10,333

 
$
3,933

 
$

 
$
206,811

 
35.9
%
Medicare
 
118,807

 

 
34,380

 

 
153,187

 
26.6

Medicaid-skilled
 
31,792

 

 

 

 
31,792

 
5.5

Subtotal
 
343,144

 
10,333

 
38,313

 

 
391,790

 
68.0

Managed care
 
86,491

 

 
7,199

 

 
93,690

 
16.3

Private and other
 
39,603

 
31,713

 
4,696

 
14,159

(1)
90,171

 
15.7

Total revenue
 
$
469,238

 
$
42,046

 
$
50,208

 
$
14,159

 
$
575,651

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2019.
 
 
Three Months Ended June 30, 2018
 
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
161,584

 
$
8,677

 
$
2,908

 
$

 
$
173,169

 
34.9
%
Medicare
 
108,237

 

 
28,576

 

 
136,813

 
27.6

Medicaid-skilled
 
28,298

 

 

 

 
28,298

 
5.7

Subtotal
 
298,119

 
8,677

 
31,484

 

 
338,280

 
68.2

Managed care
 
74,168

 

 
5,982

 

 
80,150

 
16.1

Private and other
 
36,231

 
28,487

 
3,783

 
9,455

(1)
77,956

 
15.7

Total revenue
 
$
408,518

 
$
37,164

 
$
41,249

 
$
9,455

 
$
496,386

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the three months ended June 30, 2018.
 
 
Six Months Ended June 30, 2019
 
 
Transitional and Skilled Services
 
Assisted and Independent Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
373,839

 
$
20,135

 
$
7,840

 
$

 
$
401,814

 
35.7
%
Medicare
 
235,508

 

 
65,399

 

 
300,907

 
26.8

Medicaid-skilled
 
62,243

 

 

 

 
62,243

 
5.5

Subtotal
 
671,590

 
20,135

 
73,239

 

 
764,964

 
68.0

Managed care
 
169,663

 

 
13,875

 

 
183,538

 
16.3

Private and other
 
77,243

 
62,605

 
9,211

 
27,304

(1)
176,363

 
15.7

Total revenue
 
$
918,496

 
$
82,740

 
$
96,325

 
$
27,304

 
$
1,124,865

 
100.0
%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2019.

 
 
Six Months Ended June 30, 2018
 
 
Transitional and Skilled Services
 
Assisted and Independent Living Services
 
Home Health and Hospice Services
 
All Other
 
Total Revenue
 
Revenue %
Medicaid
 
$
318,095

 
$
16,941

 
$
5,758

 
$

 
$
340,794

 
34.5
%
Medicare
 
220,190

 

 
55,937

 

 
276,127

 
27.9

Medicaid-skilled
 
55,340

 

 

 

 
55,340

 
5.6

Subtotal
 
593,625

 
16,941

 
61,695

 

 
672,261

 
68.0

Managed care
 
151,968

 

 
11,898

 

 
163,866

 
16.6

Private and other
 
69,941

 
56,336

 
7,414

 
18,702

(1)
152,393

 
15.4

Total revenue
 
$
815,534

 
$
73,277

 
$
81,007

 
$
18,702

 
$
988,520

 
100.0
%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the six months ended June 30, 2018.
Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following table sets forth selected financial data consolidated by business segment:
 
 
Three Months Ended June 30, 2019
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
469,238

 
$
42,046

 
$
50,208

 
$
14,159

 
$

 
$
575,651

Intersegment revenue(1)
 
780

 

 

 
2,149

 
(2,929
)
 

Total revenue
 
$
470,018

 
$
42,046

 
$
50,208

 
$
16,308

 
$
(2,929
)
 
$
575,651

Segment income (loss)(2)
 
$
56,652

 
$
4,821

 
$
7,306

 
$
(30,933
)
 
$

 
$
37,846

Interest expense, net of interest income
 

 

 

 

 
 
 
$
(3,369
)
Income before provision for income taxes
 

 

 

 

 
 
 
$
34,477

Depreciation and amortization
 
$
8,938

 
$
2,019

 
$
320

 
$
1,907

 
$

 
$
13,184

 
 
 
 
 
 
 
 
 
 
 
 
 

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $780. Including these expenses, home health and hospice services segment income would be $6,526. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $2,149.
(3) General and administrative expense are included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.

 
 
Three Months Ended June 30, 2018
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
408,518

 
$
37,164

 
$
41,249

 
$
9,455

 
$

 
$
496,386

Intersegment revenue(1)
 
645

 

 

 
1,112

 
(1,757
)
 

Total revenue
 
$
409,163

 
$
37,164

 
$
41,249

 
$
10,567

 
$
(1,757
)
 
$
496,386

Segment income (loss)(2)
 
$
43,210

 
$
4,966

 
$
6,268

 
$
(22,669
)
 
$

 
$
31,775

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(3,307
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
28,468

Depreciation and amortization
 
$
7,708

 
$
1,863

 
$
281

 
$
1,769

 
$

 
$
11,621

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $645.  Including these expenses, home health and hospice services segment income would be $5,623. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $1,112.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
 
 
Six Months Ended June 30, 2019
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
918,496

 
$
82,740

 
$
96,325

 
$
27,304

 
$

 
$
1,124,865

Intersegment revenue(1)
 
1,495

 

 

 
3,861

 
(5,356
)
 

Total revenue
 
$
919,991

 
$
82,740

 
$
96,325

 
$
31,165

 
$
(5,356
)
 
$
1,124,865

Segment income (loss)(2)
 
$
115,416

 
$
9,859

 
$
14,174

 
$
(63,799
)
 
$

 
$
75,650

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(6,466
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
69,184

Depreciation and amortization
 
$
17,552

 
$
3,919

 
$
580

 
$
3,731

 
$

 
$
25,782

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $1,495. Including these expenses, home health and hospice services segment income would be $12,679. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines which are included in the "All Other" category of $3,861.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.


 
 
Six Months Ended June 30, 2018
 
 
Transitional and Skilled Services(4)
 
Senior Living Services(4)
 
Home Health and Hospice Services
 
All Other(3)
 
Elimination
 
Total
Revenue from external customers
 
$
815,534

 
$
73,277

 
$
81,007

 
$
18,702

 
$

 
$
988,520

Intersegment revenue(1)
 
1,334

 

 

 
2,194

 
(3,528
)
 

Total revenue
 
$
816,868

 
$
73,277

 
$
81,007

 
$
20,896

 
$
(3,528
)
 
$
988,520

Segment income (loss)(2)
 
$
89,405

 
$
9,629

 
$
12,326

 
$
(46,606
)
 
$

 
$
64,754

Interest expense, net of interest income
 
 
 
 
 
 
 
 
 
 
 
$
(6,472
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
$
58,282

Depreciation and amortization
 
$
15,510

 
$
3,460

 
$
526

 
$
3,747

 
$

 
$
23,243

 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Intersegment revenue represents services provided at the Company's operating subsidiaries between the Company's business lines.
(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, senior living services and home health and hospice services segments. Home health and hospice services segment income also excludes intercompany expenses for services provided at transitional and skilled operations of $1,334.  Including these expenses, home health and hospice services segment income would be $10,992. Transitional and skilled services, senior living services and home health and hospice services segment income excludes intercompany expenses for services provided by the business lines that are included in the "All Other" category of $2,194.
(3) General and administrative expense is included in the "All Other" category.
(4) The Company's campuses represent facilities that offer both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective reportable segment.
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment (Tables)
6 Months Ended
Jun. 30, 2019
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment [Table Text Block]
Property and equipment, net consist of the following:
 
June 30, 2019
 
December 31, 2018
Land
$
68,081

 
$
60,420

Buildings and improvements
449,763

 
411,096

Equipment
220,402

 
202,346

Furniture and fixtures
5,465

 
5,079

Leasehold improvements
127,345

 
112,935

Construction in progress
10,195

 
9,729

 
881,251

 
801,605

Less: accumulated depreciation
(206,359
)
 
(182,731
)
Property and equipment, net
$
674,892

 
$
618,874


XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets - Net (Tables)
6 Months Ended
Jun. 30, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
 
 
Weighted Average Life (Years)
 
June 30, 2019
 
December 31, 2018
 
 
 
Gross Carrying Amount
 
Accumulated Amortization
 
 
 
Gross Carrying Amount
 
Accumulated Amortization
 
 
Intangible Assets
 
 
 
 
Net
 
 
 
Net
Lease acquisition costs
 
1.7
 
$
360

 
$
(240
)
 
120

 
$
843

 
$
(251
)
 
$
592

Favorable leases
 
2.1
 
534

 
(316
)
 
218

 
35,650

 
(8,724
)
 
26,926

Assembled occupancy
 
0.4
 
3,180

 
(3,056
)
 
124

 
2,936

 
(2,870
)
 
66

Facility trade name
 
30.0
 
733

 
(330
)
 
403

 
733

 
(317
)
 
416

Customer relationships
 
16.7
 
5,110

 
(2,146
)
 
2,964

 
4,670

 
(1,670
)
 
3,000

Total
 
 
 
$
9,917

 
$
(6,088
)
 
$
3,829

 
$
44,832

 
$
(13,832
)
 
$
31,000


Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Estimated amortization expense for each of the years ending December 31 is as follows:
Year
Amount
2019 (remainder)
$
567

2020
345

2021
249

2022
249

2023
237

2024
234

Thereafter
1,948

 
$
3,829



XML 45 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Other Indefinite-Lived Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2019
Indefinite-Lived Intangible Assets (Including Goodwill) [Abstract]  
Schedule of Goodwill [Table Text Block]
The following table represents activity in goodwill by segment as of and for the six months ended June 30, 2019:
 
Goodwill
 
Transitional and Skilled Services
 
Senior Living Services
 
Home Health and Hospice Services
 
All Other
 
Total
January 1, 2019
$
45,486

 
$
3,958


$
27,250

 
$
3,783

 
$
80,477

Additions

 

 
11,500

 
5,431

 
16,931

June 30, 2019
$
45,486

 
$
3,958

 
$
38,750

 
$
9,214

 
$
97,408


Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]
Other indefinite-lived intangible assets consists of the following:
 
June 30, 2019

December 31, 2018
Trade name
$
1,373

 
$
1,217

Medicare and Medicaid licenses
29,549

 
26,385

 
$
30,922

 
$
27,602

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Restricted and Other Assets (Tables)
6 Months Ended
Jun. 30, 2019
Other Assets [Abstract]  
Schedule of Other Assets [Table Text Block]
Restricted and other assets consist of the following:
 
June 30, 2019
 
December 31, 2018
Debt issuance costs, net
$
1,442

 
$
1,892

Long-term insurance losses recoverable asset
7,747

 
6,969

Deposits with landlords
4,148

 
8,694

Capital improvement reserves with landlords and lenders
3,535

 
3,196

Note receivable from sale of ancillary business
71

 
93

Restricted and other assets
$
16,943

 
$
20,844


XML 47 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Other Accrued Liabilities (Tables)
6 Months Ended
Jun. 30, 2019
Accrued Liabilities [Abstract]  
Schedule of Accrued Liabilities [Table Text Block]

Other accrued liabilities consist of the following:
 
June 30, 2019
 
December 31, 2018
Quality assurance fee
$
5,639

 
$
5,375

Refunds payable
27,477

 
25,118

Resident advances
4,607

 
8,495

Cash held in trust for patients
2,842

 
2,824

Resident deposits
7,753

 
6,665

Dividends payable
2,559

 
2,525

Property taxes
7,669

 
9,426

Other
11,270

 
9,356

Other accrued liabilities
$
69,816

 
$
69,784



XML 48 R37.htm IDEA: XBRL DOCUMENT v3.19.2
Debt (Tables)
6 Months Ended
Jun. 30, 2019
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments [Table Text Block]
Long-term debt consists of the following:
 
June 30, 2019
 
December 31, 2018
Term loan with SunTrust
$
109,375

 
$
113,125

Revolving credit facility with SunTrust
50,000

 
10,000

Mortgage loans and promissory note
121,664

 
122,955

 
281,039

 
246,080

Less: current maturities
(10,153
)
 
(10,105
)
Less: debt issuance costs
(2,707
)
 
(2,840
)
 
$
268,179

 
$
233,135


XML 49 R38.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards (Tables)
6 Months Ended
Jun. 30, 2019
Options and Awards [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
The Company used the following assumptions for stock options granted during the three months ended June 30, 2019 and 2018:
Grant Year
 
Options Granted
 
Weighted Average Risk-Free Rate
 
Expected Life
 
Weighted Average Volatility
 
Weighted Average Dividend Yield
2019
 
258
 
2.1%
 
6.3 years
 
34.0%
 
0.4%
2018
 
227
 
2.7%
 
6.2 years
 
32.0%
 
0.5%


The Company used the following assumptions for stock options granted during the six months ended June 30, 2019 and 2018:
Grant Year
 
Options Granted
 
Weighted Average Risk-Free Rate
 
Expected Life
 
Weighted Average Volatility
 
Weighted Average Dividend Yield
2019
 
399

 
2.2%
 
6.3 years
 
33.9%
 
0.3%
2018
 
395

 
2.7%
 
6.2 years
 
32.0%
 
0.6%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]
For the six months ended June 30, 2019 and 2018, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant Year
 
Granted
 
Weighted Average Exercise Price
 
Weighted Average Fair Value of Options
2019
 
399

 
$
53.67

 
$
19.35

2018
 
395

 
$
32.33

 
$
11.15


Schedule of Common Stock Outstanding Roll Forward [Table Text Block]
The following table represents the employee stock option activity during the six months ended June 30, 2019:
 
Number of
Options
Outstanding
 
Weighted
Average
Exercise Price
 
Number of
Options Vested
 
Weighted
Average
Exercise Price
of Options
Vested
January 1, 2019
4,188

 
$
17.35

 
2,431

 
$
12.37

Granted
399

 
53.67

 
 
 
 
Forfeited
(27
)
 
26.16

 
 
 
 
Exercised
(531
)
 
10.45

 
 
 
 
June 30, 2019
4,029

 
$
21.80

 
2,407

 
$
13.88


Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
The following summary information reflects stock options outstanding, vested and related details as of June 30, 2019:
 
 
Stock Options Outstanding
 
Stock Options Vested
 
 
 
 
 
 
 
Number Outstanding
 
Black-Scholes Fair Value
 
Remaining Contractual Life (Years)
 
Vested and Exercisable
Year of Grant
 
Exercise Price
 
 
 
 
2009
 
$4.06
-
$4.56
 
40

 
$
83

 
0
 
40

2010
 
4.77
-
4.96
 
50

 
122

 
1
 
50

2011
 
5.90
-
7.99
 
80

 
274

 
2
 
80

2012
 
6.56
-
7.96
 
217

 
797

 
3
 
217

2013
 
7.98
-
11.49
 
355

 
1,712

 
4
 
355

2014
 
10.55
-
18.94
 
1,049

 
5,953

 
5
 
1,025

2015
 
21.47
-
25.24
 
431

 
3,926

 
6
 
272

2016
 
18.79
-
19.89
 
381

 
2,652

 
7
 
180

2017
 
18.64
-
22.90
 
420

 
2,931

 
8
 
118

2018
 
26.53
-
38.59
 
607

 
7,346

 
9
 
70

2019
 
$53.50
-
$53.99
 
399

 
7,724


10


Total
 
 
 
 
 
4,029

 
$
33,520

 
 

2,407


Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2019 and changes during the six months ended June 30, 2019 is presented below:
 
Non-Vested Restricted Awards
 
Weighted Average Grant Date Fair Value
Nonvested at January 1, 2019
573

 
$
29.31

Granted
194

 
52.16

Vested
(166
)
 
38.79

Forfeited
(5
)
 
28.67

Nonvested at June 30, 2019
596

 
$
34.13


Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Share-based compensation expense recognized for the Company's equity incentive plans for the three and six months ended June 30, 2019 and 2018 was as follows:
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Share-based compensation expense related to stock options
$
1,479

 
$
1,292

 
$
2,822

 
$
2,508

Share-based compensation expense related to restricted stock awards
1,199

 
675

 
2,197

 
1,253

Share-based compensation expense related to stock options and restricted stock awards to non-employee directors
388

 
210

 
659

 
387

Total
$
3,066

 
$
2,177

 
$
5,678


$
4,148


Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block]
The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of June 30, 2019 and December 31, 2018 is as follows:
Options
 
June 30, 2019
 
December 31, 2018
Outstanding
 
$
141,531

 
$
89,806

Vested
 
103,589

 
64,222

Expected to vest
 
32,597

 
22,963

Exercisable
 
21,118

 
27,646


XML 50 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Tables)
6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
The following table summarizes the impact of the adoption of the new lease accounting guidance on the Company’s condensed consolidated balance sheet as of January 1, 2019.

 
 
Balance at December 31, 2018
 
Adjustments due to new lease guidance
 
January 1, 2019
 
Balance at June 30, 2019
Total assets(1)
 
$
1,181,958

 
$
1,015,937

 
$
2,197,895

 
$
2,321,521

Total liabilities(2)
 
579,618

 
1,006,907

 
1,586,525

 
1,644,214

Total equity
 
602,340

 
9,030

 
611,370

 
677,307

(1) Adjustment in assets includes the reclassification of intangible assets, prepaid rent and deferred rent into right-of-use assets and the decrease in deferred tax assets due to the removal of deferred gain related to sale-leaseback as of January 1, 2019.
(2) Adjustment in liabilities includes the reclassification of other liabilities into lease liabilities and the removal of deferred gain related to sale-lease back as of January 1, 2019.
Lease, Cost [Table Text Block]
The components of operating lease expense(1), are as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2019
 
2018
 
2019
 
2018
Rent - cost of services(2)
 
$
37,060

 
$
34,472

 
$
72,846

 
$
68,322

General and administrative expense
 
151

 
168

 
335

 
318

Depreciation and amortization(3)
 
495

 
495

 
990

 
990

 
 
$
37,706

 
$
35,135

 
$
74,171

 
$
69,630

(1) Operating lease expenses include short-term leases and variable lease costs, which are immaterial.
(2) Rent- cost of services includes the amortization of deferred rent of $434 and $688 for the three and six months ended June 30, 2019, respectively.
(3) Depreciation and amortization is related to the amortization of favorable and direct lease costs.
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
Future minimum lease payments for all leases as of June 30, 2019 are as follows:
Year
 
Amount
2019 (remainder)
 
$
74,865

2020
 
149,083

2021
 
148,086

2022
 
146,540

2023
 
144,852

2024
 
142,880

Thereafter
 
912,928

Total lease payments
 
1,719,234

Less: present value adjustment
 
(646,138
)
Less: variable rent
 
(25,265
)
Present value of total lease liabilities
 
1,047,831

Less: current lease liabilities
 
(59,686
)
Long-term operating lease liabilities
 
$
988,145

Future minimum lease payments for all leases as of December 31, 2018 were as follows:
Year
 
Amount
2019
 
$
142,497

2020
 
141,536

2021
 
140,524

2022
 
139,018

2023
 
137,349

Thereafter
 
967,027

Total lease payments
 
$
1,667,951



XML 51 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Description of Business (Details)
Jun. 30, 2019
business
Beds
facilities
Dec. 31, 2018
facilities
Skilled nursing, assisted living and independent living facilities [Abstract]    
Number of Real Estate Properties 77 72
Number of Real Estate Properties Leased 177 172
Number of Real Estate Properties Leased with an Option to Purchase 12 12
Number of Real Estate Properties Operated 254 244
Home Health, Hospice and Home Care Operations | business 62  
Operational Skilled Nursing Beds | Beds 20,700  
Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract]    
Operational Senior Living Units | Beds 5,900  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Description of Business Proposed Spin-Off Transaction (Details)
May 06, 2019
business
Spinoff [Member]  
Restructuring Cost and Reserve [Line Items]  
Public Companies Created 2
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Proposed Spin-Off of Subsidiaries (Details)
May 06, 2019
business
facilities
Jun. 30, 2019
business
facilities
Restructuring Cost and Reserve [Line Items]    
Home Health, Hospice and Home Care Operations | business   62
Senior Living Facilities | facilities   56
Spinoff [Member]    
Restructuring Cost and Reserve [Line Items]    
Public Companies Created | business 2  
Spin-Off Transaction Company [Member] | Spinoff [Member]    
Restructuring Cost and Reserve [Line Items]    
Home Health, Hospice and Home Care Operations | business 62  
Senior Living Facilities | facilities 51  
Remaining Company [Member] | Spinoff [Member]    
Restructuring Cost and Reserve [Line Items]    
Senior Living Facilities | facilities 28  
Common Stock [Member] | Spin-Off Transaction Company [Member] | Spinoff [Member]    
Restructuring Cost and Reserve [Line Items]    
Stockholders' Equity Note, Stock Split, Conversion Ratio 1  
Common Stock [Member] | Remaining Company [Member] | Spinoff [Member]    
Restructuring Cost and Reserve [Line Items]    
Stockholders' Equity Note, Stock Split, Conversion Ratio 2  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Divestiture (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2019
USD ($)
facilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Sale Price from Divestiture of Businesses | $ $ 1,838
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Senior Living Facility | facilities 1
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Property and Equipment (Details)
6 Months Ended
Jun. 30, 2019
Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 59 years
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Impairment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Accounting Policies [Abstract]        
Impairment of Long-Lived Assets to be Disposed of $ 0 $ 705 $ 0 $ 860
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Intangible Assets and Goodwill (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Finite-Lived Intangible Assets [Line Items]        
Goodwill and intangible asset impairment $ 0 $ 0 $ 0 $ 0
Minimum [Member]        
Finite-Lived Intangible Assets [Line Items]        
Property, Plant and Equipment, Useful Life     3 years  
Maximum [Member]        
Finite-Lived Intangible Assets [Line Items]        
Property, Plant and Equipment, Useful Life     59 years  
Trade name        
Finite-Lived Intangible Assets [Line Items]        
Finite-Lived Intangible Asset, Useful Life     30 years  
Customer relationships        
Finite-Lived Intangible Assets [Line Items]        
Finite-Lived Intangible Asset, Useful Life     20 years  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Self-Insurance General and Professional (Details) - General and Professional Liability Insurance [Member] - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve $ 45,106 $ 42,635
Self-insurance retention per claim [Member] | Parent Company [Member]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 500  
Aggregate Deductible [Member] | Parent Company [Member] | CALIFORNIA    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 750  
Aggregate Deductible [Member] | Parent Company [Member] | Non-California [Domain]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 1,000  
Blanket Aggregate [Member] | Third-Party Payor [Member] | All States Except Colorado [Domain]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 5,000  
Per Facility [Member] | Third-Party Payor [Member] | All States Except Colorado [Domain]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 3,000  
Per Facility [Member] | Third-Party Payor [Member] | COLORADO    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 3,000  
Per Occurence [Member] | Third-Party Payor [Member] | All States Except Colorado [Domain]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 1,000  
Per Occurence [Member] | Third-Party Payor [Member] | COLORADO    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve $ 1,000  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Self-Insurance Workers' Compensation (Details) - Workers' Compensation [Member] - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve $ 25,317 $ 24,624
Stop-Loss Insurance limit per claim [Member]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 500  
Stop-Loss Insurance limit per claim [Member] | TEXAS    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 750  
Loss-Sensitive limit per claim [Member] [Member] | Other states, except California, Texas and Washington [Domain]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve $ 350  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Self Insurance Recoveries (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Accounting Policies [Abstract]    
Long-term insurance losses recoverable asset $ 7,747 $ 6,969
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Self-Insurance Health Insurance (Details) - Health Liability Insurance [Member] - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve $ 6,376 $ 5,823
Stop-Loss Insurance limit per claim [Member]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve 300  
Stop Loss Deductible [Member]    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self Insurance Reserve $ 75  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies Recent Accounting Standards Adopted (Details) - USD ($)
$ in Thousands
6 Months Ended
Jan. 01, 2019
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Right-of-use assets   $ 1,074,449   $ 0
Net of Lease Liability   1,047,831    
Sale Leaseback Transaction, Deferred Gain   $ 0 $ 329  
Accounting Standards Update 2016-02 [Member]        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Right-of-use assets $ 1,051,148      
Net of Lease Liability 1,029,240      
Cumulative Effect on Retained Earnings, Net of Tax 9,030      
Sale Leaseback Transaction, Deferred Gain 658      
Favorable leases | Accounting Standards Update 2016-02 [Member]        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Right-of-use assets $ 26,939      
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue and Accounts Receivable Revenue from Medicare and Medicaid Programs (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Rate
Jun. 30, 2018
Rate
Jun. 30, 2019
Rate
Jun. 30, 2018
Rate
Total Medicare and Medicaid        
Disaggregation of Revenue [Line Items]        
Revenue by payor as a percent of total revenue 68.00% 68.20% 68.00% 68.00%
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue and Accounts Receivable Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Disaggregation of Revenue [Line Items]        
Revenue $ 575,651 $ 496,386 $ 1,124,865 $ 988,520
Percentage of revenue 100.00% 100.00% 100.00% 100.00%
Medicaid        
Disaggregation of Revenue [Line Items]        
Revenue $ 206,811 $ 173,169 $ 401,814 $ 340,794
Percentage of revenue 35.90% 34.90% 35.70% 34.50%
Medicare        
Disaggregation of Revenue [Line Items]        
Revenue $ 153,187 $ 136,813 $ 300,907 $ 276,127
Percentage of revenue 26.60% 27.60% 26.80% 27.90%
Medicaid — skilled        
Disaggregation of Revenue [Line Items]        
Revenue $ 31,792 $ 28,298 $ 62,243 $ 55,340
Percentage of revenue 5.50% 5.70% 5.50% 5.60%
Total Medicaid and Medicare        
Disaggregation of Revenue [Line Items]        
Revenue $ 391,790 $ 338,280 $ 764,964 $ 672,261
Percentage of revenue 68.00% 68.20% 68.00% 68.00%
Managed care        
Disaggregation of Revenue [Line Items]        
Revenue $ 93,690 $ 80,150 $ 183,538 $ 163,866
Percentage of revenue 16.30% 16.10% 16.30% 16.60%
Private Pay and Other        
Disaggregation of Revenue [Line Items]        
Revenue $ 90,171 $ 77,956 $ 176,363 $ 152,393
Percentage of revenue 15.70% 15.70% 15.70% 15.40%
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue and Accounts Receivable Accounts Receivable (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts Receivable $ 300,661 $ 278,985
Less: allowance for doubtful accounts (3,726) (2,886)
Accounts receivable, net 296,935 276,099
Medicaid    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts Receivable 128,069 117,984
Managed care    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts Receivable 62,605 54,682
Medicare    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts Receivable 53,232 50,994
Private Pay and Other    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts Receivable $ 56,755 $ 55,325
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.19.2
Computation of Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Numerator:            
Net income $ 28,925   $ 22,326   $ 56,532 $ 45,619
Less: net income attributable to noncontrolling interests 316 $ 235 315 $ 161 551 476
Net income attributable to The Ensign Group, Inc. $ 28,609 $ 27,372 $ 22,011 $ 23,132 $ 55,981 $ 45,143
Denominator:            
Weighted average shares outstanding for basic net income per share 53,408   51,880   53,246 51,733
Adjusted weighted average common shares outstanding 56,078   54,251   55,896 53,909
Basic net income (loss) per common share:            
Basic net income per common share attributable to The Ensign Group, Inc. $ 0.54   $ 0.42   $ 1.05 $ 0.87
Diluted net (loss) income per common share:            
Diluted net income per common share attributable to The Ensign Group, Inc. $ 0.51   $ 0.41   $ 1.00 $ 0.84
Common Class A [Member]            
Denominator:            
Weighted average shares outstanding for basic net income per share 53,408   51,880   53,246 51,733
Plus: incremental shares from assumed conversion (1) 2,670   2,371   2,650 2,176
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.19.2
Computation of Net Income Per Common Share Antidilutive Shares (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Earnings Per Share, Diluted, Other Disclosures [Abstract]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 173 196 322 398
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements (Details) - Cash and cash equivalents - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Level 1    
Cash and cash equivalents $ 39,042 $ 31,083
Level 2    
Cash and cash equivalents 0 0
Level 3    
Cash and cash equivalents $ 0 $ 0
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.19.2
Fair Value Measurements Investments (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Debt Security, Corporate, US [Member]    
Schedule of Held-to-maturity Securities [Line Items]    
Debt Securities, Held-to-maturity $ 46,932 $ 44,850
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.19.2
Business Segments (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2019
USD ($)
Segments
business
facilities
Segment Reporting Information [Line Items]  
Number of Reportable Segments | Segments 3
Transitional and Skilled Service Facilities 171
Transitional and Skilled Services and Senior Living Campuses 27
Senior Living Facilities 56
Home Health, Hospice and Home Care Operations | business 62
Sale Price from Divestiture of Businesses | $ $ 1,838
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]  
Segment Reporting Information [Line Items]  
Senior Living Facility 1
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.19.2
Business Segments Revenue by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 575,651 $ 496,386 $ 1,124,865 $ 988,520
Revenue from Contract with Customer by Payor as a Percent of Total Revenue 100.00% 100.00% 100.00% 100.00%
Transitional and Skilled Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 469,238 $ 408,518 $ 918,496 $ 815,534
Senior Living Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 42,046 37,164 82,740 73,277
Home Health and Hospice Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 50,208 41,249 96,325 81,007
All Other        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 14,159 9,455 27,304 18,702
Medicaid        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 206,811 $ 173,169 $ 401,814 $ 340,794
Revenue from Contract with Customer by Payor as a Percent of Total Revenue 35.90% 34.90% 35.70% 34.50%
Medicaid | Transitional and Skilled Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 192,545 $ 161,584 $ 373,839 $ 318,095
Medicaid | Senior Living Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 10,333 8,677 20,135 16,941
Medicaid | Home Health and Hospice Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 3,933 2,908 7,840 5,758
Medicaid | All Other        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Medicare        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 153,187 $ 136,813 $ 300,907 $ 276,127
Revenue from Contract with Customer by Payor as a Percent of Total Revenue 26.60% 27.60% 26.80% 27.90%
Medicare | Transitional and Skilled Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 118,807 $ 108,237 $ 235,508 $ 220,190
Medicare | Senior Living Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Medicare | Home Health and Hospice Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 34,380 28,576 65,399 55,937
Medicare | All Other        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Medicaid — skilled        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 31,792 $ 28,298 $ 62,243 $ 55,340
Revenue from Contract with Customer by Payor as a Percent of Total Revenue 5.50% 5.70% 5.50% 5.60%
Medicaid — skilled | Transitional and Skilled Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 31,792 $ 28,298 $ 62,243 $ 55,340
Medicaid — skilled | Senior Living Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Medicaid — skilled | Home Health and Hospice Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Medicaid — skilled | All Other        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Total Medicaid and Medicare        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 391,790 $ 338,280 $ 764,964 $ 672,261
Revenue from Contract with Customer by Payor as a Percent of Total Revenue 68.00% 68.20% 68.00% 68.00%
Total Medicaid and Medicare | Transitional and Skilled Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 343,144 $ 298,119 $ 671,590 $ 593,625
Total Medicaid and Medicare | Senior Living Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 10,333 8,677 20,135 16,941
Total Medicaid and Medicare | Home Health and Hospice Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 38,313 31,484 73,239 61,695
Total Medicaid and Medicare | All Other        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Managed care        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 93,690 $ 80,150 $ 183,538 $ 163,866
Revenue from Contract with Customer by Payor as a Percent of Total Revenue 16.30% 16.10% 16.30% 16.60%
Managed care | Transitional and Skilled Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 86,491 $ 74,168 $ 169,663 $ 151,968
Managed care | Senior Living Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Managed care | Home Health and Hospice Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 7,199 5,982 13,875 11,898
Managed care | All Other        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 0 0 0 0
Private and other payors(1)        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 90,171 $ 77,956 $ 176,363 $ 152,393
Revenue from Contract with Customer by Payor as a Percent of Total Revenue 15.70% 15.70% 15.70% 15.40%
Private and other payors(1) | Transitional and Skilled Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 39,603 $ 36,231 $ 77,243 $ 69,941
Private and other payors(1) | Senior Living Services Segment        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 31,713 28,487 62,605 56,336
Private and other payors(1) | Home Health and Hospice Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 4,696 3,783 9,211 7,414
Private and other payors(1) | All Other        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 14,159 $ 9,455 $ 27,304 $ 18,702
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.19.2
Business Segments Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Segment Reporting Information [Line Items]        
Revenue from external customers $ 575,651 $ 496,386 $ 1,124,865 $ 988,520
Intersegment revenue (1) 0 0 0 0
Total revenue 575,651 496,386 1,124,865 988,520
Segment Income (Loss) 37,846 31,775 75,650 64,754
Interest expense, net of interest income (3,369) (3,307) (6,466) (6,472)
Income before provision for income taxes 34,477 28,468 69,184 58,282
Depreciation and amortization 13,184 11,621 25,782 23,243
Transitional and Skilled Services Segment        
Segment Reporting Information [Line Items]        
Revenue from external customers 469,238 408,518 918,496 815,534
Senior Living Services Segment        
Segment Reporting Information [Line Items]        
Revenue from external customers 42,046 37,164 82,740 73,277
Home Health and Hospice Services        
Segment Reporting Information [Line Items]        
Revenue from external customers 50,208 41,249 96,325 81,007
All Other        
Segment Reporting Information [Line Items]        
Revenue from external customers 14,159 9,455 27,304 18,702
Operating Segments [Member] | Transitional and Skilled Services Segment        
Segment Reporting Information [Line Items]        
Revenue from external customers 469,238 408,518 918,496 815,534
Total revenue 470,018 409,163 919,991 816,868
Segment Income (Loss) 56,652 43,210 115,416 89,405
Depreciation and amortization 8,938 7,708 17,552 15,510
Operating Segments [Member] | Senior Living Services Segment        
Segment Reporting Information [Line Items]        
Revenue from external customers 42,046 37,164 82,740 73,277
Total revenue 42,046 37,164 82,740 73,277
Segment Income (Loss) 4,821 4,966 9,859 9,629
Depreciation and amortization 2,019 1,863 3,919 3,460
Operating Segments [Member] | Home Health and Hospice Services        
Segment Reporting Information [Line Items]        
Revenue from external customers 50,208 41,249 96,325 81,007
Operating Income & Intersegment Expense 6,526 5,623 12,679 10,992
Total revenue 50,208 41,249 96,325 81,007
Segment Income (Loss) 7,306 6,268 14,174 12,326
Depreciation and amortization 320 281 580 526
Operating Segments [Member] | All Other        
Segment Reporting Information [Line Items]        
Revenue from external customers 14,159 9,455 27,304 18,702
Total revenue 16,308 10,567 31,165 20,896
Segment Income (Loss) (30,933) (22,669) (63,799) (46,606)
Depreciation and amortization 1,907 1,769 3,731 3,747
Operating Segments [Member] | Elimination        
Segment Reporting Information [Line Items]        
Total revenue (2,929) (1,757) (5,356) (3,528)
Segment Income (Loss) 0 0 0 0
Depreciation and amortization 0 0 0 0
Consolidation, Eliminations [Member] | Transitional and Skilled Services Segment        
Segment Reporting Information [Line Items]        
Intersegment revenue (1) 780 645 1,495 1,334
Consolidation, Eliminations [Member] | Senior Living Services Segment        
Segment Reporting Information [Line Items]        
Intersegment revenue (1) 0 0 0 0
Consolidation, Eliminations [Member] | Home Health and Hospice Services        
Segment Reporting Information [Line Items]        
Intersegment revenue (1) 0 0 0 0
Intersegment Expense 780 645 1,495 1,334
Consolidation, Eliminations [Member] | Transitional and skilled services, assisted and independent living services and home health and hospice services segments [Member]        
Segment Reporting Information [Line Items]        
Intersegment Expense 2,149 1,112 3,861 2,194
Consolidation, Eliminations [Member] | All Other        
Segment Reporting Information [Line Items]        
Intersegment revenue (1) 2,149 1,112 3,861 2,194
Consolidation, Eliminations [Member] | Elimination        
Segment Reporting Information [Line Items]        
Revenue from external customers 0 0 0 0
Intersegment revenue (1) $ (2,929) $ (1,757) $ (5,356) $ (3,528)
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.19.2
Acquisitions Summary (Details)
$ in Thousands
1 Months Ended 6 Months Ended
Jul. 31, 2019
Operations
Jun. 30, 2019
USD ($)
Beds
Operations
Jun. 30, 2018
USD ($)
Jul. 01, 2019
Beds
Business Acquisition [Line Items]        
Cash payments for asset acquisitions (Note 8) | $   $ (43,176) $ (55,546)  
Payments to Acquire Business and Asset Acquisitions | $   $ 65,362    
Operational Skilled Nursing Beds | Beds   20,700    
Operational Senior Living Units | Beds   5,900    
Transitional and Skilled Services and Senior Living Campuses [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired   3    
Senior Living Facilities [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired   1    
Operational Senior Living Units | Beds   364    
621610 Home Health Care Services [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired   2    
Hospice Agencies [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired   4    
8051 Services, Skilled Nursing Care Facilities [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired   7    
Operational Skilled Nursing Beds | Beds   1,088    
Home Care Agency [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired   2    
Subsequent Event [Member] | Senior Living Facilities [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired 1      
Operational Senior Living Units | Beds       91
Subsequent Event [Member] | 8051 Services, Skilled Nursing Care Facilities [Member]        
Business Acquisition [Line Items]        
Number of Businesses Acquired 1      
Operational Skilled Nursing Beds | Beds       27
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.19.2
Acquisitions (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2019
USD ($)
Operations
Jun. 30, 2018
USD ($)
Business Acquisition [Line Items]    
Payments to Acquire Businesses, Gross $ 22,186  
Payments to Acquire Asset Acquisitions 43,176 $ 55,546
Note payable due to seller from business acquisition 924  
Goodwill & Indefinite-lived Intangible Assets [Member]    
Business Acquisition [Line Items]    
Payments to Acquire Businesses, Gross 20,251  
Building and improvements    
Business Acquisition [Line Items]    
Payments to Acquire Asset Acquisitions 33,900  
Land    
Business Acquisition [Line Items]    
Payments to Acquire Asset Acquisitions $ 7,660  
Asset Acquisition [Member]    
Business Acquisition [Line Items]    
Number of Businesses Acquired | Operations 11  
Business Combination [Member]    
Business Acquisition [Line Items]    
Number of Businesses Acquired | Operations 9  
Office Building [Member]    
Business Acquisition [Line Items]    
Payments to Acquire Asset Acquisitions   $ 31,500
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.19.2
Property and Equipment (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property and equipment $ 881,251 $ 801,605
Less: accumulated depreciation (206,359) (182,731)
Property and equipment, net 674,892 618,874
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment 68,081 60,420
Building and improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment 449,763 411,096
Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment 220,402 202,346
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment 5,465 5,079
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment 127,345 112,935
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment $ 10,195 $ 9,729
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets - Net (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2019
Dec. 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Gross $ 9,917 $ 44,832
Accumulated Amortization (6,088) (13,832)
Intangible assets, net $ 3,829 31,000
Lease acquisition costs    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 1 year 8 months 12 days  
Finite-Lived Intangible Assets, Gross $ 360 843
Accumulated Amortization (240) (251)
Intangible assets, net $ 120 592
Favorable leases    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 2 years 1 month 6 days  
Finite-Lived Intangible Assets, Gross $ 534 35,650
Accumulated Amortization (316) (8,724)
Intangible assets, net $ 218 26,926
Assembled occupancy    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 12 days  
Finite-Lived Intangible Assets, Gross $ 3,180 2,936
Accumulated Amortization (3,056) (2,870)
Intangible assets, net $ 124 66
Trade name    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 30 years  
Finite-Lived Intangible Assets, Gross $ 733 733
Accumulated Amortization (330) (317)
Intangible assets, net $ 403 416
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 16 years 8 months 12 days  
Finite-Lived Intangible Assets, Gross $ 5,110 4,670
Accumulated Amortization (2,146) (1,670)
Intangible assets, net $ 2,964 $ 3,000
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets - Net Additional Disclosures (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Jan. 01, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]            
Amortization of Intangible Assets $ 1,012 $ 691 $ 1,905 $ 1,306    
Right-of-use assets (Note 17) $ 1,074,449   $ 1,074,449     $ 0
Accounting Standards Update 2016-02 [Member]            
Finite-Lived Intangible Assets [Line Items]            
Right-of-use assets (Note 17)         $ 1,051,148  
Accounting Standards Update 2016-02 [Member] | Favorable leases            
Finite-Lived Intangible Assets [Line Items]            
Right-of-use assets (Note 17)         $ 26,939  
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.19.2
Intangible Assets - Net Future Amortization (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
2019 (remainder) $ 567  
2020 345  
2021 249  
2022 249  
2023 237  
2024 234  
Thereafter 1,948  
Intangible assets, net $ 3,829 $ 31,000
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2019
USD ($)
Goodwill [Line Items]  
January 1, $ 80,477
Additions 16,931
June 30, 97,408
Transitional and Skilled Services Segment  
Goodwill [Line Items]  
January 1, 45,486
Additions 0
June 30, 45,486
Senior Living Services Segment  
Goodwill [Line Items]  
January 1, 3,958
Additions 0
June 30, 3,958
Home Health and Hospice Services  
Goodwill [Line Items]  
January 1, 27,250
Additions 11,500
June 30, 38,750
All Other  
Goodwill [Line Items]  
January 1, 3,783
Additions 5,431
June 30, $ 9,214
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles $ 30,922 $ 27,602
Trade name    
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles 1,373 1,217
Medicare and Medicaid licenses    
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles $ 29,549 $ 26,385
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.19.2
Restricted and Other Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Other Assets [Abstract]    
Debt issuance costs, net $ 1,442 $ 1,892
Long-term insurance losses recoverable asset 7,747 6,969
Deposits with landlords 4,148 8,694
Capital improvement reserves with landlords and lenders 3,535 3,196
Note receivable from sale of ancillary business 71 93
Restricted and other assets $ 16,943 $ 20,844
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.19.2
Restricted and Other Assets Additional (Details) - Accounting Standards Update 2016-02 [Member] - USD ($)
$ in Thousands
Jan. 01, 2019
Dec. 31, 2018
Right-of-Use Asset [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Prepaid Rent $ 5,220  
Deposits with Landlords [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Prepaid Rent   $ 5,220
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.19.2
Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Accrued Liabilities [Abstract]    
Quality assurance fee $ 5,639 $ 5,375
Refunds payable 27,477 25,118
Resident advances 4,607 8,495
Cash held in trust for patients 2,842 2,824
Resident deposits 7,753 6,665
Dividends payable 2,559 2,525
Property taxes 7,669 9,426
Other 11,270 9,356
Other accrued liabilities $ 69,816 $ 69,784
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.19.2
Income Taxes Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 5,552 $ 6,142 $ 12,652 $ 12,663
Effective Income Tax Rate Reconciliation, Percent     18.30% 21.70%
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.19.2
Income Taxes Other Disclosures (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2019
USD ($)
Accounting Standards Update 2016-02 [Member]  
Operating Loss Carryforwards [Line Items]  
Cumulative Effect on Retained Earnings, Tax $ 3,044
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.19.2
Debt (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Long-term Debt, Gross $ 281,039 $ 246,080
Current maturities of long-term debt (10,153) (10,105)
Long Term Debt, net of Current Maturities and Debt Discount 268,179 233,135
SunTrust Bank [Member] | Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Revolving credit facility with SunTrust 50,000 10,000
Second Amended Credit Facility [Member] | SunTrust Bank [Member] | Revolving Credit Facility [Member]    
Debt Instrument [Line Items]    
Term loan with SunTrust 109,375 113,125
Less: debt issuance costs (2,707) (2,840)
Collateralized Debt Obligations [Member] | Notes Payable, Other Payables [Member]    
Debt Instrument [Line Items]    
Mortgage loans and promissory note $ 121,664 $ 122,955
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.19.2
Debt Additional Disclosures (Details)
$ in Thousands
Feb. 05, 2016
USD ($)
Rate
Jul. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jul. 19, 2016
USD ($)
Rate
May 30, 2014
USD ($)
Secured Debt [Member] | Senior Debt Obligations [Member]            
Long-Term Debt Additional Disclosures [Line Items]            
Increase in Letters of Credit     $ 560      
Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities     5,342      
SunTrust Bank [Member] | Revolving Credit Facility [Member]            
Long-Term Debt Additional Disclosures [Line Items]            
Revolving credit facility with SunTrust     50,000 $ 10,000    
Line of Credit Facility, Current Borrowing Capacity $ 250,000         $ 150,000
Line of Credit Facility, Maximum Borrowing Capacity $ 150,000         $ 75,000
Total Net Debt Ratio, Maximum 3.50          
Total Net Debt Ratio, Minimum 1.50          
EBITDA Ratio, Maximum 1.00          
EBITDA Ratio, Minimum 1.00          
Total Net Debt Ratio, Default 2.75          
EBITDA Ratio, Default 1.00          
Aggregate Revolving Commitment Percentage | Rate 10.00%          
SunTrust Bank [Member] | Revolving Credit Facility [Member] | Second Amended Credit Facility [Member]            
Long-Term Debt Additional Disclosures [Line Items]            
Term Loan, Amount Outstanding, Current     7,500      
Term Loan, Amount Outstanding, Noncurrent     101,875      
Line of Credit Facility, Current Borrowing Capacity         $ 450,000  
Long-term Line of Credit         300,000  
Term Loan, Borrowing Capacity         $ 150,000  
Line of Credit Facility, Interest Rate at Period End | Rate         5.00%  
Term Loan and Line of Credit Facility, Amount Outstanding     159,375      
Term loan with SunTrust     $ 109,375 $ 113,125    
SunTrust Bank [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member] | Second Amended Credit Facility [Member]            
Long-Term Debt Additional Disclosures [Line Items]            
Term loan with SunTrust   $ 111,250        
SunTrust Bank [Member] | Revolving Credit Facility [Member] | Minimum [Member]            
Long-Term Debt Additional Disclosures [Line Items]            
Line of Credit Facility, Interest Rate, Additional Margin | Rate 0.75%          
Line of Credit Facility, Interest Rate, LIBOR | Rate 1.75%          
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | Rate 0.30%          
SunTrust Bank [Member] | Revolving Credit Facility [Member] | Maximum [Member]            
Long-Term Debt Additional Disclosures [Line Items]            
Line of Credit Facility, Interest Rate, Additional Margin | Rate 1.75%          
Line of Credit Facility, Interest Rate, LIBOR | Rate 2.75%          
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | Rate 0.50%          
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.19.2
Debt Other Additional Disclosures (Details) - Collateralized Debt Obligations [Member]
$ in Thousands
2 Months Ended
Dec. 31, 2014
Rate
Dec. 27, 2017
USD ($)
facilities
Rate
Jun. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mortgages [Member]        
Debt Instrument [Line Items]        
Number of Operating Subsidiaries | facilities   17    
Prepayment Penalty Reduced Rate During First Three Years   10.00%    
Prepayment Penalty Reduced Rate During the Fourth Year   3.00%    
Prepayment Penalty Reduced Rate for the Fifth through Tenth Years   1.00%    
Prepayment penalty reduced rate 1.00%      
Notes Payable | $   $ 112,000    
Mortgages [Member] | Minimum [Member]        
Debt Instrument [Line Items]        
Debt Instrument, pre-payment fee reduction, term 3 years 5 years    
Debt Instrument, Term 12 years 30 years    
Mortgages [Member] | Maximum [Member]        
Debt Instrument [Line Items]        
Debt Instrument, pre-payment fee reduction, term 11 years 10 years    
Debt Instrument, Term 33 years 35 years    
Notes Payable, Other Payables [Member]        
Debt Instrument [Line Items]        
Notes Payable | $     $ 121,664 $ 122,955
Notes Payable, Current | $     2,653  
Notes Payable, Noncurrent | $     $ 119,011  
Notes Payable to Banks [Member]        
Debt Instrument [Line Items]        
Debt Instrument, Interest Rate, Stated Percentage   3.30%    
Notes Payable to Banks [Member] | Minimum [Member]        
Debt Instrument [Line Items]        
Debt Instrument, Interest Rate, Stated Percentage 2.60%      
Notes Payable to Banks [Member] | Maximum [Member]        
Debt Instrument [Line Items]        
Debt Instrument, Interest Rate, Stated Percentage 5.30%      
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Lead Paragraphs (Details)
shares in Thousands
3 Months Ended 6 Months Ended
May 25, 2017
installment
shares
Jun. 30, 2019
Agreements
shares
Jun. 30, 2018
shares
Jun. 30, 2019
Agreements
shares
Jun. 30, 2018
shares
Stock Options granted [Line Items]          
Number of Option Plans | Agreements   1   1  
Shares Granted or Issued, Share-based Payment Arrangement [Abstract]          
Award Vesting Period       5 years  
Options Granted   258 227 399 395
Nonvested Restricted Awards, Granted   89 217 194 274
2017 Plan [Member]          
Shares Granted or Issued, Share-based Payment Arrangement [Abstract]          
Number of Shares Available for Grant   3,908   3,908  
Number of Shares Authorized 6,881        
Conversion to Reduce Shares Availability 1        
Other than Options, Conversion to Reduce Shares Availability 2.5        
Award Vesting Period 5 years        
Award Vesting Rights, Percentage 20.00%        
Expiration Period 10 years        
2017 Plan [Member] | Director [Member]          
Shares Granted or Issued, Share-based Payment Arrangement [Abstract]          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments | installment 3        
Award Requisite Service Period 3 years        
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Valuation Assumptions (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Options and Awards [Abstract]        
Options Granted 258 227 399 395
Fair Value Assumptions and Methodology        
Weighted Average Risk-Free Rate 2.10% 2.70% 2.20% 2.70%
Expected Life 6 years 3 months 18 days 6 years 2 months 12 days 6 years 3 months 18 days 6 years 2 months 12 days
Weighted Average Volatility 34.00% 32.00% 33.90% 32.00%
Weighted Average Dividend Yield 0.40% 0.50% 0.30% 0.60%
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Exercise Price and Fair Value (Details) - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]        
Options Granted 258 227 399 395
Weighted Average Exercise Price     $ 53.67 $ 32.33
Weighted Average Fair Value of Options     19.35 11.15
Intrinsic Value of Options Granted on Grant Date [Abstract]        
Grant Date Intrinsic Value     $ 0 $ 0
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Options Outstanding Rollforward (Details) - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Options outstanding January 1,     4,188  
Weighted average exercise price January 1,     $ 17.35  
Options vested January 1,     2,431  
Weighted Average Exercise Price of Options Vested January 1,     $ 12.37  
Options Granted 258 227 399 395
Weighted Average Exercise Price, Options Granted     $ 53.67 $ 32.33
Options Forfeited in Period     (27)  
Weighted Average Exercise Price, Options Forfeited in Period     $ 26.16  
Options Exercised in Period     (531)  
Weighted Average Exercise Price, Options Exercised in Period     $ 10.45  
Options outstanding June 30, 4,029   4,029  
Weighted average exercise price June 30, $ 21.80   $ 21.80  
Options vested June 30, 2,407   2,407  
Weighted Average Exercise Price of Options Vested June 30, $ 13.88   $ 13.88  
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Options Outstanding by Exercise Price (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2019
USD ($)
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number of Outstanding Options 4,029
Black-Scholes Fair Value | $ $ 33,520
Stock Options Vested and Exercisable 2,407
2009  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 4.06
Exercise Price, Upper Range Limit | $ / shares $ 4.56
Number of Outstanding Options 40
Black-Scholes Fair Value | $ $ 83
Remaining Contractual Life (Years) 0 years
Stock Options Vested and Exercisable 40
2010  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 4.77
Exercise Price, Upper Range Limit | $ / shares $ 4.96
Number of Outstanding Options 50
Black-Scholes Fair Value | $ $ 122
Remaining Contractual Life (Years) 1 year
Stock Options Vested and Exercisable 50
2011  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 5.90
Exercise Price, Upper Range Limit | $ / shares $ 7.99
Number of Outstanding Options 80
Black-Scholes Fair Value | $ $ 274
Remaining Contractual Life (Years) 2 years
Stock Options Vested and Exercisable 80
2012  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 6.56
Exercise Price, Upper Range Limit | $ / shares $ 7.96
Number of Outstanding Options 217
Black-Scholes Fair Value | $ $ 797
Remaining Contractual Life (Years) 3 years
Stock Options Vested and Exercisable 217
2013  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 7.98
Exercise Price, Upper Range Limit | $ / shares $ 11.49
Number of Outstanding Options 355
Black-Scholes Fair Value | $ $ 1,712
Remaining Contractual Life (Years) 4 years
Stock Options Vested and Exercisable 355
2014  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 10.55
Exercise Price, Upper Range Limit | $ / shares $ 18.94
Number of Outstanding Options 1,049
Black-Scholes Fair Value | $ $ 5,953
Remaining Contractual Life (Years) 5 years
Stock Options Vested and Exercisable 1,025
2015  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 21.47
Exercise Price, Upper Range Limit | $ / shares $ 25.24
Number of Outstanding Options 431
Black-Scholes Fair Value | $ $ 3,926
Remaining Contractual Life (Years) 6 years
Stock Options Vested and Exercisable 272
2016  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 18.79
Exercise Price, Upper Range Limit | $ / shares $ 19.89
Number of Outstanding Options 381
Black-Scholes Fair Value | $ $ 2,652
Remaining Contractual Life (Years) 7 years
Stock Options Vested and Exercisable 180
2017  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 18.64
Exercise Price, Upper Range Limit | $ / shares $ 22.90
Number of Outstanding Options 420
Black-Scholes Fair Value | $ $ 2,931
Remaining Contractual Life (Years) 8 years
Stock Options Vested and Exercisable 118
2018  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 26.53
Exercise Price, Upper Range Limit | $ / shares $ 38.59
Number of Outstanding Options 607
Black-Scholes Fair Value | $ $ 7,346
Remaining Contractual Life (Years) 9 years
Stock Options Vested and Exercisable 70
2019  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise Price, Lower Range Limit | $ / shares $ 53.50
Exercise Price, Upper Range Limit | $ / shares $ 53.99
Number of Outstanding Options 399
Black-Scholes Fair Value | $ $ 7,724
Remaining Contractual Life (Years) 10 years
Stock Options Vested and Exercisable 0
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Restricted Awards Granted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Restricted awards granted [Line Items]        
Restricted Awards Grant Date Fair Value Range, Minimum     $ 41.68 $ 23.61
Restricted Awards Grant Date Fair Value Range, Maximum     $ 53.99 $ 36.61
Share-based Compensation, Restricted Awards, Exercise Price     $ 0  
Issuance of restricted stock to employees (in shares) 89 217 194 274
Award Vesting Period     5 years  
Director [Member]        
Restricted awards granted [Line Items]        
Restricted Awards Grant Date Fair Value Range, Minimum     $ 41.68  
Restricted Awards Grant Date Fair Value Range, Maximum     $ 51.78  
Options Granted to Non-employee Directors 8   14  
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Restricted Award Rollforward (Details) - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Restricted Stock Rollforward [Line Items]        
Nonvested Restricted Awards, Nonvested at January 1,     573  
Weighted Average Grant Date Fair Value, Nonvested at January 1,     $ 29.31  
Nonvested Restricted Awards, Granted 89 217 194 274
Weighted Average Grant Date Fair Value, Restricted Awards Granted in the Period     $ 52.16  
Nonvested Restricted Awards, Vested in the Period     (166)  
Weighted Average Grant Date Fair Value, Restricted Awards Vested in the Period     $ 38.79  
Nonvested Restricted Awards, Forfeited in the Period     (5)  
Weighted Average Grant Date Fair Value, Restricted Awards Forfeited in the Period     $ 28.67  
Nonvested Restricted Awards, Nonvested at June 30, 596   596  
Weighted Average Grant Date Fair Value, Nonvested at June 30, $ 34.13   $ 34.13  
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Compensation Expense (Details) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]            
Share-based compensation expense $ 3,066 $ 2,612 $ 2,177 $ 1,971 $ 5,678 $ 4,148
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term         6 years 1 month 6 days  
Stock Options            
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]            
Share-based compensation expense 1,479   1,292   $ 2,822 2,508
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract]            
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized $ 17,760       $ 17,760  
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition         3 years 10 months 24 days  
Employee Service Share-based Compensation, Nonvested Awards 1,622       1,622  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number 1,517       1,517  
Restricted Stock Awards            
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]            
Share-based compensation expense $ 1,199   675   $ 2,197 1,253
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract]            
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized 18,860       $ 18,860  
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition         3 years 11 months  
Stock awards            
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]            
Share-based compensation expense $ 388   $ 210   $ 659 $ 387
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Intrinsic Values (Details) - Stock Options - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2019
Dec. 31, 2018
Outstanding $ 141,531 $ 89,806
Vested 103,589 64,222
Expected to Vest 32,597 22,963
Exercised $ 21,118 $ 27,646
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Subsidiary Common Stock Shares and Restricted Stock (Details) - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Class of Stock [Line Items]        
Nonvested Restricted Awards, Granted 89 217 194 274
Weighted Average Grant Date Fair Value, Restricted Awards Granted in the Period     $ 52.16  
Nonvested Restricted Awards, Vested in the Period     (166)  
Award Vesting Period     5 years  
Options Granted 258 227 399 395
Subsidiaries Stock awards [Member] | Subsidiaries [Member]        
Class of Stock [Line Items]        
Common Stock Required to Settle Subsidiary Shares 328 235 328 235
Nonvested Restricted Awards, Granted     0 0
Nonvested Restricted Awards, Vested in the Period     (976) (976)
Options Granted     0 221
Minimum [Member] | Subsidiaries Stock awards [Member] | Subsidiaries [Member]        
Class of Stock [Line Items]        
Award Vesting Period     3 years  
Maximum [Member] | Subsidiaries Stock awards [Member] | Subsidiaries [Member]        
Class of Stock [Line Items]        
Award Vesting Period     5 years  
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Subsidiary Equity Plan Share-based Payments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based compensation expense $ 3,066 $ 2,612 $ 2,177 $ 1,971 $ 5,678 $ 4,148
Subsidiaries [Member] | Subsidiaries Stock awards [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based compensation expense $ 236   $ 343   $ 577 $ 681
XML 100 R89.htm IDEA: XBRL DOCUMENT v3.19.2
Options and Awards Sale of Stock by Subsidiary (Details) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
Subsidiary, Sale of Stock [Line Items]      
Payments for Repurchase of Common Stock   $ 2,293 $ 0
Proceeds from Issuance or Sale of Equity   $ 2,293 $ 0
Subsidiaries [Member] | Subsidiaries Stock awards [Member]      
Subsidiary, Sale of Stock [Line Items]      
Stock Repurchased During Period, Shares 469    
Payments for Repurchase of Common Stock $ 2,293    
Proceeds from Issuance or Sale of Equity $ 2,293    
XML 101 R90.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
USD ($)
facilities
Agreements
Renewals
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
facilities
Agreements
Renewals
Jun. 30, 2018
USD ($)
Jun. 01, 2014
facilities
Agreements
Renewals
Operating Leased Assets [Line Items]          
Master Lease Agreements | Agreements 7   7    
Facilities under Master Lease Arrangement | facilities 39   39    
Various Landlords [Member] [Member]          
Operating Leased Assets [Line Items]          
Lessee, Operating Lease, Term of Contract 15 years   15 years    
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms 2   2    
Lessee, Operating Lease, Renewal Term 5 years   5 years    
CareTrust REIT [Member]          
Operating Leased Assets [Line Items]          
Skilled Nursing, Assisted Living and Independent Living Facilities | facilities         93
Master Lease Agreements | Agreements         8
Lessee, Operating Lease, Renewal Term         5 years
Operating Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate         2.50%
Payments for Rent | $ $ 15,057 $ 14,538 $ 29,896 $ 28,956  
Minimum [Member] | Various Landlords [Member] [Member]          
Operating Leased Assets [Line Items]          
Lessee, Operating Lease, Term of Contract 5 years   5 years    
Average Term of Non-Cancellable Equipment Leases     3 years    
Minimum [Member] | CareTrust REIT [Member]          
Operating Leased Assets [Line Items]          
Lessee, Operating Lease, Term of Contract         12 years
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms         2
Maximum [Member] | Various Landlords [Member] [Member]          
Operating Leased Assets [Line Items]          
Lessee, Operating Lease, Term of Contract 20 years   20 years    
Average Term of Non-Cancellable Equipment Leases     5 years    
Maximum [Member] | CareTrust REIT [Member]          
Operating Leased Assets [Line Items]          
Lessee, Operating Lease, Term of Contract         20 years
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms         3
Cost of Sales and General and Administrative Expense [Member]          
Operating Leased Assets [Line Items]          
Rent | $ $ 37,211 $ 34,476 $ 73,181 $ 68,640  
XML 102 R91.htm IDEA: XBRL DOCUMENT v3.19.2
Leases Balance Sheet Impact on New Lease Guidance (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Mar. 31, 2019
Jan. 01, 2019
Dec. 31, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Operating Leased Assets [Line Items]              
Assets $ 2,321,521     $ 1,181,958      
Liabilities 1,644,214     579,618      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $ 677,307 $ 645,003   $ 602,340 $ 550,279 $ 525,943 $ 500,059
Accounting Standards Update 2016-02 [Member] | Adjustments Due to ASC 842 [Member]              
Operating Leased Assets [Line Items]              
Assets     $ 1,015,937        
Liabilities     1,006,907        
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest     9,030        
Accounting Standards Update 2016-02 [Member] | Calculated under New Lease Guidance in Effect [Member]              
Operating Leased Assets [Line Items]              
Assets     2,197,895        
Liabilities     1,586,525        
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest     $ 611,370        
XML 103 R92.htm IDEA: XBRL DOCUMENT v3.19.2
Leases Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Operating Leased Assets [Line Items]        
Amortization of deferred rent $ 434   $ 688  
Rent—cost of services (Note 17) 37,060 $ 34,472 72,846 $ 68,322
Operating Lease, Cost 37,706 35,135 74,171 69,630
Favorable leases        
Operating Leased Assets [Line Items]        
Rent—cost of services (Note 17) 495 495 990 990
General and Administrative Expense [Member]        
Operating Leased Assets [Line Items]        
Rent—cost of services (Note 17) $ 151 $ 168 $ 335 $ 318
XML 104 R93.htm IDEA: XBRL DOCUMENT v3.19.2
Leases Future minimum lease payments (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Leases [Abstract]    
2019 (remainder) $ 74,865  
2020 149,083  
2021 148,086  
2022 146,540  
2023 144,852  
2024 142,880  
Thereafter 912,928  
Total lease payments 1,719,234  
Less: present value adjustment (646,138)  
Lessee, Operating Lease, Liability, Variable Rent (25,265)  
Present value of total lease liabilities 1,047,831  
Less: current lease liabilities (59,686) $ 0
Long-term operating lease liabilities $ 988,145 0
2019   142,497
2020   141,536
2021   140,524
2022   139,018
2023   137,349
Thereafter   967,027
Total lease payments   $ 1,667,951
XML 105 R94.htm IDEA: XBRL DOCUMENT v3.19.2
Leases Additional Disclosures (Details)
Jun. 30, 2019
Rate
Operating Leased Assets [Line Items]  
Operating Lease, Weighted Average Remaining Lease Term 12 years
Operating Lease, Weighted Average Discount Rate, Percent 8.66%
XML 106 R95.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies Litigation (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Litigation [Line Items]    
Litigation Settlement, Amount Awarded to Other Party   $ 11,000
Payments for Legal Settlements $ 11,000  
Litigation Settlement, Return of Unclaimed Settlement $ 1,664  
XML 107 R96.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies Revenue Recoupments (Details)
Jun. 30, 2019
facilities
Probe Reviews [Abstract]  
Facilities under Medicare Probe Reviews 10
XML 108 R97.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies Other Matters (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2013
USD ($)
Other Commitments [Line Items]  
Litigation Settlement Paid to U.S. Government $ 48,000
XML 109 R98.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies Concentrations (Details) - Total Medicaid and Medicare
3 Months Ended 6 Months Ended
Jun. 30, 2019
Rate
Jun. 30, 2018
Rate
Jun. 30, 2019
Rate
Jun. 30, 2018
Rate
Dec. 31, 2018
Rate
Concentration Risk [Line Items]          
Accounts receivable by payor as a percent of total accounts receivable 60.30%   60.30%   60.60%
% of Revenue 68.00% 68.20% 68.00% 68.00%  
XML 110 R99.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies Cash in Excess of FDIC Limits (Details) - USD ($)
$ in Thousands
Jul. 30, 2019
Jun. 30, 2019
Cash in Excess of FDIC limits [Line Items]    
Cash, FDIC Insured Amount   $ 250
Subsequent Event [Member]    
Cash in Excess of FDIC limits [Line Items]    
Cash, Uninsured Amount $ 1,066  
XML 111 R100.htm IDEA: XBRL DOCUMENT v3.19.2
Common Stock (Details)
$ in Thousands
Apr. 03, 2018
USD ($)
Common Stock Transactions [Line Items]  
Stock Repurchase Program, Period in Force 11 years
Stock Repurchase Program Expiration Date Feb. 20, 2019
Common Stock [Member]  
Common Stock Transactions [Line Items]  
Stock Repurchase Program, Authorized Amount $ 30,000
EXCEL 112 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 113 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 114 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 115 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 461 476 1 false 112 0 false 13 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.ensigngroup.net/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.ensigngroup.net/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001001 - Statement - Consolidated Balance Sheets Balance Sheet (Paranthetical) Sheet http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical Consolidated Balance Sheets Balance Sheet (Paranthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Income Sheet http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1005000 - Statement - Consolidated Statement of Stockholders' Equity Statement Sheet http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement Consolidated Statement of Stockholders' Equity Statement Statements 5 false false R6.htm 1005001 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical) Sheet http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityParenthetical Consolidated Statement of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 1006000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Description of Business Sheet http://www.ensigngroup.net/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 2106100 - Disclosure - Proposed Spin-Off of Subsidiaries Sheet http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiaries Proposed Spin-Off of Subsidiaries Notes 9 false false R10.htm 2113100 - Disclosure - Significant Accounting Policies Sheet http://www.ensigngroup.net/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 2116100 - Disclosure - Revenue and Accounts Receivable Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivable Revenue and Accounts Receivable Notes 11 false false R12.htm 2119100 - Disclosure - Computation of Net Income Per Common Share Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShare Computation of Net Income Per Common Share Notes 12 false false R13.htm 2125100 - Disclosure - Fair Value Measurements Sheet http://www.ensigngroup.net/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2128100 - Disclosure - Business Segments Sheet http://www.ensigngroup.net/role/BusinessSegments Business Segments Notes 14 false false R15.htm 2134100 - Disclosure - Acquisitions Sheet http://www.ensigngroup.net/role/Acquisitions Acquisitions Notes 15 false false R16.htm 2137100 - Disclosure - Property and Equipment Sheet http://www.ensigngroup.net/role/PropertyAndEquipment Property and Equipment Notes 16 false false R17.htm 2140100 - Disclosure - Intangible Assets - Net Sheet http://www.ensigngroup.net/role/IntangibleAssetsNet Intangible Assets - Net Notes 17 false false R18.htm 2141100 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssets Goodwill and Other Indefinite-Lived Intangible Assets Notes 18 false false R19.htm 2142100 - Disclosure - Restricted and Other Assets Sheet http://www.ensigngroup.net/role/RestrictedAndOtherAssets Restricted and Other Assets Notes 19 false false R20.htm 2145100 - Disclosure - Other Accrued Liabilities Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilities Other Accrued Liabilities Notes 20 false false R21.htm 2146100 - Disclosure - Income Taxes Sheet http://www.ensigngroup.net/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 2147100 - Disclosure - Debt Sheet http://www.ensigngroup.net/role/Debt Debt Notes 22 false false R23.htm 2148100 - Disclosure - Options and Awards Sheet http://www.ensigngroup.net/role/OptionsAndAwards Options and Awards Notes 23 false false R24.htm 2149100 - Disclosure - Leases Sheet http://www.ensigngroup.net/role/Leases Leases Notes 24 false false R25.htm 2150100 - Disclosure - Commitments and Contingencies Sheet http://www.ensigngroup.net/role/CommitmentsAndContingencies Commitments and Contingencies Notes 25 false false R26.htm 2151100 - Disclosure - Common Stock Sheet http://www.ensigngroup.net/role/CommonStock Common Stock Notes 26 false false R27.htm 2213201 - Disclosure - Significant Accounting Policies Level 2 (Policies) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies Significant Accounting Policies Level 2 (Policies) Policies http://www.ensigngroup.net/role/SignificantAccountingPolicies 27 false false R28.htm 2316301 - Disclosure - Revenue and Accounts Receivable (Tables) Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivableTables Revenue and Accounts Receivable (Tables) Tables http://www.ensigngroup.net/role/RevenueAndAccountsReceivable 28 false false R29.htm 2319301 - Disclosure - Computation of Net Income Per Common Share (Tables) Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareTables Computation of Net Income Per Common Share (Tables) Tables http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShare 29 false false R30.htm 2325301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.ensigngroup.net/role/FairValueMeasurements 30 false false R31.htm 2328301 - Disclosure - Business Segments (Tables) Sheet http://www.ensigngroup.net/role/BusinessSegmentsTables Business Segments (Tables) Tables http://www.ensigngroup.net/role/BusinessSegments 31 false false R32.htm 2337301 - Disclosure - Property and Equipment (Tables) Sheet http://www.ensigngroup.net/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.ensigngroup.net/role/PropertyAndEquipment 32 false false R33.htm 2340301 - Disclosure - Intangible Assets - Net (Tables) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetTables Intangible Assets - Net (Tables) Tables http://www.ensigngroup.net/role/IntangibleAssetsNet 33 false false R34.htm 2341301 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsTables Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Tables http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssets 34 false false R35.htm 2342301 - Disclosure - Restricted and Other Assets (Tables) Sheet http://www.ensigngroup.net/role/RestrictedAndOtherAssetsTables Restricted and Other Assets (Tables) Tables http://www.ensigngroup.net/role/RestrictedAndOtherAssets 35 false false R36.htm 2345301 - Disclosure - Other Accrued Liabilities (Tables) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables Other Accrued Liabilities (Tables) Tables http://www.ensigngroup.net/role/OtherAccruedLiabilities 36 false false R37.htm 2347301 - Disclosure - Debt (Tables) Sheet http://www.ensigngroup.net/role/DebtTables Debt (Tables) Tables http://www.ensigngroup.net/role/Debt 37 false false R38.htm 2348301 - Disclosure - Options and Awards (Tables) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsTables Options and Awards (Tables) Tables http://www.ensigngroup.net/role/OptionsAndAwards 38 false false R39.htm 2349301 - Disclosure - Leases (Tables) Sheet http://www.ensigngroup.net/role/LeasesTables Leases (Tables) Tables http://www.ensigngroup.net/role/Leases 39 false false R40.htm 2401401 - Disclosure - Description of Business (Details) Sheet http://www.ensigngroup.net/role/DescriptionOfBusinessDetails Description of Business (Details) Details http://www.ensigngroup.net/role/DescriptionOfBusiness 40 false false R41.htm 2401402 - Disclosure - Description of Business Proposed Spin-Off Transaction (Details) Sheet http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails Description of Business Proposed Spin-Off Transaction (Details) Details 41 false false R42.htm 2406402 - Disclosure - Proposed Spin-Off of Subsidiaries (Details) Sheet http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails Proposed Spin-Off of Subsidiaries (Details) Details http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiaries 42 false false R43.htm 2413402 - Disclosure - Significant Accounting Policies Divestiture (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails Significant Accounting Policies Divestiture (Details) Details 43 false false R44.htm 2413405 - Disclosure - Significant Accounting Policies Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails Significant Accounting Policies Property and Equipment (Details) Details 44 false false R45.htm 2413406 - Disclosure - Significant Accounting Policies Impairment (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesImpairmentDetails Significant Accounting Policies Impairment (Details) Details 45 false false R46.htm 2413407 - Disclosure - Significant Accounting Policies Intangible Assets and Goodwill (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails Significant Accounting Policies Intangible Assets and Goodwill (Details) Details 46 false false R47.htm 2413409 - Disclosure - Significant Accounting Policies Self-Insurance General and Professional (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails Significant Accounting Policies Self-Insurance General and Professional (Details) Details 47 false false R48.htm 2413410 - Disclosure - Significant Accounting Policies Self-Insurance Workers' Compensation (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails Significant Accounting Policies Self-Insurance Workers' Compensation (Details) Details 48 false false R49.htm 2413411 - Disclosure - Significant Accounting Policies Self Insurance Recoveries (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceRecoveriesDetails Significant Accounting Policies Self Insurance Recoveries (Details) Details 49 false false R50.htm 2413412 - Disclosure - Significant Accounting Policies Self-Insurance Health Insurance (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails Significant Accounting Policies Self-Insurance Health Insurance (Details) Details 50 false false R51.htm 2413415 - Disclosure - Significant Accounting Policies Recent Accounting Standards Adopted (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails Significant Accounting Policies Recent Accounting Standards Adopted (Details) Details 51 false false R52.htm 2416402 - Disclosure - Revenue and Accounts Receivable Revenue from Medicare and Medicaid Programs (Details) Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails Revenue and Accounts Receivable Revenue from Medicare and Medicaid Programs (Details) Details 52 false false R53.htm 2416404 - Disclosure - Revenue and Accounts Receivable Revenue (Details) Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails Revenue and Accounts Receivable Revenue (Details) Details 53 false false R54.htm 2416406 - Disclosure - Revenue and Accounts Receivable Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails Revenue and Accounts Receivable Accounts Receivable (Details) Details 54 false false R55.htm 2419402 - Disclosure - Computation of Net Income Per Common Share (Details) Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails Computation of Net Income Per Common Share (Details) Details http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareTables 55 false false R56.htm 2419403 - Disclosure - Computation of Net Income Per Common Share Antidilutive Shares (Details) Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareAntidilutiveSharesDetails Computation of Net Income Per Common Share Antidilutive Shares (Details) Details 56 false false R57.htm 2425402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.ensigngroup.net/role/FairValueMeasurementsTables 57 false false R58.htm 2425403 - Disclosure - Fair Value Measurements Investments (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails Fair Value Measurements Investments (Details) Details 58 false false R59.htm 2428402 - Disclosure - Business Segments (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsDetails Business Segments (Details) Details http://www.ensigngroup.net/role/BusinessSegmentsTables 59 false false R60.htm 2428403 - Disclosure - Business Segments Revenue by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails Business Segments Revenue by Segment (Details) Details 60 false false R61.htm 2428404 - Disclosure - Business Segments Schedule of Segment Reporting Information, by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails Business Segments Schedule of Segment Reporting Information, by Segment (Details) Details 61 false false R62.htm 2434402 - Disclosure - Acquisitions Summary (Details) Sheet http://www.ensigngroup.net/role/AcquisitionsSummaryDetails Acquisitions Summary (Details) Details 62 false false R63.htm 2434404 - Disclosure - Acquisitions (Details) Sheet http://www.ensigngroup.net/role/AcquisitionsDetails Acquisitions (Details) Details http://www.ensigngroup.net/role/Acquisitions 63 false false R64.htm 2437402 - Disclosure - Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.ensigngroup.net/role/PropertyAndEquipmentTables 64 false false R65.htm 2440402 - Disclosure - Intangible Assets - Net (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetDetails Intangible Assets - Net (Details) Details http://www.ensigngroup.net/role/IntangibleAssetsNetTables 65 false false R66.htm 2440403 - Disclosure - Intangible Assets - Net Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails Intangible Assets - Net Additional Disclosures (Details) Details 66 false false R67.htm 2440404 - Disclosure - Intangible Assets - Net Future Amortization (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails Intangible Assets - Net Future Amortization (Details) Details 67 false false R68.htm 2441402 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details) Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details) Details 68 false false R69.htm 2441403 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) Details 69 false false R70.htm 2442402 - Disclosure - Restricted and Other Assets (Details) Sheet http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails Restricted and Other Assets (Details) Details http://www.ensigngroup.net/role/RestrictedAndOtherAssetsTables 70 false false R71.htm 2442403 - Disclosure - Restricted and Other Assets Additional (Details) Sheet http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails Restricted and Other Assets Additional (Details) Details 71 false false R72.htm 2445402 - Disclosure - Other Accrued Liabilities (Details) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails Other Accrued Liabilities (Details) Details http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables 72 false false R73.htm 2446402 - Disclosure - Income Taxes Expense (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesExpenseDetails Income Taxes Expense (Details) Details 73 false false R74.htm 2446405 - Disclosure - Income Taxes Other Disclosures (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails Income Taxes Other Disclosures (Details) Details 74 false false R75.htm 2447402 - Disclosure - Debt (Details) Sheet http://www.ensigngroup.net/role/DebtDetails Debt (Details) Details http://www.ensigngroup.net/role/DebtTables 75 false false R76.htm 2447403 - Disclosure - Debt Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails Debt Additional Disclosures (Details) Details 76 false false R77.htm 2447404 - Disclosure - Debt Other Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails Debt Other Additional Disclosures (Details) Details 77 false false R78.htm 2448402 - Disclosure - Options and Awards Lead Paragraphs (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails Options and Awards Lead Paragraphs (Details) Details 78 false false R79.htm 2448403 - Disclosure - Options and Awards Valuation Assumptions (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails Options and Awards Valuation Assumptions (Details) Details 79 false false R80.htm 2448404 - Disclosure - Options and Awards Exercise Price and Fair Value (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails Options and Awards Exercise Price and Fair Value (Details) Details 80 false false R81.htm 2448405 - Disclosure - Options and Awards Options Outstanding Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails Options and Awards Options Outstanding Rollforward (Details) Details 81 false false R82.htm 2448406 - Disclosure - Options and Awards Options Outstanding by Exercise Price (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails Options and Awards Options Outstanding by Exercise Price (Details) Details 82 false false R83.htm 2448407 - Disclosure - Options and Awards Restricted Awards Granted (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails Options and Awards Restricted Awards Granted (Details) Details 83 false false R84.htm 2448408 - Disclosure - Options and Awards Restricted Award Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails Options and Awards Restricted Award Rollforward (Details) Details 84 false false R85.htm 2448409 - Disclosure - Options and Awards Compensation Expense (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails Options and Awards Compensation Expense (Details) Details 85 false false R86.htm 2448410 - Disclosure - Options and Awards Intrinsic Values (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails Options and Awards Intrinsic Values (Details) Details 86 false false R87.htm 2448411 - Disclosure - Options and Awards Subsidiary Common Stock Shares and Restricted Stock (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails Options and Awards Subsidiary Common Stock Shares and Restricted Stock (Details) Details 87 false false R88.htm 2448412 - Disclosure - Options and Awards Subsidiary Equity Plan Share-based Payments (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails Options and Awards Subsidiary Equity Plan Share-based Payments (Details) Details 88 false false R89.htm 2448413 - Disclosure - Options and Awards Sale of Stock by Subsidiary (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails Options and Awards Sale of Stock by Subsidiary (Details) Details 89 false false R90.htm 2449402 - Disclosure - Leases (Details) Sheet http://www.ensigngroup.net/role/LeasesDetails Leases (Details) Details http://www.ensigngroup.net/role/LeasesTables 90 false false R91.htm 2449403 - Disclosure - Leases Balance Sheet Impact on New Lease Guidance (Details) Sheet http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails Leases Balance Sheet Impact on New Lease Guidance (Details) Details 91 false false R92.htm 2449405 - Disclosure - Leases Lease Cost (Details) Sheet http://www.ensigngroup.net/role/LeasesLeaseCostDetails Leases Lease Cost (Details) Details 92 false false R93.htm 2449406 - Disclosure - Leases Future minimum lease payments (Details) Sheet http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails Leases Future minimum lease payments (Details) Details 93 false false R94.htm 2449407 - Disclosure - Leases Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails Leases Additional Disclosures (Details) Details 94 false false R95.htm 2450401 - Disclosure - Commitments and Contingencies Litigation (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails Commitments and Contingencies Litigation (Details) Details 95 false false R96.htm 2450403 - Disclosure - Commitments and Contingencies Revenue Recoupments (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesRevenueRecoupmentsDetails Commitments and Contingencies Revenue Recoupments (Details) Details 96 false false R97.htm 2450404 - Disclosure - Commitments and Contingencies Other Matters (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails Commitments and Contingencies Other Matters (Details) Details 97 false false R98.htm 2450405 - Disclosure - Commitments and Contingencies Concentrations (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails Commitments and Contingencies Concentrations (Details) Details 98 false false R99.htm 2450406 - Disclosure - Commitments and Contingencies Cash in Excess of FDIC Limits (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails Commitments and Contingencies Cash in Excess of FDIC Limits (Details) Details 99 false false R100.htm 2451401 - Disclosure - Common Stock (Details) Sheet http://www.ensigngroup.net/role/CommonStockDetails Common Stock (Details) Details http://www.ensigngroup.net/role/CommonStock 100 false false All Reports Book All Reports ensg0630201910q.htm ensg-20190630.xsd ensg-20190630_cal.xml ensg-20190630_def.xml ensg-20190630_lab.xml ensg-20190630_pre.xml ensg063019ex321.htm ensg063019ex322.htm ensgq22019ex311.htm ensgq22019ex312.htm http://xbrl.sec.gov/sic/2011-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/naics/2017-01-31 http://fasb.org/srt/2019-01-31 true true JSON 118 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ensg0630201910q.htm": { "axisCustom": 4, "axisStandard": 33, "contextCount": 461, "dts": { "calculationLink": { "local": [ "ensg-20190630_cal.xml" ] }, "definitionLink": { "local": [ "ensg-20190630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "ensg0630201910q.htm" ] }, "labelLink": { "local": [ "ensg-20190630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ensg-20190630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ensg-20190630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 765, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 30, "http://www.ensigngroup.net/20190630": 6, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 41 }, "keyCustom": 83, "keyStandard": 393, "memberCustom": 57, "memberStandard": 53, "nsprefix": "ensg", "nsuri": "http://www.ensigngroup.net/20190630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.ensigngroup.net/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Significant Accounting Policies", "role": "http://www.ensigngroup.net/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "D2018Q1Stock", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramPeriodInForce1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451401 - Disclosure - Common Stock (Details)", "role": "http://www.ensigngroup.net/role/CommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "D2018Q1Stock", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramPeriodInForce1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:RevenueAndAccountsReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Revenue and Accounts Receivable", "role": "http://www.ensigngroup.net/role/RevenueAndAccountsReceivable", "shortName": "Revenue and Accounts Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:RevenueAndAccountsReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Computation of Net Income Per Common Share", "role": "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShare", "shortName": "Computation of Net Income Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - Fair Value Measurements", "role": "http://www.ensigngroup.net/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - Business Segments", "role": "http://www.ensigngroup.net/role/BusinessSegments", "shortName": "Business Segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134100 - Disclosure - Acquisitions", "role": "http://www.ensigngroup.net/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137100 - Disclosure - Property and Equipment", "role": "http://www.ensigngroup.net/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140100 - Disclosure - Intangible Assets - Net", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNet", "shortName": "Intangible Assets - Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141100 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets", "role": "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssets", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142100 - Disclosure - Restricted and Other Assets", "role": "http://www.ensigngroup.net/role/RestrictedAndOtherAssets", "shortName": "Restricted and Other Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145100 - Disclosure - Other Accrued Liabilities", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilities", "shortName": "Other Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146100 - Disclosure - Income Taxes", "role": "http://www.ensigngroup.net/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147100 - Disclosure - Debt", "role": "http://www.ensigngroup.net/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148100 - Disclosure - Options and Awards", "role": "http://www.ensigngroup.net/role/OptionsAndAwards", "shortName": "Options and Awards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149100 - Disclosure - Leases", "role": "http://www.ensigngroup.net/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150100 - Disclosure - Commitments and Contingencies", "role": "http://www.ensigngroup.net/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:CommonstockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151100 - Disclosure - Common Stock", "role": "http://www.ensigngroup.net/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:CommonstockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2213201 - Disclosure - Significant Accounting Policies Level 2 (Policies)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies", "shortName": "Significant Accounting Policies Level 2 (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Revenue and Accounts Receivable (Tables)", "role": "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableTables", "shortName": "Revenue and Accounts Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Computation of Net Income Per Common Share (Tables)", "role": "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareTables", "shortName": "Computation of Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001001 - Statement - Consolidated Balance Sheets Balance Sheet (Paranthetical)", "role": "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical", "shortName": "Consolidated Balance Sheets Balance Sheet (Paranthetical)", "subGroupType": "", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.ensigngroup.net/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328301 - Disclosure - Business Segments (Tables)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsTables", "shortName": "Business Segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337301 - Disclosure - Property and Equipment (Tables)", "role": "http://www.ensigngroup.net/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340301 - Disclosure - Intangible Assets - Net (Tables)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetTables", "shortName": "Intangible Assets - Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341301 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables)", "role": "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsTables", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342301 - Disclosure - Restricted and Other Assets (Tables)", "role": "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsTables", "shortName": "Restricted and Other Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345301 - Disclosure - Other Accrued Liabilities (Tables)", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables", "shortName": "Other Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347301 - Disclosure - Debt (Tables)", "role": "http://www.ensigngroup.net/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348301 - Disclosure - Options and Awards (Tables)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsTables", "shortName": "Options and Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349301 - Disclosure - Leases (Tables)", "role": "http://www.ensigngroup.net/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Income", "role": "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "facilities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - Description of Business (Details)", "role": "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails", "shortName": "Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "facilities", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2019Q1Spin_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember", "decimals": "0", "first": true, "lang": null, "name": "ensg:PublicCompaniesCreated", "reportCount": 1, "unitRef": "business", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Description of Business Proposed Spin-Off Transaction (Details)", "role": "http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails", "shortName": "Description of Business Proposed Spin-Off Transaction (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "0", "first": true, "lang": null, "name": "ensg:HomeHealthHospiceandHomeCareOperations", "reportCount": 1, "unitRef": "business", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Proposed Spin-Off of Subsidiaries (Details)", "role": "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails", "shortName": "Proposed Spin-Off of Subsidiaries (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2019Q1Spin_dei_LegalEntityAxis_ensg_SpinOffTransactionCompanyMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_SpinoffMember", "decimals": "0", "lang": null, "name": "ensg:HomeHealthHospiceandHomeCareOperations", "reportCount": 1, "unique": true, "unitRef": "business", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "ensg:SalePricefromDivestitureofBusinesses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Significant Accounting Policies Divestiture (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails", "shortName": "Significant Accounting Policies Divestiture (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD_srt_RangeAxis_srt_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Significant Accounting Policies Property and Equipment (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "Significant Accounting Policies Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Significant Accounting Policies Impairment (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesImpairmentDetails", "shortName": "Significant Accounting Policies Impairment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2018Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Significant Accounting Policies Intangible Assets and Goodwill (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "shortName": "Significant Accounting Policies Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LiabilityReserveEstimatePolicy", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_srt_ProductOrServiceAxis_us-gaap_ProfessionalLiabilityInsuranceMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413409 - Disclosure - Significant Accounting Policies Self-Insurance General and Professional (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "shortName": "Significant Accounting Policies Self-Insurance General and Professional (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LiabilityReserveEstimatePolicy", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_srt_ProductOrServiceAxis_us-gaap_ProfessionalLiabilityInsuranceMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LiabilityReserveEstimatePolicy", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_srt_ProductOrServiceAxis_us-gaap_WorkersCompensationInsuranceMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413410 - Disclosure - Significant Accounting Policies Self-Insurance Workers' Compensation (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails", "shortName": "Significant Accounting Policies Self-Insurance Workers' Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LiabilityReserveEstimatePolicy", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_srt_ProductOrServiceAxis_us-gaap_WorkersCompensationInsuranceMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EstimatedInsuranceRecoveries", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413411 - Disclosure - Significant Accounting Policies Self Insurance Recoveries (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceRecoveriesDetails", "shortName": "Significant Accounting Policies Self Insurance Recoveries (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2017Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statement of Stockholders' Equity Statement", "role": "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "shortName": "Consolidated Statement of Stockholders' Equity Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LiabilityReserveEstimatePolicy", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_srt_ProductOrServiceAxis_ensg_HealthLiabilityInsuranceMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413412 - Disclosure - Significant Accounting Policies Self-Insurance Health Insurance (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "shortName": "Significant Accounting Policies Self-Insurance Health Insurance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LiabilityReserveEstimatePolicy", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_srt_ProductOrServiceAxis_ensg_HealthLiabilityInsuranceMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SelfInsuranceReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413415 - Disclosure - Significant Accounting Policies Recent Accounting Standards Adopted (Details)", "role": "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails", "shortName": "Significant Accounting Policies Recent Accounting Standards Adopted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2019Q1Lease_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD_srt_MajorCustomersAxis_ensg_TotalMedicaidAndMedicareRevenueMember", "decimals": "3", "first": true, "lang": null, "name": "ensg:RevenueByPayorAsPercentOfTotalRevenue", "reportCount": 1, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Revenue and Accounts Receivable Revenue from Medicare and Medicaid Programs (Details)", "role": "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails", "shortName": "Revenue and Accounts Receivable Revenue from Medicare and Medicaid Programs (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - Revenue and Accounts Receivable Revenue (Details)", "role": "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails", "shortName": "Revenue and Accounts Receivable Revenue (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Revenue and Accounts Receivable Accounts Receivable (Details)", "role": "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "shortName": "Revenue and Accounts Receivable Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Computation of Net Income Per Common Share (Details)", "role": "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "shortName": "Computation of Net Income Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Computation of Net Income Per Common Share Antidilutive Shares (Details)", "role": "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareAntidilutiveSharesDetails", "shortName": "Computation of Net Income Per Common Share Antidilutive Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425402 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.ensigngroup.net/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425403 - Disclosure - Fair Value Measurements Investments (Details)", "role": "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails", "shortName": "Fair Value Measurements Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segments", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428402 - Disclosure - Business Segments (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "shortName": "Business Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segments", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1005001 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)", "role": "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityParenthetical", "shortName": "Consolidated Statement of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428403 - Disclosure - Business Segments Revenue by Segment (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "shortName": "Business Segments Revenue by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD_srt_MajorCustomersAxis_ensg_MedicaidMember_us-gaap_StatementBusinessSegmentsAxis_ensg_TransitionalandSkilledServicesSegmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428404 - Disclosure - Business Segments Schedule of Segment Reporting Information, by Segment (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "shortName": "Business Segments Schedule of Segment Reporting Information, by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "lang": null, "name": "ensg:Intersegmentrevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "ensg:PaymentstoAcquireAssetAcquisitions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434402 - Disclosure - Acquisitions Summary (Details)", "role": "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "shortName": "Acquisitions Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "lang": null, "name": "ensg:PaymentstoAcquireBusinessandAssetAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434404 - Disclosure - Acquisitions (Details)", "role": "http://www.ensigngroup.net/role/AcquisitionsDetails", "shortName": "Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437402 - Disclosure - Property and Equipment (Details)", "role": "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440402 - Disclosure - Intangible Assets - Net (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "shortName": "Intangible Assets - Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440403 - Disclosure - Intangible Assets - Net Additional Disclosures (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "shortName": "Intangible Assets - Net Additional Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440404 - Disclosure - Intangible Assets - Net Future Amortization (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails", "shortName": "Intangible Assets - Net Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441402 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details)", "role": "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441403 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details)", "role": "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember", "decimals": "-3", "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "lang": null, "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442402 - Disclosure - Restricted and Other Assets (Details)", "role": "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails", "shortName": "Restricted and Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2019Q1Lease_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_FairValueByAssetClassAxis_ensg_RightofUseAssetMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442403 - Disclosure - Restricted and Other Assets Additional (Details)", "role": "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails", "shortName": "Restricted and Other Assets Additional (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2019Q1Lease_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_FairValueByAssetClassAxis_ensg_RightofUseAssetMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445402 - Disclosure - Other Accrued Liabilities (Details)", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails", "shortName": "Other Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446402 - Disclosure - Income Taxes Expense (Details)", "role": "http://www.ensigngroup.net/role/IncomeTaxesExpenseDetails", "shortName": "Income Taxes Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOnRetainedEarningsTax1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446405 - Disclosure - Income Taxes Other Disclosures (Details)", "role": "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails", "shortName": "Income Taxes Other Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOnRetainedEarningsTax1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447402 - Disclosure - Debt (Details)", "role": "http://www.ensigngroup.net/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_DebtInstrumentAxis_us-gaap_SeniorDebtObligationsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "ensg:IncreaseinLettersofCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447403 - Disclosure - Debt Additional Disclosures (Details)", "role": "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "shortName": "Debt Additional Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_DebtInstrumentAxis_us-gaap_SeniorDebtObligationsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "ensg:IncreaseinLettersofCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2017Q4HUD_us-gaap_DebtInstrumentAxis_us-gaap_MortgagesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_CollateralizedDebtObligationsMember", "decimals": "0", "first": true, "lang": null, "name": "ensg:NumberofOperatingSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "facilities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447404 - Disclosure - Debt Other Additional Disclosures (Details)", "role": "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails", "shortName": "Debt Other Additional Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2017Q4HUD_us-gaap_DebtInstrumentAxis_us-gaap_MortgagesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_CollateralizedDebtObligationsMember", "decimals": "0", "first": true, "lang": null, "name": "ensg:NumberofOperatingSubsidiaries", "reportCount": 1, "unique": true, "unitRef": "facilities", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "0", "first": true, "lang": null, "name": "ensg:NumberofOptionPlans", "reportCount": 1, "unitRef": "Agreements", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448402 - Disclosure - Options and Awards Lead Paragraphs (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "shortName": "Options and Awards Lead Paragraphs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2017Q2NewPlan_us-gaap_PlanNameAxis_ensg_A2017PlanMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448403 - Disclosure - Options and Awards Valuation Assumptions (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails", "shortName": "Options and Awards Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Description of Business", "role": "http://www.ensigngroup.net/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448404 - Disclosure - Options and Awards Exercise Price and Fair Value (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails", "shortName": "Options and Awards Exercise Price and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448405 - Disclosure - Options and Awards Options Outstanding Rollforward (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails", "shortName": "Options and Awards Options Outstanding Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448406 - Disclosure - Options and Awards Options Outstanding by Exercise Price (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails", "shortName": "Options and Awards Options Outstanding by Exercise Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "2", "first": true, "lang": null, "name": "ensg:RestrictedAwardsGrantDateFairValueRangeMinimum", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448407 - Disclosure - Options and Awards Restricted Awards Granted (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails", "shortName": "Options and Awards Restricted Awards Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "2", "first": true, "lang": null, "name": "ensg:RestrictedAwardsGrantDateFairValueRangeMinimum", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448408 - Disclosure - Options and Awards Restricted Award Rollforward (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails", "shortName": "Options and Awards Restricted Award Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448409 - Disclosure - Options and Awards Compensation Expense (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails", "shortName": "Options and Awards Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ensg:ShareBasedCompensationScheduleOfIntrisiceValuesByOptionCategoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448410 - Disclosure - Options and Awards Intrinsic Values (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails", "shortName": "Options and Awards Intrinsic Values (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ensg:ShareBasedCompensationScheduleOfIntrisiceValuesByOptionCategoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448411 - Disclosure - Options and Awards Subsidiary Common Stock Shares and Restricted Stock (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "shortName": "Options and Awards Subsidiary Common Stock Shares and Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_AwardTypeAxis_ensg_SubsidiariesStockawardsMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448412 - Disclosure - Options and Awards Subsidiary Equity Plan Share-based Payments (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails", "shortName": "Options and Awards Subsidiary Equity Plan Share-based Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_AwardTypeAxis_ensg_SubsidiariesStockawardsMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448413 - Disclosure - Options and Awards Sale of Stock by Subsidiary (Details)", "role": "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails", "shortName": "Options and Awards Sale of Stock by Subsidiary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_AwardTypeAxis_ensg_SubsidiariesStockawardsMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:ProposedSpinOffTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Proposed Spin-Off of Subsidiaries", "role": "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiaries", "shortName": "Proposed Spin-Off of Subsidiaries", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:ProposedSpinOffTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "0", "first": true, "lang": null, "name": "ensg:MasterLeaseAgreements", "reportCount": 1, "unitRef": "Agreements", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449402 - Disclosure - Leases (Details)", "role": "http://www.ensigngroup.net/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2014Q2Spindate_srt_CounterpartyNameAxis_ensg_CareTrustREITMember", "decimals": "0", "lang": null, "name": "ensg:SkilledNursingAssistedLivingAndIndependentLivingFacilities", "reportCount": 1, "unique": true, "unitRef": "facilities", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449403 - Disclosure - Leases Balance Sheet Impact on New Lease Guidance (Details)", "role": "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "shortName": "Leases Balance Sheet Impact on New Lease Guidance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "I2019Q1Lease_ensg_LeaseInitialApplicationPeriodCumulativeEffectTransitionAxis_ensg_AdjustmentsDuetoASC842Member_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-3", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "ensg:AmortizationofDeferredRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449405 - Disclosure - Leases Lease Cost (Details)", "role": "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "shortName": "Leases Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "ensg:AmortizationofDeferredRent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449406 - Disclosure - Leases Future minimum lease payments (Details)", "role": "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases Future minimum lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449407 - Disclosure - Leases Additional Disclosures (Details)", "role": "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "shortName": "Leases Additional Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2017Q1QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450401 - Disclosure - Commitments and Contingencies Litigation (Details)", "role": "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails", "shortName": "Commitments and Contingencies Litigation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2017Q1QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "0", "first": true, "lang": null, "name": "ensg:FacilitiesunderMedicareProbeReviews", "reportCount": 1, "unique": true, "unitRef": "facilities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450403 - Disclosure - Commitments and Contingencies Revenue Recoupments (Details)", "role": "http://www.ensigngroup.net/role/CommitmentsAndContingenciesRevenueRecoupmentsDetails", "shortName": "Commitments and Contingencies Revenue Recoupments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "0", "first": true, "lang": null, "name": "ensg:FacilitiesunderMedicareProbeReviews", "reportCount": 1, "unique": true, "unitRef": "facilities", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2013Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "ensg:LitigationSettlementPaidtoU.S.Government", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450404 - Disclosure - Commitments and Contingencies Other Matters (Details)", "role": "http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails", "shortName": "Commitments and Contingencies Other Matters (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FD2013Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "ensg:LitigationSettlementPaidtoU.S.Government", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2_srt_MajorCustomersAxis_ensg_TotalMedicaidAndMedicareRevenueMember", "decimals": "3", "first": true, "lang": null, "name": "ensg:AccountsReceivableByPayorAsPercentOfTotalAccountsReceivable", "reportCount": 1, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450405 - Disclosure - Commitments and Contingencies Concentrations (Details)", "role": "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "shortName": "Commitments and Contingencies Concentrations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2018Q4_srt_MajorCustomersAxis_ensg_TotalMedicaidAndMedicareRevenueMember", "decimals": "3", "lang": null, "name": "ensg:AccountsReceivableByPayorAsPercentOfTotalAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450406 - Disclosure - Commitments and Contingencies Cash in Excess of FDIC Limits (Details)", "role": "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails", "shortName": "Commitments and Contingencies Cash in Excess of FDIC Limits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg0630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 112, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ensg_A2017PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Plan", "label": "2017 Plan [Member]", "terseLabel": "2017 Plan [Member]" } } }, "localname": "A2017PlanMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "domainItemType" }, "ensg_AccountingAcquisitionTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounting Acquisition Type [Axis]", "label": "Accounting Acquisition Type [Axis]", "terseLabel": "Business Acquisition Type [Axis]" } } }, "localname": "AccountingAcquisitionTypeAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "stringItemType" }, "ensg_AccountsReceivableByPayorAsPercentOfTotalAccountsReceivable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounts receivable by payor as a percent of total accounts receivable", "label": "Accounts receivable by payor as a percent of total accounts receivable", "terseLabel": "Accounts receivable by payor as a percent of total accounts receivable" } } }, "localname": "AccountsReceivableByPayorAsPercentOfTotalAccountsReceivable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails" ], "xbrltype": "percentItemType" }, "ensg_AdjustmentsDuetoASC842Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Difference between Lease Guidance in Effect before and after Topic 842", "label": "Adjustments Due to ASC 842 [Member]", "terseLabel": "Adjustments Due to ASC 842 [Member]" } } }, "localname": "AdjustmentsDuetoASC842Member", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails" ], "xbrltype": "domainItemType" }, "ensg_AggregateDeductibleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Deductible [Member]", "label": "Aggregate Deductible [Member]", "terseLabel": "Aggregate Deductible [Member]" } } }, "localname": "AggregateDeductibleMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_AggregateRevolvingCommitmentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Revolving Commitment Percentage", "label": "Aggregate Revolving Commitment Percentage", "terseLabel": "Aggregate Revolving Commitment Percentage" } } }, "localname": "AggregateRevolvingCommitmentPercentage", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ensg_AllOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All Other", "label": "All Other [Member]", "terseLabel": "All Other" } } }, "localname": "AllOtherMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "ensg_AllStatesExceptColoradoDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All States Except Colorado [Domain]", "label": "All States Except Colorado [Domain]", "terseLabel": "All States Except Colorado [Domain]" } } }, "localname": "AllStatesExceptColoradoDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_AmortizationofDeferredRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of deferred rent", "label": "Amortization of Deferred Rent", "terseLabel": "Amortization of deferred rent" } } }, "localname": "AmortizationofDeferredRent", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "ensg_AssembledOccupancyAcquiredMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assembled occupancy acquired [Member]", "label": "Assembled occupancy acquired [Member]", "terseLabel": "Assembled occupancy" } } }, "localname": "AssembledOccupancyAcquiredMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "ensg_AssetAcquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "These acquisitions were classified as asset acquisitions in accordance with ASC 805.", "label": "Asset Acquisition [Member]", "terseLabel": "Asset Acquisition [Member]" } } }, "localname": "AssetAcquisitionMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "domainItemType" }, "ensg_AverageTermofNonCancellableEquipmentLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average term of non-cancellable equipment leases", "label": "Average Term of Non-Cancellable Equipment Leases", "terseLabel": "Average Term of Non-Cancellable Equipment Leases" } } }, "localname": "AverageTermofNonCancellableEquipmentLeases", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "ensg_BalanceSheetParantheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Paranthetical [Abstract]", "label": "Balance Sheet Paranthetical [Abstract]" } } }, "localname": "BalanceSheetParantheticalAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_BlanketAggregateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Blanket Aggregate [Member]", "label": "Blanket Aggregate [Member]", "terseLabel": "Blanket Aggregate [Member]" } } }, "localname": "BlanketAggregateMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_BusinessAcquisitionTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition Type [Domain]", "label": "Business Acquisition Type [Domain]", "terseLabel": "Business Acquisition Type [Domain]" } } }, "localname": "BusinessAcquisitionTypeDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "ensg_BusinessCombinationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "These acquisitions were classified as business acquisitions in accordance with ASC 805.", "label": "Business Combination [Member]", "terseLabel": "Business Combination [Member]" } } }, "localname": "BusinessCombinationMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "domainItemType" }, "ensg_CalculatedunderNewLeaseGuidanceinEffectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Calculated under guidance for leases in effect for ASC 842.", "label": "Calculated under New Lease Guidance in Effect [Member]", "terseLabel": "Calculated under New Lease Guidance in Effect [Member]" } } }, "localname": "CalculatedunderNewLeaseGuidanceinEffectMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails" ], "xbrltype": "domainItemType" }, "ensg_CareTrustREITMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CareTrust REIT [Member]", "label": "CareTrust REIT [Member]", "terseLabel": "CareTrust REIT [Member]" } } }, "localname": "CareTrustREITMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ensg_CashHeldInTrustForResidents": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds.", "label": "Cash Held in Trust for Residents", "terseLabel": "Cash held in trust for patients" } } }, "localname": "CashHeldInTrustForResidents", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_CashinExcessofFDIClimitsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Cash in Excess of FDIC limits [Table]", "label": "Cash in Excess of FDIC limits [Line Items]", "terseLabel": "Cash in Excess of FDIC limits [Line Items]" } } }, "localname": "CashinExcessofFDIClimitsLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails" ], "xbrltype": "stringItemType" }, "ensg_CashinExcessofFDIClimitsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash in Excess of FDIC limits [Table]", "label": "Cash in Excess of FDIC limits [Table]", "terseLabel": "Cash in Excess of FDIC limits [Table]" } } }, "localname": "CashinExcessofFDIClimitsTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails" ], "xbrltype": "stringItemType" }, "ensg_CommonStockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock [Abstract]", "label": "Common Stock [Abstract]" } } }, "localname": "CommonStockAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_CommonStockRequiredtoSettleSubsidiaryShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock Required to Settle Subsidiary Shares", "label": "Common Stock Required to Settle Subsidiary Shares", "terseLabel": "Common Stock Required to Settle Subsidiary Shares" } } }, "localname": "CommonStockRequiredtoSettleSubsidiaryShares", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "ensg_CommonStockTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Common Stock Transactions [Table]", "label": "Common Stock Transactions [Line Items]", "terseLabel": "Common Stock Transactions [Line Items]" } } }, "localname": "CommonStockTransactionsLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "ensg_CommonStockTransactionsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock Transactions [Table]", "label": "Common Stock Transactions [Table]", "terseLabel": "Common Stock Transactions [Table]" } } }, "localname": "CommonStockTransactionsTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "ensg_CommonstockTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock", "label": "Common stock [Text Block]", "terseLabel": "Common stock [Text Block]" } } }, "localname": "CommonstockTextBlock", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "ensg_ComputationOfNetIncomePerCommonShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract]", "label": "COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract]", "terseLabel": "Net income per share:" } } }, "localname": "ComputationOfNetIncomePerCommonShareAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "ensg_CostofSalesandGeneralandAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of services and general and administrative expense", "label": "Cost of Sales and General and Administrative Expense [Member]", "terseLabel": "Cost of Sales and General and Administrative Expense [Member]" } } }, "localname": "CostofSalesandGeneralandAdministrativeExpenseMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ensg_DebtInstrumentprepaymentfeereductionterm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, pre-payment fee reduction, term", "label": "Debt Instrument, pre-payment fee reduction, term", "terseLabel": "Debt Instrument, pre-payment fee reduction, term" } } }, "localname": "DebtInstrumentprepaymentfeereductionterm", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "durationItemType" }, "ensg_DeferredRentAndOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Rental expense in excess of actual rental payments and other long-term liabilities", "label": "Deferred rent and other long-term liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "DeferredRentAndOtherLongTermLiabilities", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ensg_DepositswithLandlordsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deposits with landlords located within restricted and other assets on the balance sheet.", "label": "Deposits with Landlords [Member]", "terseLabel": "Deposits with Landlords [Member]" } } }, "localname": "DepositswithLandlordsMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails" ], "xbrltype": "domainItemType" }, "ensg_DescriptionOfBusinessAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DESCRIPTION OF BUSINESS [Abstract]", "label": "DESCRIPTION OF BUSINESS [Abstract]" } } }, "localname": "DescriptionOfBusinessAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_DivestitureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divestiture [Abstract]", "label": "Divestiture [Abstract]" } } }, "localname": "DivestitureAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_DivestituresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divestitures [Abstract]", "label": "Divestitures [Abstract]" } } }, "localname": "DivestituresAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_EBITDARatioDefault": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "EBITDA Ratio, Default", "label": "EBITDA Ratio, Default", "terseLabel": "EBITDA Ratio, Default" } } }, "localname": "EBITDARatioDefault", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "pureItemType" }, "ensg_EBITDARatioMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "EBITDA Ratio, Maximum", "label": "EBITDA Ratio, Maximum", "terseLabel": "EBITDA Ratio, Maximum" } } }, "localname": "EBITDARatioMaximum", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "pureItemType" }, "ensg_EBITDARatioMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "EBITDA Ratio, Minimum", "label": "EBITDA Ratio, Minimum", "terseLabel": "EBITDA Ratio, Minimum" } } }, "localname": "EBITDARatioMinimum", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "pureItemType" }, "ensg_EmployeeServiceShareBasedCompensationNonvestedAwards": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Service Share-based Compensation, Nonvested Awards", "label": "Employee Service Share-based Compensation, Nonvested Awards", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwards", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_EntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Entity Information [Abstract]", "label": "Entity Information [Abstract]" } } }, "localname": "EntityInformationAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_EscrowDepositsusedtoFundAcquisitions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Outflow of cash previously included in escrow deposits used to fund business and asset acquisitions in the current period.", "label": "Escrow Deposits used to Fund Acquisitions", "terseLabel": "Escrow deposits used to fund acquisitions" } } }, "localname": "EscrowDepositsusedtoFundAcquisitions", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ensg_ExercisePriceRangeEightMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Eight [Member]", "label": "Exercise Price Range Eight [Member]", "terseLabel": "2017" } } }, "localname": "ExercisePriceRangeEightMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Five [Member]", "label": "Exercise Price Range Five [Member]", "terseLabel": "2014" } } }, "localname": "ExercisePriceRangeFiveMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Four [Member]", "label": "Exercise Price Range Four [Member]", "terseLabel": "2013" } } }, "localname": "ExercisePriceRangeFourMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range", "label": "Exercise Price Range [Member]", "terseLabel": "2009" } } }, "localname": "ExercisePriceRangeMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeNineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Nine [Member]", "label": "Exercise Price Range Nine [Member]", "terseLabel": "2018" } } }, "localname": "ExercisePriceRangeNineMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range One [Member]", "label": "Exercise Price Range One [Member]", "terseLabel": "2010" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Seven [Member]", "label": "Exercise Price Range Seven [Member]", "terseLabel": "2016" } } }, "localname": "ExercisePriceRangeSevenMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Six [Member]", "label": "Exercise Price Range Six [Member]", "terseLabel": "2015" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Ten [Member]", "label": "Exercise Price Range Ten [Member]", "terseLabel": "2019" } } }, "localname": "ExercisePriceRangeTenMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Three [Member]", "label": "Exercise Price Range Three [Member]", "terseLabel": "2012" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range Two [Member]", "label": "Exercise Price Range Two [Member]", "terseLabel": "2011" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_FacilitiesunderMasterLeaseArrangement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk.", "label": "Facilities under Master Lease Arrangement", "terseLabel": "Facilities under Master Lease Arrangement" } } }, "localname": "FacilitiesunderMasterLeaseArrangement", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "integerItemType" }, "ensg_FacilitiesunderMedicareProbeReviews": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments", "label": "Facilities under Medicare Probe Reviews", "terseLabel": "Facilities under Medicare Probe Reviews" } } }, "localname": "FacilitiesunderMedicareProbeReviews", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesRevenueRecoupmentsDetails" ], "xbrltype": "integerItemType" }, "ensg_GoodwillIndefinitelivedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination and assets that lack physical substance, having a projected indefinite period of benefit.", "label": "Goodwill & Indefinite-lived Intangible Assets [Member]", "terseLabel": "Goodwill & Indefinite-lived Intangible Assets [Member]" } } }, "localname": "GoodwillIndefinitelivedIntangibleAssetsMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "ensg_GrantClassAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Grant Class [Axis]", "label": "Grant Class [Axis]", "terseLabel": "Grant Class [Axis]" } } }, "localname": "GrantClassAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "stringItemType" }, "ensg_GrantClassDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Grant Class [Axis]", "label": "Grant Class [Domain]", "terseLabel": "Grant Class [Domain]" } } }, "localname": "GrantClassDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "domainItemType" }, "ensg_HealthLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Liability Insurance [Member]", "label": "Health Liability Insurance [Member]", "terseLabel": "Health Liability Insurance [Member]" } } }, "localname": "HealthLiabilityInsuranceMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_HomeCareAgencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Home Care Agency [Member]", "label": "Home Care Agency [Member]", "terseLabel": "Home Care Agency [Member]" } } }, "localname": "HomeCareAgencyMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "ensg_HomeHealthHospiceandHomeCareOperations": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Home Health, Hospice and Home Care Operations", "label": "Home Health, Hospice and Home Care Operations", "terseLabel": "Home Health, Hospice and Home Care Operations" } } }, "localname": "HomeHealthHospiceandHomeCareOperations", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "integerItemType" }, "ensg_HomeHealthandHospiceAgenciesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Home Health and Hospice Agencies [Axis]", "label": "Home Health and Hospice Agencies [Axis]", "terseLabel": "Home Health and Hospice Agencies [Axis]" } } }, "localname": "HomeHealthandHospiceAgenciesAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails" ], "xbrltype": "stringItemType" }, "ensg_HomeHealthandHospiceAgenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Home Health and Hospice Agencies [Axis]", "label": "Home Health and Hospice Agencies [Domain]", "terseLabel": "Home Health and Hospice Agencies [Domain]" } } }, "localname": "HomeHealthandHospiceAgenciesDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails" ], "xbrltype": "domainItemType" }, "ensg_HomeHealthandHospiceSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Home Health and Hospice Segment", "label": "Home Health and Hospice Segment [Member]", "terseLabel": "Home Health and Hospice Services" } } }, "localname": "HomeHealthandHospiceSegmentMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "ensg_HospiceAgenciesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hospice Agencies", "label": "Hospice Agencies [Member]", "terseLabel": "Hospice Agencies [Member]" } } }, "localname": "HospiceAgenciesMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "ensg_IncreaseDecreaseInInsuranceSubsidiaryDepositsAndInvestments": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Change in captive insurance subsidiary cash and cash equivalents and debt security investements", "label": "Increase (Decrease) in Insurance subsidiary deposits and investments", "terseLabel": "Insurance subsidiary deposits" } } }, "localname": "IncreaseDecreaseInInsuranceSubsidiaryDepositsAndInvestments", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ensg_IncreaseDecreaseinOperatingRightofUseAsset": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Operating Right-of-Use Asset", "label": "Increase (Decrease) in Operating Right-of-Use Asset", "terseLabel": "Operating lease obligations" } } }, "localname": "IncreaseDecreaseinOperatingRightofUseAsset", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ensg_IncreaseinLettersofCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase in Letters of Credit", "label": "Increase in Letters of Credit", "terseLabel": "Increase in Letters of Credit" } } }, "localname": "IncreaseinLettersofCredit", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ensg_IndefiniteLivedIntangibleAssetsIncludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS [Abstract]", "label": "Indefinite-Lived Intangible Assets (Including Goodwill) [Abstract]" } } }, "localname": "IndefiniteLivedIntangibleAssetsIncludingGoodwillAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_InsuranceCoverageLimitTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Insurance Coverage Limit Type [Axis]", "label": "Insurance Coverage Limit Type [Axis]", "terseLabel": "Insurance Coverage Limit Type [Axis]" } } }, "localname": "InsuranceCoverageLimitTypeAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "ensg_InsuranceCoverageLimitTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Insurance Coverage Limit Type [Domain]", "label": "Insurance Coverage Limit Type [Domain]", "terseLabel": "Insurance Coverage Limit Type [Domain]" } } }, "localname": "InsuranceCoverageLimitTypeDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_InsuranceSubsidiaryDepositsAndInvestments": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Captive insurance subidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity.", "label": "Insurance subsidiary deposits and investments", "terseLabel": "Insurance subsidiary deposits and investments" } } }, "localname": "InsuranceSubsidiaryDepositsAndInvestments", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ensg_IntersegmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intersegment Expense", "label": "Intersegment Expense", "terseLabel": "Intersegment Expense" } } }, "localname": "IntersegmentExpense", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "ensg_Intersegmentrevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Intersegment revenue", "label": "Intersegment revenue", "terseLabel": "Intersegment revenue (1)" } } }, "localname": "Intersegmentrevenue", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "ensg_IntrinsicValueOfOptionsGrantedOnGrantDateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intrinsic Value of Options Granted on Grant Date [Abstract]", "label": "Intrinsic Value of Options Granted on Grant Date [Abstract]", "terseLabel": "Intrinsic Value of Options Granted on Grant Date [Abstract]" } } }, "localname": "IntrinsicValueOfOptionsGrantedOnGrantDateAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails" ], "xbrltype": "stringItemType" }, "ensg_LeaseInitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease information about effect of transition method for cumulative effect in initial period of application.", "label": "Lease Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Lease Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "LeaseInitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/LeasesIncomeStatementImpactOnNewLeaseGuidanceDetails" ], "xbrltype": "stringItemType" }, "ensg_LeaseInitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Lease information about effect of transition method for cumulative effect in initial period of application.", "label": "Lease Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Lease Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "LeaseInitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/LeasesIncomeStatementImpactOnNewLeaseGuidanceDetails" ], "xbrltype": "domainItemType" }, "ensg_LesseeLeasingArrangementsOperatingLeasesNumberofRenewalTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms", "label": "Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms", "terseLabel": "Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms" } } }, "localname": "LesseeLeasingArrangementsOperatingLeasesNumberofRenewalTerms", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "integerItemType" }, "ensg_LesseeOperatingLeaseLiabilityVariableRent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Variable Rent", "label": "Lessee, Operating Lease, Liability, Variable Rent", "negatedTerseLabel": "Lessee, Operating Lease, Liability, Variable Rent" } } }, "localname": "LesseeOperatingLeaseLiabilityVariableRent", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LineofCreditFacilityInterestRateAdditionalMargin": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate margin added to a specified base rate to determine total interest rate on borrowings.", "label": "Line of Credit Facility, Interest Rate, Additional Margin", "terseLabel": "Line of Credit Facility, Interest Rate, Additional Margin" } } }, "localname": "LineofCreditFacilityInterestRateAdditionalMargin", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ensg_LineofCreditFacilityInterestRateLIBOR": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate margin added to the LIBOR rate to determine total interest rate on borrowings.", "label": "Line of Credit Facility, Interest Rate, LIBOR", "terseLabel": "Line of Credit Facility, Interest Rate, LIBOR" } } }, "localname": "LineofCreditFacilityInterestRateLIBOR", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ensg_LitigationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Litigation [Table]", "label": "Litigation [Line Items]", "terseLabel": "Litigation [Line Items]" } } }, "localname": "LitigationLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails" ], "xbrltype": "stringItemType" }, "ensg_LitigationSettlementPaidtoU.S.Government": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Litigation Settlement Paid to U.S. Government", "label": "Litigation Settlement Paid to U.S. Government", "terseLabel": "Litigation Settlement Paid to U.S. Government" } } }, "localname": "LitigationSettlementPaidtoU.S.Government", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LitigationSettlementReturnofUnclaimedSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount was returned as unclaimed settlement funds", "label": "Litigation Settlement, Return of Unclaimed Settlement", "terseLabel": "Litigation Settlement, Return of Unclaimed Settlement" } } }, "localname": "LitigationSettlementReturnofUnclaimedSettlement", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LitigationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Litigation [Table]", "label": "Litigation [Table]", "terseLabel": "Litigation [Table]" } } }, "localname": "LitigationTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails" ], "xbrltype": "stringItemType" }, "ensg_LocationStateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location, State [Axis]", "label": "Location, State [Axis]", "terseLabel": "Location, State [Axis]" } } }, "localname": "LocationStateAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "ensg_LocationStateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location, State [Domain]", "label": "Location, State [Domain]", "terseLabel": "Location, State [Domain]" } } }, "localname": "LocationStateDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_LongTermDebtAdditionalDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Long-Term Debt Additional Disclosures [Table]", "label": "Long-Term Debt Additional Disclosures [Line Items]", "terseLabel": "Long-Term Debt Additional Disclosures [Line Items]" } } }, "localname": "LongTermDebtAdditionalDisclosuresLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ensg_LongTermDebtAdditionalDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-Term Debt Additional Disclosures [Table]", "label": "Long-Term Debt Additional Disclosures [Table]", "terseLabel": "Long-Term Debt Additional Disclosures [Table]" } } }, "localname": "LongTermDebtAdditionalDisclosuresTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long Term Debt, net of Current Maturities and Debt Discount", "label": "Long Term Debt, net of Current Maturities and Debt Discount", "terseLabel": "Long Term Debt, net of Current Maturities and Debt Discount" } } }, "localname": "LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LossSensitivelimitperclaimMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss-Sensitive limit per claim", "label": "Loss-Sensitive limit per claim [Member] [Member]", "terseLabel": "Loss-Sensitive limit per claim [Member] [Member]" } } }, "localname": "LossSensitivelimitperclaimMemberMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_ManagedCareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from managed care payors [Member]", "label": "Managed Care [Member]", "terseLabel": "Managed care" } } }, "localname": "ManagedCareMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MasterLeaseAgreements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Master Lease agreements", "label": "Master Lease Agreements", "terseLabel": "Master Lease Agreements" } } }, "localname": "MasterLeaseAgreements", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "integerItemType" }, "ensg_MedicaidMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from Medicaid for custodial services [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicaidSkilledMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from Medicaid for skilled services [Member]", "label": "Medicaid-skilled [Member]", "terseLabel": "Medicaid \u2014 skilled" } } }, "localname": "MedicaidSkilledMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareProbeReviewsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Probe Reviews [Abstract]", "label": "Medicare Probe Reviews [Abstract]", "terseLabel": "Probe Reviews [Abstract]" } } }, "localname": "MedicareProbeReviewsAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesRevenueRecoupmentsDetails" ], "xbrltype": "stringItemType" }, "ensg_MedicareandMedicaidLicensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare licenses for home health and hospice segment and all other segment.", "label": "Medicare and Medicaid Licenses [Member]", "terseLabel": "Medicare and Medicaid licenses" } } }, "localname": "MedicareandMedicaidLicensesMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails" ], "xbrltype": "domainItemType" }, "ensg_NonCaliforniaDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-California [Domain]", "label": "Non-California [Domain]", "terseLabel": "Non-California [Domain]" } } }, "localname": "NonCaliforniaDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Non-cash Lease Expense", "label": "Non-cash Lease Expense", "negatedTerseLabel": "Non-cash leasing arrangement (Note 17)" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ensg_NoncontrollingInterestPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets.", "label": "Noncontrolling Interest [Policy Text Block]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestPolicyTextBlock", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "ensg_NumberOfRealEstatePropertiesLeased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Real Estate Properties Leased", "label": "Number of Real Estate Properties Leased", "terseLabel": "Number of Real Estate Properties Leased" } } }, "localname": "NumberOfRealEstatePropertiesLeased", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Real Estate Properties Leased with an Option to Purchase", "label": "Number of Real Estate Properties Leased with an Option to Purchase", "terseLabel": "Number of Real Estate Properties Leased with an Option to Purchase" } } }, "localname": "NumberOfRealEstatePropertiesLeasedWithOptionToPurchase", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesOperated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Properties Operated", "label": "Number of Real Estate Properties Operated", "terseLabel": "Number of Real Estate Properties Operated" } } }, "localname": "NumberOfRealEstatePropertiesOperated", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberofOperatingSubsidiaries": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating subsidiaries entered into mortgage loans that are insured with HUD.", "label": "Number of Operating Subsidiaries", "terseLabel": "Number of Operating Subsidiaries" } } }, "localname": "NumberofOperatingSubsidiaries", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberofOptionPlans": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Option Plans", "label": "Number of Option Plans", "terseLabel": "Number of Option Plans" } } }, "localname": "NumberofOptionPlans", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "integerItemType" }, "ensg_OperatingIncomeIntersegmentExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses and intercompany expense from operating revenues.", "label": "Operating Income & Intersegment Expense", "terseLabel": "Operating Income & Intersegment Expense" } } }, "localname": "OperatingIncomeIntersegmentExpense", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "ensg_OperationalSeniorLivingUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operational Assisted Living and Independent Living Units", "label": "Operational Senior Living Units", "terseLabel": "Operational Senior Living Units" } } }, "localname": "OperationalSeniorLivingUnits", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_OperationalSkilledNursingAssistedLivingAndIndependentLivingBedsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract]", "label": "Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract]", "terseLabel": "Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract]" } } }, "localname": "OperationalSkilledNursingAssistedLivingAndIndependentLivingBedsAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "ensg_OperationalSkilledNursingBeds": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of skilled nursing beds available for use at a skilled nursing facility", "label": "Operational Skilled Nursing Beds", "terseLabel": "Operational Skilled Nursing Beds" } } }, "localname": "OperationalSkilledNursingBeds", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_OptionsGrantedtoNonemployeeDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Options granted to non-employee directors", "label": "Options Granted to Non-employee Directors", "terseLabel": "Options Granted to Non-employee Directors" } } }, "localname": "OptionsGrantedtoNonemployeeDirectors", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "sharesItemType" }, "ensg_OptionsandAwardsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Options and Awards [Abstract]", "label": "Options and Awards [Abstract]" } } }, "localname": "OptionsandAwardsAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_OtherstatesexceptCaliforniaTexasandWashingtonDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other states, except California, Texas and Washington", "label": "Other states, except California, Texas and Washington [Domain]", "terseLabel": "Other states, except California, Texas and Washington [Domain]" } } }, "localname": "OtherstatesexceptCaliforniaTexasandWashingtonDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_PaymentstoAcquireAssetAcquisitions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments to Acquire Asset Acquisitions", "negatedTerseLabel": "Cash payments for asset acquisitions (Note 8)", "terseLabel": "Payments to Acquire Asset Acquisitions" } } }, "localname": "PaymentstoAcquireAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentstoAcquireBusinessandAssetAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments to Acquire Business and Asset Acquisitions", "terseLabel": "Payments to Acquire Business and Asset Acquisitions" } } }, "localname": "PaymentstoAcquireBusinessandAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "monetaryItemType" }, "ensg_PayorAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Payor [Axis]", "label": "Payor [Axis]", "terseLabel": "Payor [Axis]" } } }, "localname": "PayorAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ensg_PayorDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Payor [Domain]", "label": "Payor [Domain]", "terseLabel": "Payor [Domain]" } } }, "localname": "PayorDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ensg_PerFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per Facility [Member]", "label": "Per Facility [Member]", "terseLabel": "Per Facility [Member]" } } }, "localname": "PerFacilityMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_PerOccurenceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per Occurence [Member]", "label": "Per Occurence [Member]", "terseLabel": "Per Occurence [Member]" } } }, "localname": "PerOccurenceMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringFirstThreeYears": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the first three years.", "label": "Prepayment Penalty Reduced Rate During First Three Years", "terseLabel": "Prepayment Penalty Reduced Rate During First Three Years" } } }, "localname": "PrepaymentPenaltyReducedRateDuringFirstThreeYears", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringtheFourthYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the fourth year.", "label": "Prepayment Penalty Reduced Rate During the Fourth Year", "terseLabel": "Prepayment Penalty Reduced Rate During the Fourth Year" } } }, "localname": "PrepaymentPenaltyReducedRateDuringtheFourthYear", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRatefortheFifththroughTenthYears": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years.", "label": "Prepayment Penalty Reduced Rate for the Fifth through Tenth Years", "terseLabel": "Prepayment Penalty Reduced Rate for the Fifth through Tenth Years" } } }, "localname": "PrepaymentPenaltyReducedRatefortheFifththroughTenthYears", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ensg_Prepaymentpenaltyreducedrate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced over time", "label": "Prepayment penalty reduced rate", "terseLabel": "Prepayment penalty reduced rate" } } }, "localname": "Prepaymentpenaltyreducedrate", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "ensg_PrivatePayAndOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from self-pay and Other payors [Member]", "label": "Private Pay and Other [Member]", "terseLabel": "Private Pay and Other", "verboseLabel": "Private and other payors(1)" } } }, "localname": "PrivatePayAndOtherMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_ProposedSpinOffAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Proposed Spin-Off [Abstract]", "label": "Proposed Spin-Off [Abstract]" } } }, "localname": "ProposedSpinOffAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_ProposedSpinOffTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Proposed Spin-Off [Text Block]", "label": "Proposed Spin-Off [Text Block]", "terseLabel": "Proposed Spin-Off [Text Block]" } } }, "localname": "ProposedSpinOffTextBlock", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiaries" ], "xbrltype": "textBlockItemType" }, "ensg_PublicCompaniesCreated": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Public companies created due to the proposed spin-off transaction", "label": "Public Companies Created", "terseLabel": "Public Companies Created" } } }, "localname": "PublicCompaniesCreated", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "integerItemType" }, "ensg_QualityAssuranceFee": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days", "label": "Quality Assurance Fee", "terseLabel": "Quality assurance fee" } } }, "localname": "QualityAssuranceFee", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RemainingCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Ensign Group, Inc.", "label": "Remaining Company [Member]", "terseLabel": "Remaining Company [Member]" } } }, "localname": "RemainingCompanyMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "ensg_ResidentDeposits": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Resident Deposits", "label": "Resident Deposits", "terseLabel": "Resident deposits" } } }, "localname": "ResidentDeposits", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ResidentRefundsPayable": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Resident refunds payable includes amounts due to residents for overpayments and duplicate payments", "label": "Resident Refunds Payable", "terseLabel": "Refunds payable" } } }, "localname": "ResidentRefundsPayable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RestrictedAwardsGrantDateFairValueRangeMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Awards Grant Date Fair Value Range, Maximum", "label": "Restricted Awards Grant Date Fair Value Range, Maximum", "terseLabel": "Restricted Awards Grant Date Fair Value Range, Maximum" } } }, "localname": "RestrictedAwardsGrantDateFairValueRangeMaximum", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ensg_RestrictedAwardsGrantDateFairValueRangeMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Awards Grant Date Fair Value Range, Minimum", "label": "Restricted Awards Grant Date Fair Value Range, Minimum", "terseLabel": "Restricted Awards Grant Date Fair Value Range, Minimum" } } }, "localname": "RestrictedAwardsGrantDateFairValueRangeMinimum", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "perShareItemType" }, "ensg_RestrictedStockRollforwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Restricted Stock Rollforward [Table]", "label": "Restricted Stock Rollforward [Line Items]", "terseLabel": "Restricted Stock Rollforward [Line Items]" } } }, "localname": "RestrictedStockRollforwardLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "ensg_RestrictedStockRollforwardTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock Rollforward [Table]", "label": "Restricted Stock Rollforward [Table]", "terseLabel": "Restricted Stock Rollforward [Table]" } } }, "localname": "RestrictedStockRollforwardTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "ensg_RestrictedawardsgrantedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Restricted awards granted [Table]", "label": "Restricted awards granted [Line Items]", "terseLabel": "Restricted awards granted [Line Items]" } } }, "localname": "RestrictedawardsgrantedLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "stringItemType" }, "ensg_RestrictedawardsgrantedTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted awards granted [Table]", "label": "Restricted awards granted [Table]", "terseLabel": "Restricted awards granted [Table]" } } }, "localname": "RestrictedawardsgrantedTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "stringItemType" }, "ensg_RevenueAndAccountsReceivableAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "REVENUE AND ACCOUNTS RECEIVABLE [Abstract]", "label": "REVENUE AND ACCOUNTS RECEIVABLE [Abstract]" } } }, "localname": "RevenueAndAccountsReceivableAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_RevenueAndAccountsReceivableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue and accounts receivable [Text Block]", "label": "Revenue and Accounts receivable [Text Block]", "terseLabel": "Revenue and Accounts receivable [Text Block]" } } }, "localname": "RevenueAndAccountsReceivableTextBlock", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivable" ], "xbrltype": "textBlockItemType" }, "ensg_RevenueByPayorAsPercentOfTotalRevenue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue by payor as a percent of total revenue [Line Items]", "label": "Revenue by payor as a percent of total revenue", "terseLabel": "% of Revenue", "verboseLabel": "Revenue by payor as a percent of total revenue" } } }, "localname": "RevenueByPayorAsPercentOfTotalRevenue", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails" ], "xbrltype": "percentItemType" }, "ensg_RevenuefromContractwithCustomerIncludingIntersegmentRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from Contract with Customer Including Intersegment Revenue", "label": "Revenue from Contract with Customer Including Intersegment Revenue", "terseLabel": "Total revenue" } } }, "localname": "RevenuefromContractwithCustomerIncludingIntersegmentRevenue", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RevenuefromContractwithCustomerbyPayorasaPercentofTotalRevenue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from Contract with Customer by Payor as a Percent of Total Revenue", "label": "Revenue from Contract with Customer by Payor as a Percent of Total Revenue", "terseLabel": "Revenue from Contract with Customer by Payor as a Percent of Total Revenue", "verboseLabel": "Percentage of revenue" } } }, "localname": "RevenuefromContractwithCustomerbyPayorasaPercentofTotalRevenue", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails" ], "xbrltype": "percentItemType" }, "ensg_RightofUseAssetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-Use Asset [Member]", "terseLabel": "Right-of-Use Asset [Member]" } } }, "localname": "RightofUseAssetMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails" ], "xbrltype": "domainItemType" }, "ensg_SaleLeasebackTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale Leaseback Transactions [Abstract]", "label": "Sale Leaseback Transactions [Abstract]" } } }, "localname": "SaleLeasebackTransactionsAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_SalePricefromDivestitureofBusinesses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The price associated with the amount received from the sale of a portion of the Company's businesses.", "label": "Sale Price from Divestiture of Businesses", "terseLabel": "Sale Price from Divestiture of Businesses" } } }, "localname": "SalePricefromDivestitureofBusinesses", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ScheduleofSelfInsuranceReservesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Self-Insurance Reserves [Table]", "label": "Schedule of Self-Insurance Reserves [Line Items]", "terseLabel": "Schedule of Self-Insurance Reserves [Line Items]" } } }, "localname": "ScheduleofSelfInsuranceReservesLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SelfInsuranceReservesDetails" ], "xbrltype": "stringItemType" }, "ensg_ScheduleofSelfInsuranceReservesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Self-Insurance Reserves [Table]", "label": "Schedule of Self-Insurance Reserves [Table]", "terseLabel": "Schedule of Self-Insurance Reserves [Table]" } } }, "localname": "ScheduleofSelfInsuranceReservesTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SelfInsuranceReservesDetails" ], "xbrltype": "stringItemType" }, "ensg_SecondAmendedCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second Amended Credit Facility with a Lending Consortium Arranged by SunTrust (the Second Amended Credit Facility) [Member]", "label": "Second Amended Credit Facility [Member]", "terseLabel": "Second Amended Credit Facility [Member]" } } }, "localname": "SecondAmendedCreditFacilityMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "domainItemType" }, "ensg_SelfInsuranceReservesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Self-Insurance Reserves [Abstract]", "label": "Self-Insurance Reserves [Abstract]" } } }, "localname": "SelfInsuranceReservesAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_SelfInsuranceRetentionPerClaimMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Self-insurance retention per claim [Member]", "label": "Self-insurance retention per claim [Member]", "terseLabel": "Self-insurance retention per claim [Member]" } } }, "localname": "SelfInsuranceRetentionPerClaimMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "ensg_SeniorLivingFacilities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Assisted and Independent Living Facilities", "label": "Senior Living Facilities", "terseLabel": "Senior Living Facilities" } } }, "localname": "SeniorLivingFacilities", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "integerItemType" }, "ensg_SeniorLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assisted Living Facilities [Member]", "label": "Senior Living Facilities [Member]", "terseLabel": "Senior Living Facilities [Member]" } } }, "localname": "SeniorLivingFacilitiesMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "ensg_SeniorLivingFacility": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of a senior living facility", "label": "Senior Living Facility", "terseLabel": "Senior Living Facility" } } }, "localname": "SeniorLivingFacility", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "integerItemType" }, "ensg_SeniorLivingServicesSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assisted and Independent Living Services Segment [Member]", "label": "Senior Living Services Segment [Member]", "terseLabel": "Senior Living Services Segment" } } }, "localname": "SeniorLivingServicesSegmentMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Expected to Vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "As of the balance sheet date, the number of shares into which fully vested stock options outstanding can be converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number", "periodEndLabel": "Options vested June 30,", "periodStartLabel": "Options vested January 1," } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "ensg_ShareBasedCompensationRestrictedAwardsExercisePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Restricted Awards, Exercise Price", "label": "Share-based Compensation, Restricted Awards, Exercise Price", "terseLabel": "Share-based Compensation, Restricted Awards, Exercise Price" } } }, "localname": "ShareBasedCompensationRestrictedAwardsExercisePrice", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ShareBasedCompensationScheduleOfIntrisiceValuesByOptionCategoryTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block]", "label": "Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block]", "terseLabel": "Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block]" } } }, "localname": "ShareBasedCompensationScheduleOfIntrisiceValuesByOptionCategoryTableTextBlock", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsTables" ], "xbrltype": "textBlockItemType" }, "ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value", "terseLabel": "Black-Scholes Fair Value" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofInstallments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofInstallments", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "integerItemType" }, "ensg_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversiontoReduceSharesAvailability": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion to Reduce Shares Availability", "terseLabel": "Conversion to Reduce Shares Availability" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsConversiontoReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "pureItemType" }, "ensg_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsConversiontoReduceSharesAvailability": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Conversion to Reduce Shares Availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Conversion to Reduce Shares Availability", "terseLabel": "Other than Options, Conversion to Reduce Shares Availability" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsConversiontoReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "pureItemType" }, "ensg_SkilledNursingAssistedLivingAndIndependentLivingFacilities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Skilled Nursing, Assisted Living and Independent Living Facilities", "label": "Skilled Nursing, Assisted Living and Independent Living Facilities", "terseLabel": "Skilled Nursing, Assisted Living and Independent Living Facilities" } } }, "localname": "SkilledNursingAssistedLivingAndIndependentLivingFacilities", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledNursingAssistedLivingAndIndependentLivingFacilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Skilled nursing, assisted living and independent living facilities [Abstract]", "label": "Skilled nursing, assisted living and independent living facilities [Abstract]", "terseLabel": "Skilled nursing, assisted living and independent living facilities [Abstract]" } } }, "localname": "SkilledNursingAssistedLivingAndIndependentLivingFacilitiesAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "ensg_SkilledNursingandSeniorlivingFacilitiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Skilled Nursing, Assisted Living and Independent living Facilities [Axis]", "label": "Skilled Nursing and Senior living Facilities [Axis]", "terseLabel": "Skilled Nursing, Assisted Living and Independent living Facilities [Axis]" } } }, "localname": "SkilledNursingandSeniorlivingFacilitiesAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "ensg_SkilledNursingandSeniorlivingFacilitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Skilled Nursing, Assisted Living and Independent living Facilities [Axis]", "label": "Skilled Nursing and Senior living Facilities [Domain]", "terseLabel": "Skilled Nursing, Assisted Living and Independent living Facilities [Domain]" } } }, "localname": "SkilledNursingandSeniorlivingFacilitiesDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "domainItemType" }, "ensg_SpinOffTransactionCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operated by the Spin-off company", "label": "Spin-Off Transaction Company [Member]", "terseLabel": "Spin-Off Transaction Company [Member]" } } }, "localname": "SpinOffTransactionCompanyMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "ensg_StockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock awards [Member]", "label": "Stock awards [Member]", "terseLabel": "Stock awards" } } }, "localname": "StockAwardsMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "ensg_StockOptionsgrantedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Stock Options granted [Table]", "label": "Stock Options granted [Line Items]", "terseLabel": "Stock Options granted [Line Items]" } } }, "localname": "StockOptionsgrantedLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "stringItemType" }, "ensg_StockOptionsgrantedTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Options granted [Table]", "label": "Stock Options granted [Table]", "terseLabel": "Stock Options granted [Table]" } } }, "localname": "StockOptionsgrantedTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "stringItemType" }, "ensg_StopLossDeductibleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stop Loss Deductible [Member]", "label": "Stop Loss Deductible [Member]", "terseLabel": "Stop Loss Deductible [Member]" } } }, "localname": "StopLossDeductibleMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_StopLossInsuranceLimitPerClaimMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stop-Loss Insurance limit per claim[Member]", "label": "Stop-Loss Insurance limit per claim [Member]", "terseLabel": "Stop-Loss Insurance limit per claim [Member]" } } }, "localname": "StopLossInsuranceLimitPerClaimMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "ensg_SubsidiariesStockawardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Subsidiaries Stock awards [Member]", "label": "Subsidiaries Stock awards [Member]", "terseLabel": "Subsidiaries Stock awards [Member]" } } }, "localname": "SubsidiariesStockawardsMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ensg_SubsidiaryEquityPlanAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Subsidiary Equity Plan [Abstract]", "label": "Subsidiary Equity Plan [Abstract]" } } }, "localname": "SubsidiaryEquityPlanAbstract", "nsuri": "http://www.ensigngroup.net/20190630", "xbrltype": "stringItemType" }, "ensg_SummaryofBusinessOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Summary of Business Operations [Table]", "label": "Summary of Business Operations [Line Items]", "terseLabel": "Summary of Business Operations [Line Items]" } } }, "localname": "SummaryofBusinessOperationsLineItems", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "ensg_SummaryofBusinessOperationsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of Business Operations [Table]", "label": "Summary of Business Operations [Table]", "terseLabel": "Summary of Business Operations [Table]" } } }, "localname": "SummaryofBusinessOperationsTable", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "stringItemType" }, "ensg_SunTrustBankMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SunTrust Bank [Member]", "label": "SunTrust Bank [Member]", "terseLabel": "SunTrust Bank [Member]" } } }, "localname": "SunTrustBankMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "domainItemType" }, "ensg_TermLoanAmountOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions of the outstanding balance for the term loan.", "label": "Term Loan, Amount Outstanding", "terseLabel": "Term loan with SunTrust" } } }, "localname": "TermLoanAmountOutstanding", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "ensg_TermLoanAmountOutstandingCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Term Loan, Amount Outstanding, Current", "label": "Term Loan, Amount Outstanding, Current", "terseLabel": "Term Loan, Amount Outstanding, Current" } } }, "localname": "TermLoanAmountOutstandingCurrent", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ensg_TermLoanAmountOutstandingNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Term Loan, Amount Outstanding, Noncurrent", "label": "Term Loan, Amount Outstanding, Noncurrent", "terseLabel": "Term Loan, Amount Outstanding, Noncurrent" } } }, "localname": "TermLoanAmountOutstandingNoncurrent", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ensg_TermLoanBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Borrowing capacity under the term loan", "label": "Term Loan, Borrowing Capacity", "terseLabel": "Term Loan, Borrowing Capacity" } } }, "localname": "TermLoanBorrowingCapacity", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ensg_TermLoanandLineofCreditFacilityAmountOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Term loan and line of credit facility outstanding amount for current and noncurrent", "label": "Term Loan and Line of Credit Facility, Amount Outstanding", "terseLabel": "Term Loan and Line of Credit Facility, Amount Outstanding" } } }, "localname": "TermLoanandLineofCreditFacilityAmountOutstanding", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ensg_TotalMedicaidAndMedicareRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total revenue from Medicaid and Medicare [Member]", "label": "Total Medicaid and Medicare Revenue [Member]", "terseLabel": "Total Medicare and Medicaid", "verboseLabel": "Total Medicaid and Medicare" } } }, "localname": "TotalMedicaidAndMedicareRevenueMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "ensg_TotalNetDebtRatioDefault": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Net Debt Ratio, Default", "label": "Total Net Debt Ratio, Default", "terseLabel": "Total Net Debt Ratio, Default" } } }, "localname": "TotalNetDebtRatioDefault", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Net Debt Ratio, Maximum", "label": "Total Net Debt Ratio, Maximum", "terseLabel": "Total Net Debt Ratio, Maximum" } } }, "localname": "TotalNetDebtRatioMaximum", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Net Debt Ratio, Minimum", "label": "Total Net Debt Ratio, Minimum", "terseLabel": "Total Net Debt Ratio, Minimum" } } }, "localname": "TotalNetDebtRatioMinimum", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "pureItemType" }, "ensg_TransitionalandSkilledServiceFacilities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional and Skilled Service Facilities", "label": "Transitional and Skilled Service Facilities", "terseLabel": "Transitional and Skilled Service Facilities" } } }, "localname": "TransitionalandSkilledServiceFacilities", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails" ], "xbrltype": "integerItemType" }, "ensg_TransitionalandSkilledServiceFacilitiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional and skilled service facilities [Axis]", "label": "Transitional and Skilled Service Facilities [Axis]", "terseLabel": "skilled nursing, assisted living and independent living facilities [Axis]" } } }, "localname": "TransitionalandSkilledServiceFacilitiesAxis", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails" ], "xbrltype": "stringItemType" }, "ensg_TransitionalandSkilledServicefacilitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional and skilled service facilities [Domain]", "label": "Transitional and Skilled Service facilities [Domain]", "terseLabel": "Skilled nursing, assisted living and independent living facilities [Domain]" } } }, "localname": "TransitionalandSkilledServicefacilitiesDomain", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails" ], "xbrltype": "domainItemType" }, "ensg_TransitionalandSkilledServicesSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional and Skilled Services Segment", "label": "Transitional and Skilled Services Segment [Member]", "terseLabel": "Transitional and Skilled Services Segment" } } }, "localname": "TransitionalandSkilledServicesSegmentMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "ensg_TransitionalandSkilledServicesandSeniorLivingCampuses": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional and Skilled Services and Assistant and Independent Living Campuses", "label": "Transitional and Skilled Services and Senior Living Campuses", "terseLabel": "Transitional and Skilled Services and Senior Living Campuses" } } }, "localname": "TransitionalandSkilledServicesandSeniorLivingCampuses", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails" ], "xbrltype": "integerItemType" }, "ensg_TransitionalandSkilledServicesandSeniorLivingCampusesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional and Skilled Services and Senior Living Campuses [Member]", "label": "Transitional and Skilled Services and Senior Living Campuses [Member]", "terseLabel": "Transitional and Skilled Services and Senior Living Campuses [Member]" } } }, "localname": "TransitionalandSkilledServicesandSeniorLivingCampusesMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "ensg_TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transitional and skilled services, assisted and independent living services and home health and hospice services segments.", "label": "Transitional and skilled services, assisted and independent living services and home health and hospice services segments [Member]", "terseLabel": "Transitional and skilled services, assisted and independent living services and home health and hospice services segments [Member]" } } }, "localname": "TransitionalandskilledservicesassistedandindependentlivingservicesandhomehealthandhospiceservicessegmentsMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "ensg_VariousLandlordsMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Various Landlords[Member]", "label": "Various Landlords [Member] [Member]", "terseLabel": "Various Landlords [Member] [Member]" } } }, "localname": "VariousLandlordsMemberMember", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ensg_WeightedAverageDividendYield": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Dividend Yield", "label": "Weighted Average Dividend Yield", "terseLabel": "Weighted Average Dividend Yield" } } }, "localname": "WeightedAverageDividendYield", "nsuri": "http://www.ensigngroup.net/20190630", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "naics_ZZ524292": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "524292 Third Party Administration of Insurance and Pension Funds [Member]", "terseLabel": "Third-Party Payor [Member]" } } }, "localname": "ZZ524292", "nsuri": "http://xbrl.sec.gov/naics/2017-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "naics_ZZ621610": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "621610 Home Health Care Services [Member]", "terseLabel": "621610 Home Health Care Services [Member]" } } }, "localname": "ZZ621610", "nsuri": "http://xbrl.sec.gov/naics/2017-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "sic_Z8051": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "8051 Services, Skilled Nursing Care Facilities [Member]", "terseLabel": "8051 Services, Skilled Nursing Care Facilities [Member]" } } }, "localname": "Z8051", "nsuri": "http://xbrl.sec.gov/sic/2011-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r432" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationEliminationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation, Eliminations [Member]", "terseLabel": "Consolidation, Eliminations [Member]" } } }, "localname": "ConsolidationEliminationsMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r148", "r158" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r66", "r110" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case Type [Domain]", "verboseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r161", "r253", "r256", "r422" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r425", "r431" ], "lang": { "en-US": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "srt_OfficeBuildingMember": { "auth_ref": [ "r425", "r431" ], "lang": { "en-US": { "role": { "label": "Office Building [Member]", "terseLabel": "Office Building [Member]" } } }, "localname": "OfficeBuildingMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Parent Company [Member]", "terseLabel": "Parent Company [Member]" } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r160", "r253", "r255", "r420", "r421" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]", "verboseLabel": "Insurance Policy [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]", "verboseLabel": "Insurance Policy [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/IncomeTaxesRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r230", "r377" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/IncomeTaxesRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r261", "r373", "r375" ], "lang": { "en-US": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Subsidiaries [Member]" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r163", "r374" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CALIFORNIA", "terseLabel": "CALIFORNIA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "stpr_CO": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "COLORADO", "terseLabel": "COLORADO" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "TEXAS", "terseLabel": "TEXAS" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r164" ], "calculation": { "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r33", "r405" ], "calculation": { "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "totalLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r15", "r33", "r164", "r165", "r254" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $3,726 and $2,886 at June 30, 2019 and December 31, 2018, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "auth_ref": [ "r300", "r395", "r416" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.", "label": "Accrual for Taxes Other than Income Taxes", "terseLabel": "Property taxes" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r44", "r216" ], "calculation": { "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Life (Years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Additional Cash Flow Elements, Operating Activities [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r34" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amortization [Abstract]", "terseLabel": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r116" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r264", "r293", "r298" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Employee stock award compensation", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r170", "r178", "r180", "r182" ], "calculation": { "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Less: allowance for doubtful accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r100", "r348" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r100", "r198", "r206" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareAntidilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r153", "r386", "r407" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r18", "r20", "r65" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "auth_ref": [ "r212" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.", "label": "Assets Held-for-sale, Not Part of Disposal Group, Current", "terseLabel": "Assets held for sale - current" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r265", "r295" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies [Text Block]" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r314", "r315" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r104", "r105", "r106" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r41", "r102" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase/(decrease) in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Cash, FDIC Insured Amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash financing and investing activity:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralizedDebtObligationsMember": { "auth_ref": [ "r175", "r259" ], "lang": { "en-US": { "role": { "documentation": "Securities collateralized by a pool of assets.", "label": "Collateralized Debt Obligations [Member]", "terseLabel": "Collateralized Debt Obligations [Member]" } } }, "localname": "CollateralizedDebtObligationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r57", "r229", "r396", "r414" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 15, 17 and 18)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r228", "r231" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends Per Share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r32", "r238" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance - June 30 (in shares)", "periodStartLabel": "Balance - January 1 (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical", "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r32" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.001 par value; 100,000 shares authorized; 55,809 and 53,272 shares issued and outstanding at June 30, 2019, respectively, and 55,089 and 52,584 shares issued and outstanding at December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r140", "r141", "r142", "r143", "r343", "r344" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r250", "r251", "r254" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Resident advances" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r77" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r76" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expense" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect of new accounting change, net of tax" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.", "label": "Cumulative Effect on Retained Earnings, Net of Tax", "terseLabel": "Cumulative Effect on Retained Earnings, Net of Tax" } } }, "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeEffectOnRetainedEarningsTax1": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the related income tax effect of a cumulative effect on retained earnings.", "label": "Cumulative Effect on Retained Earnings, Tax", "terseLabel": "Cumulative Effect on Retained Earnings, Tax" } } }, "localname": "CumulativeEffectOnRetainedEarningsTax1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r25", "r27", "r28", "r387", "r389", "r404" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r28", "r233", "r389", "r404" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term Debt, Gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r402" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r55", "r112", "r239", "r242", "r243", "r244", "r346", "r347", "r349", "r403" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt Instrument, Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r350" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "negatedTerseLabel": "Less: debt issuance costs" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r46", "r348" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r308" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Escrow deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r100", "r151" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueFromMedicareAndMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwards" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/DivestituresDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/DivestituresDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r214", "r220" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r245", "r401" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividends declared", "terseLabel": "Accrued dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r27", "r29", "r388", "r408" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r175", "r259", "r262" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Debt Security, Corporate, US [Member]", "terseLabel": "Debt Security, Corporate, US [Member]" } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r73", "r117", "r122", "r126", "r127", "r128", "r131", "r399", "r418" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per common share attributable to The Ensign Group, Inc." } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic:", "verboseLabel": "Basic net income (loss) per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r73", "r117", "r122", "r126", "r127", "r128", "r131", "r399", "r418" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per common share attributable to The Ensign Group, Inc." } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted:", "verboseLabel": "Diluted net (loss) income per common share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted, Other Disclosures [Abstract]", "terseLabel": "Earnings Per Share, Diluted, Other Disclosures [Abstract]" } } }, "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareAntidilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r113", "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued wages and related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimatedInsuranceRecoveries": { "auth_ref": [ "r46" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.", "label": "Estimated Insurance Recoveries", "terseLabel": "Long-term insurance losses recoverable asset" } } }, "localname": "EstimatedInsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceRecoveriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r332", "r333" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r332", "r338" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r259", "r260", "r262", "r333", "r378" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r332", "r333", "r334", "r335", "r339" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r259", "r260", "r262", "r333", "r379" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r259", "r260", "r262", "r333", "r380" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r259", "r260", "r262", "r333", "r381" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "verboseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r337", "r339" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r107", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r179", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r205" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r207" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 7.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2019 (remainder)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r207" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r207" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r207" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r207" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r199", "r202", "r205", "r209", "r384" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r205", "r384" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r199", "r204" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r205" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net (Note 17)", "totalLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r229" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Return of unclaimed class action settlement (Note 18)" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r74" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability.", "label": "General Liability [Member]", "verboseLabel": "General and Professional Liability Insurance [Member]" } } }, "localname": "GeneralLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r193", "r194" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "June 30,", "periodStartLabel": "January 1,", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r195" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Additions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Goodwill and intangible asset impairment" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Indefinite-Lived Intangibles [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r107", "r196", "r203" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r174", "r176" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity", "terseLabel": "Debt Securities, Held-to-maturity" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r100", "r213" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment of Long-Lived Assets to be Disposed of", "verboseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesImpairmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]", "terseLabel": "Net income per share attributable to The Ensign Group, Inc.:" } } }, "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r117", "r385", "r397", "r419" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r322" ], "calculation": { "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DivestituresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r11", "r12", "r220", "r221" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DivestituresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails", "http://www.ensigngroup.net/role/IncomeTaxesRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails", "http://www.ensigngroup.net/role/IncomeTaxesRateReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r152", "r311" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/IncomeTaxesExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r69", "r107", "r301", "r302", "r306", "r307", "r309", "r312", "r430" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r96", "r103" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued wages and related liabilities" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liability" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Investments and change in other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedTerseLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Increase (Decrease) in Self Insurance Reserve", "terseLabel": "Accrued self-insurance liabilities" } } }, "localname": "IncreaseDecreaseInSelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r123", "r130" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Plus: incremental shares from assumed conversion (1)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r201", "r208" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r208" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Other indefinite-lived intangibles" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r201", "r208" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets Disclosure [Text Block]" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r70", "r150", "r345", "r348", "r400" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r91", "r95", "r103" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Elimination" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r80", "r149" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "verboseLabel": "Rent" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesAcquiredInPlaceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.", "label": "Leases, Acquired-in-Place [Member]", "terseLabel": "Lease acquisition costs" } } }, "localname": "LeasesAcquiredInPlaceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases and Leasehold Improvements" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, Operating Lease, Renewal Term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r50" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r38", "r391", "r412" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityReserveEstimatePolicy": { "auth_ref": [ "r107", "r415", "r424" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).", "label": "Liability Reserve Estimate, Policy [Policy Text Block]", "terseLabel": "Self-Insurance" } } }, "localname": "LiabilityReserveEstimatePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r28", "r389", "r404" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r48", "r112" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of Credit Facility, Current Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Revolving credit facility with SunTrust" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedTerseLabel": "Current maturities of long-term debt", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt\u2014less current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Notes Payable, Noncurrent" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r55", "r232" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r63", "r390", "r411" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distribution to noncontrolling interest holder" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages [Member]" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by/(used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r94", "r98", "r101" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r67", "r68", "r72", "r101", "r130", "r398", "r417" ], "calculation": { "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income attributable to The Ensign Group, Inc.", "totalLabel": "Net income attributable to The Ensign Group, Inc.", "verboseLabel": "Net Income (Loss) Attributable to the Ensign Group, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r67", "r68", "r325", "r329" ], "calculation": { "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net income attributable to noncontrolling interests", "verboseLabel": "Net income attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r116", "r118" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "auth_ref": [ "r104", "r105", "r106" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "terseLabel": "Note receivable from sale of ancillary business" } } }, "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r246", "r323", "r327" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Noncontrolling interest attributable to subsidiary equity plan (Note 16)" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r104", "r105", "r106" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued", "terseLabel": "Note payable due to seller from business acquisition" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r28", "r389", "r409" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Mortgage loans and promissory note", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Notes Payable, Current" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Notes Payable, Other Payables [Member]" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks [Member]" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesReceivableFairValueDisclosure": { "auth_ref": [ "r61" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.", "label": "Notes Receivable, Fair Value Disclosure", "terseLabel": "Note receivable from sale of ancillary business" } } }, "localname": "NotesReceivableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of Businesses Acquired" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of Real Estate Properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffMarketFavorableLeaseMember": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.", "label": "Off-Market Favorable Lease [Member]", "terseLabel": "Favorable leases" } } }, "localname": "OffMarketFavorableLeaseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Segment Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r363", "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r359" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent\u2014cost of services (Note 17)" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Net of Lease Liability", "verboseLabel": "Present value of total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r358" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current lease liabilities", "terseLabel": "Lease liabilities\u2014current (Note 17)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r358" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term lease liabilities\u2014less current portion (Note 17)", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r360", "r364" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r357" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets (Note 17)", "verboseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r367", "r370" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r366", "r370" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/LeasesIncomeStatementImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Total lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r352", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage points added to the reference rate to compute the variable rate on the lessee's operating lease.", "label": "Operating Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate", "terseLabel": "Operating Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate" } } }, "localname": "OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r148", "r158" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r13", "r331" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r395", "r416" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities", "totalLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Assets [Abstract]" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "Other Assets Disclosure [Text Block]" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "totalLabel": "Restricted and other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r22", "r51" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Liabilities Disclosure [Text Block]" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest expense, net of interest income", "totalLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherRestrictedAssets": { "auth_ref": [ "r46" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.", "label": "Other Restricted Assets", "terseLabel": "Capital improvement reserves with landlords and lenders" } } }, "localname": "OtherRestrictedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestrictedAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets that are pledged or subject to withdrawal restrictions, classified as other.", "label": "Other Restricted Assets, Noncurrent", "terseLabel": "Restricted and other assets (Note 17)" } } }, "localname": "OtherRestrictedAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Payments for Legal Settlements" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions": { "auth_ref": [ "r114" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net cash outflow or inflow from the amount given in advance to show intention to complete the acquisition piece of land, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Payments for (Proceeds from) Deposits on Real Estate Acquisitions", "negatedTerseLabel": "Escrow deposits" } } }, "localname": "PaymentsForProceedsFromDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Payments for Rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of shares of common stock and subsidiary shares (Note 16)", "verboseLabel": "Payments for Repurchase of Common Stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r89" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payments of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r83", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r83" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Cash payments for business acquisitions (Note 8)" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r84" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r265", "r295" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities": { "auth_ref": [ "r382" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the date of the latest financial statement presented of securities which are owned but transferred to serve as collateral for letter of credit arrangements, and for which the transferee does not have the right by contract or custom to sell or re-pledge them to an unrelated party.", "label": "Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities", "terseLabel": "Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities" } } }, "localname": "PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r18", "r39", "r40" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidRent": { "auth_ref": [ "r16", "r19", "r191", "r192" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Rent", "terseLabel": "Prepaid Rent" } } }, "localname": "PrepaidRent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r17", "r19", "r191", "r192" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "auth_ref": [ "r98", "r103" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.", "label": "Proceeds from Income Tax Refunds", "terseLabel": "Income tax refund" } } }, "localname": "ProceedsFromIncomeTaxRefunds", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "auth_ref": [ "r90", "r93" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.", "label": "Proceeds from Insurance Settlement, Operating Activities", "terseLabel": "Cash received from insurance proceeds related to replacement properties and business interruptions" } } }, "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r86" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from revolving credit facility and other debt (Note 15)" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r85" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from sale of subsidiary shares (Note 16)", "verboseLabel": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "auth_ref": [ "r114" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.", "label": "Proceeds from (Payments to) Noncontrolling Interests", "terseLabel": "Non-controlling interest distribution" } } }, "localname": "ProceedsFromPaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": { "auth_ref": [ "r82" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.", "label": "Proceeds from Sales of Assets, Investing Activities", "terseLabel": "Cash proceeds from the sale of assets and insurance proceeds" } } }, "localname": "ProceedsFromSalesOfAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r85", "r296" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalLiabilityInsuranceMember": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Contract providing insurance coverage against loss by professional in course of practice.", "label": "Professional Liability Insurance [Member]", "terseLabel": "General and Professional Liability Insurance [Member]" } } }, "localname": "ProfessionalLiabilityInsuranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r67", "r68", "r92", "r153", "r159", "r322", "r324", "r326", "r329", "r330" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r44", "r217" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r43", "r215" ], "calculation": { "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r23", "r24", "r217", "r413" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r42", "r107", "r217" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r23", "r217" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r23", "r215" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r75", "r181" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstatePropertiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by ownership of the property.", "label": "Real Estate Property Ownership [Axis]", "terseLabel": "Real Estate Property Ownership [Axis]" } } }, "localname": "RealEstatePropertiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents categories of ownership of real estate properties.", "label": "Real Estate Properties [Domain]", "terseLabel": "Real Estate Properties [Domain]" } } }, "localname": "RealEstatePropertiesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r155", "r157" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r155", "r157" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r88" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on revolving credit facility and other debt (Note 15)" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r35", "r245", "r410" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r252", "r253" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Revenue from external customers" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r108", "r258" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r365", "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleLeasebackTransactionCurrentPeriodGainRecognized": { "auth_ref": [ "r354" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of the deferred gain that was recognized in the current period.", "label": "Sale Leaseback Transaction, Current Period Gain Recognized", "negatedTerseLabel": "Amortization of deferred gain on sale-leaseback (Note 17)", "terseLabel": "Sale Leaseback Transaction, Deferred Gain" } } }, "localname": "SaleLeasebackTransactionCurrentPeriodGainRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleLeasebackTransactionDeferredGainNet": { "auth_ref": [ "r354" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of the gain that will be recorded as income or a reduction in rent expense in future periods less amounts recognized in the current period.", "label": "Sale Leaseback Transaction, Deferred Gain, Net", "terseLabel": "Deferred gain related to sale-leaseback (Note 17)" } } }, "localname": "SaleLeasebackTransactionDeferredGainNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleLeasebackTransactionDescriptionAxis": { "auth_ref": [ "r355", "r372" ], "lang": { "en-US": { "role": { "documentation": "Information pertinent to a sale and leaseback transaction, by transaction.", "label": "Sale Leaseback Transaction, Description [Axis]", "terseLabel": "Sale Leaseback Transaction, Description [Axis]" } } }, "localname": "SaleLeasebackTransactionDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesSaleLeasebackTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleLeasebackTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Sale Leaseback Transaction [Line Items]", "terseLabel": "Sale Leaseback Transaction [Line Items]" } } }, "localname": "SaleLeasebackTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesSaleLeasebackTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleLeasebackTransactionNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The name of the significant provisions of the transaction involving the sale of property to another party and the lease of the property back to the seller.", "label": "Sale Leaseback Transaction, Name [Domain]", "terseLabel": "Sale Leaseback Transaction, Name [Domain]" } } }, "localname": "SaleLeasebackTransactionNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesSaleLeasebackTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleLeasebackTransactionTable": { "auth_ref": [ "r351", "r355", "r372" ], "lang": { "en-US": { "role": { "documentation": "A summary of the elements of a transaction involving the entity's sale of property to another party and the lease of the property back to the entity.", "label": "Sale Leaseback Transaction [Table]", "terseLabel": "Sale Leaseback Transaction [Table]" } } }, "localname": "SaleLeasebackTransactionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesSaleLeasebackTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r62" ], "lang": { "en-US": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.", "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]" } } }, "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r314", "r315" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsPriorPeriodAcquisitionsDetails", "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r55", "r112", "r239", "r242", "r243", "r244", "r346", "r347", "r349", "r403" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r122", "r124", "r128", "r131" ], "lang": { "en-US": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "auth_ref": [ "r122", "r124", "r128", "r131" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r78", "r122", "r124", "r125", "r128", "r131" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r264", "r292", "r298" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r264", "r292", "r298" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r199", "r204" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r199", "r204" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Held-to-maturity Securities [Line Items]", "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity [Table]", "terseLabel": "Debt Securities, Held-to-maturity [Table]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r208", "r210" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "auth_ref": [ "r426", "r427", "r428", "r429" ], "lang": { "en-US": { "role": { "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Insurance Type and Tier Identifier [Axis]", "terseLabel": "Insurance Type and Tier Identifier [Axis]" } } }, "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SelfInsuranceReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r116", "r118", "r133", "r134", "r135" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/LeasesDetails", "http://www.ensigngroup.net/role/LeasesIncomeStatementImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Other Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r44", "r217" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "verboseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/PropertyAndEquipmentDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r224", "r225", "r226" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r147", "r153", "r154", "r156", "r196" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r147", "r153", "r154", "r156", "r196" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r265", "r295" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r58", "r111", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt [Member]" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r64" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Deposits with landlords" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegments" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self Insurance Reserve" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "terseLabel": "Accrued self-insurance liabilities\u2014current" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveNoncurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Noncurrent", "terseLabel": "Accrued self-insurance liabilities\u2014less current portion" } } }, "localname": "SelfInsuranceReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorDebtObligationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Borrowing with the highest claim on the assets of the entity in event of bankruptcy or liquidation.", "label": "Senior Debt Obligations [Member]", "terseLabel": "Senior Debt Obligations [Member]" } } }, "localname": "SeniorDebtObligationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r99" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award Requisite Service Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted Average Grant Date Fair Value, Restricted Awards Forfeited in the Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Restricted Awards Granted in the Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested Restricted Awards, Nonvested at June 30,", "periodStartLabel": "Nonvested Restricted Awards, Nonvested at January 1," } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Nonvested at June 30,", "periodStartLabel": "Weighted Average Grant Date Fair Value, Nonvested at January 1," } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Nonvested Restricted Awards, Vested in the Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Restricted Awards Vested in the Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "verboseLabel": "Fair Value Assumptions and Methodology" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted Average Risk-Free Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted Average Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price of Options Vested June 30,", "periodStartLabel": "Weighted Average Exercise Price of Options Vested January 1," } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "terseLabel": "Grant Date Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Fair Value of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r272", "r295" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding June 30,", "periodStartLabel": "Options outstanding January 1," } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price June 30,", "periodStartLabel": "Weighted average exercise price January 1," } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r263", "r269" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]", "verboseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options Exercised in Period" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Options Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r107", "r265", "r270" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise Price, Lower Range Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Stock Options Vested and Exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Number of Outstanding Options" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise Price, Upper Range Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r288", "r297" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance - June 30 (in treasury shares)", "periodStartLabel": "Balance - January 1 (in treasury shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r26", "r392", "r393", "r394", "r406" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Investments\u2014current" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SpinoffMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares.", "label": "Spinoff [Member]", "terseLabel": "Spinoff [Member]" } } }, "localname": "SpinoffMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r153", "r196", "r219", "r223", "r227", "r420" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r30", "r31", "r32", "r238" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r60", "r238" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails", "http://www.ensigngroup.net/role/IncomeTaxesRateReconciliationDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome", "http://www.ensigngroup.net/role/FairValueMeasurementsDetails", "http://www.ensigngroup.net/role/IncomeTaxesRateReconciliationDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Shares Granted or Issued, Share-based Payment Arrangement [Abstract]", "terseLabel": "Shares Granted or Issued, Share-based Payment Arrangement [Abstract]" } } }, "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r31", "r32", "r238", "r245" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r31", "r32", "r238", "r245" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Nonvested Restricted Awards, Forfeited in the Period" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r238", "r245" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Nonvested Restricted Awards, Granted", "verboseLabel": "Issuance of restricted stock to employees (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryCommonStockSharesAndRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r31", "r32", "r238", "r245", "r274" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options Exercised in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r31", "r32", "r238", "r245" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramExpirationDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.", "label": "Stock Repurchase Program Expiration Date", "terseLabel": "Stock Repurchase Program Expiration Date" } } }, "localname": "StockRepurchaseProgramExpirationDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Repurchase Program, Period in Force", "terseLabel": "Stock Repurchase Program, Period in Force" } } }, "localname": "StockRepurchaseProgramPeriodInForce1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r31", "r32", "r238", "r245" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Stock Repurchased During Period, Shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r32", "r36", "r37", "r172" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Ensign Group, Inc. stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity:", "verboseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r320", "r321", "r328" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance - June 30,", "periodStartLabel": "Balance - January 1,", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets", "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "http://www.ensigngroup.net/role/CommonStockDetails", "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "http://www.ensigngroup.net/role/CommonStockDetails", "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/AcquisitionsSummaryDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails", "http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails", "http://www.ensigngroup.net/role/CommonStockDetails", "http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/CommonStockDetails", "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/OptionsAndAwardsSaleOfStockBySubsidiaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r166", "r167", "r168", "r169", "r171", "r173" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r59", "r248" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r59", "r248" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Common stock in treasury, at cost" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r59", "r248", "r249" ], "calculation": { "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Common stock in treasury, at cost, 1,941 and 1,932 shares at June 30, 2019 and December 31, 2018, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeAndTierIdentifierDomain": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Type and Tier Identifier [Domain]", "terseLabel": "Type and Tier Identifier [Domain]" } } }, "localname": "TypeAndTierIdentifierDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SelfInsuranceReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/LeasesBalanceSheetImpactOnNewLeaseGuidanceDetails", "http://www.ensigngroup.net/role/RestrictedAndOtherAssetsAdditionalDetails", "http://www.ensigngroup.net/role/RevenueAndAccountsReceivableImpactOfNewRevenueGuidanceDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails", "http://www.ensigngroup.net/role/SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsDetails", "http://www.ensigngroup.net/role/DescriptionOfBusinessProposedSpinOffTransactionDetails", "http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails", "http://www.ensigngroup.net/role/ProposedSpinOffOfSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r136", "r137", "r138", "r139", "r144", "r145", "r146" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r121", "r128" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "verboseLabel": "Adjusted weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding:", "verboseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r120", "r128" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding for basic net income per share", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WorkersCompensationInsuranceMember": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death.", "label": "Workers' Compensation Insurance [Member]", "terseLabel": "Workers' Compensation [Member]" } } }, "localname": "WorkersCompensationInsuranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1311-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=77912953&loc=d3e400-110220" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164451&loc=d3e36991-112694" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=108788860&loc=d3e50609-112754" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77913982&loc=d3e50796-112755" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888430&loc=SL77919786-209982" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.13(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "9C", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884803&loc=SL65671395-207642" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/subtopic&trid=2560295" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9100-115647" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9113-115647" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "720", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9127-115647" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r434": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r435": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r436": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r437": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r438": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.21)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3337-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080549-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" } }, "version": "2.1" } ZIP 119 0001125376-19-000102-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001125376-19-000102-xbrl.zip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�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�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�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�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end

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�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